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CHAPTER 1 
 
AN INTRODUCTION TO DNA – DISCOVERY, STRUCTURE, 
FUNCTION AND IMPORTANCE OF dsDNA RECOGNITIONI 
 
It is a misconception that American biologist James Watson and 
English physicist Francis Crick discovered DNA in the 1950s. DNA 
was in fact first identified several decades before Watson & Crick 
by Swiss chemist Friedrich Miescher1, 2 in the late 1860s. Of course 
at the time no one knew what it was or that it even existed. Miescher 
first identified what he called as “nuclein” present inside human 
white blood cells. (The name nuclein was later changed to nucleic 
acid and eventually to deoxyribonucleic acid or “DNA”.) Decades 
later, other scientists – notably, Russian biochemist Phoebus 
Levene3 and Austrian biochemist Erwin Chargaff4 – carried out a 
series of systematic studies that revealed additional details about 
DNA. The most important among those details were identifying its 
primary chemical components and the ways in which they were 
connected with each other. Another noteworthy contribution was 
that of the English Chemist and crystallographer Rosalind Franklin5 
for her work on X-ray diffraction images of DNA. If this scientific 
foundation had not existed, Watson and Crick would probably not 
have reached their revolutionary conclusion in 1953: that the DNA 
molecule exists in the form of a three-dimensional double helix.6 
 
1.1 Basic constituents of DNA 
 
Despite its complexity, it is quite amazing that DNA comprises only of four basic nucleotides 
(building blocks of DNA). A nucleotide, in turn, is made up of three sub units – a nitrogenous base, a 
sugar, and a phosphate group. The nitrogenous base can be either a pyrimidine or a purine. The three 
pyrimidines are: cytosine (C), thymine (T), and uracil (U). All three pyrimidines are made up of a 
single ring. The chemical structures of the two purines, adenine (A) and guanine (G), are also shown 
(Figure 1.1). Each purine is made up of a fused double ring. A nitrogenous base is attached to a ribose 
or deoxyribose sugar, forming a molecule called a nucleoside. When a phosphate moiety is attached to 
the other side of the sugar, the phosphate, sugar and base together form a nucleotide. Note that DNA 
does not contain Uracil (U). Thus, A, G, C and T form the four basic nucleotides which constitute 
DNA. 
                                                          
I Note: Throughout this chapter, wherever possible or available, the source has been mentioned for individual images. If not, 
the general rules regarding copyright are as follows: You may reproduce this material, without modifications, in print or 
electronic form for your personal, non-commercial purposes or for non-commercial use in an educational environment. 
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IIFigure 1.1: The chemical structure of a nucleotide 
1.2 Structure of dsDNA 
The simplified illustration of dsDNA, which is shown in Figure 1.2, indicates certain important 
properties of dsDNA: 
1. The first is that the two strands of the helix are arranged in an anti-parallel manner. This is 
evident from the grey ribbons, which represent the sugar-phosphate backbone, which have 
arrows that run in opposite directions.  
2. The second is that the upper end of one strand is labelled five prime (5’), and the lower end of 
the same strand is labelled three prime (3’). Also, the upper end of the opposite strand is 
labelled 3’, and the lower end of the same strand is labelled 5’. As a result, the 5' end of one 
strand matches up with the 3’ end of the other strand on each end of the double helix.  
3. The third is that the two strands are held together by the pairing of complementary nucleotide 
bases on opposite DNA strands. The nucleotide bases are shown as differently coloured 
rectangles. These blocks fit together like pieces of a puzzle (meeting in the middle). The 
nucleotide guanine (G, shown in blue) binds with the nucleotide cytosine (C, shown in 
orange). The nucleotide adenine (A, shown in green) binds with the nucleotide thymine (T, 
shown in red). The base pairs between the two strands look like the rungs of a ladder. The 
distance between two base pairs, or “rungs”, as proposed by Watson and Crick was 0.34 
nanometres. The length of one turn of the double-helix was proposed to be 3.4 nanometres. 
The width of the DNA molecule was proposed to be two nanometres. Subsequent 
measurements over the years however revealed that this was not the case and that every turn 
                                                          
II Reproduced from Pray, L. (2008) Discovery of DNA structure and function: Watson and Crick. Nature Education 1(1):100 
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was in fact closer to 3.5-3.6 Å (or 0.35-0.36 nanometres and not 0.34) and it was found that 
10.4-10.5 base pairs (and not 10) constituted a helix turn (ref. 7). 
4. A space-filling molecular model is depicted on the right. The colour codes are: gold spheres 
for phosphorus atoms, grey spheres for carbon atoms, white spheres for hydrogen atoms, red 
spheres for oxygen atoms, and blue spheres for nitrogen atoms. The DNA molecule’s sugar-
phosphate backbone is made up of phosphorus, carbon, hydrogen and oxygen. The bases, 
which contain hydrogen, oxygen, nitrogen and carbon, connect the two sugar-phosphate 
backbone chains. 
 
IIIFigure 1.2: The double-helical structure of DNA as proposed by Watson and Crick along with the formation 
of major and minor grooves. 
5. Another key aspect of DNA assembly is the formation of major and minor grooves. This will 
be of great importance in the subsequent sections when we discuss DNA recognition. The 
major and minor grooves form as a result of the offset pairing between the two single strands 
of DNA as can be seen in Figure 1.2.  
  
                                                          
III Reproduced from Pray, L. (2008) Discovery of DNA structure and function: Watson and Crick. Nature 
Education 1(1):100 
Major 
Groove 
Minor 
Groove 
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IVFigure 1.3: Base pairing in DNA as correctly elucidated by Watson & Crick 
Figure 1.3 shows the molecular structure of a DNA region illustrated in detail to show the pairing of 
the bases. The key points of the figure can be summarized as follows: 
1. The simplified illustration on the left of Figure 1.2 depicts the basic structure of the DNA 
double helix. This structure has been explained in detail in the previous section. In this figure, 
the bottom of the DNA molecule has been expanded to elaborate upon the following: the 
strand on the left is labelled three prime hydroxyl (OH), and the strand at the right is labelled 
five prime phosphate (OPO3-). The bottom four base pairs are shown flattened instead of 
twisted, so that this region (marked with a black box) can be easily expanded to depict a more 
interesting, in-depth, close-up view. 
2. The expanded section shows the individual atoms and bonds in the DNA molecule. Phosphate 
groups are depicted within light brown spheres. The bonds between the phosphate and oxygen 
atoms are also shown. The grey pentagons represent the sugars. The carbon atoms are 
unmarked to avoid over-crowding of the figure. From the figure, it is clear that the oxygen 
atoms and hydrogen atoms are attached to the carbon atoms. An oxygen atom from each 
phosphate moiety is connected by a solid black line to a carbon atom from the sugar moiety. 
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Covalent bonds between the sugars and phosphate groups are also represented by solid black 
lines. Each sugar molecule is individually attached to a single nitrogenous base. The 
nitrogenous bases from the two DNA strands form the central part of the molecule. The bases 
interact with each other and are thus linked via hydrogen bonds (shown by dotted, red lines).  
3. Further introspection of the base pairing reveals that top-most the guanine base with two 
fused rings (G, shown in blue) is bound to a cytosine base with a single ring (C, shown in 
yellow) on the opposite strand. These two bases are held together by three hydrogen bonds. 
Below this base pair, a thymine base with a single ring (T, shown in red) is bound to an 
adenine base with two fused rings (A, shown in green) on the opposite strand. These two 
bases are held together by only two hydrogen bonds. Below this pair, a single-ringed cytosine 
base is bound to a double-ringed guanine base by three hydrogen bonds. In the final pair, an 
adenine base with two fused rings is bound to a single-ringed thymine by two hydrogen 
bonds. 
 
 
VFigure 1.4: Three different conformations of the DNA double helix8 
Although Watson & Crick’s original model depicting the structure of dsDNA has remained more or 
less unchanged for decades, over time scientists have elaborated on the original model. One important 
discovery worth mentioning is the identification of three different conformations of the DNA double 
helix. In simpler terms, the precise geometries and dimensions of the double helix of DNA can vary. 
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It should be noted here that most DNA double helices are right-handed. The simplest way to visualize 
this is to do as follows: hold your right hand out, with your thumb pointed up and your fingers curled 
around your thumb. For a right handed double helix, your thumb would represent the axis of the helix 
and your fingers would represent the sugar-phosphate backbone. Based on the directions of the helix, 
three different conformations of the DNA double helix exist: B-DNA, A-DNA and Z-DNA (Figure 
1.5). Only one type of DNA, the Z-DNA, is left-handed. The most common conformation in most 
living cells (which is the one depicted in most diagrams of the double helix, the one proposed by 
Watson and Crick and the one which will be referred to throughout this thesis) is known as B-DNA. 
There are also two other less common conformations: A-DNA – a shorter and wider form of DNA 
found in dehydrated samples of DNA. A-DNA is rarely found under normal physiological 
circumstances. The other is Z-DNA, a left-handed conformation. Z-DNA is a transient form of DNA. 
Z-DNA only occasionally exists in response to certain types of biological activity. Z-DNA was first 
discovered in 1979, but it was considered unimportant resulting it being largely ignored until recently. 
Since then, however, scientists have discovered that certain proteins bind very strongly to Z-DNA. It 
is therefore a possibility that Z-DNA has a key biological role in protection against viral disease.9 
 
Figure 1.5: Figure showing the difference in conformation of the deoxyribose sugar ring between A-DNA and 
B-DNA. 
The major difference between A-DNA and B-DNA10 is in the conformation of the deoxyribose sugar 
ring. It is in the C2’ endoconformation for B-DNA, whereas it is in the C3’ endoconformation in A-
DNA (Figure 1.5). For steric reasons, the 3’ and 2’ carbons present in the ribose ring will shift 
from the plane of the ring. As it can be seen, the C3’-endo A-form will hold the phosphate groups 
closer to the 3’ OH whereas the C2’-endo B-form holds it further. 
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1.3 Structural basis of dsDNA recognition 
Studying the three-dimensional structure of dsDNA (especially the B form) is critical to 
understanding dsDNA-protein interactions (which will be discussed extensively in the subsequent 
sections). Before this, however, an understanding on the available functional moieties within the 
major and minor grooves of dsDNA is necessary.  
 
VIFigure 1.6: Points of recognition in the major (M) and minor (m) grooves of dsDNA for each of the four base 
pairs. a, electron acceptor; d, electron donor; me, methyl group. Hydrogen bonding in base pairs is indicated by 
dashed lines. dR in circles denotes the deoxyribose-phosphate backbone of dsDNA. 
Sequence specificity in dsDNA can be achieved through a direct readout mechanism. This mainly 
involves various non-covalent interactions such as hydrogen bonding, electrostatic forces, salt bridges 
and van der Waals contacts (described in section 1.6) between the functional groups of the amino 
acids and/or back bone atoms of the protein and the functional groups available on the bases in the 
major and minor grooves of the DNA.11 If there is no disruption in the normal Watson–Crick 
hydrogen bonding, each of the four types of base pair (AT, TA, GC, CG) presents a distinct pattern of 
hydrogen donor, hydrogen acceptor and hydrophobic groups available for bonding (Figure 1.6). A 
protein can thus easily distinguish between the four possibilities (through interaction in the major 
groove) by using two hydrogen bonds. In the minor groove, it is possible to distinguish GC/CG from 
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AT/TA through the presence of a hydrogen donor from the 2 amino group of guanine. However, in 
order to reduce the degeneracy further, discrimination of GC from CG or AT from TA in the minor 
groove must involve highly sensitive means exploiting the subtle different steric positioning and 
spacing between atoms. Alternatively, the slight difference in hydrogen bond energies to the O2 of 
pyrimidines versus the N3 of purines can also be used to distinguish GC from CG or AT from TA. 
Such selectivity is possible and has been described in literature.12, 13 The sequence selectively of 
DNA-binding proteins which allows them to bind to sequences containing certain DNA base pairs 
over others arises as a result of their unique structural characteristics (described in section 1.5). In 
majority of the cases, study of different sites of a protein bound to DNA reveals a general basis for 
sequence selective recognition. 
 
1.4 Functions of DNA 
 
Our previous discussion allowed us to understand more about the structure of DNA. The more 
important question, however, is “what is the function of DNA”?14 Unfortunately, no one knows for 
sure the full range of functions DNA can perform. Research is a continuous process and in terms of 
decoding the full range of functions performed by DNA, we have barely scratched the surface. That 
being said, certain things are known for sure. There is absolutely no doubt that the functions of DNA 
are vital for inheritance, for the coding of proteins and that DNA is the very genetic blueprint of life 
itself. Given the enormous number of functions DNA performs in the human body and the fact that it 
is invaluable in terms of growth and maintenance of life, it is not surprising that the discovery of DNA 
has led to countless developments in treating disease. In short, DNA holds the instructions for an 
organism’s development, reproduction and ultimately, its survival. Some of the most essential known 
functions of DNA, namely the coding for proteins, replication and the role DNA plays in defining our 
genetic code have been discussed here in the simplest possible terms and some of them will be 
discussed in more depth and detail throughout the course of this thesis. 
 
 1.4.1 Coding for Proteins 
 
DNA holds the code for proteins, which are complex three dimensional molecules that are either 
involved in majority of the chemical reactions and/or which play critical roles and are vital for the 
structure, function and regulation of tissues in our body. Depending on the function they perform, 
proteins can be of the following types: antibodies, enzymes, messenger proteins. Special proteins may 
also provide structure and support for cells and transport cells or store small molecules throughout the 
body. Information in DNA is initially ‘read’ by certain proteins (called Transcription Factors, TFs) 
and it is then transcribed into messenger RNA (Ribonucleic acid). This process is known as 
transcription which is explained in more detail in section 1.5.2. Thereafter, the information held in this 
messenger molecule is translated (the process is known as translation) into a “language” that the body 
can understand. This language is nothing but that of amino acids, which are essentially the building 
blocks of proteins. There are twenty natural amino acids from which proteins are made. It is this 
specific language that dictates how the amino acids should produce a particular protein. Given that 
there are twenty different kinds of amino acids, it is but obvious that their ordering can produce a 
staggering number of varied proteins. 
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VIIFigure 1.7: The flow of information from DNA to protein. 
  
1.4.2 DNA Replication 
 
DNA replication is a vital and virtually endless process occurring with a phenomenal speed and 
accuracy in the human body. DNA replication is a must for survival given the wide range of functions 
it is needed for – ranging from reproduction to maintenance and growth of cells, tissues and all body 
systems. To replicate itself, a DNA molecule essentially ‘unwinds and unzips’ (Figure 1.7), thus 
resulting in a series of bases without pairs along the backbone of the molecule. As explained 
previously, DNA has four bases – all part of a nucleotide that also consists of a sugar and phosphate. 
The base pairing in DNA is extremely specific and only 2 pairs can be formed out of the 6 possible 
pairs. This means that adenine will only pair with thymine and guanine will only pair with cytosine. 
As the free nucleotides start to assemble and pair up with the unpaired bases on the backbone of the 
DNA molecule, they build a new strand. This strand can complement or match up with the original 
sequence. The end result is the formation of a new strand which is a perfect match to the original one 
before the whole replication process began. Cells in the body replicate for purposes such as making 
new skin or blood cells. When mistakes occur, there are repair systems in place to remedy the mistake 
or alternatively, a cell has a marker for destruction. If a cell survives a mutation, there may still be 
benefits to an organism. In fact, this concept is essentially the basis for evolution. 
 
 
VIIIFigure 1.8: A simple schematic showing the DNA replication process 
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 1.4.3 Genetic Code 
 
One of the more complex functions of DNA is genetic coding, in the sense that it transfers genetic 
messages to all of the cells in your body. The basic physical and functional unit of heredity is called a 
gene which is made up of DNA. Without delving into too much detail, think about DNA in a 
reproductive sense: Consider the joining of an egg and sperm to create your first cell. This first cell 
already contains your complete genetic code that your body would use your entire life. Within that 
initial cell, half of your chromosomes which contain your DNA came from your father and half came 
from your mother. 
 
To conclude, DNA clearly plays important roles in the human body and decoding the structure and 
function of DNA is one of the most significant discoveries of the twentieth century. Ongoing research 
into DNA and furthering our knowledge of DNA functions will definitely help us to learn even more 
about this all-important molecule. 
 
1.5 Importance of dsDNA recognition 
 
We have already discussed in detail the structure of dsDNA and established the importance of DNA 
in various functions in the human body. We have also briefly discussed the process of coding of 
proteins and DNA replication. In this section, we will take a closer look at why these processes are so 
important, what is cancer, what is transcription, the process of transcription and how Transcription 
Factors and cancer therapy relate to one another.  
 
 1.5.1 What is cancer? 
 
Cancer can be defined as the out-of-control proliferation of a particular cell type. In all cases, this 
proliferation originates with an unwanted mutation15. This is subsequently followed by a large 
accumulation of defects in different classes of genes. There are two well-known types of primary 
genes that govern cell division and are responsible for cancer: 
1. Protooncogenes (gain-of-function) are the first type of genes. These genes speed up the 
process of activation of the cell cycle. 
2. The second are tumour suppressor genes (loss-of-function). These do the opposite, i.e. they 
slow down the growth of cells. 
Till recently, there were 17 known signal transduction16 (the process of transmitting molecular signals 
from the exterior of a cell to its interior) pathways, in addition to at least two stress-response 
pathways. All of these appear to be highly conserved in nematodes (roundworms), flies and all 
vertebrates. Ultimately, TFs participate at the ends of all 19 pathways. They cause the up- or down-
regulation of specific genes. All primary and modifier genes which lead to cancer participate in one or 
another of these pathways. Countless exogenous and (autocrine and paracrine) endogenous signals 
bombard our cells each day. All these signals are channelled through these 19 pathways, leading to 
the cell’s response to these signals. In simplistic terms, tumour progression represents a loss of normal 
cross-talk between cells. This may also involve breakdown in communication between classes of 
genes, DNA methylation abnormalities, genetic instability, and hypermutability. Cancer is thus an 
extremely complex disease: a multitude of defects in hundreds if not thousands of genes, over an 
extended period of time, leading to an invasive and lethal disease17. 
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In the broadest of terms, two categories of cancer exist: 
1. The inherited form occurs when an individual is born with a mutation in one of his primary 
cancer genes.  
2. Oxidative DNA damage is the ultimate result of environmental agents. Additionally, 
endogenous compounds can also lead to reactive oxygenated metabolites and reactive oxygen 
species.  
Not all damage is repaired and therefore goes on to become fixed mutations, resulting in defective 
gene by-products. With each increasing year of life, therefore, these mutations become more and more 
likely to cause crucial defects in primary and modifier cancer genes. This in turn leads to tumour 
initiation and progression in one or another specific cell type. 
 
 1.5.2 The process of transcription 
 
The expression of genes is vital for functions of the body. The genes present in the nucleus of a cell 
need to be “read and decoded” for the biosynthesis of proteins or functional RNAs. This occurs 
through the processes of transcription (conversion of dsDNA into single stranded mRNA) and 
translation which is the subsequent production of proteins. RNA can be regarded as the chemical 
cousin of DNA. RNA is made up of A’s, U’s (no T’s are present in RNA), G’s and C’s. RNA can be 
regarded as the set of molecules primarily involved with most of the interpretation and 
communication with primary DNA. 
IXFigure 1.9: The DNA Transcription process in detail. 
 
Gene expression begins when a chemical signal is originated inside or is received from outside the 
cell. This signal triggers a cascade of intracellular signalling and events. “Initiation” is the first step of 
the “transcription” phase of gene expression. Transcription Factors (TFs) perform intracellular 
signalling via binding to and regulating an enzyme called DNA polymerase. DNA polymerase itself 
attaches to a specific promoter region of DNA. The promoter region of DNA will be entirely 
dependent on the transcription factor. Once attached “elongation” begins, the RNA polymerase 
complex acts like a zipper and moves along the DNA sequence step-by-step. This unwinds the DNA, 
making a copy of the template strand of DNA. The template strand is defined as the strand from 
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which RNA is transcribed. Free-roaming A’s, U’s, G’s and C’s bind to the template strand creating a 
temporary RNA-DNA hybrid region, which ultimately creates the messenger RNA (mRNA) in the 
process. As the DNA polymerase moves along the DNA strand, it unwinds the DNA from the front 
while simultaneously stitching up the DNA at the back. Until a specific terminating region is reached, 
this process will continue. Finally, the mRNA will detach itself from the DNA, completing the 
“termination” phase. 
 
 1.5.3 Transcription factors in cancer therapy 
 
In human cancer, three main groups of transcription factors are known to be important. The steroid 
receptors, for example, were among the first to be recognized. Oestrogen receptors in breast cancer 
and androgen receptors in prostate cancer are two examples involving steroid receptors. Compounds 
such as amoxifen and bicalutamide which are anti-oestrogen and anti-androgen respectively have 
been in clinical use for many years. The ability to induce apoptosis, at least in lymphoid cells, have 
also resulted in the wide use of active glucocorticoids.18, 19, 20 
 
The second group of transcription factors that were identified to have a role in cancer are resident 
nuclear proteins, which are activated by serine kinase cascades.21 In 1987, JUN was shown to be an 
oncogene. Initially, the v-JUN of a retrovirus, then the normal cellular form, c-JUN. Soon thereafter, 
JUN was found to be a transcription factor. This was initially based on its similarity in a DNA-
binding domain to the yeast transcription factor, GCN422 23 which was already identified at the time. 
(The GCN4 TF will be discussed in detail in the subsequent chapters). This was a highly significant 
discovery as it provided the first concrete example, besides steroid receptors, that directly linked 
cancer to transcriptional factors. Subsequent work showed that c-JUN was phosphorylated on two 
specific serines residues – serine 63 and 73. This was a result of the activation of signalling cascades, 
which made c-JUN very highly effective in stimulating transcription.22, 24 c-JUN is just one among the 
few hundreds of nuclear proteins that are targets of serine kinase cascades. The entire set of nuclear 
proteins are initiated in the cytoplasm. It is now known that there are more than 500 serine kinases.25 
(Figure 1.10) 
 
A third group of transcription factors which were only recently recognized to have oncogenic 
potential are latent cytoplasmic factors. The activation of these TFs is normally triggered by receptor–
ligand interaction at the cell surface21. Direct activation of the latent cytoplasmic proteins can be 
achieved through tyrosine or serine kinases at the cell surface. Alternatively, they can also be 
activated by various different cytoplasmic biochemical events. These events may feature kinases 
(some regulated by Ca2+ flux) or specifically regulated proteolysis. Despite the pathways appearing 
different, they all have one thing in common which is a protein−protein interaction at the cell surface. 
This protein-protein interaction triggers cytoplasmic reactions, which result in delivery to the nucleus 
of a protein. The delivery of the protein in turn increases transcription via interaction with one or 
more of the many proteins affecting the initiation of transcription (Figure 1.10). 
 
There is a high possibility that an oversupply or over-activity of one or more transcription factors 
from the above mentioned three classes will be required for the survival, unrestricted growth and 
metastatic behaviour of all human cancers.22, 21, 26 Effective anticancer therapy can therefore be 
developed via a direct and promising route by the inhibition of excess transcription-factor activity. 
The therapeutics which have been developed to inhibit the steroid receptors form one such example.19, 
20 However, there is still a big knowledge deficit with regards to the other transcription-factor classes. 
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Further research into the prominent features of their activation and function, with special focus on 
their interactions with other nuclear proteins, should reveal a wider range of therapeutic targets. 
XFigure 1.10: The figure shows the generalized signalling pathways summarizing key reactions in humans. 
Information for a few thousand cell-surface protein receptors and in general small, secreted proteins which are 
ligands for these receptors are contained in the human genome. The biochemistry of intracellular signalling has 
been very widely studied. Latent transcription factors (Figure 1.9, top) might be activated at the cell membrane 
by either tyrosine (STATs) or serine (SMADs) phosphorylation. The latent TFs then bind to the transport 
proteins called importins which convert them into an active TF. This active TF then enters the nucleus to 
participate in regulated gene transcription. Phosphorylation is one of the other, less direct pathways of activation 
for latent cytoplasmic factors. These events may be stimulated or inhibited and most often block or trigger 
proteases. The final result is importin-mediated delivery of an ‘active transcription factor’ (orange) to the 
nucleus. In a different set of pathways, the kinase enters the nucleus (Figure 1.9, right) and causes an activation 
of resident nuclear-transcription factors. The active transcription factors (in combination with DNA) can bind 
other transcription factors forming what can be called an “enhanceosome”. This can attract co-activators which 
may include several dozen possible proteins. This ultimately leads to the final step of attracting the actual RNA 
synthesis machinery which comprises RNA polymerase II (Pol II) and general transcription factors (GTFs).  
 
To summarize, it is clear that several complex mechanisms involving various TFs are involved in the 
onset of cancer. Therefore, despite years of research, there is still a lack of clear understanding and 
knowledge about the disease itself. This lack of knowledge has significantly hampered the 
development of gene therapy strategies in the past. Therefore, the study of TFs has gained a lot of 
traction in recent years, especially where other therapeutic strategies fail. The prevention of specific 
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genes from being transcribed could ultimately result in a therapeutic platform with diverse biomedical 
applications.27 The past few years have been no doubt fruitful with medicinal chemists & biologists 
making considerable progress targeting specific genes. In nature, certain proteins interact with DNA 
in a sequence-specific manner by means of their recognition domains, which consists of a short 
sequence of amino acids. Simplification of known TFs could ultimately lead to a peptide-based drug 
in cancer treatment. Moreover, due to the improvements in peptide manufacturing, peptide drugs can 
be produced on a large scale through synthetic methods and techniques. Therefore, the continuing 
study of Transcription Factors (TFs) in even greater detail for the modification of gene expression can 
be of considerable importance for the development of new anti-cancer therapies.  
1.6 Interactions between DNA and proteins: A key factor regulating transcription 
Section 1.2 described in detail the structure of dsDNA. In order to better understand the interactions 
between DNA and proteins, a closer look at the structural features of proteins along with their 
increasing levels of complexity is necessary.  
 
1. Primary structure: The exact sequence of amino acids which constitute a protein and the 
type of covalent bonds (amide, ester, disulphide etc.) between various amino acids. 
 
2. Secondary structure: The parts within a protein which are folded or coiled. Examples 
include α-helices and β-sheets. Most secondary structures are stabilized via hydrogen bonding 
or Van der Waals forces. 
 
3. Tertiary structure: The final three-dimensional structure of a protein, formed as a result of a 
large number of non-covalent interactions between its constituent amino acids. 
 
4. Quaternary structure: Large number of non-covalent interactions that bind multiple proteins 
or peptides into a single, larger protein. Example: Haemoglobin has quaternary structure due 
to association of two alpha globin and two beta globin polyproteins. 
 
It has been established that certain Transcription Factors can specifically recognize and bind to short 
regulatory DNA sequences which control the gene. These interactions between DNA and proteins are 
extremely specific and of a very high affinity. Studying these interactions holds the key for synthesis 
of mimics of transcription factors which could be eventually used for cancer therapy. 
 
The interactions between DNA and proteins is extremely complex. The lack of a general recognition 
code for the interaction between amino acid sequences within a protein and its corresponding specific 
DNA-binding site has been a major challenge in the study of the structure of TFs since this makes the 
prediction of its binding site virtually impossible. Although a general formulation of these interactions 
has not been achieved, some general rules can be followed, providing a starting point for the 
molecular basis of specific DNA recognition. 
 
Due to the fact that secondary structures in case of proteins are extremely well defined, very specific 
interactions take place between TFs and dsDNA. In case of TFs, all these interactions occur in the 
major groove of the DNA, which is wide enough to accommodate the α-helix recognition unit.  A 
detailed explanation of the four major forces between proteins and nucleic acids can be summarized 
as follows: 
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1. Electrostatic forces in the form of salt bridges: Long range, electrostatic interactions between 
groups of opposite charges are quite dominant due to the negatively charged DNA as a result 
of the phosphodiester backbone and the positively charged basic side chains of the amino 
acids of the protein, such as Lys, Arg and His. Electrostatic forces are unspecific and 
therefore only affect the free energy of association and not the specificity. 
2. Dipolar forces in the form of hydrogen bonds: Short range interactions that contribute to a 
high degree to the specificity of the interactions that occur between DNA and proteins also 
occur in a substantial number. These interactions mainly occur between the polar side chains 
in the proteins and the sugars and bases in the DNA. Higher degrees of specificity can be 
achieved by bidentate hydrogen bonds between a base or base pair in the DNA with a single 
side chain present in the protein.  
3. Van der Waals forces due to a hydrophobic effect: These are short range, non-directional 
forces which contribute to the free energy of association. Non-polar contacts also occur 
between the apolar amino acid side chains and the DNA base pairs. 
4. Water-mediated hydrogen bonds: Water molecules are essential for indirect hydrogen 
bonding between the DNA and proteins. They also behave as space fillers in the DNA-protein 
complexes. Hydrogen bond donors and acceptors present especially at the edge of a DNA-
protein complex are more influenced by water. 
 
From strongest to weakest, the order of forces in an aqueous medium between DNA and proteins are 
generally: electrostatic forces > Water-mediated hydrogen bonds > Dipolar forces > Vander Waals 
forces. Electrostatic forces dominate due to the high number of negative charges present in DNA 
being strongly attracted to the positively charged proteins. Although an individual Hydrogen bond is 
not the strongest, the cumulative effect of a large number of hydrogen bonds makes this is dominating 
force in case of DNA-protein interactions. Dipolar forces are weaker than electrostatic forces and 
hydrogen bonds, but still stronger than Van der Waals forces. 
 
1.7 Families of transcription factors: dsDNA recognition in the major groove 
 
At present, there is great interest in the area involving human transcriptional regulation. However, 
very little is known about Transcription factors which regulate human transcription. Several questions 
come to mind. For example, how many TFs are present in the human genome? How are they 
expressed in various tissues? A list of 1,391 sequence-specific dsDNA-binding transcription factors, 
their functions, genomic organization and evolutionary conservation have been described in an 
excellent review article28. Despite this, a great deal remains unexplored. The study of TFs in detail is 
beyond the scope of this thesis; however, a short summary of the relevant families of TFs for this 
thesis is provided in this section29. 
 
The protein structure of TFs has been divided into two broad domains for the purpose of easy 
understanding: 
1. The DNA binding domain: This part of the protein is responsible for the selective interaction 
with the DNA control sequence for transcription.  
2. The DNA activation domain: This part is responsible for the interaction with other TFs or 
with the RNA polymerase II.  
 
There are several DNA binding domains found in TFs in eukaryotic cells: Helix-turn-helix, zinc 
finger and the basic domain. 
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1.7.1 The Helix-turn-helix (HTH) motif 
 
The helix-turn-helix was the first DNA-binding protein motif to be discovered. It was first identified 
in bacterial proteins, but now this motif is known to be found in hundreds of DNA-binding proteins in 
both eukaryotes and prokaryotes. It has a very simple secondary structure consisting of two α helices 
connected together by a short slightly elongated chain of amino acids which constitute the “turn”. 
(Figure 1.11). The angle between the two helices does not change, mainly due to interactions between 
the two helices. The helix which is more towards the C terminus is called the recognition helix. It gets 
its name from the fact that it can fit perfectly into the major groove of DNA. The amino acid side 
chains of the recognition helix differ from protein to protein, which enables it to recognize the specific 
DNA sequence to which the protein is required to bind. 
 
XIFigure 1.11: The helix-turn-helix motif is shown in (A). Each white circle denotes the α-carbon atom of 
an amino acid. The C-terminal α helix, i.e. the recognition region, is shown (red). Part (B) of the figure shows 
how this helix fits into the major groove of DNA, where it is in contact with the edges of the base pairs. It is 
clear from the figure that the N-terminal α-helix (blue) is present primarily to provide a structural component 
which helps to position the recognition helix. 
 
 1.7.2 Zinc-finger motifs 
 
The Zinc-finger motifs are a second important group of DNA-binding motifs. They are known as 
Zinc-finger motifs because their structure contains one or more zinc ions. There are several types of 
zinc finger motifs, only one of which will be discussed here. Although we refer to all zinc-coordinated 
DNA-binding motifs as zinc fingers, this name refers only to the way they appear in schematic 
drawings ever since they were discovered (Figure 1.12). Structural studies over the years have shown 
that they can be divided into a number of distinct structural groups. Only the first one discovered is 
described here. The protein shown in Figure 1.12 belongs to the Cys-Cys-His-His family of Zinc 
finger proteins. It is known to activate the transcription of a eukaryotic ribosomal RNA gene. The 
structure is simple, consisting of two parts – an α helix and a β sheet which are held together by a zinc 
ion (Figure 1.12B). This type of zinc finger is often found in combination with additional zinc fingers 
which are arranged in succession so that the α helix of each monomeric unit can interact with the 
major groove of the DNA. The result is a near continuous stretch of α helices along the major groove 
of the DNA. Interaction at multiple points ensures that the DNA and protein bind very tightly to each 
other via a repeating basic structural unit (Fig 1.12A). During evolution, the number of zinc finger 
repeats can be adjusted thereby tuning the strength and specificity of the DNA-protein interaction. No 
other TF discussed here has this unique ability to form repeating chains. 
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XIIFigure 1.12: A schematic of the Cys-Cys-His-His family of zinc finger proteins. (A) Schematic drawing of a 
zinc finger showing the amino acid sequence from a frog protein belonging to this class. (B) Schematic showing 
the three-dimensional structure of this type of zinc finger comprising an antiparallel β sheet followed by an α 
helix. Amino acids 1 to 10 make up the β sheet and amino acids 12 to 24 make up the α helix. The four amino 
acids that bind to the zinc atom (Cys 3, Cys 6, His 19, and His 23) hold one end of the α helix tightly connecting 
it to one end of the β sheet.30 
 
 1.7.3 The Leucine Zipper motif 
 
The leucine zipper motif is unique in the sense that, unlike other DNA binding motifs described 
previously, it binds to DNA via a dimer instead of a monomer. Usually, the portion of 
the protein responsible for the dimeric structure is distinct from the portion that is responsible for 
DNA recognition and binding. This motif, however, combines these two functions in a simple way. 
The leucine zipper motif, gets its name because of the way the two α helices provided by each 
monomer are joined together to form a short coiled-coil. The helices are held together due to strong 
hydrophobic interactions between the amino acid side chains particularly of leucines extending from 
one side of either helix. Almost immediately beyond the dimerization interface, the two α helices 
diverge, forming a Y-shaped structure thus allowing their side chains to interact with the major 
groove of DNA. The dimer grips the DNA double helix like a pair of tweezers (Figure 1.13).  
 
 
                                                          
XII Reproduced from DNA-Binding Motifs in Gene Regulatory Proteins Cover of Molecular Biology of the Cell. 4th edition. 
Alberts B, Johnson A, Lewis J, et al. New York: Garland Science; 2002. 
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XIIIFigure 1.13: A leucine zipper dimer bound to DNA. It is clear from the figure that the bottom part of the two 
α-helical monomers are involved in DNA-binding whereas the top, α-helical, leucine zipper region allows for 
dimerization.  Each of the two α helices binds to one-half of a symmetric DNA sequence. The structure shown is 
of the yeast GCN4 protein studied extensively in the subsequent chapters. The GCN4 TF regulates transcription 
in response to the availability of amino acids in the environment.31 
 
 1.7.4 Helix-loop-helix motif 
 
The final important DNA-binding motif discussed here and related to the leucine zipper motif, is 
the helix-loop-helix (HLH) motif. It is to be noted that HLH should not be confused with the HTH 
discussed in section 1.7.1. An HLH motif consists of a short α helix connected to a second, longer α 
helix by a loop. The loop provides flexibility allowing one helix to fold back and squeeze against the 
other. As shown in Figure 1.14, this two-helix structure binds to DNA while at the same time binding 
to the HLH motif of a second HLH protein. Similar to the case of leucine zipper proteins, the second 
HLH protein can be the same resulting in a homodimer or different resulting in a heterodimer. In 
either case, the two α helices extending from the dimerization interface specifically interact with the 
DNA. 
                                                          
XIII Reproduced from DNA-Binding Motifs in Gene Regulatory Proteins Cover of Molecular Biology of the Cell. 4th edition. 
Alberts B, Johnson A, Lewis J, et al. New York: Garland Science; 2002. 
Chapter 1: An introduction to DNA 
21 
 
XIVFigure 1.14: Schematic showing a helix-loop-helix dimer bound to DNA. The two monomeric units are held 
together in a four-helix bundle. Two α helices arise from each unit and are connected by a flexible loop 
of protein (red). The HLH is capable of recognizing a specific DNA sequence due to the two α helices that 
protrude out from the four-helix bundle.32 
 
1.7 Recognition of dsDNA in the minor groove – the polyamides 
 
In the previous sections, we have extensively studied the structure of natural dsDNA, the four 
Watson-Crick base pairs, the importance of DNA and how the information stored in DNA is 
manipulated in nature through major groove recognition via transcription factors. We now look upon 
briefly at an entirely different class of molecules, namely the minor groove binders or the polyamides 
capable of decoding the information stored in dsDNA. Minor groove recognition is also found in 
nature, although quite rarely. Two noteworthy examples are the natural products Distamycin A 
composed of three aromatic N-methylpyrrole rings (Figure 1.15A), capable of recognition of the A.T 
region in double stranded DNA. Distamycin, along with its close relative netropsin (Figure 1.15B), 
possess anti-viral, anti-tumor, and anti-bacterial properties. Unfortunately, these two molecules 
proved too toxic for clinical use. They have, however, been studied extensively to understand their 
base-specific minor-groove DNA-binding. 
  
                                                          
XIV Adapted from DNA-Binding Motifs in Gene Regulatory Proteins Cover of Molecular Biology of the Cell. 4th edition. 
Alberts B, Johnson A, Lewis J, et al. New York: Garland Science; 2002. 
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Figure 1.15: Structure of naturally occurring DNA minor groove binders A. Distamycin A and B. Netropsin 
 
Both Distamycin and Netropsin have been shown to bind in the minor groove of A.T rich sequences 
of DNA in 1:133 and 2:1 complexes34 (Figure 1.16). The charge distribution along DNA is sequence 
dependant. Uninterrupted A.T base pairs provide the greatest negative potential, whereas successive 
G.C base pairs give the most positive potential.35 The differences in the potential in either groove 
between AT- and GC-rich sequences are due to the specific arrangement of polar groups at the base 
edges. The difference in potential can contribute significantly to sequence specific DNA recognition.36 
The majority of minor groove DNA binders carry positive charges, which helps explain their 
increased affinity for A.T rich sequences. Due to the backbone hydrogen atoms, the minor groove 
wall is also more hydrophobic than the major groove. This also contributes to the sequence selectivity 
of these binders to the minor groove. Further studies have shown that van der Waals forces are more 
dominant than initially anticipated.37 
 
Figure 1.16: (A) Distamycin complexed with 5’-GGCCAATTGG-3’ duplex DNA in a 1:1 binding mode. 
PBID: 1K2Z; DOI: 10.2210/pdb1k2z/pdb. (B) Distamycin complexed with 5’-GTATATAC-3’ duplex DNA in 
a 2:1 binding mode. PBID: 378D; DOI: 10.2210/pdb378d/pdb. Images modified using Discovery Studio 4.5. 
A B
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Many studies involving the NMR and crystal structures of DNA-protein complexes involve the major 
groove of B-type DNA. The wide, deep surface is rich with hydrogen bonding potential and, 
therefore, optimum for interactions.35 In contrast to this, it is now widely accepted that minor-groove 
interactions generally result in a serious deformation of the DNA. It can be noticed from figure 1.16 
that the binding of two Distamycin units has caused the widening of the minor groove and has 
subsequently distorted the DNA structure. In terms of TF binding, if a polyamide binds to the minor 
groove adjacent to the major groove to which the TF binds, there will be a detrimental effect on the 
binding affinity of the TF. This is, in fact, the keystone for cancer therapy using minor groove 
binders27.  
 
Inspired by the structure of Distamycin and Netropsin, a series of “synthetic ligands” were developed 
by Prof. Peter B. Dervan and, therefore, are also known as the Dervan peptides38. Chemically, they are 
N-methylimidazole (Im) and N-methylpyrrole (Py) rings connected with each other via amide bonds. 
Depending on the sequence of side-by-side pairings, they are capable of differentiating between the 
A.T, G.C and C.G base pairs present in dsDNA. A pairing between Im opposite Py targets a G.C base 
pair, whereas a Py opposite Im targets a C.G base pair. A Py-Py combination targets both T.A and 
A.T base pairs39 40 41 (Figure 1.17). 
 
 
XVFigure 1.17: A schematic representation of the polyamide base pairing rules in their simplest form 
 
The specificity of the Py/Im units in case of the G, C base pairs arises from the formation of a 
hydrogen bond between the imidazole N3 and the exocyclic amino group of guanine39, 40, 41. The 
generality of the pairing rules has been extensively proven over the years by targeting a wide variety 
of DNA sequences and through several NMR structure studies42.  
 
 
  
                                                          
XV Reproduced from Preparation and use of bifunctional molecules having DNA sequence binding specificity. 
http://www.google.com/patents/US6555692 
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1.8 Blocking transcription factors using polyamides: an example 
 
The introduction of hairpin polyamides capable of recognizing the C.G, A.T & T.A and G.C Watson-
Crick base pairs (Figure 1.17) has allowed for the development of new molecular tools and reagents to 
block transcription factors which is an important strategy for cancer therapy. Figure 1.18 illustrates 
how the polyamides work through a typical example: 
(a) An example of the blocking of GCN4 binding using a polyamide is shown in Figure 1.18a.  
As the α-helical GCN4 dimer (green-yellow) attempts binding to the adjacent major grooves, 
there is a steric hindrance between the tripeptide tail (shown in green) and the GCN4 TF 
preventing simultaneous binding. The point of steric crowding is shown by a black arrow.  
(b) The hydrogen-bonding model of the eight-ring hairpin (hairpin denotes the turn) polyamide 
ImPyPyPy-γ-PyPyPyPy-β-RPR bound to the minor groove of 5’-TGTTAT-3’. γ represents 
the hairpin and β is short for β – alanine. The RPR tripeptide shown in green is attached to the 
C-terminus of the polyamide. 
(c) The GCN4 binding site is shown in square brackets. The polyamide binding site is adjacent to 
the GCN4 binding site. The RPR tripeptide protruding into the adjoining major grove allows 
for blocking of the GCN4 transcription factor. 
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XVIFigure 1.18: Mechanism of action of a hairpin polyamide through a typical example. 
 
1.10 Conclusion: DNA – the past, present & future 
  
To conclude this chapter, it is obvious that the discovery of the dsDNA structure, as well as 
understanding the functions and recognition of dsDNA has played a pivotal role in cancer therapy. 
Continuing research into TFs and cancer therapy will eventually lead to new breakthroughs, as they 
have in the past. In the next three chapters of this Ph.D. thesis, we will apply the concepts discussed in 
this chapter for the synthesis of artificial mimics of TFs in an attempt to develop our own set of 
molecules capable of recognizing dsDNA. 
 
  
                                                          
XVI Reproduced from Hurley, L. H. DNA and its associated processes as Targets for Cancer Therapy. Nat. Rev. 
Cancer 2, 188–200 (2002) 
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CHAPTER 2 
 
TOWARDS SEQUENCE SELECTIVE CROSS-LINKING TO dsDNA 
USING FURAN CONTAINING POLYAMIDES  
 
In chapter 1, we have extensively discussed the major groove dsDNA binders (Transcription factors) 
and also briefly discussed the minor groove dsDNA binders (polyamides). In subsequent chapters, we 
will discuss more about the mimics of transcription factors developed in the OBCR group at UGent 
under the guidance of Prof. Dr. Annemieke Madder. In this chapter, we will discuss our initial efforts 
to develop the polyamides into probes for sequence selective cross-linking to dsDNA. The lab in 
UGent has considerable expertise in cross-linking via furan chemistry1 using combinations involving 
DNA2, 3, peptides4, 5, RNA6 and PNA7. On the other hand, the research group at Lincoln University 
under Dr. Ishwar Singh has developed extensive expertise in the design and development of 
polyamide-based minor groove binders8, 9. A collaborative effort as a part of this joint PhD, is to 
create a series of minor groove binding DNA modifiers through design and synthesis of minor groove 
recognizing polyamides equipped with suitable furan moieties for DNA crosslinking. 
 
2.1 Introduction 
Chapter 1 covered the interaction of proteins and DNA which has always been of great interest for a 
number of reasons. These interactions hold the key for decoding the mechanisms of essential 
functions such as DNA replication, transcription, and degradation. Developing drugs that can block 
processes like transcription are highly challenging due to very high selectivity and affinity that DNA 
binding proteins have for their target, even in a complex cellular environment.10 In order to decode a 
protein-DNA interface, a common approach has been to covalently link proteins and DNA using 
cross-linking moieties, resulting in a covalently linked complex allowing analysis via crystal 
structures. For this purpose, several photoactivatable functionalities11, 12, 13, 14 such as phenylazides, 
diazirines, and benzophenones have been used to form DNA−protein cross-links (DPCs). 
Unfortunately, there are several limitations to these systems. First, there is a major lack of selectivity, 
as the generated reactive species such as nitrenes in case of phenylazides, carbenes in case of 
diazirines and a bi-radical in case of benzophenone can target any amino acid. This makes the 
identification of the amino acid residues responsible for selective recognition at the DNA−protein 
binding interface almost impossible. Secondly, due to the occurrence of high-energy intermediates, 
the resulting final structure of the cross-linked molecule can be quite different from the actual 
structure, in the absence of the cross-link5. Thirdly, obtained DPC yields are, in general, rather low 
(10−20%)15. Finally, these approaches render the selective targeting of natural dsDNA virtually 
impossible, as they require the modification of one or more of the nucleotide base/bases. An excellent 
review has been published by Madder et. al. explaining in detail the methodology and applications of 
furan based cross-linking1. In this section, we will briefly discuss some of the aspects of the furan 
based chemistry developed at UGent relevant to this thesis. 
 
2.2 An overview of the furan cross-linking technique developed in the OBCR group 
 
Furan is a small heterocycle, normally stable under standard atmospheric conditions. However, if 
ingested, furan is known to undergo metabolic oxidation into butenedial by the enzyme cytochrome 
P450.16 Butenedial is highly reactive towards nucleophiles such as amines, which are present in the 
DNA bases cytosine, adenine and guanine and also in amino acid side chains of lysine (amine) and 
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thiols present in proteins containing cysteines making it toxic for living tissue. Although, in general, a 
reaction is possible with A, C and G, we only observe this with A & C due to specific positioning of 
the furan moiety in the major groove. The relative inertness of furan before oxidation and its high 
reactivity after oxidation was one of the reasons the OBCR group at UGent under the guidance of 
Prof. Annemieke Madder ventured into the world of furan chemistry. 
It all began more than ten years ago, when an article was published by the Madder group which 
describes the first efforts towards the development of a furan cross-linking strategy17. The article was 
focused mainly on DNA interstrand cross-linking. The strategy described in the article is to “first 
synthesize a furan containing oligonucleotide strand followed by selective in situ oxidation of the 
furan moiety to a reactive enal species in the presence of a complementary DNA strand which gives 
rise to a fast and efficient interstrand cross-link” (Figure 2.1). 
 
 
Figure 2.1: Schematic representation of the proposed cross-linking strategy as described in ref. 17  
Over the years, the furan cross-linking methodology has been developed considerably owing to the 
synthesis of various furan containing building blocks18, 19, 20, 21 and via the improvement of techniques 
for selective furan oxidation3. Synthetically, oxidation of furan incorporated in DNA19 and RNA6 
using NBS followed by cross-linking (Figure 2.2) has been the most widely used. Bromination of the 
furan ring can be an unwanted side-product, particularly when furan is conjugated to an aromatic 
system (Figure 2.3). The synthesis and incorporation of furan modified building blocks into DNA 
sequences are less relevant for this thesis and therefore will not be discussed. However, the 
mechanisms of furan oxidation established through this work are quite interesting and relevant and 
will be discussed as part of this chapter. 
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Figure 2.2: Mechanism of furan oxidation using N-Bromosuccinimide (NBS) resulting in the reactive aldehyde 
which undergoes cross-linking in the presence of proximal nucleophiles such as A. the amines of DNA bases 
dC, dA or dG and B. with a lysine side-chain. Adapted from ref. 1 
 
 
Figure 2.3: Formation of a brominated side reaction occurring in case of a substitution at the C2 position of 
furan. Adapted from ref. 1 
Recent developments with more biocompatible singlet oxygen strategy (Figure 2.4) through the use of 
photosensitizers such as methylene blue and Rose bengal and visible light3 allows for an even wider 
application of furan based cross-linking. Using 1O2 with organic solvents without a subsequent 
reduction step results in products containing an extra oxygen as shown in figure 2.4 (A) a-c 22. In 
aqueous solution, however, furan oxidation using 1O2 yields 4-oxo-enal (d) type products (as in the 
case of NBS/H2O described previously). 
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Figure 2.4: Overview of possible products resulting from singlet oxygen oxidation in (A) MeOH and (B) H2O. 
Adapted from ref. 3 
It is well established that furan incorporation and subsequent oxidation in peptides is straightforward, 
as the furan ring is stable under the conditions for peptide synthesis. Moreover, various furan 
derivatives are commercially available or can be synthesized in a straightforward manner (Figure 2.5), 
allowing for the synthesis of different furan-containing polyamides. Considerable work has been done 
at UGent involving furan and nucleic acids and it has been proven that selective activation by 
oxidation to generate a reactive aldehyde is possible and can be carried out after duplex formation. 
This allows for minimization of formation of by products and enables site-selective cross-link 
formation2, 3, 17, 23,. High yields and selectivity thus make the furan-oxidation methodology a general 
procedure to achieve DNA inter-strand cross-linking24. Further application of the furan-oxidation 
methodology has been demonstrated by Summerer, et. al. wherein genetically modified proteins 
containing a furan-amino acid have been cross-linked to RNA25. In this chapter, we attempt to expand 
the scope of the furan-oxidation cross-linking methodology even further to target natural, dsDNA in 
order to achieve a much broader application of furan-based probes. Unfortunately, furan cross-linking 
from any given molecule to dsDNA does not normally occur1, as the nucleophiles present in dsDNA 
essential for a cross-link are involved in stable Watson-Crick base pairing which is inherent in the 
structure of natural dsDNA. 
 
 
Figure 2.5: Furan building blocks for incorporation into peptides: I. 3-(furan-2-yl)propanoic acid. II. Fmoc-L-2-
furylalanine. 
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2.3 Local disruption of dsDNA base-pairing 
 
In earlier work at OBCR it was attempted to use furan-modified triplex-forming oligonucleotides 
(TFOs) to achieve cross-linking to dsDNA26. It was however shown in that study that the Watson-
Crick base pairing within dsDNA, as opposed to ssDNA, significantly reduces the nucleophilic 
capacity of the exocyclic amine on the nucleobases to attack the aldehyde functionality generated 
upon furan oxidation. Therefore, in order to achieve a cross-link between polyamides and dsDNA, a 
local disruption between the base pairs must be externally introduced at the point of the cross-link. 
For this purpose, bulky amino acids such as racemic 2-([1,1'-biphenyl]-4-yl)-2-aminoacetic acid or L-
-α-cyclohexylglycine (Figure 2.6) can be used.27 These amino acids are known to locally disrupt the 
DNA duplex, which should allow for a cross-link to be formed between an oxidized furan moiety and 
an unpaired base. 
 
 
 
Figure 2.6: Amino acid building blocks for incorporation into polyamides: I. racemic 2-([1,1'-biphenyl]-4-
yl)-2-aminoacetic acid. II. L-α-Cyclohexylglycine. 
2.4 Using furan containing polyamides for cross-linking to dsDNA 
 
As discussed in section 1.7, hairpin polyamides (or Dervan peptides) can distinguish all four base 
pairs combinations (GC, CG, AT and TA) in the minor groove of DNA.28 Moreover, they bind only to 
dsDNA with very high affinities (their Kd is in the low nM range, even at room temperature)29 and 
specificities30 and can be designed to read DNA sequences up to 16 base pairs in length31. The 
protocols for the synthesis of hairpin polyamides have been greatly optimized over the years, making 
them synthetically accessible via standard solid phase synthesis.9, 32 Mimics of transcriptions factors 
possessing these qualities, on the other hand, are complex and synthetically challenging.33, 34 There 
are examples where polyamides have successfully been used to cross-link to dsDNA35 and in 
continuation of our efforts towards simplified transcription factor models with high affinity for 
dsDNA we decided to combine the expertise areas of UGent and Lincoln in the development of furan 
modified polyamides as potential alternative cross-linking minor groove binders. 
 
2.5 Design and synthesis of polyamides 
A challenge to be overcome, if cross-linking to DNA using Dervan peptides is to be made feasible, 
was the incorporation followed by selective oxidation of the furan ring in presence of the Py/Im rings. 
The initial part of this project was to obtain conditions under which furan could be selectively 
oxidised in the presence of the aromatic Py/Im rings. Selective oxidation of furan in case of peptides 
containing aromatic Trp and Tyr residues has been achieved in the lab in UGent (unpublished results). 
Chapter 2: Cross-linking to dsDNA 
34 
However, oxidation of furan in case of polyamides proved to be tricky (Table 2.1). The following 
polyamides were synthesised initially for testing furan oxidation: 
  
Figure 2.8: Polyamide I was designed as a control. Polyamide II was the furan containing polyamide. 
 
For initial testing, only Py containing polyamides were chosen. Polyamide I was chosen as the control 
and does not contain any furan moiety. This allowed us to check for degradation of the Py rings when 
tested against the oxidation conditions described in Table 2.1. Polyamide II contains an N-terminal 
furan. An N-terminal furan was specifically chosen as it was less sterically hindered and, therefore, 
was expected to be more susceptible to oxidation. 
 
2.6 Summary of results 
Sr. 
No. 
Reagent Eq. Time Results (analysis using MALDI-MS) 
1. mCPBA 5 2h No oxidation/degradation of 
polyamides 
2. mCPBA 50 6h Trace oxidation of polyamide II 
3. NBS 2 1h Oxidation/minor degradation of both 
polyamides 
4. Rose Bengal + 1O2 (generated using 
white light) 
0.02 30s >80% degradation of both 
polyamides 
5. Rose Bengal + 1O2 (generated using 
blue light) 
0.02 30s >80% degradation of both 
polyamides 
Table 2.1: Summary of the best results obtained using different oxidizing agents, equivalents and times for 
furan oxidation on polyamide I & II (Figure 4.4) 
2.7 Conclusion 
 
Based on the experiments conducted thus far (refer experimental section for details) it can be 
concluded that use of 1O2 resulted mainly in degradation of the polyamide. mCPBA on the other hand 
is too mild resulting in poor yields of the desired oxidized product. NBS gave the best results, 
however, optimization of the experimental conditions is required. At this stage of the project, in order 
to avoid orthogonality problems such as the sensitivity of the polyamide to oxidation/degradation 
while trying to selectively oxidize the furan, we decided to focus on an alternative non-polyamide 
based major groove binding peptide approach which we will discuss in chapters 3 & 4. Nonetheless, 
conditions suitable for the oxidation of peptides containing sensitive residues such as Tyr, Trp, His 
and Met are currently being developed at UGent on a related project. These conditions could be 
modified and used for selective furan oxidation in polyamides. 
 
Chapter 2: Cross-linking to dsDNA 
35 
2.8 References: 
 
1. Carrette, L. L. G., Gyssels, E., De Laet, N. & Madder, A. Furan oxidation based cross-linking: 
a new approach for the study and targeting of nucleic acid and protein interactions. Chem. 
Commun. 52, 1539–1554 (2015). 
2. De Beeck, M. O. & Madder, A. Unprecedented C-selective interstrand cross-linking through in 
situ oxidation of furan-modified oligodeoxynucleotides. J. Am. Chem. Soc. 133, 796–807 
(2011). 
3. Beeck, M. Op De & Madder, A. Sequence Specific DNA Cross-Linking Triggered by Visible 
Light. J. Am. Chem. Soc. 134, 10737–10740 (2012). 
4. Hoogewijs, K., Buyst, D., Winne, J. M., Martins, J. C. & Madder, A. Exploiting furan’s 
versatile reactivity in reversible and irreversible orthogonal peptide labeling. Chem. Commun. 
49, 2927–9 (2013). 
5. Carrette, L. L. G., Morii, T. & Madder, A. Toxicity Inspired Cross-Linking for Probing DNA-
Peptide Interactions. Bioconjug. Chem. 24, 2008–14 (2013). 
6. Carrette, L. L. G., Gyssels, E., Loncke, J. & Madder,  a. A mildly inducible and selective 
cross-link methodology for RNA duplexes. Org. Biomol. Chem. 12, 931–5 (2014). 
7. Manicardi, A., Gyssels, E., Corradini, R. & Madder, A. Furan-PNA: a mildly inducible 
irreversible interstrand cross-linking system targeting single and double stranded DNA. J. Am. 
Chem. Soc. 52, 6930–6933 (2016). 
8. Singh, I. et al. Sequence-selective detection of double-stranded DNA sequences using pyrrole-
imidazole polyamide microarrays. Journal of the American Chemical Society (2013). 
9. Fallows, A. J., Singh, I., Dondi, R., Cullis, P. M. & Burley, G. A. Highly Efficient Synthesis of 
DNA-Binding Polyamides Using a Convergent Fragment-Based Approach. Org. Lett. 16, 
4654–4657 (2014). 
10. Verzele, D., Carrette, L. L. G. & Madder, A. Peptide scalpels for site-specific dissection of the 
DNA-protein interface. Drug Discov. Today Technol. 7, e115–e123 (2010). 
11. Tate, J. J., Persinger, J. & Bartholomew, B. Survey of four different photoreactive moieties for 
DNA photoaffinity labeling of yeast RNA polymerase III transcription complexes. Nucleic 
Acids Res. 26, 1421–1426 (1998). 
12. Winnacker, M., Breeger, S., Strasser, R. & Carell, T. Novel diazirine-containing DNA 
photoaffinity probes for the investigation of DNA-protein-interactions. Chembiochem 10, 109–
18 (2009). 
13. Shigdel, U. K., Zhang, J. & He, C. Diazirine-based DNA photo-cross-linking probes for the 
study of protein-DNA interactions. Angew. Chemie - Int. Ed. 47, 90–93 (2008). 
14. Zhu, G. & Lippard, S. J. Photoaffinity labeling reveals nuclear proteins that uniquely recognize 
cisplatin-DNA interstrand cross-links. Biochemistry 48, 4916–4925 (2009). 
15. G. Dolinnaya, N. Design and Synthesis of 2-Functionalised Oligonucleotides. Their 
Application for Covalent Trapping the Protein – DNA Complexes. Curr. Org. Chem. 13, 
1029–1049 (2009). 
16. Peterson, L. A. Electrophilic intermediates produced by bioactivation of furan. Drug Metab. 
Rev. 38, 615–26 (2006). 
17. Halila, S., Velasco, T., Clercq, P. De & Madder, A. Fine-tuning furan toxicity: fast and 
quantitative DNA interchain cross-link formation upon selective oxidation of a furan 
containing oligonucleotide. Chem. Commun. 936–938 (2005). doi:10.1039/b415092a 
18. Stevens, K. & Madder, A. Furan-modified oligonucleotides for fast, high-yielding and site-
selective DNA inter-strand cross-linking with non-modified complements. Nucleic Acids Res. 
37, 1555–1565 (2009). 
Chapter 2: Cross-linking to dsDNA 
36 
19. Beeck, M. Op De & Madder, A. Unprecedented C-Selective Interstrand Cross-Linking through 
in Situ Oxidation of Furan-Modified Oligodeoxynucleotides. J. Am. Chem. Soc. 133, 796–807 
(2011). 
20. Stevens, K. et al. Furan-oxidation-triggered inducible DNA cross-linking: Acyclic versus 
cyclic furan-containing building blocks - On the benefit of restoring the cyclic sugar backbone. 
Chem. - A Eur. J. 17, 6940–6953 (2011). 
21. Jawalekar, A. M., Op de Beeck, M., van Delft, F. L. & Madder, A. Synthesis and incorporation 
of a furan-modified adenosine building block for DNA interstrand crosslinking. Chem. 
Commun. 47, 2796–2798 (2011). 
22. Wilkinson, F. & Brummer, J. G. Rate constants for the decay and reactions of the lowest 
electronically excited singlet state of molecular oxygen in solution. J. Phys. Chem. Ref. Data 
10, 809 (1981). 
23. Stevens, K. & Madder, A. Furan-modified oligonucleotides for fast , high-yielding and site-
selective DNA inter-strand cross-linking with non-modified complements y. Nucleic Acids 
Res. 37, 1555–1565 (2009). 
24. Carrette, L. L. G., Gyssels, E. & Madder, A. DNA interstrand cross-link formation using furan 
as a masked reactive aldehyde. Curr. Protoc. Nucleic Acid Chem. 54, Unit 5.12. (2013). 
25. Schmidt, M. J. & Summerer, D. Angewandte Red-Light-Controlled Protein – RNA 
Crosslinking with a Genetically Encoded Furan. Angew. Chemie 52, 4690–4693 (2013). 
26. Gyssels, E., Carrette, L. L. G., Vercruysse, E., Stevens, K. & Madder, A. Triplex Crosslinking 
through Furan Oxidation Requires Perturbation of the Structured Triple-Helix. ChemBioChem 
16, 651–658 (2015). 
27. Singh, I., Hecker, W., Prasad, A. K., Parmar, V. S. & Seitz, O. Local disruption of DNA-base 
stacking by bulky base surrogates. Chem. Commun. 5, 500–1 (2002). 
28. Dervan, P. B. & Bürli, R. W. Sequence-specific DNA recognition by polyamides. Curr. Opin. 
Chem. Biol. 3, 688–693 (1999). 
29. Trauger, J. W., Baird, E. E. & Dervan, P. B. Recognition of DNA by designed ligands at 
subnanomolar concentration. Nature 382, 559–561 (1996). 
30. White, S., Szewczyk, J. W., Turner, J. M., Baird, E. E. & Dervan, P. B. Recognition of the 
four Watson-Crick base pairs in the DNA minor groove by synthetic ligands. Nature 391, 468–
71 (1998). 
31. Trauger, J. W., Baird, E. E. & Dervan, P. B. Recognition of 16 Base Pairs in the Minor Groove 
of DNA by a Pyrrole-Imidazole Polyamide Dimer. J. Am. Chem. Soc. 120, 3534–3535 (1998). 
32. Su, W., Gray, S. J., Dondi, R. & Burley, G. a. Highly efficient synthesis of DNA-binding 
hairpin polyamides via the use of a new triphosgene coupling strategy. Org. Lett. 11, 3910–3 
(2009). 
33. Mosquera, J., Jiménez-Balsa, A., Dodero, V. I., Vázquez, M. E. & Mascareñas, J. L. Stimuli-
responsive selection of target DNA sequences by synthetic bZIP peptides. Nat. Commun. 4, 
1874 (2013). 
34. Ruiz García, Y. et al. Sequence-selective DNA recognition and enhanced cellular up-take by 
peptide–steroid conjugates. Chem. Commun. 51, 17552–17555 (2015). 
35. Wang, Y. D. et al. DNA crosslinking and biological activity of a hairpin polyamide-
chlorambucil conjugate. Nucleic Acids Res. 31, 1208–1215 (2003). 
 
Chapter 3: The GCN4 Transcription Factor 
37 
CHAPTER 3 
 
THE GCN4 TRANSCRIPTION FACTOR AND AN OVERVIEW OF THE 
SYNTHETIC MIMICS DEVELOPED IN THE OBCR GROUP AT 
UGENT 
 
The GCN4 Transcription Factor (TF) is arguably one 
of the most studied transcription factors. Although this 
transcription factor is a yeast amino acid metabolism 
regulatory transcription factor1 controlling the 
activation of several genes in response to amino acid 
starvation, it is of particular importance especially to 
synthetic chemists due to its well-defined dimerization 
domain (encircled in blue) and DNA recognition 
region. Its crystal structure bound to dsDNA was 
determined by Ellenberger et. al. in 19922. This makes 
it one of the relatively easy TFs to study and mimic, 
which in turn allows chemists to make a diverse range 
of synthetic mimics of the GCN4 TF – a strategy 
which could eventually be used in cancer therapy by 
targeting TFs in humans3. 
 
 
 
3.1 Introduction 
 
In the previous chapter, we studied some of the families of TFs. In this chapter, we will study one 
model transcription factor in particular – the yeast TF GCN4 (General Control Nonderepressible). The 
GCN4 TF belongs to a family of TFs known as the basic region Leucine Zipper (bZIP). Over 30 
known eukaryotic proteins contain the bZip DNA-binding motif. They are known as the bZIP because 
of the unique and well defined geometry of the bZIP region which firmly holds the two helices in 
place. The bZIP also gives these TFs a very high degree of specificity towards their respective DNA 
sequences by restricting not only the free movement of the helices with respect to each other, but also 
their rotation along a Z-axis. Genes containing the DNA sequence 5’-ATGACTCAT-3’ are activated 
by the GCN4 TF. The GCN4 binds to its target DNA as a dimer which is critical for DNA binding. 
However, the TF is known to form stable dimers even in the absence of DNA4. 
 
3.2 Analysis of the primary & secondary structures of the GCN4 TF bound to its target 
DNA 
 
The GCN4 TF is a relatively large protein comprising of 281 amino acids with a molecular weight 
slightly over 31kDa5. The full length sequence, although known, is of little importance. The amino 
acids forming the two important domains – the dimerization domain and the basic recognition region 
(Figure 3.1A) are, however, of much interest. The very first crystal structure of the GCN4 TF bound 
to DNA was solved with a resolution of 2.9 Å by Ellenberger in 19922. Subsequently, Keller 
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improved it further, obtaining a resolution of 2.2 Å in 1995 for the same TF bound to DNA and 
containing the ATF/CREB recognition sequence. Crystallographic data is freely available at Protein 
Data Bank (pdb: 1YSA). A complete set of interactions is described in figure 3.1. 
 
IFigure 3.1. The protein and DNA sequences of the GCN4-DNA complex crystallized and complete interaction 
summary. 
A: GCN4-bZIP domain numbered according to the full-length sequence. Residues that make one or more DNA 
contacts are indicated: b, direct to base; w, via water to base; p, direct to phosphate; x, via water to phosphate.  
B: Self-complementary, 18 bp palindromic ATF/CREB DNA with terminal thymidine. A molecular and 
crystallographic 2-fold axis passes through the C −1G1 base step. The specific recognition sequence is marked 
with a bar. 
C: Protein-DNA interaction summary for one basic domain and DNA half-site. The location of the 2-fold axis is 
indicated. Direct and water (W) mediated interactions with bases are shown as continuous lines, interactions 
                                                          
I Reproduced from J. Mol. Biol. (1995) 254, 657-667 
C
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with the phosphate backbone as broken lines and hydrophobic interactions as dotted lines. Arrows indicate the 
direction of hydrogen bonds. 
 
The secondary structure of the GCN4 TF is quite well defined and is a perfect example of a 
homodimer. The bZIP dimer is a pair of continuous α helices that form a parallel coiled coil over the 
C-termini of the recognition regions. The recognition region is around 30 residues and gradually 
diverges towards the N-termini while simultaneously passing through the major groove of the DNA-
binding site. The interactions between the bases and phosphate groups present in DNA and the basic 
residues present in the protein constitute the main contacts of this region between the DNA and the 
protein. 
The leucine zipper region of the GCN4 TF is stabilized due to the hydrophobic and non-polar 
interactions within the monomer forming an extensive van der Waals contact surface. Intra and inter-
helical salt bridges are also present. Although these are lower in number, they also contribute to the 
formation of the dimer.  
The basic region of each monomer adopts the optimal conformation to bind to its respective half-site 
of the target DNA sequence. Although there are no sharp bends or kinks in either GCN4 monomer, 
the rigid coiled coil imposes a gentle bend of the α-helix towards the axis of the DNA. Consequently, 
it is able to grip the major groove like a pair of tweezers and interact specifically with the base pairs 
located there. The contacts of this region with the major groove are based on the positively charged 
polar residues namely the arginines and lysines, which establish hydrogen bonds with the oxygen 
atoms of the phosphate backbone and the base pairs. The N-terminal end of the basic region continues 
as a helix beyond the point of DNA contact and is the most flexible part of the protein. 
3.3 Mimics of the GCN4 TF developed in the OBCR Group 
 
As explained previously, the GCN4 TF is relatively easy to mimic due to its well-defined 
dimerization domain and basic recognition region. Synthetic chemists from several research groups 
have exploited this aspect and have designed and synthesized artificial mimics of the GCN4 TF6. The 
most noteworthy among them are the contributions from Mascarenhas7, 8, 6, Morii9, 10, 11, Schepartz12, 13 
and Kim14. From literature, it can be concluded that the minimum basic recognition domain can be 
reduced to the following 23 amino acids: DPAALKRARNTEAARRSRARKLQ. 
Figure 3.2: General schematic showing the most common strategy for the synthesis of artificial mimics of the 
GCN4 TF using the minimum basic recognition region and substituting the dimerization domain (encircled in 
blue) with a scaffold. 
Recognition Region
H2N-DPAALKRARNTEAARRSRARKLQ-CONH2
≡
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The Organic & Biomolecular Research Group (OBCR) at UGent has also been actively involved in 
phosphate recognition, especially focussing on the development of artificial DNA binders for the 
GCN4 TF. The initial work was started by Dieter Verzele15 and was continued by Lieselot Carrette16. 
 
Yara Ruiz and myself further developed this work through the synthesis of new mimics of the GCN4 
TF. The initial synthetic mimics were designed by replacing the dimerization domain of the GCN4 TF 
using rigid, modified deoxycholic acid steroid17 and bi-functional cyclodextrin18 scaffolds.  
Subsequently, as part of this PhD thesis, simplified and synthetically less-challenging monomeric 
mimics were designed and synthesized using stapled peptides19. All the constructs developed were 
also tested for cellular uptake as part of the master thesis of Dorien Van Lysebetten. The work done 
using stapled peptides has been described in detail in the next chapter. In this chapter, we will discuss, 
in brief, the constructs based on the dimerization of the GCN4 TF using functionalized steroid and 
cyclodextrin scaffolds. 
 
3.4 DNA recognition and enhanced cellular uptake using peptide-steroid conjugates and 
cylcodextrin-peptide conjugates for DNA binding 
 
This design, syntheses and purification of the final peptide-steroid conjugates was carried out by Yara 
Ruiz as part of her PhD thesis17 along with myself and my former master thesis student Dorien at 
UGent who was also responsible for performing the biological studies. The overview of the synthesis 
is briefly described in this section. The complete work in the form of publications can be found in 
Annex I. 
 
 
IIFigure 3.3: Overview of the design and syntheses of artificial DNA binders through a convergent approach 
using a Copper Azide-Alkyne Cycloaddition (CuAAC) reaction involving: (A) Replacement of the dimerization 
                                                          
II Modified & reproduced from Ruiz García, Y. Iyer A. et al. Sequence-selective DNA recognition and enhanced cellular up-
take by peptide–steroid conjugates. Chem. Commun. 51, 17552–17555 (2015) 
Peptide functionalization
at the C-terminus
for CuAAC conjugations
Basic region GCN4 D226-Q248
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domain with a steroid scaffold equipped with a suitable linker and (B) The basic DNA recognition region 
peptide containing an azide or alkyne functionality at the C-terminus for conjugation to the modified scaffold. 
Initial attempts to synthesize a mimic of the GCN4 TF using a linear and direct solid phase peptide 
synthesis approach were successful16 but resulted in the final product with low yields and purity. 
Therefore, a new, convergent approach was designed as shown in figure 3.2. The dimerization domain 
was once again substituted with a rigid steroid scaffold possessing a suitable linker, but unlike the 
previous approach the scaffold and peptide were synthesized separately and conjugated via a CuAAC 
reaction. 
 
Four different scaffolds with functionalised linkers capable of forming cycloaddition products (Figure 
3.3: Scaffolds 1-4) were designed and synthesized for peptide dimerization of the GCN4 basic region. 
Although the four scaffolds are deoxycholic acid derivatives, they possess linkers of varying lengths, 
flexibilities and functionalities (Fig. 3.3). In order to attach different linkers, the alcohol positions 
were modified using Steglich esterification which yielded the final scaffolds (1-3). The linkers chosen 
for the study were pentynoic acid, azido glycine, 4-azidomethyl-benzoic acid and (N-
propynoylamino)-p-toluic acid (PATA). The PATA linker possess an active alkyne and has been used 
previously for preparation of peptide–oligonucleotide conjugates via CuAAC20. Due to the high 
reactivity of the PATA linker it was necessary to synthesize the diamino derivative of deoxycholic 
acid21 as esterification resulted in byproducts. 
 
For synthesis of the peptides, the unnatural amino acids propargyl glycine or azido homoalanine 
possessing an alkyne and azide functionality respectively were first loaded onto the resin to provide 
an attachment point for the peptides to the steroid scaffold. Peptides 5 and 6 (Figure 3.4) were 
synthesized using automated SPPS on Rink Amide Chemmatrix resin suitable for longer, difficult 
peptides. Four different transcription factor models (7-10) were synthesized using the peptides 5 & 6. 
A DMSO/H2O = 3:1 combination capable of dissolving both the hydrophobic scaffold and 
hydrophilic peptide was found to be optimal for the CuAAC reaction. After performing the reaction 
with different Cu catalysts such as Cu(OAc)2, CuBr, CuI and CuSO4, Cu(CH3CN)4PF6 gave the best 
results. The presence of a large number of guanidine groups probably resulted in a high Cu 
complexation and therefore excess catalyst was needed to drive the reaction forward. The excess 
copper ions can be removed after completion of the reaction by using EDTA20. The desired product 
was surprisingly achieved through the use of excess scaffold and not excess peptide as expected. The 
reaction was complete after stirring the mixture for 3 hours at room temperature with the dipodal 
construct being the main product and without any major side products being formed despite the 
presence of unprotected amino acids side chains. The resulting final compounds 7-10 were purified 
using RP-HPLC. 
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 IIIFigure 3.4: Complete list of peptides and peptide-steroid conjugates synthesized for DNA binding and 
cellular uptake. 
 
To investigate the cellular uptake of a peptide-steroid conjugate, the best DNA binding construct 7 
was suitably modified and synthesized with a fluorescein tag (Figure 3.4, 14). The properties of this 
construct were compared the monomer 11, the GCN4 peptide dimer 12 and the monomeric steroid 
conjugate 13.   
 
Additionally, GCN4 protein mimics were also synthesized by replacing the Leucine Zipper region 
with α, β and γ-cyclodextrins equipped with azide functionalities18. The peptides were conjugated via 
CuAAC reaction under the same conditions as those described before. The DNA binding studies, cell 
uptake studies and the published article can be found in Annex I. 
                                                          
III Reproduced from Ruiz García, Y. Iyer A. et al. Sequence-selective DNA recognition and enhanced cellular up-take by 
peptide–steroid conjugates. Chem. Commun. 51, 17552–17555 (2015) 
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3.5 Conclusion: 
 
In conclusion, we have described in detail the structure of the GCN4 TF and have subsequently 
designed and synthesized new artificial DNA binders which are mimics of the TF. This has been 
achieved using a convergent approach involving the GCN4 basic recognition region peptide and 
steroid as well as cyclodextrin scaffolds. The dissociation constant (KD’s) for the mimics of the TFs to 
their native DNA sequence are in the nM range. The synthetic route has been simplified as compared 
to previous models described in literature. It is the first time relatively long, cell permeable peptide-
steroid conjugates have been synthesized and tested for cell uptake. The constructs show enhanced 
cell uptake even at 4°C and increased membrane interaction. Through this work we are a step closer 
to understanding the parameters which affect DNA recognition and cell uptake in case of the GCN4 
TF. 
 
3.6 References: 
 
1. Pathak, D. & Sigler, P. B. Updating structure-function relationships in the bZip family of 
transcription factors. 116, 116–123 (1992). 
2. Ellenberger, T. E., Brandl, C. J., Struhl, K. & Harrison, S. C. The GCN4 Basic Region Leucine 
Zipper Binds DNA as a Dimer of Uninterrupted Helices : Crystal Structure of the Protein-
DNA Complex. Cell 71, 1223–1237 (1992). 
3. Darnell, J. E. Transcription Factors as Targets for Cancer Therapy. Nature 2, 740–749 (2002). 
4. Hopel, I. A. & Struhl, K. GCN4, a eukaryotic transcriptional activator protein, binds as a dimer 
to target DNA. EMBO J. 6, 2781–2784 (1987). 
5. Saccharomyces Genome Database. at 
<http://www.yeastgenome.org/locus/S000000735/overview> 
6. Pazos, E., Mosquera, J., Vazquez, M. E. & Mascarenas, J. L. DNA Recognition by Synthetic 
Constructs. Chembiochem 12, 1958–1973 (2011). 
7. Mosquera, J., Jiménez-Balsa, A., Dodero, V. I., Vázquez, M. E. & Mascareñas, J. L. Stimuli-
responsive selection of target DNA sequences by synthetic bZIP peptides. Nat. Commun. 4, 
1874 (2013). 
8. Caaman, A. M., Va, M. E., Castedo, L. & Mascaren, J. L. Design and Synthesis of a Peptide 
That Binds Specific DNA Sequences through Simultaneous Interaction in the Major and in the 
Minor Groove. 4723–4725 (2001). 
9. Morii, T., Simomura, M. & Morimoto, S. Sequence-Specific DNA Binding by a Geometrically 
Constrained Peptide Dimer. J. Am. Chem. Soc. 32, 1150–1151 (1993). 
10. Morii, T., Tanaka, T., Sato, S., Hagihara, M. & Aizawa, Y. A General Strategy To Determine 
a Target DNA Sequence of a Short Peptide : Application to a D -Peptide. 124, 2001–2002 
(2002). 
11. Shin-ichi Sato, Masaki Hagihara, Kenji Sugimoto, Takashi, M. Design of new DNA binding 
peptides Chemical Approaches Untangling Sequence-Specific DNA Binding. Chem. - A Eur. 
J. 5066–5071 (2002). 
12. Cuenoud, B. & Schepartz, A. Design of a metallo-bZIP protein that discriminates between 
CRE and AP1 target sites: Selection against AP1. Proc. Natl Acad. Sci. USA 90, 1154–1159 
(1993). 
13. Zondlo, N. J. & Schepartz, A. Highly Specific DNA Recognition by a Designed Miniature 
Protein. J. Am. Chem. Soc. 121, 6938–6939 (1999). 
14. Talanlan, R. V, Mcknight, C. J. & Kim, P. S. Sequence-Specific DNA Binding by a Short 
Chapter 3: The GCN4 Transcription Factor 
44 
Peptide Dimer. Nature 33, 769–771 (1990). 
15. Verzele, D. & Madder, A. Synthetic Progress in cMyc-Max Oncoprotein Miniaturization: 
Semi-On-Line Monitoring gives Solid-Phase Access to Hydrophobic b(-HLH-)ZIP 
Peptidosteroid Tweezers. European J. Org. Chem. 673–687 (2013). 
16. Carrette, L. L. G., Morii, T. & Madder, A. Peptidosteroid Tweezers Revisited: DNA Binding 
Through an Optimised Design. European J. Org. Chem. 2014, 2883–2891 (2014). 
17. Ruiz García, Y. et al. Sequence-selective DNA recognition and enhanced cellular up-take by 
peptide–steroid conjugates. Chem. Commun. 51, 17552–17555 (2015). 
18. Ruiz García, Y. et al. Cyclodextrin–peptide conjugates for sequence specific DNA binding. 
Org. Biomol. Chem. 13, 5273–5278 (2015). 
19. Iyer, A. et al. Stapling monomeric GCN4 peptides allows for DNA binding and enhanced 
cellular uptake. Org. Biomol. Chem. 13, 3856–3862 (2015). 
20. Wenska, M. et al. An activated triple bond linker enables ‘click’ attachment of peptides to 
oligonucleotides on solid support. Nucleic Acids Res. 39, 9047–9059 (2011). 
21. Verzele, D. & Madder, A. Short Synthesis of Orthogonally Protected 3α,12α-Diamino-5β-
cholan-24-oic Acid, a Dipodal Steroid Scaffold for Combinatorial Chemistry. European J. 
Org. Chem. 2007, 1793–1797 (2007). 
 
 
Chapter 4: Stapled Peptides 
45 
CHAPTER 4 
 
SYNTHETIC MIMICS OF THE GCN4 TF USING STAPLED PEPTIDES 
FOR DNA RECOGNITION AND ENHANCED CELLULAR UPTAKE 
 
The basic DNA 
recognition region 
of the GCN4 protein 
comprising 23 
amino acids has 
been modified to 
contain two 
optimally positioned 
cysteines which have 
been linked and 
stapled using cross-
linkers of suitable 
lengths. This results 
in stapled peptides 
with a stabilized α-
helical conformation 
which allows for 
DNA binding and concurrent enhancement of cellular uptake. 
4.1 Introduction 
 
As explained in Chapters 1 and 3, Transcription Factors (TFs) by definition are responsible for the 
decoding of genetic information from dsDNA to mRNA.1 In the quest for sequence selective DNA 
recognition, TF proteins can be regarded as nature’s models to design synthetic DNA binders. TFs are 
usually classified according to the fold of their DNA-binding domains and grouped into a small 
number of families, like the bZIP, bHLH, homeodomain, HTH, and zinc fingers which have already 
been studied in detail.2 Most transcription factors are large proteins possessing complex secondary 
structures, rendering it difficult to design smaller synthetically accessible versions thereof retaining 
Enhanced cell uptake
Allows DNA binding
No DNA binding
Lower cell uptake
Wild Type peptide
Stapled peptideTranscription factor
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the DNA binding capacity.3 The GCN4 leucine zipper is, however, a relatively easy protein to mimic 
due to its well-defined dimerization domain and basic recognition region.  
 
It has already been shown that dimerization of basic region peptides through non-peptide scaffolds 
can allow DNA binding.4 However, construction of such smaller dimeric mimics of this TF, although 
feasible, has proven to be synthetically challenging.5, 6 Previous attempts at more thorough structural 
minimization and reduction of complexity using the monomeric GCN4 peptide have shown that DNA 
binding is greatly reduced due to loss of secondary structure.7 Indeed, since the basic region of the 
GCN4 transcription factor cannot adopt a helical fold  in solution by itself nor bind to DNA8 due to 
entropic reasons,9 an external factor forcing the peptide into a helical conformation is needed. For this 
reason, unlike the existing synthetic bZip models in which DNA binding is induced via  
dimerization,10, 5 we here aim to stabilize a single α helix via peptide stapling, reasoning that 
enhancing the helicity within the monomer should sufficiently stabilize the conformation to allow 
DNA binding.7 Stapled peptides have been used extensively for improving helicity,11 increasing cell-
penetration,12, 13 proteolytic stability and enhancing peptide-protein interactions (PPIs).14 In all the 
above-mentioned cases, the benefits of stapled peptides have been demonstrated.15 However, the use 
of stapled peptides in the miniaturization of zipper proteins has remained largely unexplored.  
 
4.2 Stapled peptides as GCN4 TF mimics & selection of the stapling methodology 
 
In this work, we have examined the DNA binding induced by stapling using the monomeric GCN4 
transcription factor basic region as a model peptide, by comparing the i, i+4 and i, i+7 stapling 
methods and varying the positions of the staple along the helix. The cellular uptake of the constructs 
was also investigated using fluorescently labelled versions of the peptide. 
 
Initial studies were dedicated to selecting the most suitable method for peptide stapling among the 
ones reported in literature.12, 16, 17, 18, 19 The idea was to adopt a method as general as possible to be 
applicable to any potential DNA binding peptide by increasing its helicity. To ensure easy and cost-
effective modification, the use of unnatural amino acids was avoided. The hydrocarbon stapling is 
generally considered as the best stapling methodology for improving helicity of peptides for 
subsequent enhancement of peptide-protein interactions. However, the labor intensive preparation of 
the required modified amino acid building blocks, coupling of the non-natural amino acids as well as 
peptide folding on resin is a cause for concern when stapling a peptide through this method.20 
Therefore, in the current study, we opted for cysteine cross-linking,15 in view of the commercial 
availability and/or easy synthesis of cross-linking moieties, mild reactions conditions and easy 
scalability due to synthesis in solution. 
 
4.3 Design and Synthesis of stapled peptides 
 
A detailed analysis of the essential contacts for binding of the GNC4 protein to its cognate DNA 
sequence, as derived from the reported crystal structure, was described earlier by Ellenberger (pdb 
file: 1YSA).21 Various dimeric peptides based on the D226-Q248 basic region of the GCN4 TF have 
been shown to retain their DNA binding properties.22, 10  
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Figure 4.1: Schematic showing the stapling possibilities – the i, i+4 peptide stapling capable of 
stabilising a single helix turn and the i, i+7 peptide stapling capable of stabilising two helix turns.  
 
Based on these studies, amino acids within this sequence, indicated as not involved in DNA 
contacts,23 were identified and systematically replaced by Cys according to an i,i+4 or i,i+7 format 
(Figure 4.1). These positions were specifically chosen as they stabilise a peptide helix. Ideally, there 
are 3.6 amino acids per turn of a peptide helix. However, since it is not possible to stabilise the 3.6th 
amino acid we chose the nearest integer values, 4 (for one turn of the helix) and 7 (for two turns of the 
helix). Furthermore, molecular modelling aided visualisation based on the pdb file 1YSA21 was used 
to ensure that the introduced linkers point away from the DNA and not towards it, thereby avoiding 
any steric repulsion which may arise due to peptide stapling. In this way, three different peptides, 
comprising the D226-Q248 sequence from the DNA binding basic region of GCN4, containing a 
double Cys substitution (at positions 237/244 for 1, 229/233 for 2 and 233/237 for 3) were 
synthesized on solid support, cleaved and subsequently treated with various linkers yielding a series 
of five stapled peptides as shown in Figure 4.2. 
 
Figure 4.2: Synthetic stapled peptides 1a-c, 2d, 3d for DNA binding and unmodified basic region peptide 4. The 
peptides are N-terminally capped with a p-acetylamino benzoic acid (ABA) moiety to ensure UV-based 
detection and analysis in the case of DNA binding. For cell uptake studies, the ABA moiety was replaced by 
fluorescein. 
 
2 turns1 turn
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The stapled peptides and the unmodified WT basic region peptide were successfully synthesized. The 
cross-linkers a, c & d are commercially available. The stapling moiety b has not been used thus far 
for peptide stapling and was designed and synthesized as a more polar alternative to the biphenyl and 
bipyridine cross-linkers. 
 
4.4 DNA binding studies 
Next, the DNA binding capacity of all peptides was evaluated through electrophoretic mobility shift 
assay (EMSA) titration of various peptide concentrations to the DNA sequence 5’ – CGG ATG ACG 
TCA TTT TTT TTC – 3’ (Figure 4.3) containing the cognate monomeric GCN4 binding site GTCAT. 
The WT peptide 4 does not bind DNA under the given EMSA conditions. For all the synthetic 
constructs 1a-c, 2d & 3d, we see enhanced DNA binding as compared to peptide 4. Earlier, DNA 
binding with monomeric peptides was observed through the use of a grafting strategy, whereby the 
crucial contact residues of the GCN4 binding region are specifically positioned on an avian pancreatic 
polypeptide.24 Apparently, our simple and straightforward stapling strategy also allows constraining 
the peptide into a suitable conformation for DNA binding. In the case of peptides, 1a-c binding is only 
observed at higher concentrations of peptide as compared to 2d and 3d. The more hydrophobic nature 
of the biphenyl cross-linker makes peptide 1a more susceptible to aggregation (followed by 
precipitation), as can be seen from the complete disappearance of the bands in the last lane. On the 
other hand, peptides 1b and 1c are less prone to aggregation, but the onset of binding occurs at higher 
concentrations than in the case of 1a. Compared to peptides 1a-c, the DNA binding pattern in gel 2d 
is different. We propose that the appearance of two bands related to DNA-peptide complex formation 
is due to the presence of two binding sites in the CRE sequence (…GTCAT…). 
Figure 4.3: EMSA titrations for peptides 1a-c, 2d & 3d.  Loading mixture comprises 5 µL from a mixture of 10 
µL mQ, 4 µL sucrose, 2 µL loading buffer, 2 µL DNA, 2 µL peptide resulting in a total DNA concentration of 
167 nM.  The loading buffer consists of 20 µL Tris 1 M, pH = 7.6, 20 µL KCl 0.2 M, 20 µL MgCl2 0.1 M, 40 
µL EDTA 0.025 M. Peptide concentrations from left to right (in µM) are indicated below each gel. 
Chapter 4: Stapled Peptides 
49 
It can be noticed that after full occupation of one binding site by the peptide, remaining non-bound 
peptide can interact with the second binding site. The binding pattern of peptide 2d is unique and only 
visible in the case of the two sequences that bind at a lower concentration range. It can further be 
noticed that peptide 3d shows a similar binding pattern as peptide 2d but suffers from non-specific 
interactions, which cause aggregation, bands getting blurred or disappearance of all bands. 
 
From the experiments described in literature7, 25 and from our own data, a general conclusion can be 
made regarding DNA binding stapled peptides. The major challenge in case of DNA binding peptides 
is that, increasing the helicity has to be complemented with a degree of flexibility in order to account 
for the conformational change which occurs when the peptide binds to DNA. Since this 
conformational change is more significant in the case of DNA binding peptides as compared to PPIs, 
a too-tight locking of the peptide into a helical conformation may result in the inability to achieve 
DNA binding. Indeed, our data show that peptide stapling by providing an N or C terminal helix 
stabilization, rather than centrally in the sequence, gives better results in terms of DNA binding, as 
observed from the binding pattern of peptides 2d & 3d versus 1a-c. Though in the absence of DNA a 
low helical content is observed (see CD measurement results in SI), apparently the conformation can 
be adjusted into a structure whereby the contacts between the positively charged side chains, mainly 
involving the Lys and Arg residues, and the negatively charged backbone of the DNA can be 
maximized without a high entropic penalty. We believe peptide 2d fits these criteria and hence is the 
best DNA binder from the constructs synthesized. Moreover, peptide 2d is able to bind in a dimeric 
fashion without having been artificially dimerized.  
 
4.5 Cell uptake & toxicity studies 
 
Dorien Van Lysebetten, Benoit Louage and Prof. Bruno De Geest are thanked for their valuable 
contribution. 
 
The previously related yeast derived GCN4 peptide (231-252) has been classified as a membrane 
permeable peptide.26, 27 It varies slightly from the basic region peptide used in this article, which was 
specifically chosen for its DNA binding abilities in its dimeric form.22 It has further been postulated 
that stabilization of the secondary structure via peptide stapling can enhance cell uptake28. Peptides 
with hydrocarbon staples in particular have shown considerable increase in uptake, as compared to 
their non-stapled counterparts13,29. Here, the fluorescently labelled versions of peptides Ia-c & IId 
were tested in a cellular environment using RAW 264.7 mouse macrophages. Confocal microscopy 
confirmed that cell uptake is achieved even at a low concentration of 0.25 µM for all peptides at 37°C 
using an incubation time of 3h, including native GCN4 sequence IV, as can be seen from fluorescence 
of fluorescein in figure 3A-E. 
Chapter 4: Stapled Peptides 
50 
 
Fig. 4.4: Confocal microscopy images of the uptake of peptides (A) Ib, (B) IId, and (C) IV at 37 °C. The upper 
panel shows accumulated images of DNA in the nucleus (blue), cell membrane (red) and fluorescein (green).  
The lower panel shows the fluorescein image. 
 
Quantification of the uptake by flow cytometry shows a concentration dependence as well as a 
temperature dependence on the mean fluorescence values measured (Fig. 4.5). At 37°C, a 
considerably larger uptake is observed at a 1 µM concentration of peptides. Furthermore, the mean 
fluorescence of the cells increased considerably for an i, i+7 staple, as can be seen from the results for 
Ia-c. Incubation at 4°C provides insight into the mode of uptake, as endocytic pathways are shut down 
at this temperature. Comparison of the data obtained at 4°C and 37°C with flow cytometry (Fig. 4.5) 
showed that there is significant uptake at 37 °C but almost no uptake at 4°C. This was further 
confirmed by confocal microscopy in a separate systematic study where we compared cell uptake for 
the non-stapled reference peptide IV and stapled peptide Ib, both at 4°C and 37°C (Fig. 5). Except for 
slight accumulation in and around the cell membrane, there was no uptake at 4°C. Thus, active uptake 
is the main internalization pathway for these peptides, based on the results obtained from flow 
cytometry and confocal microscopy. 
 
Fig. 4.5: Mean fluorescence of fluorescently labelled peptides by incubation at (A) 0.25 µM, 4°C, (B) 1 µM, 
4°C, (C) 0.25 µM, 37°C, (D) 1 µM, 37°C. 
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Fig. 4.6: Confocal microscopy images of the uptake of (A) peptide IV at 37°C, (B) peptide Ib at 37°C, (C) 
peptide IV at 4°C and (D) peptide Ib at 4°C at 0.25 µM. The upper panel shows accumulated images of DNA 
(blue), cell membrane (red) and fluorescein (green).  The lower panel shows the fluorescein image. 
 
The cell uptake properties even at low concentrations for the current peptides are combined with low 
cytotoxicity values, as observed in an MTT-assay (Fig 4.7). From the MTT assay, we can conclude 
that for peptides IV, Ia, Ib, Ic and IId in general, more than 70% of the cells are viable at a 
concentration of 0.25 µM. Cell viability was evaluated according to the ISO10993-5 norms, which 
state that the compounds are cytotoxic if the assay points to a cell viability lower than 70%. Clearly, 
we see that the stapled peptides are not toxic at a concentration of 0.25 or 1 µM, except for IId which 
seems to be slightly toxic at a 1 µM concentration. 
 
Fig. 4.7: MTT assay for fluorescently labelled peptides IV, Ia, Ib, Ic & IId measured at concentrations of 0.25 
µM and 1 µM. 
 
4.6 Peptide Stability 
Dorien Van Lysebetten is thanked for performing the peptide stability tests. 
 
Many hydrocarbon stapled peptides exhibit increased proteolytic resistance, proportional to the degree 
of α-helicity and number of staples introduced, resulting in enhanced therapeutic properties30. In case 
of cysteine cross-linking, no systematic comparison of peptide stability of stapled versus unstapled 
peptides has been reported. As a high number of Arg and Lys are present, the peptides will be very 
C DBA
Chapter 4: Stapled Peptides 
52 
susceptible to cleavage of trypsin. Therefore, a trypsin digest experiment was carried out using a 
trypsin to peptide ratio of 1/1000 wt% and samples were analysed after 0 min, 30 min, 1 h, 2 h and 24 
h using RP-HPLC and MALDI-TOF. As expected, the control peptide IV was more susceptible to 
degradation than the stapled peptides, which can be seen in the higher number of different degradation 
products (fig. 4.8). The degradation products clearly reflect the influence of the staple on the cleavage 
process. Remarkably, while peptide IV was completely degraded after 24 h, between 20% (Ic) and 80 
% (Ib) was left for the different stapled peptides (see experimental section for chapter 4 Fig. 51).  
 
Fig. 4.8: Trypsin digestion of peptides showing different cleavage sites indicated by the arrows, observed with 
RP-HPLC analysis. 
 
4.7 Conclusion 
 
The elegant nature of the synthesis in combination with the observed DNA binding and cellular 
uptake properties render these constructs to be of considerable and specific interest among the mimics 
of the GCN4 transcription factor reported to date. Through this work and due to the nature of the 
stapled peptides, we believe that a general method is now at our disposal to allow DNA binding and 
enhance cellular uptake of a given DNA binding peptide, while avoiding tedious synthetic routes. It 
has been further shown that N-terminal helix stabilization, as in the case of 2d, is more effective for 
enhancing DNA binding than stapling in the middle of the sequence (1a-c).  For cell uptake, however, 
the more helical i, i+7 stapled peptides Ia-c have shown better uptake than IV. Although the two are 
not mutually exclusive, for future applications such as DNA binding in cellulo, a balance will have to 
be found between a peptide’s DNA binding and cell penetration abilities. 
 
The knowledge gained in the areas of peptide synthesis, transcription factors and in particular from 
the cell uptake studies carried out at UGent have helped tremendously to establish a platform for 
expanding the scope of peptides as a delivery system. Peptide based drug delivery into Gram negative 
bacteria will form the main discussion of this PhD thesis in the subsequent chapters.  
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CHAPTER 5 
 
ANTIBIOTIC RESISTANCE: PAST, PRESENT & FUTURE 
 
The problem of 
Antibiotic Resistance 
has plagued the 21st 
century with a host of 
acute problems. It has 
been estimated that by 
2050 an additional 10 
million people yearly 
will succumb to drug 
resistant infections.1 
In 2013, the excess 
healthcare costs due 
to resistant infections 
in the US/EU totalled 
to a staggering $20/€ 
1.6 billion!2 Excess 
hospital days caused 
by resistant infections in the US and EU tallied to 8 and 2.5 million!3 The list just never ends…and 
what’s more... it is only going to get worse from here if something isn’t done soon. In the previous 
chapters, we developed peptide based transcription factor models using cell permeable stapled 
peptides which could be further developed as anti-cancer drugs. In the subsequent chapters, we will 
use the experience gained in the area of cell penetrating peptides described in chapters 2 & 3 to 
establish a new peptide based delivery system for drugs capable of crossing the protective outer 
membrane of Gram negative bacteria which are mainly responsible for ushering of the antibiotic 
resistance. Before we venture into that aspect, however, we will first take a brief look at the reasons 
behind antibiotic resistance, the current drugs/strategies and what can be done to avoid the dreaded 
“post-antibiotic era”.  
 
5.1 Introduction 
 
Truth be told, it is not entirely surprising that antibiotic resistance has emerged in the 21st century. 
Ever since the dawn of the antibiotic era, almost every scientist in the field knew that this day would 
eventually come. What they did not expect, however, was the alarming rate at which resistance would 
emerge. The past twenty years have seen a drastic rise in resistant strains of bacteria. The alarming 
rate at which new bacteria are emerging, coupled with a significant decline in new antibiotics, is a 
cause for major concern. Several questions arise from this, starting with what actually is antibiotic 
resistance? How does it occur? What can be done to prevent it? What does the future hold? In the 
subsequent chapters of this PhD, we will do our best to answer these questions providing details of the 
research that has been done in the University of Lincoln by me under the guidance of Dr. Ishwar 
Singh to develop new antibiotics. 
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 5.1.1 Antibiotics & antibiotic resistance 
 
An antibiotic can be defined as “Any substance that inhibits the growth and replication of a bacterium 
or kills it outright”.4 Antibiotic resistance can be defined as “The resistance of a microorganism to an 
antibiotic that was originally effective for treatment of infections caused by it”.5 It is to be noted here 
that antibiotics are different from antimicrobial compounds. In fact, antibiotics are a particular type of 
antimicrobial specially designed for the treatment of bacterial infections within (or on) the body. This 
makes them different from antiseptics (used to sterilize surfaces of living tissue) or disinfectants 
(which kill a wide range of organisms). Bacteria aren’t the only microbes harmful to us. There’s fungi 
and viruses too for which there are antifungals and antiviral compounds – but we will not discuss 
those here.  
 
 5.1.2 Targets of antibiotics 
 
Research has shown that there are around 200 conserved essential proteins in bacteria. Unfortunately, 
the number of currently exploited targets is very small6. The most successful antibiotics target only a 
few of these pathways: cell wall synthesis7 (β-lactams, such as penicillin or cephalosporins), DNA 
gyrase8 (quinolones), DNA-directed RNA polymerase9 (rifampicin) protein synthesis, i.e. the 
ribosome10 consisting of 50S and 30S subunits, (examples include macrolides, chloramphenicol, 
clindamycin, aminoglycosides, tetracyclines and oxazolidinones) and enzymes11 (sulphonamides and 
trimethoprim). A simple schematic of some of the known targets of antibiotics has been shown in 
Figure 5.1. 
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I IIFigure 5.1: Schematic showing some of the known targets of antibiotics.  
                                                          
I Reproduced from Lewis, K. Platforms for antibiotic discovery. Nat. Rev. Drug Discov. 12, 371–87 (2013)  
II Original article: Coates, A., Hu, Y., Bax, R. & Page, C. The future challenges facing the development of new antimicrobial 
drugs. Nat. Rev. Drug Discov. 1, 895–910 (2002). 
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 5.1.3 Mechanisms of antibiotic resistance and tolerance  
 
The progress science and medicine makes is severely hampered by the rise and spread of antibiotic 
resistance. An abbreviation ‘ESKAPE’ has been assigned to multidrug resistant organisms which pose 
the most serious threat to human health. ESKAPE stands for Enterococcus spp., Staphylococcus 
aureus, Klebsiella spp., Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter spp.12 
(Note: spp stands for several species/subspecies) For A. baumannii, a resistant strain of Gram 
Negative Bacteria, there are reports saying “no available antibiotics”13. The general principle behind 
the design of an antibiotic is to attempt to shut down or disrupt essential cellular functions thereby 
considerably slowing down or killing entirely the growth of bacteria. Resistance mechanisms, on the 
other hand, operate on the strategy of preventing a drug from reaching its target. Majority of clinically 
relevant resistance mechanisms have been studied extensively and are therefore generally well 
understood14, 15 (Figure 5.2). Examples include destruction of the antibiotic (by β-lactamases for 
example); target modification (Resistance to streptomycin is due to a mutation in the 30S ribosomal 
protein RpsL); as well as decreased penetration and/or efflux of the drug (efflux of linezolid by the 
AcrAB–TolC multidrug pump)16, 17.  
III IVFigure 5.2: Schematic showing some of the common ways in which antibiotic resistance has developed. 
                                                          
III Reproduced from Lewis, K. Platforms for antibiotic discovery. Nat. Rev. Drug Discov. 12, 371–87 (2013)  
IV Original article: Coates, A., Hu, Y., Bax, R. & Page, C. The future challenges facing the development of new 
antimicrobial drugs. Nat. Rev. Drug Discov. 1, 895–910 (2002). 
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Antibiotic resistance, therefore, is reasonably well-understood and manageable, but tolerance, 
however, is an entirely different challenge altogether. The main reason for the tolerance of pathogens 
to antibiotics is what is called a “persister” or a specialized survivor18, 19. Interestingly, persisters are 
not mutants, as one would expect. They are, in fact, phenotypic variants of cells which divide actively. 
They are produced unexpectedly in the population. Their relative abundance slowly rises and even at 
the late-exponential phase of growth does not rise to more than 1%20. It may not seem like much, but 
persisters are quite unlike the normal cells encountered. They are non-growing21, dormant22, 23 cells, 
which explains to a high degree their tolerance to bactericidal antibiotics since antibiotics need active 
targets for killing the cell24. From the aforementioned pathogens so far, all of them form persisters19, 
but the mechanisms through which the persisters emerge is mostly unknown. In Escherichia coli, 
which can be regarded as the model organism for study, it has been shown that toxin–antitoxin 
modules are the key mechanism of persister formation.23, 24, 25, 26 Unfortunately, it was also uncovered 
that the  pathways of persister formation are highly redundant27. This redundancy makes target 
identification for drug discovery extremely challenging.  
 
There is a close link between persisters and the emergence of drug tolerance. This was shown when 
an unexpectedly high number of persisters were selected in antimicrobial therapy in infections caused 
by Pseudomonas aeruginosa28. Overall, we can conclude that an important role is played by persisters 
in the development of antibiotic-resistant variants. Even if we do manage to kill them, persisters are 
killed rather slowly and more significantly resume growth when the antibiotic concentrations fall. 
This result is catastrophic because it results in a relapsing infection with a significant relative 
population size which will have a very high tendency to develop resistance29. Although the 
importance of persisters in drug resistant pathogens raises the bar considerably for drug discovery and 
is definitely something worth mentioning and considering, it is currently beyond the scope of this PhD 
thesis which will be more focussed on the discovery of new antibiotics capable of targeting the non-
persisters. 
 
5.2 Gram positive & Gram negative bacteria 
 
It is common knowledge that there are two major types of bacteria: Gram positive and Gram negative. 
Their names arise from the Danish bacteriologist Hans Christian Gram who developed the Gram stain 
in 1884 comprising primarily of crystal violet and safranin. He noticed certain type of bacteria retain 
his stain and turn violet whereas others do not retain his stain and when counterstained, turn red. He 
therefore named the former Gram-positive bacteria and the latter Gram-negative bacteria. Little did he 
realize the significance of his discovery at that time. Today, of course, we know a lot more about 
Gram positive and Gram negative bacteria – the major difference being the presence of a robust outer 
membrane present in Gram negative bacteria but absent in Gram positive bacteria (Figure 5.3), 
making Gram negative bacteria particularly efficient in keeping out drugs. For the current thesis, we 
will be more focussed on development of antibiotics towards the more resistant Gram negative 
bacteria. 
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VFigure 5.3: Figure showing the difference between (a) Gram positive cell wall & (b) Gram negative cell wall. 
 
5.3 Gram negative bacteria: Other modes of resistance 
 
The current focus has been towards the development of drugs against Gram-positive bacteria such as 
vancomycin resistant enterococci (VRE) and methicillin-resistant Staphylococcus aureus (MRSA). 
The newly discovered antibiotic teixobactin (Figure 5.4) is an excellent example of an antibiotic 
active against MRSA30. We have already seen some of the modes of resistance in bacteria in general. 
However, Gram negative bacteria such as Klebsiella pneumoniae (K. pneumoniae), Acinetobacter 
baumannii (A. baumannii) and Pseudomonas aeruginosa (P. aeruginosa) in particular pose a more 
serious challenge to human health due to their natural ability to acquire resistance via multiple 
modes31. 
 
  
Figure 5.4: Structure of teixobactin.   
                                                          
V Reproduced from Solomon, Biology, 5th Edition, Figure 23.10 
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There has been virtually no new antibiotic for Gram negative bacteria in decades. Therefore, the 
polymyxins (described in section 5.4.2) discovered more than 50 years ago, have been revived and are 
being used as a drug of last resort against these bacteria32 despite reports of their toxicity as well as 
increasing resistance33. Thus, the problem of antibacterial resistance is only getting worse – especially 
against the drug resistant Gram negative bacteria34, 35. Therefore, there is an urgent need to develop 
new antimicrobial compounds particularly against the resistant Gram negative bacteria. The outer 
membrane (OM) of Gram negative bacteria significantly limits the access of antibiotics to reach their 
targets, while no such barrier is present in Gram positive bacteria. One of the key challenge which is 
necessary to overcome to develop new antibiotics against Gram negative bacteria36 is the lack of 
compounds which can penetrate through the outer  membrane which acts as a barrier protecting these 
bacteria. The multidrug resistance (MDR) efflux pumps37, 38 and the transfer of resistant genes in 
Gram negative bacteria via multiple modes such as Horizontal Gene Transfer (HGT)39, 40  are the other 
challenges especially in resistant Gram negative bacteria. In what follows, we will briefly discuss the 
major problems associated with finding novel antibiotics against Gram negative bacteria. 
 
5.3.1 Impermeable barrier 
 
The major problem associated with antibiotic discovery against Gram negative bacteria is the 
presence of an impermeable outer membrane protecting it from a vast majority of compounds. The 
outer leaflet of the outer membrane bilayer is composed of an unusual lipid, lipopolysaccharide 
(LPS), compared to the usual glycerophospholipid found in most other biological membranes. Three 
main parts make up the LPS: a proximal hydrophobic lipid A region, a core oligosaccharide region 
and O-antigen (a repetitive glycan polymer)41. Essentially, all drugs are amphipathic due a dual 
requirement: Firstly, they need to be water soluble and secondly, they need to be able to cross the 
cytoplasmic membrane. Since the vast majority of clinically important antibiotics show some 
hydrophobicity it allows them to diffuse across the membrane especially through the lipid A region. 
However, since the LPS is an asymmetric bilayer, the bacterial outer membrane still serves as an 
efficient barrier considerably slowing down the penetration of lipophilic antibiotics. 
 
 
VIFigure 5.5: Figure showing the outer membrane of Gram negative bacteria. 
 
Since the outer membrane of Gram negative bacteria prevents the majority of molecules from 
entering, bacteria with this barrier have developed other methods to bring in nutrients from their 
surroundings. The outer membrane of Gram negative bacteria contains porins, a special class of 
                                                          
VI Modified from https://en.wikipedia.org/wiki/Bacterial_outer_membrane#/media/File:Gram_negative_cell_wall.svg 
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proteins, which produce non-specific aqueous diffusion channels across the membrane. Porin 
channels exclude antibiotics from crossing them by having a very small diameter (7 to 10 Å at the 
most) which considerably slows down or completely shuts down antibiotic influx. The porin channels 
are also lined with charged amino acid residues. This orients the water molecules in a fixed direction 
making the channel quite hydrophilic. These charged residues make the influx of lipophilic molecules 
difficult due to an energetically unfavourable orientation of the water molecules. Nutrients can diffuse 
into the cells through mycobacterial porin – a protein present in very small amounts and allowing only 
very slow diffusion of small molecules through its channel42. Antibiotics are severely restricted in 
entering the bacteria by the low permeability of the porin channels and the lipid matrix, which allows 
a high degree of resistance for these bacteria. 
 
5.3.2 Multidrug resistance efflux pumps 
 
Four general mechanisms responsible for antibiotic resistance have been identified by the World 
Health Organization (WHO). They are: resistance including target alteration, drug inactivation, 
decreased permeability and increased efflux. Among these, drug expulsion by the multidrug efflux 
pumps is an important mechanism of MDR. Efflux pumps have the ability to pump out a broad range 
of antibiotics due to their polysubstrate specificity38. Additionally, they can also enable the bacteria to 
acquire additional resistance mechanisms by lowering the intracellular antibiotic concentration as a 
result of their action, and subsequently promoting mutation accumulation. Over-expression of 
multidrug efflux pumps is a major challenge associated typically with drug resistance. More studies 
have revealed that efflux pumps are not just for the development of bacterial resistance but also play 
important physiological functions in bacteria43. This makes their expression very tightly regulated in 
response to various environmental and physiological signals. A thorough understanding of the 
mechanisms of drug expulsion and regulation and physiological functions of efflux pumps is 
necessary for the development of anti-resistance methodologies. It is to be noted here that the 
importance of efflux pumps to bacteria makes them a good target for antibiotics, and drugs which 
target these pumps have met with success44.  
 
5.3.3 Horizontal Gene Transfer 
 
Mutation is not the only way in which bacteria evolve rapidly. Transfer of DNA can result in strains 
with mutations from more than one source making the new bacteria even more resistant to antibiotics. 
Evidence of Horizontal Gene Transfer (HGT) was documented as early as 1928 when researchers 
observed the transference of virulent determinants between pneumococci in infected mice. This 
phenomenon was later shown to be mediated by the uptake of the genetic material DNA in a process 
called transformation45. This transformation requires the release of naked DNA with subsequent 
uptake and recombination. DNA-repair processes and homologous recombination usually tend to limit 
this to DNA from similar bacteria. However, there is always the possibility that a gene moves onto a 
broad-host-range plasmid. In that case, it might be able to spread rapidly and without the need for 
recombination. Gram negative bacteria (among others), in particular, have the natural ability to 
acquire DNA46 as part of their genetic trait, giving them access to not only nutrients or genetic 
information but also allowing them to acquire new modes of resistance. 
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5.4 Leading drugs against Gram negative bacteria 
 
A vast majority of drugs against Gram negative bacteria are present on the market and therefore we 
will not discuss all of them in detail. The aim of this section is to get a concise overview of drugs 
against the resistant Gram negative bacteria as a background for the subsequent chapters. For a more 
detailed overview of the current drugs47 and the evolution of drugs, several reviews are available48, 33, 
49. Some of the classes of drugs against Gram negative bacteria relevant for this thesis (with 
examples) are described below. 
 
5.4.1 β-lactams, resistance to β-lactams and their sub-classes 
 
Despite their structural diversity, all β-lactams possess a common four-membered β-lactam ring (i.e. a 
four membered ring with an amide bond) which serves as the active pharmacophore for this class of 
antibiotics. β-lactams are a very old class of antibiotics – the first one discovered was benzylpenicillin 
(penicillin G, Figure 5.5) back in 192836. The most approved class of antibiotics by the FDA are β-
lactams. They also on top (in terms of numbers) of WHOs list of critically important antibiotics to 
human medicine. 28 β-lactams, including antibiotic/ β-lactamase inhibitor combinations, comprising 
three subclasses: penicillins, cephalosporins, and carbapenems are listed as critically important50. 
Their antibacterial activity is a result of their ability to act as suicide substrates for penicillin binding 
proteins (PBPs). They also inhibit cell wall biosynthesis, especially the maintenance of peptidoglycan. 
This leads to cell stress which ultimately results in cell lysis51. The currently used β-lactams have 
broad spectrum activity against most gram-positive and negative bacteria. This, coupled with low 
toxicity profiles makes them popular first-line antibiotics16.  
Resistance to β-lactams usually occurs via the hydrolysis of the β-lactam ring mediated by a wide 
range of β-lactamases with diverse classifications. We will briefly study the classification of these 
enzymes and which drugs they target. The new Ambler classification system has been updated in 
2010 and three groups have been formed52. However, for simplicity, we will study them according to 
their classes:  
1. Class A: Consisting of Klebsiella Pneumoniae Carbapenamase (KPCs) and most Extended 
Spectrum β-lactamases (ESBLs). 
2. Class B: Metallo-β-lactamases (MBLs). 
3. Class C: AmpC β-lactamases (AmpC). 
4. Class D: OXA β-lactamases (OXA). 
 
Many enzymes which can hydrolyze penicillins and cephalosporins, including some that can 
hydrolyze monobactams (β-lactams where the β-lactam ring is alone and not fused with other rings) 
and KPCs capable of hydrolyzing carbapenems, all belong to class A53. The ESBLs belonging to this 
class are mediated via plasmids which has aided in their diffusion to multiple species54. MBLs use 
divalent cations such as zinc as cofactors. Integrons55 are genetic units possessing a unique ability to 
capture and incorporate gene cassettes (which contain a gene and recombination site) by site-specific 
recombination. Many are encoded in class 1 integrons – a major problem in antibacterial resistance56. 
Typically, they also affect gene cassettes responsible for coding aminoglycoside modifying enzymes 
(AMEs), found on transposons (a small piece of DNA capable of inserting itself into another part of 
the genome, thereby creating or reversing mutations), thereby facilitating their spread57. MBLs are 
capable of inactivating many β-lactams including carbapenems with currently no improved inhibitors 
for them. However, they have no activity against the monobactam aztreonam (Figure 5.9 I)58.  
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AmpC β-lactamases are typically chromosomally encoded. Inactivation of many β-lactams including 
aztreonam occurs through AmpC and other class C β-lactamases. They show preferential activity 
against cephalosporins, but do not show any activity against carbapenems53-59. Many OXAs are 
encoded on integrons60, 61, 62, 63. Class D comprising only of OXAs are capable of hydrolysing 
cephalosporins and aztreonam . Some of them have carbapenemase activity as well53-64. Although they 
are not as potent as MBLs they are particularly problematic because they are the most commonly 
found β-lactamase in Acinetobacter54. Streptococci, in particular can possess altered PBPs, making the 
role of β-lactamases difficult65. Production of low affinity PBP2a in MRSA has caused resistance to 
Methicillin (5) and other β-lactam in greater than 90% of isolates66. A similar problem has been 
observed in S. pneumoniae due to expression of a variety of low affinity PBPs16. Resistance to β-
lactams can also be caused by efflux by RND and ABC efflux pumps,67 and outer membrane 
impermeability68. 
 
 1. The penicillin subclass 
The penicillin subclass of β-lactams form the oldest antibiotics developed. β-lactams have advanced 
mainly via semi-synthetic modifications. Amongst the penicillin subclass (Fig. 5.6) some early 
synthetic modifications were aimed at increasing stability to penicillinases through the attachment of 
bulky side chains as in the cases of methicillin (Figure 5.6 II) and oxacillin (Figure 5.6 III). A separate 
set of modifications were made to penicillin G (Figure 5.6 I) which is relatively narrow-spectrum to 
make it effective against gram-negatives. Examples include the aminopenicillins such as ampicillin 
(Figure 5.6 IV) and amoxicillin (Figure 5.6 V), and ureidopenicillins like piperacillin (Figure 5.6 VI). 
Despite most bacteria today being resistant to this class, many penicillins still remain important first- 
line antibiotics16. 
 
Figure 5.6: β-lactams of the Penicillin subclass. The β-lactam moiety is highlighted in blue. 
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 2. The cephalosporins 
The cephalosporins are a subclass of β-lactam antibiotics originally derived from 
the fungus Acremonium, known previously as “Cephalosporium”. The first cephalosporin was 
cephalosporin C (Figure 5.7 I), discovered in 1948. Initial semi-synthetic cephalosporins were mainly 
developed to improve pharmacokinetics and increase spectrum of activity particularly against gram-
negative bacteria through increased cellular penetration. The subsequent generations have become 
increasingly focused on combating β-lactam resistance16. Currently, the fifth generation of 
cephalosporins are in production. They possess excellent safety profiles and increased spectrum of 
activity, which have made them some of the most highly utilized first-line antibiotics. Ceftaroline 
(Figure 5.7 III), a fifth generation cephalosporin approved by the FDA in 2010, has shown increased 
activity against MRSA. Unfortunately, it is not potent against MDR gram-negatives by itself69, 70. 
However, a combination of ceftaroline with the β-lactamase inhibitor, tazobactam (Figure 5.10 II) was 
found to be quite effective against resistant strains, although its inactivation via certain β-lactamases 
could not be prevented53. Cubist’s ceftolozane (Figure 5.7 II), which is in phase III trials, has shown 
activity complementary to Ceftaroline. It has low activity against MRSA, but is active against many 
MDR gram-negative bacteria including E. coli and K. pneumoniae strains. Most notably, it has 
extremely good activity against P. aeruginosa including strains with AmpC β-lactamases and 
upregulated efflux71. There is a strong likelihood of it being used in combination with tazobactam 
(Figure 5.9 II), which should broaden its range of activity72. 
 
Figure 5.7: I-III. Structures of some of the cephalosporin subclass β-lactams. The β-lactam moiety is 
highlighted in blue. 
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 3. The Carbapenems 
The first carbapenem to be identified was Imipenem (Figure 5.8 I) in 1976. Their resistance to ESBLs 
makes carbapenems quite potent against many anaerobic and gram-negative bacteria compared to 
other β-lactams although more recently evolved carbapenmases have resulted in a decreased activity. 
P. aeruginosa has developed resistance to imipenem (Figure 5.8 II) and meropenem (Figure 5.8 II) 
through the loss of OprD porins and MexAB-OprM efflux upregulation54. Doripenem (Figure 5.8 III), 
was approved in Japan in 2005 and in the US in 2007. It is unaffected by certain KPCs and OXAs, but 
remains susceptible to all MBLs73. It shows similar activity as imipenem against most bacteria but it is 
superior to other carbapenems against P. aeruginosa. It, however, lacks activity against MRSA12, 74. 
Meropenem and biapenem (Figure 5.8 IV) (approved in Japan) have been used successfully against 
some imipenem resistant, MBL producing P. aeruginosa75. A carbapenem in phase II trials, 
Razupenem (Figure 5.6 V), has shown promising activity against E. faecium (gram positive) which is 
resistant to ampicillin76. 
 
Figure 5.8: Structures of the Carbapenem subclass belonging to the β-lactam family. The β-lactam moiety is 
highlighted in blue. 
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 4. The Monobactams 
The first and only FDA-approved monobactam thus far, aztreonam (Figure 5.9 I), was identified in 
1981. Though it is active only against gram-negative pathogens, it stands apart from all other 
antibiotics in its class because of its imperviousness to some of the most dreadful class B β-
lactamases16, 58. Basilea’s BAL30072 is still in phase I clinical trials (Figure 5.9 II), but has already 
proven to be a promising monobactam. It has shown excellent activity against MBL producing P. 
aeruginosa and Acinetobacter along with many KPC producing Enterobacteriaceae77. Likewise, it 
has also shown synergistic activity with meropenem (Figure 5.8 II) against Acinetobacter. 
 
Figure 5.9: Structures of the monobactam subclass belonging to the β-lactam family. The β-lactam moiety is 
highlighted in blue. 
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 5. The β-lactamases inhibitors 
The first identified β-lactamase inhibitor was Clavulanic acid (Figure 5.10 I), which was discovered in 
1976. A combination therapy of clavulanic acid (Figure 5.10 I) and amoxicillin (Figure 5.6 I), known 
as augmentin, is still amongst the most successful antibiotics on the market. Some P. aeruginosa 
infections, including those producing ESBLs, can be treated using piperacillin (Figure 5.6 VI) and 
tazobactam (Figure 5.10 II)54. Sulbactam (Figure 5.10 III) was initially used in combination with 
ampicillin in the past, with some success. Renewed interest in sulbactam was reported when it showed 
good activity in combination with meropenem (Figure 5.7 II) against a wide range of A. baumannii 
strains, although this combination is not yet clinically approved78. An interesting new β-lactamase 
inhibitor Avibactam (Figure 5.10 IV) is reported with broad spectrum activity against class A, C and 
D β-lactamases79. There are a number of β-lactam inhibitors, containing or not containing a β-lactam, 
that are either clinically approved or in clinical trials in combination with β-lactam antibiotics. Quite a 
few of these have activity against KPC, AmpC, and OXA β-lactamases80. However, there are very 
few with activity against MBLs and none that are currently clinically approved81. Some combinations 
of inhibitors, including ones that have siderophore (Greek for iron carriers; Siderophores are among 
the strongest known Fe3+ binders) activity, have shown some promise against MBLs53. Tricyclic 
competitive inhibitors of certain MBLs have also been isolated82. 
 
Figure 5.10: Structures of the β-lactamase inhibitors. The β-lactam moiety is highlighted in blue. 
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5.4.2 Polymyxins 
 
The Polymyxins A-E are natural products of Bascillus, first discovered in 1947. Structurally, they are 
cyclic peptides with peptidyl side chains and a hydrophobic, saturated alkyl tail capping the N-
terminus (Fig. 5.11). Colistin (polymyxin E, Figure 5.11 I) has been on the market since 1950. The 
polymyxins were discontinued due to significant nephrotoxicity and neurotoxicity83 until recently, 
when interest was renewed due to a rapid increase of multidrug resistant bacteria. They are still, 
however, considered drugs of last resort. Recent studies have shown that the nephrotoxicity of colistin 
may have been overestimated possibly because of errors in dosing or inferior formulation84, 85. 
Polymyxins are polycationic due to the presence of as many as six diaminobutanoic acid residues, five 
of which have free amines (Figure 5.11 I). They operate by displacing stabilizing magnesium and 
calcium ions, allowing them to electrostatically interact with the outer layer of gram negative cell 
membranes containing anionic lipopolysaccharide (LPS). This disrupting interaction by polymyxins 
leads to an increase in bacterial cell membrane permeability, leakage, and rapid cell death86. Colistin 
has the added benefit of having potent anti-endotoxin activity87. 
 
 
Figure 5.11: Figure I. showing the polymyxins B1 & B2 & collistin and Figure II. showing NAB739, the 
preclinical polymyxin B analogue. 
 
The polymyxins are quite potent against most gram-negative bacteria (broad spectrum) although some 
reports say strains of K. pneumoniae, P. aeruginosa, A. baumannii and others have developed 
resistances35. Overall, however, resistance to polymyxins is quite uncommon, although its frequency 
varies significantly by bacterial species and by geographic region88. E. coli and P. aeruginosa have 
been known to express lower affinity modified LPS. This can also lead to resistance. P. aeruginosa 
can also upregulate membrane protein H1, thereby replacing divalent cations in the LPS and 
decreasing polymyxin affinity. K. pneumoniae is capable of increasing production of its capsule 
polysaccharide, which restricts polymyxin penetration to the LPS layer. Certain B. polymyxa are 
known to produce a degrading colistinase, but there are no reports which suggest these have spread to 
pathogenic bacteria strains89. 
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Colistin is currently being used in the treatment of MDR gram-negative pathogens where other 
treatment options are unavailable. MDR resistant strains such as Pseudomonas, Klebsiella, and 
Acinetobacter including the NDM-190 producers can be targeted using Colistin. Recent studies have 
shown that reducing the overall positive charge in Polymyxin B analogues has maintained their 
antibacterial activity, while significantly improving in vitro toxicity profiles. One of these molecules, 
NAB739 (Figure 5.5II), is being actively developed in pre-clinical studies by Northern Antibiotics 
Ltd.91, 92, 93, 94 
 
5.5 Conclusion: Learning from our mistakes to build a better future 
 
A brief overview has been provided in this chapter covering the antibiotic problem in the 21st century, 
Gram positive & multidrug resistant Gram negative bacteria and the differences between them, 
mechanisms of antibiotics, modes of resistance and an overview of the drugs in the market or in 
development to cope against emerging resistance. 
 
There is no denying that several mistakes have been made in the field of antibiotics research. After 
what was defined as the golden era of antibiotic research till the 1960s95, there was a massive lull 
period for almost 20 years where nearly no new antibiotic was discovered. Significant complacency, 
ignorance coupled with irresponsible policies and practices, have time and again hampered antibiotic 
research. That being said, the situation today is far better than in the 1990s. The alarming rise of 
resistant bacteria has revived antibiotic research. The new 21st century has ushered in fresh 
perspectives. Advances in synthesis and technology have greatly helped in checking the further rise of 
resistant pathogens. The approval of new classes of antibiotics is definitely a step in the right 
direction. However, a lot of work remains to be done in the area of antibiotic research. The important 
thing is to keep steady on the path of science and constantly strive to avoid the dreaded “post-
antibiotic” era. 
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CHAPTER 6 
 
DEVELOPING MOENOMYCIN A AS AN ANTIBIOTIC AGAINST 
GRAM NEGATIVE BACTERIA 
 
Although it was discovered in 1965, the full 
potential of Moenomycin A (MoeA, 3D ball and 
stick model shown on the leftI) has not been 
exploited till date. The recent surge of antimicrobial 
resistant bacteria has seen the revival of several 
underused molecules and MoeA is at the forefront. 
Revived interest in MoeA has allowed for a better 
understanding of the mechanisms of action of MoeA 
as well as problems and possible solutions towards 
developing MoeA as an antibiotic. Thus far, MoeA 
has only been used to target Gram positive 
bacteria. Herein, we present the first unique 
approach which enables MoeA to target the 
resistant Gram negative bacteria making it a 
potential new antibiotic against Gram negative 
bacteria. Subsequently, we have designed specific “delivery” peptides which bind to MoeA and 
enable it to cross the negatively-charged outer membrane of Gram negative bacteria. Peptides rich in 
Arg, Lys and/or Trp have been known for their cell permeability. This was shown in chapter 3 where 
we used stapled DNA binding peptides rich in Lys and Arg for enhancing cellular uptake. This is, 
however, the first instance where we have used short, cell permeable peptides to deliver MoeA. This 
has resulted in a 30 times improvement in antimicrobial activity of MoeA against the resistant 
Pseudomonas aeruginosa. Detailed NMR analysis gives valuable insight into the structure of the non-
covalent complex between the lead delivery peptide and MoeA. 
Note: Several people have contributed to this work. Their names are mentioned as and when their 
work is described. 
 
6.1 Introduction 
 
As we have seen in the previous chapter, the rise of antibiotic resistance poses a serious threat to 
human health. To keep up with the increasing threat of resistance, academia and industry are 
constantly researching for new and improved antibiotics, particularly against the resistant Gram 
negative bacteria. At the same time however, there is a renewed interest in exploring some of the 
existing validated targets using novel approaches. A notable example of a validated target is the 
bacterial cell wall biosynthesis pathway. The peptidoglycan biosynthetic machinery is well-
established. It is now well-known that a number of these antimicrobial targets are present at or beyond 
the extra-cytoplasmic surface of the bacterial cell membrane. Moreover, they are also well-conserved 
across all bacterial species making them perfect targets for antibiotics1, 2.  
 
                                                          
I Obtained from the RSCB protein data bank. The data is freely available at: 
http://ligand-expo.rcsb.org/pyapps/ldHandler.py?formid=cc-index-search&target=M0E&operation=ccid 
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In the previous chapter, we have reviewed the development of a large number of β-lactam based 
antibiotics. These antibiotics target the transpeptidase function of the penicillin binding proteins 
(PBPs)3, 4. Unfortunately, there has been relatively little development in the area of the essential 
transglycosylase (TG) function5. We will discuss the mechanism of the TG inhibitor MoeA in the 
subsequent sections. One of the reasons for the lack of research into the active site of the TG enzymes 
is probably because these exist at the membrane surface. This has been viewed as a difficult interface 
to target6 particularly against Gram negative bacteria which possess robust outer membranes which 
protect the TG and prevent most molecules from accessing the inner membrane surface. Additionally, 
keeping the catalytic function of the enzymes in mind, the transglycosylase enzymes have long and 
extended active sites, which also make them difficult to target7. Despite these difficulties, nature has 
provided a perfect solution to this issue in the form of the moenomycin group of antimicrobials. The 
moenomycins appear to mimic the polymerised form of the substrate within the transglycosylase 
active site. Unfortunately, poor pharmacokinetics has disallowed the use of moenomycins in humans. 
Interestingly, the moenomycins (in the form of commercially available flavomycin) have been used 
for decades as cattle fodder with almost no reports of resistance indicating that the transglycosylase 
activity could be an excellent target for developing antibiotics8. 
 
6.2 Structure of MoeA 
 
The moenomycins are a naturally occurring family of phosphoglycolipid antibiotics produced by 
Streptomyces ghananensis. MoeA (Figure 6.1) represents the most active compound among the 
moenomycins with potent antimicrobial activity8, 9. MoeA consists of a pentasaccharide of units B, C, 
D, E and F (green) with a chromophore (unit A, black). The unusual isoprenoid C25 lipid chain 
(shown in red) is connected to the F saccharide via a phosphoglycerate linker (blue). The C25 chain is 
essential for antimicrobial activity. A closer look reveals that the MoeA structure resembles that of the 
lipid IV (dimer of Lipid II, figure 6.1 B) product formed within the transglycosylase active site10. 
Moenomycin has amphiphilic properties due to the hydrophilic nature of the A ring and the 
carbohydrate units (green, rings B-F), the phosphate group of the 3-phosphoglyceric acid 
phosphorglycerate linker (blue) and the hydrophobic domain formed by the lipid chain (red).11  
 
 
Figure 6.1: (A) Structure of MoeA and (B) Structure of Lipid II. 
 
6.3 Biosynthetic pathway for the polymerisation of lipid II 
 
The biosynthetic pathway which ultimately results in the formation of the peptidoglycan precursor 
lipid II and the general scheme for the polymerisation of lipid II into the peptidoglycan layer is well 
understood and documented. The short explanation is as follows4:  
1. UDP-MurNAc-L-Ala-D-Glu-L-(Lys/meso-DAP)-D-Ala-D-Ala (Systematic name for UDP-
MurNac: Uridine 5’Diphospho N-acetyl) or its L-lysine derivative UDP-MurNAcL-Ala-D-
Glu-L-(Lys)-D-Ala-D-Ala (donor, part of the molecule shown in black in figure 6.2) is first 
produced in the cytoplasmic pathway.  
A
B
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2. It then links at the cytoplasmic membrane surface to an undecaprenyl (C55) carrier lipid prior 
to the addition of GlcNAc (a phosphate transferase enzyme), forming lipid II.12  
3. This peptidoglycan precursor is then transferred to the outer surface of the cytoplasmic 
membrane where it is polymerised by monofunctional transglycosylases and class A 
bifunctional Penicillin Binding Proteins (PBPs) into long glycan chains13 (Fig. 6.2).  
4. The transpeptidase activity of Class A and B PBPs then produce inter-strand peptide cross-
links from pentapeptides emanating from adjacent glycan chains.  
 
The result is the formation of a polymer possessing high mechanical strength and rigidity sufficient to 
resist cytoplasmic osmotic stress. This polymer forms a scaffold for a number of extracellular 
structures and functions. 
 
 
IIFigure 6.2: Schematic diagram of the transglycoylase active site showing donor and acceptor sites. Residue 
numbers in the acceptor sites are in accordance with those determined for S. aureus monofunctional 
transglycosylase in relation to lipid II analogue as described by Huang et al.14 
 
  
                                                          
II Reproduced from Galley, N. F., O’Reilly, A. M. & Roper, D. I. Prospects for novel inhibitors of peptidoglycan 
transglycosylases. Bioorg. Chem. 55, 16–26 (2014) 
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6.4 The inhibition of transglycosylase via MoeA: key interactions 
 
There are two known natural molecules which bind to the transglycosylase domain of PBPs, MoeA 
and lipid II. Lipid II is the natural substrate while MoeA is the most potent inhibitor. The reason for 
this must lie in the structural differences between the two. A proper understanding of how these two 
molecules interact and bind to the transglycosylase domain is imperative if we wish to pursue the 
inhibition of transglycosylase using MoeA.  
 
It is well known that MoeA binds with high affinity to the transglycosylase domain of several Class A 
PBPs.  It is the most potent known inhibitor of the transglycosylase function of PBPs with MICs as 
low as 0.01–0.1 µg/mL9. The mode of inhibition by MoeA is via the direct (although reversible) 
binding to the active site of the transglycosylase domain preventing lipid II polymerisation. It first 
anchors itself to the cytoplasmic membrane via its lipid chain (which is shorter but similar to the C55 
of lipid II), and then, owing to its sugar moieties, binds to the donor site of the transglycosylase. 
 
Five motifs representing the GT51 fold-family15  are part of the transglycosylase domain. The number 
of motifs may vary depending on the species but in general, these motifs are conserved among mono- 
and bi-functional PBPs. Six residues in the transglycosylase domain have been identified as important 
in the interaction with MoeA in Aquifex aeolicus PBP1A16, 17 which are also conserved across other 
species. These 6 residues are known to bind to the F-ring and the phosphoglycerate portion of MoeA. 
As mentioned earlier, the transglycosylase active site is buried in the bacterial inner membrane. The 
lipid of MoeA is therefore required for interaction with the membrane, in order to grant access to the 
lipid II. It is believed that the C25 chain of MoeA interacts with the transmembrane (TM) segment of 
E. coli PBP1B18, increasing the binding affinity of MoeA to the transglycosylase domain by 5-fold 
and highlighting the importance of the TM domain for activity. The C2 on the E ring, C3 on the F 
ring, the phosphoglycerate moiety and possibly the C10 region of the lipid tail are believed to be the 
other regions of MoeA that make essential contacts with the transglycosylase domain. The phosphoryl 
group and the carboxylate moiety interact with conserved active site residues of the transglycosylase 
domain19. The A ring is not essential for the interaction but provides higher binding affinity8. 
 
6.5 Problem, strategy and solution: Using MoeA against Gram negative bacteria 
 
MoeA is highly active against Gram positive bacteria but largely inactive against Gram negative 
bacteria8.  We are now aware that the activity is a result of the inhibition of the Glycosyltransferase 
enzyme (more specifically GT51) which is responsible for the peptidoglycan synthesis in the bacterial 
cell wall biosynthesis4 14. So what makes GT51 such an attractive target? Peptidoglycan biosynthesis 
is mediated by Penicillin-Binding Proteins (PBPs) such as PBP1b. In E.coli this is a four domain 
protein comprising of the transglycosylase domain (GT51), transpeptidase domain (TP), 
transmembrane (TM) domain and UB2H domain20. The GT51 is an attractive target to develop new 
antibacterial drugs because the polysaccharide backbone (peptidoglycan) remains highly conserved in 
drug resistant bacteria. GT51 is essential for the survival of bacteria. It is ubiquitous to bacteria and 
thus confers high specificity with no mammalian couterpart21. Mutations in GT51 that would abolish 
its binding with MoeA are expected to be lethal to bacteria. This is because a number of amino acids 
involved in MoeA binding are also essential for catalysis of bacterial cell wall synthesis. Mutations 
that would decrease/abolish MoeA binding may also undermine GT51 activity. The occurrence of 
such mutations would not be advantageous for bacteria, thus slowing down the development of 
resistance. This is supported by a recent report, which described that a single point mutation in GT51 
was lethal to bacteria and caused major cell division defects in S aureus22.   
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Despite its high potency against gram positive bacteria (Minimum Inhibitory Concentration (MIC) ~1 
µg/mL against S. aureus) and unique ability to disrupt the cell biosynthesis inhibiting GT51, interest 
in developing MoeA as an antibiotic was not pursued further because of its poor pharmacokinetic 
properties. In recent years, however, a phenomenal rise in drug resistant pathogens has once again 
revived interest in MoeA8. In this study, we have reasoned that MoeA is inactive against Gram 
negative bacteria because GT51 is inaccessible to MoeA due to the outer membrane barrier in Gram 
negative bacteria. To date, little research has been undertaken to enable MoeA to overcome this 
barrier in Gram negative bacteria. Polymyxin B (discussed in section 5.4.2) has been used to improve 
the delivery of MoeA in E. coli but the study was limited to only this organism23. Moreover, there 
have been no published studies with regards to MoeA delivery in resistant Gram negative bacteria. 
MoeA shows activity against E. coli BAS849 (which have damaged outer membranes24) as well as 
against stomach H. pylori21 thereby providing strong evidence that the antibiotic potency of MoeA is 
limited by its ability to reach the GT51 target in case of the Gram negative bacteria. Additionally, it 
has been shown that the binding constant of MoeA to the full length PBPs isolated from 16 different 
species of bacteria (Gram negative and Gram positive) is in the same nM range in case of both 
bacteria18. The binding constants are indicative of the in vitro antimicrobial activity of MoeA. 
However, a similar trend is not observed for the in vivo model wherein MoeA is active against Gram 
positive bacteria and not against the Gram negative bacteria. This further suggests the inability of 
MoeA to reach its target GT51 in case of Gram negative bacteria. The main focus of the current work 
is to enable MoeA to reach its target GT51 in Gram negative bacteria by improving its delivery using 
a non-covalent approach. Through this approach we are exploiting the non-covalent interactions 
between MoeA and peptides, which result in the formation of non-covalent complexes capable of 
crossing the negatively charged barrier of Gram negative bacteria. Within this study, a non-covalent 
peptide based delivery system has been developed to enable the delivery of MoeA across the Gram 
negative outer membrane with the aim of improving localized MoeA concentrations in proximity to 
the GT51 target. The effect on activity MIC (minimal inhibitory concentration) was determined for 18 
individual peptides in combination with MoeA. The structure for the peptide-MoeA complex for one 
of the leading compounds was determined by NMR spectroscopy. 
 
6.6 Proposed Mechanism of delivery of MoeA in Gram negative bacteria 
 
The surface of the outer membrane (OM) in Gram negative bacteria is overall anionic due to an 
excess of negatively-charged head-groups on the lipopolysaccharides (LPS) such as phosphates.25 
MoeA is negatively charged due to the presence of a phosphate and a carboxylate functionality, and as 
a result these negative charges of LPS and MoeA are expected to repel each other. For this reason, 
short cationic as well as amphipathic peptides have been selected in view of their known non-covalent 
interactions with negatively charged cell membranes (phosphates) and as they provide critical 
electrostatic, hydrogen bonding and hydrophobic interactions26. Interaction of cationic or amphipathic 
peptides with MoeA will mask the negative charges of MoeA thereby minimising repulsion and 
enabling the delivery of MoeA to the target GT51 in Gram negative bacteria. A series of short, 
cationic delivery peptides has been developed, which act as delivery agents. The peptide sequences 
are chosen based on their known ability to cross cell barriers and in certain instances deliver suitable 
cargoes such as proteins, drugs and fluorophores27, 28. They can be easily synthesized using automated 
Solid Phase Peptide Synthesis (SPPS) and commercially available, natural amino acids. Moreover, the 
syntheses do not require any special amino acid building blocks or complex steps and can therefore be 
done a highly cost-effective and efficient manner. MoeA is isolated in high purity from the 
commercially available Flavomycin using the procedure described in literature10. 
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Figure 6.3: A. Scheme for the proposed mechanism of the delivery of MoeA using MoeA-peptide non-covalent 
complexes in case of Gram Negative Bacteria. B. The crystal structure of PBP1b is represented as a ribbon 
diagram. The TM, UB2H, TG, and TP domains are color coded in cyan, yellow, red, and blue respectively. All 
figures of 3D structural representations were made with PyMOL (www.pymol.org).  C. Section showing 
Moenomycin A (bound) as a ball and stick model. 
 
Simple mixing of these peptides with MoeA (in a 1:1 ratio in terms of moles) resulted in MoeA-
peptide non-covalent complexes, the formation of which has been verified by NMR. An in depth 
NMR study described in subsequent sections further supports the hypothesis that MoeA-peptide 
complexes are able to cross the outer membrane barrier in Gram negative bacteria thereby enabling 
MoeA to reach its intended target – GT51 (Figure 6.3). This is the first strategy of its kind for MoeA 
and can be further expanded and developed into a screening platform for testing delivery capabilities 
of different peptides in Gram negative bacteria via a simple mixing approach. 
 
6.7 Peptide Design and syntheses 
 
Most antimicrobial peptides (AMPs) such as pexiganan (22 amino acids) are long and rich in positive 
charges. Short AMPs, such as MP196 (synthetic hexapeptides) are not active against Gram negative 
bacteria29, 30. For this study we have designed non-toxic short peptides (4-9 amino acids) as delivery 
systems for MoeA. Choosing longer peptides which have antimicrobial activity by themselves is not 
advisable in this case because that would result in increased toxicity31. 
 
In the current study, the residues of the delivery peptides have been tuned to obtain the most suitable 
peptide depending on the target bacteria. MoeA in itself is ineffective against P. aeruginosia and K. 
pneumoniae which are resistant to Ampicillin as well. However, it does show activity against A. 
baumannii (MIC ~4 µg/mL). In the other two cases, the most likely reason for inactivity is due to the 
like charge repulsion mainly between the phosphate and the carboxylate of MoeA with the phosphates 
of the bacterial outer membrane. This results in a non-insertion of the compound into the outer cell 
membrane. The hypothesis is that the cationic peptides rich in Arg32 and Lys synthesized, known for 
their cell permeability, manage to mask the repulsion between MoeA and the outer cell membrane of 
Gram Negative Bacteria, enabling MoeA to reach its target. For the purpose of this study, the linear 
peptide sequences in Table 6.1 have been designed and synthesized as the most suited candidates for 
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the delivery of MoeA. The common denominator between all the peptides is the high percentage of 
cationic residues.  These residues are vital for delivery of the negatively charged MoeA. 
Sr. 
No. 
Code Peptide # of Arg/Lys 
residues 
Max.  
Theoretical Chargea 
1 1 RRRRRRRRR 9/0 10+ 
2 2 KRRKRRKRR 6/3 10+ 
3 3 KKKKKKKKK 0/9 10+ 
4 4 RRRRRRRR 8/0 9+ 
5 5 RKKRRQRRR 6/2 9+ 
6 6 KKKKKKKK 0/8 9+ 
7 7 RRWWRRWRR 6/0 7+ 
8 8 KKKKKR 1/5 7+ 
9 9 RRRRR 5/0 6+ 
10 10 KKKKK 0/5 6+ 
11 11 RRRR 4/0 5+ 
12 12 KKKK 0/4 5+ 
13 13 RRR 3/0 4+ 
14 14 KKK 0/3 4+ 
15 15 RR 2/0 3+ 
16 16 KK 0/2 3+ 
17 17 H2N-R-COOH 1/0 1+ 
18 18 H2N-K-COOH 0/1 1+ 
Table 6.1: List of delivery peptides designed and synthesized (N-terminal free, C terminal amide except for 
entries 17 & 18). aMax Theoretical charge = No. of cationic residues + 1 due to the free N terminus except for 
entries 17 & 18. 
 
Figure 6.4: Schematic showing the membrane targeting of bacteria using cationic peptides and specificity 
arising due to differences in the outer membrane structure. Modified from ref. 33 
 
The common denominator between all these peptides is the high percentage of cationic residues.  
These residues are vital for the delivery of the negatively charged MoeA. An additional advantage of 
these cationic peptides lies in the fundamental difference in the structure and composition of the 
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membranes of microbes versus mammalian cells (Figure 6.4). Based on the current understanding, 
bacterial membranes in Gram negative bacteria are organized in such a way that the outer membrane 
is exposed to the environment. This membrane is heavily populated by lipids with negatively charged 
phospholipid head groups. In contrast, the outer leaflet of the membranes of plants and animals is 
composed principally of lipids with no net charge. As described by the Shai-Matsuzaki-Huang (SMH) 
model34, 35, 36 most of the lipids with negatively charged head groups are segregated into the inner 
leaflet, facing the cytoplasm33 (Figure 6.4). In case of the bacterial outer membrane the model 
proposes that the interaction of the peptide with the membrane is generally followed by displacement 
of lipids, alteration of membrane structure, and in certain cases entry of the peptide into the interior of 
the target cell. In case of plants and animals, the presence of cholesterol in the target membrane 
reduces the permeabilization capacity of cationic peptides in general, either due to stabilization of the 
lipid bilayer or due to interactions between cholesterol and the peptide.34 We thus envisage obtaining 
selectivity towards bacterial membranes via this cationic peptide delivery approach.  
The synthesis of hydrophobic protected peptides, particularly R8 which contains 8 Pbf protecting 
groups required special protocols to avoid deletion sequences. Therefore, optimized µwave assisted 
Fmoc Solid Phase Peptide Synthesis (SPPS) on a pure PEG based resin such as Rink Amide 
Chemmatrix Resin was used for the syntheses of the peptides. A hydrophilic resin backbone ensured 
that the sequence does not fold back on to the resin. Furthermore, DIC/Oxyma was used as the 
coupling mixture ensuring efficient coupling.37 The peptides were subsequently cleaved using 
standard TFA conditions and purified using RP-HPLC (for detailed protocols see experimental 
section for chapter 6). 
 
Figure 6.5: Amide bond coupling mechanism using DIC/Oxyma as a coupling mixture. PG stands for 
protecting group. X denotes the linker attached to the resin. The amide bond is marked in red.  
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6.8 Antibacterial activity: Minimum Inhibitory Concentration (MIC) values 
 
MIC testing was performed by Charlotte S. Vincent who is thanked for her valuable contribution to 
this work. A summary of the MIC results are shown below: 
 
 
Table 6.2: Summary of results when the delivery peptides are used with Moenomcyin in a ratio 1:1 (in terms of 
mM). MIC: Minimum Inhibitory concentration (in µM). GAW = Growth in all wells even at a concentration of 
256 µg/mL. Strains used: K. pneumoniae ATCC 700603, A. baumannii ATCC 19606, P. aeruginosa ATCC 
27853. Best MIC values have been marked in red. 
 
In order to investigate the role of a peptide delivery system on MoeA activity three resistant Gram 
negative bacterial strains were selected namely, K. pneumoniae, A. baumannii and P. aeruginosa. In 
first instance, all the peptides were tested in the absence of MoeA for antibacterial activity and no 
activity was observed (Table 2, full table included in SI). Secondly, MoeA in the absence of a delivery 
peptide gave MICs of 40.46 µM, 2.53 µM and 161.86 µM for the three bacteria – K. penumoniae, A. 
baumannii and P. aeruginosa, respectively. The bacteria were found to be resistant to Ampicillin. 
Finally, a combination of 1:1 molar ratios of peptide to MoeA were tested. The main observations for 
each bacterium can be summarized as follows: 
 
P. aeruginosa. Peptide 7 (Table 1) was found to be the best delivery peptide in case of P. aeruginosa 
closely followed by peptide 2 since their corresponding non-covalent complexes (formed by mixing 
the peptide with MoeA in ratio 1:1 in terms of moles), 2+MoeA and 7+MoeA (Table 6.2, entries 20 & 
Sr. 
No. 
Code Sample 
Name 
K. pneumoniae  A. baumannii  P. aeruginosa  
   MIC MIC MIC 
1 19 1+Moe A 10.65 10.65 10.65 
2 20 2+Moe A 5.48 5.48 5.48 
3 21 3+Moe A 11.63 0.73 11.63 
4 22 4+Moe A 11.24 11.24 11.24 
5 23 5+Moe A 2.74 21.92 10.96 
6 24 6+Moe A 12.20 0.38 12.20 
7 25 7+Moe A 10.34 1.29 5.17 
8 26 8+Moe A 13.36 6.68 13.36 
9 27 9+Moe A 13.45 0.21 13.45 
10 28 10+Moe A 28.58 0.45 14.29 
11 29 11+Moe A 7.20 0.22 14.39 
12 30 12+Moe A 15.16 0.24 30.32 
13 31 13+Moe A 15.48 0.97 30.96 
14 32 14+Moe A 32.27 1.01 32.27 
15 33 15+Moe A 33.49 1.05 33.49 
16 34 16+Moe A 34.50 1.08 69.01 
17 35 17+Moe A 36.45 1.14 36.45 
18 36 18+Moe A 37.04 1.16 74.08 
19 37 Moe A 40.46 2.53 161.86 
20 38 Ampicillin GAW - GAW 
21 39 Entries 1-18 GAW GAW GAW 
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25) showed MIC values of 5.17 μM and 5.48 μM, respectively, which amounts to a 30 times 
improvement in antibacterial activity compared to MoeA alone (MIC 161.86 μM).  We reasoned that 
the structure of polyarginine is possibly too rigid and also the fact that it binds too tightly to MoeA 
itself (polyarginines are particularly attracted to the phosphates as is observed in case of DNA binding 
peptides that all contain a significant percentage of arginines38) to be a suitable delivery peptide. 
Subsequently, insertion of Lys residues at positions 1, 3 & 6 of R9 was considered resulting in the 
sequence KRRKRRKRR of peptide 2. It was indeed shown that peptide 2 shows better delivery 
capability for MoeA than 1. Besides Arg and Lys, a very important residue for cell permeability is 
Tryptophan (Trp). Trp, has been known to interact with lipid membranes and especially within basic 
peptides it can trigger glycosaminoglycan-dependent endocytosis39. Certain Trp containing cationic 
peptides also have antimicrobial properties40. However, since Trp interacts strongly with lipids, it is a 
concern that it will interact strongly with the lipid tail of MoeA and render it useless. Therefore, the 
number of Trp residues is to be restricted in case of designing delivery peptides. We chose a Trp-
mutant of the TAT peptide described in literature40 (7) as the most suitable Trp containing delivery 
peptide for MoeA and from the MIC it is clear that 7 is indeed the lead peptide. Among the 
polyarginines, R9+MoeA (19) showed only a slight improvement in MIC as compared to R8+MoeA 
(22) with MoeA, but an overall 15 times improvement in antibacterial activity. The polylysines K9 (3) 
and K8 (6) also follow a similar efficiency profile with K9+MoeA (21) showing marginally improved 
activity over K8+MoeA (24). The truncated TAT sequence 5+MoeA (23), has comparable activity to 
those of the polylysines and polyarginines. The complexes 8+MoeA (26) and 9+MoeA (27) show 
almost the same activity and so do 10+MoeA (28) and 11+MoeA (29). Interestingly, there is a 
difference of only 3.15 μM in terms of antibacterial activity for the complexes formed using R8 (22) 
and R4 (29). This is quite an unexpected result as R8 in particular is known to have a much higher cell 
penetration ability as compared to R441. However, this makes the methodology quite valuable since 
longer Arg or Lys sequences are not required for the delivery of MoeA thereby considerably reducing 
the complexity of the system, meanwhile providing a simultaneous saving on material cost and 
synthesis time. Since the guanidium group of arginine is more basic (pKa ~12.5) than the side chain 
of Lysine (pKa ~10.5)42, it was expected that R9 and R8 should have better permeabilization 
capacities and hence perform better delivery than K9 (3) and K8 (6)43. However, this was not the case 
as the MICs observed in case of 1+MoeA & 4+MoeA (19 & 22) as compared to 3+MoeA & 6+MoeA 
(21 & 24) are almost the same. 
 
K. pneumoniae. Peptide 5, truncated from the original TAT sequence (47-57) thereby resulting in the 
new sequence RKKRRQRRR was found to be the best delivery peptide in case of K. pneumoniae 
with its corresponding complex with MoeA (5+MoeA, 23) giving an MIC of 2.74 µM, a 15 times 
improvement compared to MoeA alone. Two other impressive delivery peptides were found in case of 
K. pneumoniae, namely KRRKRRKRR (2) & R4 (11). Their corresponding complexes with MoeA 
gave MICs of 5.48 µM (~7.3 times increase) and 7.2 µM (~5.5 times increase), respectively. Peptide 7 
RRWWRRWRR in combination with MoeA (25) shows a ~4 times improvement in activity with an 
MIC of 10.34 μM closely followed by R9 1+MoeA (19) with an MIC of 10.65 μM.  
 
A. baumannii. It is to be noted that MoeA in itself gives an impressive MIC of 2.53 μM in A 
baumannii. This value further improves with certain peptides. To summarize, we have seen a ~10 
times improvement in MIC with values of 0.21 µM, 0.22 µM and 0.24 µM when the delivery peptides 
R5 (9), R4 (11) and K4 (12) were used in combination with MoeA (27, 29 and 30), respectively. 
Surprisingly K8+MoeA (24) showed almost twice as much activity as K9+MoeA (21). The shorter 
peptide K5 (10) + MoeA (28) also showed an impressive 5.5 times improvement in antibacterial 
activity. Peptide sequences having 4 or lower than 4 positive charges show a comparable MIC value 
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with an overall 2 times improvement in MIC as can be seen from Table 2 entries 31-36. We thus have 
a large number of peptide-MoeA non-covalent complexes with excellent activity against A baumannii 
which is critical for antibiotic development since A. baumannii has developed resistance against 
almost all known classes of antibiotics.44 The MIC trend when different peptides are used in 
combination with MoeA is thus quite interesting. Shorter sequences have shown an improvement in 
MIC as discussed above, whereas longer sequences such as R9 (1), KRRKRRKRR (2), R8 (4) and the 
truncated TAT sequence (5) have actually resulted in poorer MIC values. Rigidity and phosphate 
binding once again could be an explanation for this discrepancy in expected trend of MIC values 
particularly in the cases of R9 (1) and R8 (4). 
 
Based on the MIC results summarized in table 6.2 we can conclude that at least 4 positively charged 
residues are required in the peptide sequence for effective delivery of MoeA. The higher number of 
charges are required for the efficient neutralization of the two negative charges of MoeA. We can also 
conclude that Trp is an important residue if activity is required in combination with a lower number of 
positive charges. A balance of Arg and Lys residues is required when targeting P. aeruginosa and K. 
pneumoniae, however, A. baumannii has higher affinity for Lys than Arg. Therefore, substitution of 
Arg with Lys permits the selective targeting of this bacterial species. 
 
We have established that the inability of MoeA to cross the outer bacterial membrane and reach its 
target GT51 situated on the periphery of the inner membrane is the main reason for its inactivity. We 
have also shown that through the use of bacterial membrane permeable peptides, MoeA can be made 
effective against Gram negative bacteria. It is obvious that the higher the delivery capability of a 
peptide in a specific strain of bacteria, the better the delivery of MoeA. Increased antibiotic 
concentration results in a lower MIC. Although the MIC will also depend on the binding capacity of 
the peptides to MoeA, the MICs of peptide-MoeA complexes still provide a good indication of the 
delivery capability of peptides into bacterial membranes. In order to check for permeability into cells 
(as described in chapter 4) fluorescent labelling is almost always required. Currently, to the best of 
our knowledge, there are almost no general screening protocols capable of testing the permeability of 
peptides through gram negative bacterial membranes without labelling. Through the formation of 
peptide-MoeA complexes and measurement of MICs, we have essentially established protocols for 
the screening of peptides in terms of their delivery capacities without the requirement of any labelling. 
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6.9 Cytotoxicity Studies 
 
Timea Palmai Pallag is thanked for her valuable contribution for testing the compounds for toxicity. 
 
One of the key aspects in designing a delivery peptide is low toxicity. Therefore, we tested all the lead 
peptides without (refer experimental section) and in combination with MoeA (Figure 6.6) against the 
HeLa cell line and did not observe any significant toxicity (relative survival 70-90%) until a 
concentration of 100 µM. It should be noted that the Trp containing peptide 7 is more toxic compared 
to the other peptides at a 100 µM concentration. 
 
Figure 6.6. Toxicity results showing relative survival vs. Concentration (in µM). 
 
6.10 NMR studies: Decoding the molecular structure of the MoeA-Peptide 7 non-covalent 
complex 
 
Dr. Stephen Prior is thanked for his invaluable contribution in performing the NMR experiments on 
the MoeA-peptide 7 non-covalent complex, structural calculations, figures, the structural 
determination of the complex and its description. 
 
In order to better explain the reasons behind the activity of the MoeA-peptide non-covalent complex, 
extensive NMR studies were performed, followed by detailed structural calculations. For this purpose, 
the MoeA-peptide 7 complex was chosen as it is one of the leading non-covalent complexes capable 
of targeting all three Gram negative bacteria. 
 
The structures of MoeA and peptide 7 were fully assigned at both 4 and 27°C (see experimental 
section for chapter 6, table 3 for chemical shifts). By following the linewidth of well-resolved protons 
throughout the titration of MoeA into peptide, the complex was shown to be in intermediate exchange, 
thus severely hampering spectral interpretation. Cooling the sample down to 4°C was found to move 
the complex into the fast to intermediate exchange regime. This sharpened the peaks considerably (for 
instance the NOE cross-peak between 4TrpHε1 and 4TrpHε3/Hζ2 sharpened from a half-height peak 
width of ~65 Hz at 27°C to ~20 Hz at 4°C) and therefore enabled the detection of significantly more 
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NOEs (Figure S36). Despite the relatively broad peaks ~600 NOEs were unambiguously assigned of 
which ~100 were intermolecular (Table 3), which was sufficient to allow a full structural 
characterisation of the complex (Figure 6.6A). 
 
The resulting ensemble of the complex converged to a pairwise ordered-atom RMSD of 1.3 Å 
(experimental section for chapter 6, table 3 and table 4), with the MoeA component accounting for the 
majority of this variation, with an RMSD of 1.5 Å. The well-ordered atoms include the heavy atoms 
of the peptide; and sugars C, D, E and F, and the lipid tail of MoeA. Sugars A and B were found to be 
disordered. This is not surprising for a large flexible molecule involved in a complex of moderate 
affinity, and the structural flexibility of MoeA has been observed previously.11 The peptide, by 
contrast, was extremely well resolved (RMSD of 0.9 Å). The complex is of sufficient resolution to 
identify the nature of the interaction. Central to this interaction is the indole ring of 4Trp which 
exhibits a number of strong NOEs to the lipid tail of MoeA (Figure S36). In the final structure this 
indole ring is observed to bury itself into a hydrophobic pocket formed by the lipid tail and sugars F, E 
and D of MoeA (Figure 4B). This buries a total of 92.9 ± 12.3 Å2 at the interface. The interaction is 
further stabilised by hydrogen bonds between 1Arg and 9Arg of the peptide and sugars C and F 
(Figure 4 B), which provide the hydrophobic pocket with a slightly polar rim. Sugar A was not 
involved in any intermolecular interactions and therefore considerably more disordered in solution. 
Quite surprisingly the charged phosphate moiety of MoeA plays no part in the interaction. 
 
It is an interesting observation that the MoeA-distal surface of the peptide is almost perfectly planar 
and projects a number of arginine and tryptophan side chains, thus putting these side chains in a 
perfect orientation to interact with a cell membrane: tryptophan and arginine are often involved in 
membrane recognition events45, and could therefore facilitate trafficking of the MoeA across the 
bacterial membrane. 
 
A schematic representation of the MoeA-peptide 7 complex has been displayed in figure 6.8 through 
which it is clear that the hydrophobic interaction between the side chain of the Trp residue and rings 
C, E and F and lipid tail of MoeA (figure 5) are the most dominant interactions of the complex. 
Hydrogen bonding between the N-terminal Arg and ring B of MoeA and the C-terminal Arg with the 
lipid tail and ring D further stabilize the MoeA-peptide non-covalent complex. A third hydrogen bond 
is observed between the C terminal amide and D ring of MoeA. Furthermore, the phosphate is a non-
participant and is far away from the MoeA-peptide interface. This result provides a plausible 
explanation for the comparable activities of 11+MoeA, 1+MoeA and 4+MoeA. Longer, polyarginine 
peptide sequences containing several basic residues show significantly higher phosphate binding 
affinity and could, in theory, also bind to the phosphate of MoeA. Since the phosphate is essential for 
activity, increasing the number of arginines does not ensure a better delivery peptide. It could also 
explain why Lys residues in combination with Arg show better activity (refer table 2, entry 1+MoeA 
& 2+MoeA) as, although polylysine is equally prone to unspecific interactions, Lys is less basic than 
Arg and consequently binds less tightly, thereby making these interactions reversible indicating a 
possibility of MoeA release once inside the periplasm. Trp in certain instances has been known to 
influence the binding of the peptide to lipids.46 Moreover, given a polar protic medium like water, 
hydrophobic interactions have been known to have significant effect in Trp containing cationic 
peptides47. A similar result has been observed in this case making Trp containing peptides valuable for 
the delivery of MoeA. 
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Figure 6.7: Solution 
structure of complex formed 
between peptide and 
Moenomycin A.  
 
(A) NMR ensemble of 7 
lowest energy conformers 
derived from 600 observed 
NOEs. Ensemble converged 
to an ordered atom pairwise 
RMSD of 1.33 Å. Peptide 
shown as teal lines; MoeA 
by gold lines. The conformer 
most structurally similar to 
the ensemble average is 
shown in sticks, and the 
peptide as surface. Sugars A 
and B were found to be 
disordered in solution. For 
clarity, hydrogen atoms have 
been omitted.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(B) The lipid tail and 
phosphate-proximal sugar 
rings of MoeA form a 
hydrophobic pocket with a 
relatively polar rim into 
which 4Trp of the peptide 
inserts, which is stabilised 
by hydrogen bonds donated 
by 1Arg and 9Arg to the 
polar rim. Peptide shown as 
teal sticks; MoeA by gold 
surface; hydrogen bonds as 
green dashes; and 
hydrophobic contacts (C-C 
distance < 3.9 Å) as teal 
dots.  
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Figure 6.8. Schematic representation of observed contacts between peptide 7 and MoeA. Peptide 7 
(from N to C, left to right) is shown as black lines; MoeA moeities are shown in red; hydrogen bonds 
are shown as blue stipples; areas of hydrophobic contact are shown as grey arcs. 
 
A schematic showing the MoeA-peptide 7 complex has been shown in figure 6.8. From the schematic, 
one can clearly observe that the hydrophobic interaction between the side-chain of the Trp residue and 
the rings C, E and F and lipid tail of MoeA (figure 6.8) are the most dominant interactions of the 
complex. Hydrogen bonding between the N-terminal Arg and ring B of MoeA and the C-terminal Arg 
with the lipid tail and ring D further stabilize the MoeA-peptide non-covalent complex. A third 
hydrogen bonding is observed between the C terminal amide and D ring of MoeA. Furthermore, the 
phosphate is a non-participant and is far away from the MoeA-peptide interface. Since the phosphate 
is essential for the activity of MoeA, it could explain why having several basic residues, as in case of 
R8 and R9, does not improve the activity beyond a certain limit, as these peptides could, in theory, 
bind to the phosphate, thereby destroying the activity of MoeA. It could also explain why Lys 
residues in combination with Arg show better activity (refer table 2, entry 1+MoeA & 2+MoeA) as 
although polylysine is equally prone to unspecific interactions, Lys binds less tightly being a 
monodentate ligand as compared to Arg which is a bidentate ligand. Therefore, interactions involving 
lysine can be reversible, indicating a possibility of MoeA release once inside the periplasm. Trp, in 
certain instances, has been known to influence the binding of the peptide to lipids46. Moreover, given 
a polar, protic medium like water, hydrophobic interactions have been known to have significant 
effect in Trp containing cationic peptides.47 A similar result has been observed in this case, making 
Trp containing peptides valuable for the delivery of MoeA. 
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A summary of the structural statistics of the MoeA-peptide 7 complex is mentioned here: 
 
Pairwise RMSD of complex components 
    Peptide heavy atom (Å) 0.91 ± 0.26 
    Moenomycin  
        Core atoms (Å) 1.48 ± 0.23 
        Heavy atomIII (Å) 1.81 ± 0.43 
    Complex  
        Core atoms (Å) 1.33 ± 0.17 
        Heavy atom (Å) 1.62 ± 0.34 
Experimental restraints  
    Peptide NOEs 397 
    Moenomycin NOEs 112 
    Complex NOEs  
        Intermolecular   98 
        Total 607 
    Restraint violations > 0.3 Å     3 
RMSD from idealised covalent geometry 
    Bond lengths (Å) 0.01 ± 0.00 
    Bond angles (°) 1.41 ± 0.05 
    Ramachandran analysis (determined by PROCHECK48) 
        Allowed regions (%)  93.9 
        Generously allowed regions (%)   6.1 
Statistics of overall structural quality 
    PROCHECK G-factor -0.33 ± 0.05 
    ProSA49 Z-score   0.81 ± 0.08 
    MolProbity50 clash score   4.82 ± 0.09 
Table 6.3. Structural statistics of peptide/MoeA complex ensemble 
 
6.11 Conclusion 
 
We have successfully identified poor delivery of MoeA as one of the key problems for its lack of 
activity against resistant Gram negative bacteria. Subsequently, we have designed a novel peptide-
based, non-covalent delivery system specifically for MoeA, which enables for the first time in over 
five decades to target three resistant Gram Negative bacterial strains – K. pneumoniae, A. baumannii 
and P. aeruginosa. Furthermore, we have shown that although all three are Gram negative bacterial 
species with similar robust outer membranes, they behave quite differently towards the same set of 
peptide-MoeA non-covalent complexes. We have tuned the peptides in order to obtain up to 30 times 
improvement in MIC values. Until now, it has been believed that longer, synthetically more 
challenging polyarginine sequences are required for drug delivery51. We have shown, for the first time 
that MoeA delivery can be achieved effectively even through shorter sequences such as R4. By 
designing different delivery peptides (which are combined with MoeA via a simple mixing approach) 
we have demonstrated the selectivity of our approach to target a specific bacterial strain. Peptides 9 
(R5), 11 (R4) & 12 (K4) promote the delivery of MoeA best in A. baumannii, whereas 5 
                                                          
III Core atoms are well ordered moieties. These are: the heavy atoms of the peptide; and sugars C, D, E and F, and the lipid 
tail of MoeA. Sugars A and B were found to be disordered. 
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(RKKRRQRRR) is selective for MoeA delivery in K. pneumoniae. Peptide 2 (KRRKRRKRR) on the 
other hand can perform delivery in all 3 species of bacteria simultaneously. 7 
(RRWWRRWRR)+MoeA shows excellent activity in P. aeruginosa and moderate to high activity in 
A. baumannii and K. pneumoniae. As toxicity is one of the key factors in case of delivery, we have 
established that all peptides as well as the MoeA-peptide non-covalent complexes they form are not 
toxic towards mammalian cell lines up to a tested concentration of 100 µM. 
  
We have performed a detailed NMR analysis followed by extensive structural calculations revealing 
for the first time the molecular structure of a peptide-MoeA complex at an extremely impressive 1.3 Å 
resolution. We have proven that the two components interact in a 1:1 ratio further supporting the 
mechanism that the peptides bind to MoeA and then enable its delivery in Gram negative bacteria. We 
were thus able to deduce the key interactions between peptide 7 and MoeA. Surprisingly, we observe 
that the phosphate is not part of the interaction showing an example where although arginines and 
phosphates are present in the same solution, they need not necessarily interact with one another. 
Moreover, a simple mixing approach provides a platform to test the delivery capability of different 
peptides using MoeA without any conjugation. 
 
Thus, we believe this work to be crucial for any further development of MoeA especially in the case 
of resistant Gram negative bacteria. In a time where new and novel antibiotics particularly against 
these resistant bacteria are critical, this work lays the foundation for the development of new 
antibiotics based on MoeA. 
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CHAPTER 7 
 
PEPTIDE-MOENOMYCIN A CONJUGATES AS MULTIFUNCTIONAL 
ANTIBIOTICS AGAINST GRAM NEGATIVE BACTERIA 
 
 
In the previous 
chapter, we 
described a novel 
approach for the 
delivery of 
Moenomycin A 
(MoeA) in Gram 
negative bacteria 
and proposed a 
plausible 
explanation for the 
mechanism of 
action. In this 
chapter, we will 
take a look at some 
of the chemical 
modifications of 
MoeA described in 
literature, along 
with resistance to 
MoeA. We also 
describe an optimized synthetic route which allows, for the first time, covalent linkage of peptides to 
MoeA. A simple visualization of a peptide-MoeA covalent conjugate is shown on the left. The 
conjugate retains the structure of MoeA and the peptide is linked through MoeA via a suitable linker. 
Other molecules conjugated to MoeA have, in most instances, resulted in a decrease in antimicrobial 
activity against Gram positive bacteria. However, in this case, we have seen ~30 times improvement 
in antimicrobial activity of the peptide-MoeA conjugate against the resistant Pseudomonas 
aeruginosa. 
 
7.1 Introduction 
 
The results described in Chapter 6 show that MoeA can be used as an antibiotic against the resistant 
Gram negative bacteria. Other aspects need to be considered however if MoeA is to be developed into 
an antibiotic, such as resistance to MoeA particularly in case of Gram negative bacteria. As described 
in chapter 5, these bacteria have a tendency to develop resistance much more quickly than Gram 
positive pathogens. The other problem is binding of MoeA to plasma proteins which results in a low 
unbound fraction, decreased potency and poor pharmacokinetic properties of MoeA making it 
unsuitable for human use. In this chapter we will describe the covalent linkage of suitable peptides to 
MoeA resulting in a single molecule. Through this approach we envisage to further improve the 
potency of MoeA against Gram negative bacteria and reduce its plasma binding capability thereby 
increasing the scope for therapeutic applications. 
Peptide
Lipid 
Tail of 
MoeA
Linker
Sugars (B-F) 
of MoeA
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7.2 Structure-activity relationships of MoeA 
 
Through selective degradation of MoeA and the synthesis of di- and trisaccharide analogues, it is now 
believed that sugars C, E & F, the 3-phosphoglyceric acid and the lipid tail constitute the minimum 
pharmacophore of MoeA (Figure 7.2, highlighted in blue)1, 2, 3. The degradation of MoeA to chemical 
entities containing the carbohydrate units C, E and F can be performed. These molecules  retain the 
transglycosylase inhibition and antibacterial activity4, 5. Degradation with removal of the C unit in 
addition to the A and B units to retain only the E and F carbohydrate units, still allows for 
transglycosylase inhibition but no antibacterial activity2. The C25 lipid chain is crucial for obtaining 
maximum anti-bacterial activity of MoeA. Unfortunately, it also results in an unusually long half-life 
in addition to poor bioavailability and making it incompatible as an antibiotic for humans6. The 
inhibitory ability of MoeA is directly proportional to the decrease in the length of the lipid chain5, 
most likely as a result of a loss of ability to anchor itself into the cytoplasmic membrane. Modifying 
or truncating the lipid chain has been known to improve pharmacokinetic properties. However, the 
loss of activity needs to be compensated by maintaining essential polar active-site contacts or by the 
incorporation of other hydrophobic chemophores with suitable properties7. 
 
 
Figure 7.1: Structure of MoeA showing the minimal inhibitory pharmacophore (in blue) which can be used as a 
scaffold for the design of new potential inhibitors for bacterial transglycosylases. Modified from ref. 8 
 
A break-up of the importance and roles of the individual units of MoeA can be summarized as 
follows8: 
1. A & B units: These rings are not part of the minimal inhibitory pharmacophore of MoeA and, 
therefore, are ideal for chemical modification, and may be used as attachment points for other 
molecules. 
2. Sugar Units C, E & F: These are the minimum units of the pentasaccharide required for 
antibacterial activity. 
3. Rings C and E: These rings bind in the same way as a N-Acetylglucosamine-N-
Acetylmuramic acid sugars (NAM-NAG disaccharide) of the lipid II substrate. 
4. Rings E and F: The structure of ring E is similar to that of NAG whereas that of F is similar 
to NAM in Lipid II. 
5. D Ring: Losing the D ring does not affect antibacterial activity.  
6. Phosphoric Acid diester group: This group is similar in structure to the pyrophosphate in 
Lipid II and probably mimics it. The function of this group could be to direct the C25 lipid 
chain towards the membrane. 
7. C25 lipid chain: The lipid chain part of MoeA is similar to the C35 chain in Lipid II and 
enables anchoring of MoeA. 
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8. Both the C25 chain and the phosphoglycerate are essential for the binding of MoeA to the 
transglycosylase. The phosphoryl group forms electrostatic interactions with conserved 
residues in the TG active site. 
 
7.3 Important analogues of MoeA described in literature 
 
The revival of MoeA ensured in-depth research into the molecule. From a synthetic point of view, the 
total synthesis of MoeA9, synthesis of its analogues as well as degradation products8 were published. 
Most of the analogues of MoeA described here are less potent than the parent molecule. We will not 
discuss those molecules which show little or no antimicrobial activity10, 11, 12. Some of the analogues 
possess antibacterial activity, particularly against a wide variety of Gram positive bacteria, and are 
also important from a synthetic point of view, and are therefore worth mentioning. One or two, 
however, are more potent than the parent molecule against certain species, particularly those with 
lipid tail modifications  are of particular interest7. Depending on the type of modification, two types of 
analogues of MoeA are described herein: 1. degradation products of MoeA and 2. lipid tail 
modifications of MoeA. Some of the important studies, with brief descriptions of the analogues, are 
summarized herewith: 
 
 7.3.1 Type I: Degradation products of MoeA 
 
1. The fact that the degradation products of MoeA exhibit inhibitory activity against 
transglycosylases led to a study in 1999 by Sofia et al. As part of this study, a combinatorial 
library consisting of 1300 analogues of the MoeA disaccharide core was synthesized.13 These 
analogues were focussed on modifications at C2 of the E ring and C3 of the F ring of MoeA, 
which form the critical interaction points of MoeA with the transglycosylase domain. 
Modifications included aromatic groups attached to the E and F rings and a lipid tail of 12 
rather than 25 carbons. Three compounds showed particular promise14 (Figure 7.2, I-III. 
Original names: TS30153, TS30663 and TS30888 respectively). These compounds were 
significantly less potent than MoeA (<100 fold), but had IC50 values in the range of 10–15 
µM.15 Most noteworthy is that these analogues exhibited activity against Gram-positive 
strains, particularly Enterococcus faecium, which has tolerance to MoeA. This indicates 
simple degradation compounds of MoeA are capable of showing potency against clinically 
relevant pathogens. 
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Figure 7.2: Analogues of MoeA as described in ref. 14. 
 
2. In 2006, Halliday et al.16 revisited the 
disaccharide scaffold described by Sofia et al. in 
1999. His class of compounds also involved 
maintaining the important transglycosylase 
binding regions. MIC values of 1-4 µg/mL were 
obtained for the lead compounds against a broad 
range of Gram-positive organisms.16 13 One 
example compound from this class is ACL 
19273 (Figure 7.3). This molecule showed 
direct binding and inhibition of the 
transglycosylase domain. The binding site, 
however, is unknown and could be either the 
acceptor or donor site of the enzyme. Inhibitors 
that bind to the transglycosylase acceptor site are of particular interest, as it is in complete 
contrast to where MoeA binds. This makes the study of these small disaccharides of particular 
interest, especially if they bind to the acceptor site. Determining the binding site of the 
inhibitors of transglycosylase is crucial in elucidating their mode of action.  
  
 7.3.2 Type II: Modification of the lipid tail of MoeA 
  
1. He et al. in (2000) isolated a MoeA analogue, AC326-α (Figure 7.4)17 which has a cyclic 
moenocinol chain, i.e. a diumycinol chain. The analogue has properties very similar to MoeA, 
except in case of certain Gram positive bacteria such as Enterococcus faecium where it is 
active (MIC 0.06-0.25 µg/mL and MoeA is not active). 
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Figure 7.4: Structure of MoeA analogue AC326-α as described in ref. 17. 
 
2. Several lipid modifications of MoeA were performed by Kahn, et. al. and are described in 
literature.7 Only one example is shown herein, which is of particular interest. In this case, the C25 
moenocinol chain has been replaced by a simple C20 fully saturated chain. The analogue (figure 
7.5) shows a 4-fold lower activity than MoeA in S. auerus but a 4-fold and 2-fold improvement in 
activity is observed in case of E. coli MG1655 and MR698 respectively. 
 
 
Figure 7.5: Structure of a MoeA analogue as described in ref. 7. 
 
7.4 Design and syntheses of peptide-MoeA covalent conjugates 
 
Our previous work involved the synthesis of MoeA-peptide non-covalent complexes. Although these 
complexes show up to 30-times improvement in antimicrobial activity, the non-covalent complexes 
have their limitations. The interactions between the lead peptide and MoeA in a non-covalent complex 
are strong enough to ensure that the MoeA-peptide complex is carried through the outer membrane in 
case of bacteria. However, the complex could break down if MoeA delivery is attempted in case of 
more complex multicellular organisms using the same approach. Therefore, there is a need to 
covalently link the delivery peptides to MoeA. 
 
Three important parameters are considered in the development of the peptide-MoeA conjugates: 1. 
The synthesis strategy. 2. The choice of peptide. 3. The choice of linker linking the cationic peptide 
and negatively charged MoeA. To ensure that MoeA is carried through the outer bacterial membrane, 
cationic peptides were chosen for conjugation to MoeA. New delivery peptides as well as modified 
existing delivery peptides for MoeA delivery have also been reported through this work. The key 
residues for the delivery of MoeA have been identified as lysine and arginine. 
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Figure 7.6: General strategy for the synthesis of a peptide-Moenomycin A conjugate via A ring conjugation 
A general conjugation methodology (Figure 7.6) has been designed and optimized specially for 
peptide conjugation to MoeA based on the use of a commercially available 5-amino-2-nitrobenzoic 
acid (Figure 7.8, denoted by X) linker12. This linker can be directly coupled to the peptide on solid 
phase through an amide bond linkage using standard coupling condtions without the need for any 
protecting group due to the differences in pKa of the aromatic and aliphatic amines. MoeA has been 
known to react selectively with diazonium salts at the enolized β-diketone unit18 (Figure 7.7 step 2A). 
The initial coupling product undergoes a Japp-Klingemann cleavage19 forming an amidrazone (Figure 
7.7 step 2B), which then cyclizes (Figure 7.7 step 2C) to form the final product which is a triazole. 
The initial diazonium salt formation (Figure 7.7 step 1) is very selective towards the aromatic amine, 
once again due to the differences in pKa between the amines present in the lysine and arginine side 
chains of the peptide and the amine present in the 5-amino-2-nitrobenzoic acid linker. Moreover, the 
reaction occurs at the A ring of MoeA, which has a minimal effect on the antimicrobial activity5, 8, 
making this strategy perfect for peptide conjugation to MoeA. 
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Figure 7.7: Proposed two-step mechanism of the formation of a peptide-MoeA conjugate. 
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Figure 7.8: Structures of 5-amino-2-nitrobenzoic acid (X), PEG2 linker (PEG2), PEG3 linker (PEG3) and 6-
Aminohexanoic acid linker (Ahx) used for the syntheses of peptides 1-22 (Table 7.1). 
 
Another very important aspect in the synthesis and development of the peptide-MoeA conjugates was 
the choice of the linker. MoeA is a doubly negatively charged molecule in water, due to the presence 
of a phosphate and carboxylate group. On the other hand, the peptides are cationic due to the presence 
of multiple lysine and/or arginine groups. A linker is, therefore, essential; first to have flexibility for 
the overall peptide-MoeA conjugate and, more importantly, to prevent folding of the molecule onto 
itself due to intramolecular electrostatic interactions. Three linkers were chosen for this purpose: The 
commercially available 6-aminohexanoic acid (Ahx, 7 atoms) hydrophobic linker, which was coupled 
once or twice if a longer linker was needed, and a longer PEG3 (16 atoms) hydrophilic linker. A PEG2 
(14 atoms) linker was chosen as the third linker and as a substitute for the PEG3 linker in order to 
have the exact same length as two Ahx linkers. In order to have a peptide-MoeA conjugate which 
acted as a control, peptides without linkers were also synthesized. In these cases, the 5-amino-2-
nitrobenzoic acid (X) linker was directly coupled to the peptide. 
 
Based on our previous discussion and experience in the delivery of MoeA particularly against Gram 
Negative Bacteria, a select list of 22 peptides was chosen as most suitable for conjugation to MoeA 
(Table 7.1). These peptides are primarily polylysine and polyarginine sequences including 
combinations of Lys and Arg ranging from 4 to 10 amino acids. With the exceptions of peptides 2, 8, 
11 and 15, which were assigned as control peptides, all the peptides contain at least one of the three 
flexible linkers shown in Figure 7.5. The following list of peptides were synthesized for conjugation 
to MoeA: 
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Sr. No. Code / Code for 
conjugate 
Peptide sequence Max. Theoretical 
Charge 
1. 1 / 23 X-Ahx-RRRR 4+ 
2. 2 / 24 X-RRRRRRRR 8+ 
3. 3 / 25 X-Ahx-RRRRRRRR 8+ 
4. 4 / 26 X-(Ahx)2-RRRRRRRR 8+ 
5. 5 / 27 X-Ahx-RRRRRRRRR 9+ 
6. 6 / 28 X-Ahx-RRRRRRRRRR 10+ 
7. 7 / 29 X-Ahx-KKRRRRRRRR 10+ 
8. 8 / 30 X-KRRKRRKRR 9+ 
9. 9 / 31 X-Ahx-KRRKRRKRR 9+ 
10. 10 / 32 X-(Ahx)2-KRRKRRKRR 9+ 
11. 11 / 33 X-KKKKKR 6+ 
12. 12 / 34 X-Ahx-KKKKKR 6+ 
13. 13 / 35 X-(Ahx)2-KKKKKR 6+ 
14. 14 / 36 X-Ahx-RRWWRRWRR 6+ 
15. 15 / 37 X-R 1+ 
16. 16 / 38 X-(PEG)3-KKKKKR 6+ 
17. 17 / 39 X-(PEG)2-KKKKKR 6+ 
18. 18 / 40 X-(PEG)3-RRRRRRRR 8+ 
19. 19 / 41 X-(PEG)2-RRRRRRRR 8+ 
20. 20 / 42 X-(PEG)3-RRRR 4+ 
21. 21 / 43 X-(PEG)3-RRRRR 5+ 
22. 22 / 44 X-(PEG)2-RRRR 4+ 
Table 7.1: Complete list of peptides synthesized. All peptides have a C-terminal amide. Code for conjugate 
refers to the covalent conjugate between the corresponding peptide and MoeA. 
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7.5 Minimum Inhibitory Concentration (MIC) data 
Charlotte S. Vincent is thanked for testing all the compounds for providing the MIC data. 
Sr. 
No. 
Code K. pnumoniae  A. baumannii  P. aeruginosa  
  MIC MIC MIC 
1. 23 25.49 12.74 GAW 
2. 24 42.35 2.65 42.35 
3. 25 20.41 10.21 81.64 
4. 26 2.46 19.70 9.85 
5. 27 GAW 9.72 77.77 
6. 28 GAW 18.56 74.25 
7. 29 4.99 2.49 39.90 
8. 30 GAW 1.29 41.36 
9. 31 GAW 18.87 75.48 
10. 32 77.09 4.82 38.55 
11. 33 24.90 1.56 24.90 
12. 34 23.85 0.37 23.85 
13. 35 22.89 0.72 45.77 
14. 36 18.93 GAW 18.93 
15. 37 33.16 2.07 132.66 
16. 38 11.36 45.43 11.36 
17. 39 11.43 45.71 5.71 
18. 40 78.30 4.89 78.30 
19. 41 78.71 19.68 78.71 
20. 42 GAW 2.86 GAW 
21. 43 GAW 0.38 GAW 
22. 44 97.40 3.04 GAW 
23. MoeA 40.46 2.53 161.83 
24. Peptides 1-22 GAW GAW GAW 
 
Table 7.2: Complete list of MIC values obtained for the three Gram negative bacteria (in μM). GAW: Growth 
in all wells even at a concentration of 256 μg/mL. MIC values highlighted in red are of particular interest. 
Strains used: K. pneumoniae ATCC 700603, A. baumannii ATCC 19606, P. aeruginosa ATCC 27853. 
The conjugates 23-44 were tested for their antimicrobial properties against three resistant Gram 
negative bacteria K. pneumoniae, A. baumannii and P. aeruginosa. Given the varied library of 
compounds synthesized, we obtained an intriguing set of MIC results. One very important aspect was 
that different peptide sequences showed selectivity against different bacteria and we can thus 
selectively target a single strain of bacteria by tuning the peptide sequence and the linker. Three lead 
peptides (4, 12 and 17) and their corresponding conjugates (26, 34 and 39) have been identified which 
are capable of selectively targeting K. pneumoniae (~16 times improvement in MIC), A. baumannii 
(~7 times improvement in MIC) and P. aeruginosa (~28 times improvement in MIC) respectively. 
Apart from the lead compounds, there were several noteworthy improvements in the activity of the 
peptide-MoeA conjugates, as compared to MoeA, for all three bacteria. The results can be 
summarized as follows: Conjugate 43 shows ~7 times improvement in antibacterial activity followed 
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by 35 which shows ~3 times improvement in MIC against A. baumannii. Conjugate 29 shows ~8 
times improvement in antibacterial activity against K. pneumonaie. Conjugates 26 shows ~16 times 
improvement against P. aeruginosa followed by 16 and 36 which show ~14 and ~8.5 times 
improvement in MIC against P. aeruginosa. A complete list of MIC data is shown in table 7.2. 
With the exception of conjugate 43 which is active in A. baumannii, it can be concluded that peptides 
containing at least six positive charges are required for their corresponding conjugates to show 
noticeable improvement in MIC. This could be attributed to the fact (as in case of the MoeA-peptide 
non-covalent complexes) that the negative charges of MoeA must first be masked in order for better 
MoeA delivery. With the notable exception of conjugate 34, we can also conclude that longer linkers 
such as (Ahx)2 in case of 26, (PEG)3 and (PEG)2 in case of 38 and 39 respectively result in better 
antibacterial activity. The main reason for this could be that a considerable degree of flexibility is 
required for the overall structure and that longer linkers prevent the folding of the peptide onto MoeA 
as proposed in section 7.4. 
 
7.6 Synthesis of a Polymyxin-MoeA conjugate and its antimicrobial activity 
 
Based on the discussions of Chapter 6, we know that the polymyxins are among the few molecules 
active against Gram negative bacteria, particularly against P. aeruginosa. Polymyxin B has been 
known to improve the delivery capability of MoeA against E. coli, but studies were limited to only 
this species of bacteria.5 We, therefore, decided to pursue this further and hypothesized that a 
Polymyxin-MoeA conjugate should allow for better delivery of MoeA as compared to the linear 
peptides discussed in Section 7.3. Analogues of polymyxin have provided encouraging results in the 
past.20 Moreover, the total synthesis of polymyxin B1 is known21, allowing us to gain access to 
synthetic analogues of the molecule. We, therefore, developed a scheme for the modification of 
polymyxin B allowing us to covalently link it to MoeA. 
 
 
Figure 7.9: Structure of Polymyxin B1 
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Figure 7.10: Scheme for the synthesis of polymyxin analogue 44 starting from 2-chlorotritylchloride resin, 
initial loading = 1.2 mmol/g. Reagents used are as follows: (a) 4 eq. Fmoc-Thr(tBu)-OH, 8 eq. DIPEA in DCM, 
3 h, followed by capping with MeOH/DIPEA/DCM = 1:1:3, 30 min. loading = 0.68 mmol/g (b) Couplings were 
performed using 4 eq. Amino acid, 4 eq. DIC/Oxyma in DMF using microwave assisted SPPS. (c) Fmoc 
deprotection was performed using 20% piperidine in DMF by shaking for 3 min using a µwave, followed by 10 
min at r.t. (d) Alloc removal was performed using 0.2 eq. Pd(PPh3)4 and 24 eq. PhSiH3 in DCM (2 x 1h). (e) 
Partial cleavage was performed using 2% TFA/5% TIS in DCM, 2h. (f) Cyclization was performed using 1 eq. 
HATU/10 eq. DIPEA in DMF (peptide concentration: 15 mg/mL). (g) Full cleave was performed using 95% 
TFA/ 2.5% TIS/2.5% H2O, 2h. (Refer to the experimental section for details.) 
 
Figure 7.11: Structure of compound 45: the covalent conjugate of 44 with MoeA. 
 
44 was conjugated to MoeA and the conjugate was purified using the protocols described in the 
experimental section to obtain the corresponding conjugate 45. 44 was tested against P. aeruginosa 
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with and without MoeA. The conjugate 45 was also tested against P. aeruginosa. These results were 
compared with those for commercially available polymyxin B. 
 
Sr. 
No. 
Code P. aeruginosa 
  MIC (µM) 
1. 44 11.43 
2. 44 + MoeA 1.37 
3. 45 5.57 
4. Polymyxin B (commercial) 0.77 
Table 7.3: MIC values obtained for the synthesized polymyxin analogue 44, 44 + MoeA, 45 and commercially 
available Polymyxin B (in µM) when tested against P. aeruginosa ATCC27853. 
 
The polymyxin analogue was found to be 16 times less effective, as compared to the commercially 
available polymyxin B. We reasoned that this was due to the attachment of the 5-amino-2-
nitrobenzoic acid to the N-terminus of the lipid, resulting in a considerably more polar N-terminus as 
compared to that of polymyxin B. There was 9 times improvement in antibacterial activity when 
MoeA was mixed with 44, suggesting that the polymyxin analogue allows for delivery of MoeA 
against Gram negative bacteria. Moreover, there was a 2 times improvement in antibacterial activity 
for compound 45 (as compared to 44) suggesting that conjugation of the polymyxin analogue to 
MoeA improves the antibacterial activity of MoeA. Commercially available polymyxin has 5 positive 
charges, whereas compound 45 has only 2 net positive charges as 3 positive charges are neutralised by 
the phosphate and carboxylate of MoeA and the additional carboxylate generated due to the 
degradation of the A ring as a result of peptide conjugation to MoeA. The decrease in number cationic 
charges from 5+ to 2+ could be resulting in poor membrane permeability of the conjugate. We 
believe, synthesis of a polymyxin-MoeA conjugate containing additional cationic charges should help 
improve the permeability and MIC value. 
 
7.7 Resistance to MoeA 
 
The previous and current chapters of this thesis have established that there is great, unused potential 
for the development of MoeA as an antibiotic, particularly against the resistant Gram negative 
bacteria. However, development of an antibiotic, particularly against Gram negatives, is very 
challenging and time-consuming. Therefore, it is imperative to consider all aspects before venturing 
into this daunting task. One of the key aspects is development of resistance. We have established from 
the discussions in Chapter 5 that Gram negatives are particularly notorious for developing resistances 
against antibiotics via multiple mechanisms. Since MoeA has never been used against Gram negatives 
there are no reports pertaining to resistance regarding the same; however, there is an excellent review 
by Walker et. al. regarding resistance to MoeA1 which we will discuss here.  
 
Given that MoeA was first discovered in 1965, it is actually quite surprising that there are no reports 
which suggest significant animal22 or human23 resistance to MoeA. Several Enterococcus faecium 
strains are reported to be naturally resistant to MoeA. However, given varying experimental 
conditions and the fact that the very definition “resistant” has become a bit ambiguous makes the 
drawing of such conclusions unreliable. An important fact is that no significant natural cross-
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resistance has been revealed between MoeA and other clinically useful classes of antibiotics. Plasmid-
borne MoeA resistance has also not been reported.22  
 
Resistances to cell-wall-active antibiotics, particularly to Vancomycin, are known. 24 25 Since MoeA is 
one of them, it is but natural that the bacteria will be resistant to MoeA as well. 17  Other, rarer, 
obscure examples of resistance to MoeA can be found. For example1, null mutations in bamB 
(formerly yfgL) suppress outer membrane defects in E. coli due to mutations in lptD (formerly imp). 
This suppression leads to increased resistance to vancomycin as well as MoeA.26 Studies on Gram 
positive bacteria suggest that changes in membrane makeup or charge could result in resistance to 
MoeA. In S. aureus, reduced content of lysyl-phosphatidylglycerol has led to resistance to MoeA and 
Vancomycin.27 The ruminal microbe Prevotella bryantii also suggests that increased availability of 
undecaprenylpyrophosphate may account for resistance to MoeA, as well as to vancomycin and 
bacitracin.28 
 
The examples mentioned above relate to non-specific mechanisms of defence against MoeA. 
Currently, no dedicated MoeA resistance mechanisms have been described, although bacteria resistant 
to MoeA have been reported a long time ago.29 Mutations in PGTs that would nullify its binding of 
MoeA have not yet been identified despite repeated efforts. 24 25 26 27  Since quite a few amino acids 
involved in MoeA binding are also essential for catalysis, mutations that would decrease/abolish 
MoeA binding may also undermine PGT activity. If this is indeed true, such mutations would be 
unfavourable for the cell, thus slowing down the resistance development.28 There is a recent report 
from Walker et. al. which proves MoeA resistance occurring in S. Aureus via a single point mutation 
in PGT (GT51) resulted in major cell defects and was lethal for the species.30 Cleavage or 
modification of MoeA is, however, a viable resistance mechanism. Indeed, a Bacillus strain 
DSM4675 (isolated from contaminated moenomycin fermentation broth) was shown to cleave the 
phosphoglycosidic bond of MoeA.31 No other moenomycin-modifying bacteria have been reported in 
literature thus far. Given that MoeA is excreted intact from animal body, degradation of MoeA does 
not occur rapidly, at least in the mammalian and avian microflora1. 
 
S. ghanaensis and S. clavuligerus gene clusters producing moenomycin do not carry resistance genes.1 
This raises the question: How do producers of MoeA avoid suicide? Analysis of a big collection of 
various moenomycin non-producers (such as S. coelicolor32), revealed their uniformly high resistance 
to MoeA33. S. albus J1074 is the only exception, but moenomycin-resistant clones of this strain occur 
frequently.34 Resistance to MoeA appears to be a general trait of actinobacteria (Gram-positive 
bacteria with high guanine and cytosine content in their DNA), which may be a result of their PGT 
having low affinity to MoeA, or subtle differences in their cell wall organization compared to other 
bacteria.1 
 
The fact that resistance to MoeA is quite uncommon is encouraging; however, little is known 
regarding the mechanisms of resistance to MoeA. Furthermore, there is no data regarding resistance 
of MoeA in case of Gram negatives. Therefore, we are currently conducting our own research into the 
development of resistance against MoeA, MoeA-peptide non-covalent complexes and MoeA-peptide 
covalent conjugates through a series of tests. At the time of writing this thesis, however, this data was 
not available. 
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7.8 Conclusion 
 
The results of this chapter definitely prove that MoeA can be used to target resistant Gram negative 
bacteria. We have optimized the protocol for unprecedented MoeA-peptide conjugates. Conjugation 
of peptides has not only shown considerable improvement in antibacterial activity, but also allowed 
for specific targeting of individual bacteria. By varying the peptide sequences and linkers, the 
methodology can be developed into an effective screening technique to test the capability of peptides 
for delivery of MoeA. Moreover, the MoeA-peptide conjugates make use of cheap, commercially 
available and non-toxic starting materials, allowing for easy scaling up. Easy diversification allows us 
to synthesize multifunctional antibiotics synthesized using this approach. In a time where new 
antibiotics are the need of the hour, MoeA-peptide conjugates could prove to be a very useful class of 
antibiotics, particularly against resistant Gram negative bacteria and this work lays the foundation for 
the development for the same. 
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CHAPTER 8 
 
SUMMARY, CONCLUSION & PERSPECTIVES  
 
8.1 Summary of work 
 
This thesis contains the work done by me as part of a joint PhD between Ghent University, Belgium 
and University of Lincoln in the UK. The duration of this PhD was 4 years. The first 2 years of the 
PhD (Sep. 2012-Aug. 2014) were carried out at Ghent University in Belgium. Subsequently, I moved 
to the UK where I completed the remaining 2 years of my PhD (Sep. 2014-Aug. 2016) at the 
University of Lincoln. The joint PhD was designed so that I may use the skills gained in Ghent 
University to further my research in the University of Lincoln. 
Figure 8.1: An overview of the work done involving stapled peptides for DNA recognition and enhanced 
cellular uptake at UGent. 
 
My project at UGent involved the sequence specific recognition of dsDNA. An overview of the 
existing literature in this regard has been described in chapter 1. The aim was to look into and further 
develop existing stapling methods and subsequently apply them to enhance the DNA binding potential 
of the basic binding region of the GCN4 protein consisting of the 23 amino acids H2N-
DPAALKRARNTEAARRSRARKLQ-OH. The amino acid residues depicted in bold represent the 
essential residues which interact specifically with DNA1. We have replaced and cross-linked two 
selectively positioned, non-DNA-contacting amino acids on the GCN4 peptide resulting in stapled 
peptides in an effort to achieve DNA binding and enhance cellular uptake.  Classic families of 
transcription factors like the bZIP, bHLH, homeodomain, HTH, and zinc fingers have already been 
Enhanced cell uptake
Allows DNA binding
No DNA binding
Lower cell uptake
Wild Type peptide
Stapled peptideTranscription factor
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studied and models have been developed2. However, unlike the existing synthetic bZip peptide 
models which induce α helicity via a dimeric structure, we here use a single α helix stabilized via 
peptide stapling. This work was successfully completed in Ghent University, Belgium and is 
described in chapters 3 & 4. Alternatively, the work has also been published through the following 
articles (see Annex I for full text): 
 A. Iyer, D. Van Lysebetten, Y. Ruiz García, B. Louage, B. G. De Geest and A. Madder, Org. 
Biomol. Chem., 2015, 13, 3856–3862. 
 Y. Ruiz García, A. Iyer, D. Van Lysebetten, Y. Vladimir Pabon, B. Louage, M. Honcharenko, 
B. G. De Geest, C. I. Edvard Smith, R. Strömberg and A. Madder, Chem. Commun., 2015, 51, 
17552–17555 
 Y. Ruiz García, J. Zelenka, Y. V. Pabon, A. Iyer, M. Buděšínský, T. Kraus, C. I. Edvard Smith 
and A. Madder, Org. Biomol. Chem., 2015, 13, 5273–5278 
During my time in Ghent I also successfully synthesized a cyclic-RGD peptide as part of an additional 
project. The peptide was conjugated to deoxynivalenol in order to develop new monoclonal 
antibodies. This work was subsequently published as (see Annex I for full text): 
 M. Sanders, Y. Guo, A. Iyer, Y. Ruiz García, A. Galvita, A. Heyerick, D. Deforce, M. D. P. 
Risseeuw, S. Van Calenbergh, M. Bracke, S. Eremin, A. Madder and S. De Saeger, Food 
Addit. Contam. Part A. Chem. Anal. Control. Expo. Risk Assess., 2014, 1–9. 
As I arrived at the University of Lincoln, I was already quite well trained in peptide synthesis, 
purification and analysis. The joint PhD gave me the opportunity to apply my skills in three different 
areas of research. The peptide skills – especially the syntheses and purification of arginine rich 
cationic peptides and use of orthogonal protection strategies for peptide synthesis which I learned at 
UGent helped me immensely to complete my PhD projects at the University of Lincoln. A brief 
description of the projects follows: 
1. The problem of antibiotic resistance & the development of Moenomycin A as a drug 
candidate 
The problem of antibiotic resistance poses a serious threat to human health3. There is a great demand 
for new antibiotics particularly against the resistant Gram negative bacteria. The various problems 
arising due to antibiotic resistance, brief description of the drugs available on the market along with 
the modes of resistance in bacteria to these drugs have been described in chapter 5. Subsequently, 
efforts have been made as part of this PhD under the guidance of Dr. Ishwar Singh at the University of 
Lincoln to develop our own set of antibiotics based on the natural product Moenomycin A.  
 
 
Figure 8.2: Structure of MoeA. 
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Research into Moenomycin A (MoeA) has not drawn the attention that was expected, although it was 
discovered more than 50 years ago. However, the recent surge of antimicrobial resistant bacteria has 
seen the revival of several underused molecules and MoeA is at the forefront. Thus far, MoeA has 
only been used to target Gram positive bacteria. Herein, we have developed the first unique approach 
which enables MoeA to target the resistant Gram negative bacteria. Subsequently, we have designed 
specific “delivery” peptides which bind to MoeA and enable it to cross the negatively charged outer 
membrane of Gram negative bacteria. Peptides rich in Arg, Lys and/or Trp have been known for their 
cell permeability. This was shown in chapter 3 where we used stapled DNA binding peptides rich in 
Lys and Arg to enhance cellular uptake. However, this is the first instance where we have used short, 
cell permeable peptides to deliver MoeA. This has resulted in a 30-times improvement in 
antimicrobial activity of MoeA against the highly resistant Pseudomonas aeruginosa. Detailed NMR 
analysis gives valuable insight into the structure of the non-covalent complex between the delivery 
peptide and MoeA. Furthermore, we have also covalently linked these peptides using suitable linkers 
to form peptide-MoeA covalent conjugates. The work has been described in detail in chapters 6 & 7. 
 
2. The total syntheses & biological activities of teixobactin and its analogues 
  
Figure 8.3: Structure of teixobactin. 
The majority of work regarding the total syntheses & biological activities of recently discovered 
teixobactin4 and its analogues has been done by my friend and colleague, Anish Parmar at the 
University of Lincoln and therefore has not been included as part of this thesis. Briefly, “we have 
performed the total syntheses and biological activities of two teixobactin analogues. The approach is 
simple, efficient and has several advantages: it uses commercially available building blocks (except 
AllocHN-D-Thr-OH), has a single purification step and a good recovery (22%). We have also 
established that the D-amino acids are critical for the antimicrobial activity of these analogues5.” 
Along these lines, we have synthesized more than ten analogues of teixobactin (unpublished work). 
Part of this work has been published as (see Annex I for full text): 
 A. Parmar, A. Iyer, et. al. Efficient total syntheses and biological activities of two teixobactin 
analogues. Chem. Commun. 52, 6060–6063 (2016). 
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3. The syntheses of furan containing polyamides for dsDNA cross-linking 
Complementary to my work on stapled peptides which were based on transcription factors which 
operate via major grove recognition of dsDNA (chapter 4), we also synthesized furan containing 
polyamides for dsDNA cross-linking in the minor groove. Although the syntheses of polyamides as 
well as the furan cross-linking strategy are well established, the following major challenges are to be 
overcome if cross-linking to dsDNA using this strategy is to be made feasible: 
1. Selective oxidation of furan in presence of the Py/Im rings. 
2. Local disruption of the DNA duplex in order to achieve cross-linking. 
 
The initial part of this project was to obtain conditions under which furan could be selectively 
oxidised in the presence of the aromatic Py/Im rings. Through a series of experiments carried out (as 
described in chapter 2), we have been able to selectively oxidize an N-terminal furan contained in a 
polyamide, however, further optimization of conditions is required. 
8.2 Conclusion 
 
The work done over the past four years by me as part of my PhD thesis mainly revolves around the 
wide and versatile application of peptides – particularly cationic peptides which allow for DNA 
recognition and enhanced cell uptake via peptide stapling and the application of cationic peptides for 
the delivery of Moenomycin A, a compound with known antibacterial properties through bacterial 
membranes. 
 
The initial part of this PhD involved the understanding of the dsDNA structure, transcription factors 
which recognize the major groove of DNA and polyamides which recognize the minor grove of DNA. 
We applied the concepts learned to develop our own set of molecules capable of recognizing dsDNA 
in the major and minor grooves. Based on the collective knowledge of Prof. Annemieke Madder at 
UGent and Dr. Ishwar Singh at University of Lincoln we designed and synthesized furan containing 
polyamides for minor groove cross-linking to dsDNA. Through a series of experiments, we concluded 
that it is possible to selectively oxidize furan in the presence of Pyrrole/Imidazole containing 
polyamides using N-Bromosuccinimide. 
We also developed synthetic major groove DNA binders capable of mimicking the GCN4 
Transcription Factor (TF) through the design and syntheses of five stapled peptides. Through this 
work we established a general method to allow for DNA binding and enhance cellular uptake of a 
given DNA binding peptide, while avoiding tedious synthetic routes. Furthermore, we showed that N-
terminal helix stabilization is more effective for enhancing DNA binding than stapling in the middle 
of the sequence.  For cell uptake, however, we observed that the more helical peptides are taken up 
better into cells. It can be concluded that although the two are not mutually exclusive, for future 
applications such as DNA binding in cellulo, a balance will have to be found between a peptide’s 
DNA binding and cell penetration abilities. 
 
As a result of the knowledge gained through our work on TFs involving cell permeable peptides, a 
new application of these peptides has been developed in the form of a peptide based delivery system 
for the antimicrobial compound Moenomycin A (MoeA). The system is based on our correct 
assessment that the delivery of MoeA is the key problem for its lack of activity against resistant Gram 
negative bacteria. The system is a novel peptide-based, non-covalent delivery system specifically for 
MoeA, which enables it to target three resistant Gram Negative bacterial strains – K. pneumoniae, A. 
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baumannii and P. aeruginosa. We have hypothesized and correctly proven that the peptides bind to 
MoeA and form non-covalent complexes and subsequently “carry” them across the outer bacterial 
membrane present in Gram negative species. Furthermore, we have shown that despite all of them 
being Gram negative bacteria, they behave quite differently towards the same set of peptide-MoeA 
non-covalent complexes. We have tuned the peptides in order to obtain up to 30 times improvement in 
MIC values. Until now, it has been believed that longer, synthetically more challenging polyarginine 
sequences are required for drug delivery6. We have shown, for the first time that MoeA delivery can 
be achieved as effectively even through shorter sequences such as R4. By designing different delivery 
peptides (which are combined with MoeA via a simple mixing approach) we have demonstrated the 
selectivity of our approach to target a specific bacterial strain. Peptides R5, R4 & K4 promote the 
delivery of MoeA best in A. baumannii, whereas the HIV-TAT 49-57 peptide RKKRRQRRR is 
selective for MoeA delivery in K. pneumoniae. The sequence KRRKRRKRR on the other hand can 
perform delivery in all three species of bacteria simultaneously. The Arg rich peptide containing Trp 
RRWWRRWRR in combination with MoeA shows excellent activity in P. aeruginosa and moderate 
to high activity in A. baumannii and K. pneumoniae. As toxicity is one of the key factors in case of 
delivery, we have established that all peptides as well as the MoeA-peptide non-covalent complexes 
they form are not toxic towards mammalian cell lines up to a tested concentration of 100 µM. 
  
We have performed a detailed NMR analysis followed by extensive structural calculations revealing 
for the first time the molecular structure of a peptide-MoeA complex at an extremely impressive 1.3 Å 
resolution. We have proven that the two components interact in a 1:1 ratio further supporting the 
mechanism that the peptides bind to MoeA and then enable its delivery in Gram negative bacteria. We 
were thus able to deduce the key interactions between peptide RRWWRRWRR and MoeA. 
Surprisingly, we observe that the phosphate is not part of the interaction showing an example where 
although arginines and phosphates are present in the same solution, they need not necessarily interact 
with one another. Moreover, a simple mixing approach provides a platform to test the delivery 
capability of different peptides using MoeA without any conjugation. This work is crucial for any 
further development of MoeA especially in the case of resistant Gram negative bacteria. In a time 
where new and novel antibiotics particularly against these resistant bacteria are critical, this work lays 
the foundation for the development of new antibiotics based on MoeA. 
 
Following the excellent results obtained through the formation of peptide-MoeA non-covalent 
complexes, we developed the protocol for unprecedented MoeA-peptide covalent conjugates. The 
results obtained through this work definitely prove that MoeA can be used to target resistant Gram 
negative bacteria. Conjugation of peptides to MoeA has not only shown considerable improvement in 
antibacterial activity, but also allowed for specific targeting of individual bacteria. By varying the 
peptide sequences and linkers, the methodology can be developed into an effective screening 
technique to test the capability of peptides for delivery of MoeA. Moreover, both the MoeA-peptide 
non-covalent complexes and covalent conjugates make use of cheap, commercially available and non-
toxic starting materials, allowing for easy scaling up. Easy diversification allows us to synthesize 
multifunctional antibiotics synthesized using these approaches. 
 
The work of this thesis has thus provided and expanded upon two major applications of peptides – 
stapled peptides for phosphate recognition and improvement cell permeability and the delivery of 
cargo through peptides into bacterial membranes. Although there is still considerable work to be done, 
I believe, this thesis lays the foundation for the development of new peptide based therapeutics. 
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8.3 Perspectives 
 
Improvement in terms of binding affinity towards dsDNA in case of the synthetic major groove DNA 
binding stapled peptides has been proposed through the synthesis of a dimeric stapled peptide. 
Furthermore, since the GCN4 stapled peptides do not enter the nucleus, the conjugation of a Nuclear 
Localization Signal (or Sequence, in short NLS) to a GCN4 stapled peptide should help with nuclear 
uptake. This could allow for DNA binding in cellulo which is an important step towards the 
development of peptide based therapeutics. 
 
In case of the polyamides, we have proposed to carry out the oxidation of the furan containing 
polyamides in the presence of dsDNA. As the Py/Im rings would be tightly bound to the dsDNA they 
would be less susceptible to oxidation as compared to the furan which would be unbound. 
Subsequently, we have also proposed to improve our design polyamides through the incorporation of 
amino acids capable of local disruption of DNA in addition to furan to enable cross-link formation. 
 
Although we have had considerable success using linear peptides to inhibit the activity of MoeA, 
work still needs to be done to improve the MIC values if these compounds are to be converted into 
potential drug candidates. We have already observed improvement in MIC through the covalent 
conjugation of a modified polymyxin derivative to MoeA. Along those lines, we have proposed the 
syntheses of branched and cyclic peptides instead of the existing linear ones to be used as delivery 
peptides in a non-covalent manner. Cyclic peptides work better than linear peptides for cargo delivery 
for two main reasons: 
1. Cyclization increases charge density thereby they are able to penetrate better into 
cell/bacterial membranes7.  
2. The backbone and the N/C termini of cyclic peptides is protected making them less 
susceptible to enzymatic degradation 
 
If this is a success, they can then be modified to contain the 5-amino-2-nitrobenzoic acid 
linker which would allow for subsequent covalent conjugation to MoeA. Cyclic R6, R5, K6 
and K5 are among the potential candidates for initial testing. 
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EXPERIMENTAL SECTION FOR CHAPTER 2 
 
I. Materials 
 
The materials used for polyamide synthesis common to peptide synthesis are mentioned in Chapter 3. 
HATU, Boc-β-Ala-PAM resin were purchased from Iris Biotech GmbH. Boc-GABA-OH, HOAt 
solution 0.6M in DMF, 3-(Dimethylamino)-1-propylamine and BTC were purchased from Sigma 
Aldrich.  
 
II. Manual synthesis protocol 
 
 1. General preparation of resin for deprotection and coupling 
 
Note: If Boc-β-Ala-PAM resin of a loading higher than 0.26 mmol/g is purchased, the loading needs to 
be lowered to that value using HATU/Acetic acid/DIPEA in DMF before the first coupling. 
 
For the first deprotection cycle, Boc-β-Alanine-PAM resin (100 mg; loading = 0.26 mmol/g, 0.026 
mmol) was placed in a Teflon lined reaction vessel. The Boc protecting group was removed using three 
cycles of a TFA:Phenol:Water (TPW) mixture (92.5:5:2.5) (2 x 1 min, and 1 x 5 min) with shaking. 
The general deprotection procedure using TPW is as follows: 1 x 1 min, then 2 x 3 minute for pyrrole 
and 1 minute, 3 minutes then 20 minutes for imidazole. 
 
For all couplings in general, the resin was then washed with DMF (3 x 1 min) and then washed with 
dry solvent (DMF for DCC/HOAt and HATU couplings, THF for BTC couplings) for 1 min before the 
vessel was drained. The activated monomer was added to the pre-swelled resin and the reaction mixed 
to form a slurry. The couplings were allowed to proceed for the required amount of time (dependant on 
sequence and coupling method), before being drained and washed with DMF (4 x 1 min) 
 
 2. General cleavage protocol and recovery of polyamides 
 
The polyamides were cleaved from the resin by placing them into a sealed container with the appropriate 
cleavage amine and heating to 55 °C for 16 hours. The expired resin was removed by filtration through 
cotton wool and washed with a 1 mL of DCM. The crude material was precipitated by addition of cold 
diethyl ether and following centrifugation the supernatant was removed. The polyamide was washed 
twice more by dissolving in DCM (1 ml) and re-precipitating with diethyl ether to yield the crude 
material. 
 
 3. HPLC analysis and purification 
 
Reported analytical HPLC retention times were acquired using 0.1 % TFA in water as buffer A and 
acetonitrile as buffer B with a flow rate of 1 mL/minute, starting at 5 % B and holding for 3 minutes 
before increasing to 95 % B over 20 minutes. Unless otherwise stated, polyamides were purified by 
semi-preparative HPLC with a gradient starting at 10 % B and holding for 3 minutes before increasing 
to 60 % B over 20 minutes and a constant flow rate of 4.5 mL/minute. 
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III. General activation protocols for polyamide synthesis 
 
 1. Activation with HATU 
 
General procedure for 100 mg of Beta-Ala-Pam resin (loading = 0.26 mmol/g): Monomer (4 
equivalents; 0.104 mmol) and HATU (3.6 equivalents; 0.3744 mmol; 36 mg) were dissolved in dry 
DMF (1 mL). Upon addition of DIEA (150 μL; 0.9 mmol) the solution was left to activate for 2 minutes, 
before being added to the resin. 
 
 2. Activation with DCC/HOAt 
 
Before a DCC/HOAt coupling, the resin must be neutralized by washing it with 1 mL 10% DIPEA/DMF 
(for 100 mg resin) for 1x1 min. 
 
General procedure for 100 mg of Beta-Ala-Pam resin (loading = 0.26 mmol/g): Monomer (4 
equivalents; 0.104 mmol) was added to DCC (19.31 mg; 0.0936 mmol; 3.6 equivalents) and HOAt 
(13.45 mg; 0.0988 mmol; 3.8 equivalents) in dry DMF (1 mL) were mixed together in a vial and 
activated for 2 hours with constant shaking. The precipitated DCU is filtered off and the solution added 
to resin. 
 
 3. Activation with BTC 
 
General procedure for 100 mg of Beta-Ala-Pam resin (loading = 0.26 mmol/g): To a solution of 
monomer (4 equivalents; 0.104 mmol) and BTC (9.6 mg; 0.0324 mmol; 1.2 equivalents) in dry THF (1 
mL) was added 2,3,5-collidine (50 μL; 0.38 mmol) forming a white emulsion which was allowed to 
mix for 2 minutes. This was then added to resin with DIEA (150 μL; 0.9mmol).1  
 
IV. Synthesis of polyamides 
 
The Boc-Py-OH, and Boc-Im-OH monomers were synthesized using the protocols as described by 
Dervan et. al.2 
 
 
 
Figure 1: Polyamides synthesized for optimizing the conditions which would allow for selective 
oxidation of furan. I. is the control to check for degradation. 
 
                                                          
1 W. Su, S. J. Gray, R. Dondi, and G. A. Burley, Organic letters, 2009, 11, 3910–3 
2 Baird, E. E. & Dervan, P. B. Solid Phase Synthesis of Polyamides Containing Imidazole and Pyrrole Amino 
Acids. J. Am. Chem. Soc. 118, 6141–6146 (1996). 
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For both polyamides the coupling conditions were as follows: Couplings 1-5 (including turn) 
HATU/DIPEA. Coupling 6-7: BTC. In case of II. Coupling 8: HATU/DIPEA, 3 eq., 2h. 
 
V. HPLC/MALDI-TOF Data 
 
For MALDI-TOF, spectra were recorded up to 4 decimal places. However, information only up to 2 
decimal places was considered accurate as a result of the calibration of the MALDI-TOF. 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: HPLC trace of HPLC purified polyamide I. r.t. = 12.511 min 
Figure 3: MALDI-TOF spectra for polyamide I. Exact mass calcd. 990.49, found M+ Na+ = 1013.98, 
M+K+ = 1029.92 
 
 
 
 
min0 5 10 15 20 25 30
mAU
0
100
200
300
400
500
600
700
800
 DAD1 D, Sig=310,16 Ref=off (D:\DATA\14-08-18\EA00019.D)
 3.
02
4
 3.
61
2
 12
.27
2
 12
.51
1
 30
.77
2
699.0 829.4 959.8 1090.2 1220.6 1351.0
Mass (m/z )
0
1676
0
10
20
30
40
50
60
70
80
90
100
%
 In
te
n
s
it
y
Voyager Spec #1[BP = 1013.9, 1676]
1013.9849
1014.9641
1029.9285
861.5042
703.3774 1016.0079
1030.9903
862.5415
914.4508 1028.9739
845.4624
1043.8909
737.6977704.6592 1061.8223952.8648877.4611 915.4518792.3630 844.7800 991.8654706.2442 1125.52761025.9707878.5199748.7392 1174.25161060.9740950.0896 1289.8803793.4834 916.3479839.5454 988.0907 1221.5201716.8518 1139.4290763.2207 1098.8348947.1335 1276.43171038.5630 1184.2134 1241.9819
Experimental Section for Chapter 2 
124 
 
 
 
 
 
Figure 2: HPLC trace of HPLC purified polyamide I.  
 
 
Figure 4: HPLC trace of HPLC purified polyamide II. r.t. = 12.842 min 
 
Figure 5: MALDI-TOF spectra for polyamide II. Exact mass calcd. 1112.53, found M+ H+ = 1113.84. 
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VI. Results obtained for various oxidation conditions 
 
1a. Polyamide concentration (polyamide I, no furan) = 250 µM, Rose Bengal concentration = 5 
µM. Irradiation using white light (big lamp, all wavelengths), time = 2 min. 
 
Figure 6: HPLC trace of polyamide I at t = 0 min. 
 
Figure 7: HPLC trace of polyamide I at t = 2 min, more than 80% of the polyamide has degraded (based 
on UV absorption) 
 
1b. Polyamide concentration (polyamide II, contains furan) = 250 µM, Rose Bengal 
concentration = 5 µM. Irradiation using white light (big lamp, all wavelengths), time = 2 min. 
Figure 8: HPLC trace polyamide II at t = 0 min. 
 
 
Figure 9: HPLC trace of polyamide II at t = 2 min, more than 80% of the polyamide has degraded 
(based on UV absorption) 
min0 5 10 15 20 25 30
mAU
0
100
200
300
400
500
 DAD1 B, Sig=260,16 Ref=off (D:\DATA\14-08-18\EA00019.D)
min0 5 10 15 20 25 30
mAU
0
100
200
300
400
500
600
700
 DAD1 D, Sig=310,16 Ref=off (D:\DATA\14-08-18\EA00019.D)
min0 5 10 15 20 25 30
mAU
-20
0
20
4
60
 DAD1 B, Sig=260,16 Ref=off (D:\DATA\14-08-18\EA00022.D)
min0 5 10 15 20 25 30
mAU
-20
0
20
40
60
80
 DAD1 D, Sig=310,16 Ref=off (D:\DATA\14-08-18\EA00022.D)
min0 5 10 15 20 25 30
mAU
0
100
200
300
400
500
 DAD1 B, Sig=260,16 Ref=off (D:\DATA\14-08-18\EA00021.D)
min0 5 10 15 20 25 30
mAU
0
200
400
600
800
 DAD1 D, Sig=310,16 Ref=off (D:\DATA\14-08-18\EA00021.D)
min0 5 10 15 20 25 30
mAU
-20
-10
0
10
20
30
40
50
60
 DAD1 B, Sig=260,16 Ref=off (D:\DATA\14-08-18\EA00023.D)
min0 5 10 15 20 25 30
mAU
-20
0
20
40
60
80
 DAD1 D, Sig=310,16 Ref=off (D:\DATA\14-08-18\EA00023.D)
Experimental Section for Chapter 2 
126 
2a. Polyamide I (without furan) concentration 10 µM, Rose Bengal conc. 0.5 µM, volume = 100 
µL using green light filter (λ=495-570 nm). Analyzed after irradiating for 30s + 30s + 2 min 
 
Figure 10: Overlay of HPLC traces for polyamide I. Blue = no light, Green = 30s irradiation, pink = 
30s + 30s irradiation, Red = 30s + 30s + 2 min irradiation 
 
 
Figure 11: Overlay of HPLC traces (zoomed in) for polyamide I. Blue = no light, Green = 30s 
irradiation, pink = 30s + 30s irradiation, Red = 30s + 30s + 2 min irradiation 
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2b Polyamide II (with furan) concentration 10 µM, Rose Bengal conc. 0.5 µM, volume = 100 µL 
using green light filter (λ=495-570 nm). Analyzed after irradiating for 30s + 30s + 2 min 
 
 
Figure 12: Overlay of HPLC traces for polyamide II. Red = no light, Green = 30s irradiation, pink = 
30s + 30s irradiation, Blue = 30s + 30s + 2 min irradiation 
 
• Concentration of polyamide: 10 µM, different concentrations of mCPBA, PBS buffer pH = 
7.4 
Figure 13: Overlay of HPLC traces for polyamide II. Red = no light, Green = 30s irradiation, pink = 
30s + 30s irradiation, Blue = 30s + 30s + 2 min irradiation 
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3.  Using mCPBA 
Figure 14: Overlay of HPLC traces for polyamide I using mCPBA. Blue = 1 eq. mCPBA. red = 2 eq. 
mCPBA , Green = 5 eq. mCPBA. time = 2 hrs. No change in peak was observed therefore no noticeable 
degradation. 
 
 
 
Figure 15: Overlay of HPLC traces for polyamide II using mCPBA. Blue = 1 eq. mCPBA. red = 2 
eq. mCPBA , Green = 5 eq. mCPBA. time = 2 hrs. No change in peak was observed. 
 
min0 5 10 15 20 25 30
mAU
0
20
40
60
80
100
120
140
160
*DAD1 D, Sig=310,16 Ref=off (D:\DATA\14-10-29\EA00019.D)
*DAD1 D, Sig=310,16 Ref=off (D:\DATA\14-10-29\EA00015.D)
*DAD1 D, Sig=310,16 Ref=off (D:\DATA\14-10-29\EA00017.D)
min0 5 10 15 20 25 30
mAU
0
20
40
60
80
100
*DAD1 D, Sig=310,16 Ref=off (D:\DATA\14-10-29\EA00014.D)
*DAD1 D, Sig=310,16 Ref=off (D:\DATA\14-10-29\EA00016.D)
*DAD1 D, Sig=310,16 Ref=off (D:\DATA\14-10-29\EA00018.D)
Experimental Section for Chapter 2 
129 
 
Figure 15: Overlay of HPLC traces for polyamide II using mCPBA. Red = 50 eq. mCPBA 6h; blue = 
5 eq. mCPBA, 2 h. Different intensities due to different volumes of injection, but peak appears to have 
shifted. 
 
 
Figure 16: MALDI-TOF spectra for polyamide II after treating with 50 eq. mCPBA for 6h. Exact mass 
calcd. 1112.43, found M+ Na+ = 1135.53, M + K+ (or M + Na+ + O?) = 1152.03, M + K+ + O = 1167.53. 
Trace amounts of oxidation. 
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4. Using NBS 
 
Figure 17: MALDI-TOF spectra for polyamide I after treating with 5 eq. NBS for 1h. Exact mass 
calcd. 990.49, found M+ H+ = 992.69, found M+ Na+ = 1013.49, M+K+ (or M + Na+ + O?) = 1029.49, 
M + H+ + O = 1008.11. Degradation of polyamide (since no furan is present) 
 
Figure 18: MALDI-TOF spectra for polyamide II after treating with 5 eq. NBS for 1h. Exact mass 
calcd. 1112.53, found M+ H+ = 1114.29. M + O = 1130.28, M+K+ (or M + Na+ + O?) = 1151.53, M + 
O + O = 1146.27. Clear oxidation product formed along with over-oxidation/degradation. 
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Figure 19: MALDI-TOF spectra for polyamide II after treating with 5 eq. NBS for 2h. Exact mass 
calcd. 1112.53, found M+ H+ = 1114.04. M + O = 1130.28, M+K+ (or M + Na+ + O?) = 1152.02, M + 
O + O = 1146.27. Clear oxidation product formed along with over-oxidation/degradation. 
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EXPERIMENTAL SECTION FOR CHAPTER 4 
 
I. Materials 
 
All amino acids, Trifluoroacetic acid (TFA) and coupling reagent HBTU were purchased from Iris 
GmbH.  L-amino acids were used throughout the syntheses.  The protecting groups for the amino acids 
are tBu for Asp, Glu, Ser, Thr, Boc for Lys, Pbf for Arg and Trt for Cys, Asn, Gln. 4-acetamidobenzoic 
acid (ABA), 4-4’ Bis(bromomethyl)biphenyl, α,α’-Dibromo-m-xylene, p-Phenylenediamine, Ethyl 
Acetate, Acetonitrile, Methanol, Diethyl Ether DIPEA, supplied as extra dry, redistilled, 99.5 % pure 
and Triisopropylsilane were purchased from Sigma Aldrich. Bromoacteylbromide was purchased from 
Acros Organics.  Dimmethylformamide (DMF) and N-Methylpyrolidine (NMP) peptide synthesis 
grade were purchased from Biosolve.  HPLC grade quality Hexane and Chloroform were purchased 
from Fisher Scientific. Deuterated solvents D2O (99.9% atom D) and DMSO-d6 (99.8% atom D) were 
obtained from Eurisotop. Water with the Milli-Q grade standard was obtained in-house either from a 
Millipore ROs 5 purification system or a Sartorius Arium 611 DI. Rink-Amide ChemMatrix (100-200 
μm, manufacturer’s loading: 0.52-0.54 mmol/g) was obtained from Biotage. NHS-Fluorescein was 
purchased from Thermo Scientific as a 5-6 isomer. All reagents were acquired from commercial sources 
and used without prior purification. All chemicals were used without further purification.  All 
oligonucleotides used were commercially purchased from Eurogentec (HPLC purified using a RP-
cartridge-Gold, 200 nm scale) and were used as such. 
 
II. Methods 
 
1. Peptide syntheses  
 
Automated peptide syntheses were performed on a 24-reactor block SYRO Multiple Peptide 
Synthesizer equipped with a vortexing unit (Multisyntech, Witten, Germany). Peptides were 
synthesized by standard Fmoc/tBu strategy using HBTU/DIPEA couplings. All automated peptide 
synthesis were performed using Rink Amide Chemmatrix resin, loading = 0.54 mmol/g on a 
100 mg scale using 10 eq. of  amino acid, 10 eq. of HBTU and 20 eq. of DIPEA in DMF using 
single couplings of 1h. Fmoc deprotection was performed using 20% piperidine in DMF and 
shaking for 2, 5 and 15 min. For coupling fluorescein to the N-terminus 3 eq. of NHS 
fluorescein along with 3 eq. HOBt and 6 eq. of DIPEA was used and the reaction mixture was 
shaken overnight. The peptides were cleaved off using TFA/TIS/H2O = 95/2.5/2.5 and 
precipitated using cold MTBE. 
 
For peptide stapling, 10 mg of crude peptide was dissolved in 2-3 mL of NH4HCO3 solution (depending 
on the solubility) with 1.5 eq. of tris(2-carboxyethyl) phosphine (TCEP) and was stirred for 15 min at 
room temperature.  Then 2.5 eq. of cross-linker dissolved in 1 mL of dry DMF was added drop-wise to 
the reaction mixture and was stirred for another 2-2.5h after which the crude reaction mixture was 
analyzed by MALDI-TOF to observe the progress.  If starting material was detected, 1.5 eq. of cross-
linker in 1 mL dry DMF was added and the reaction was continued for another 1.5-2h.  MALDI-TOF 
samples were taken every 45 min.  The solvents were removed and the peptides were obtained by 
precipitation (twice) by centrifugation at 4000 rpm at 0°C in cold MTBE (-20°C).  The pellet was then 
redissolved in mQ H2O and purified using RP-HPLC to give pure stapled peptides. 
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2. Analyses  
 
LC-MS data were collected on an Agilent 1100 Series instrument with a Phenomenex Kinetex C18 
100Å column (150 x 4.6 mm, 5 μm at 35 °C) connected to an ESMSD type VL mass detector with a 
flow rate of 1.5 ml/min was used with the following solvent systems: (A): 0.1% HCOOH in H2O and 
(B) MeCN. The column was flushed with 100% A for 2 min, then a gradient from 0 to 100% B over 6 
min was used, followed by 2 min of flushing with 100% B.  RP-HPLC analyses and purification were 
performed on an Agilent 1100 Series instrument with a Phenomenex Luna C18 column (250 x 4.6 mm, 
5 μm at 35 °C). A flow rate of 1 ml/min was used with the following solvent systems: (A): 0.1% TFA 
in H2O and (B): MeCN. The column was flushed for 2 min with 100% A, then a gradient from 0 to 
100% B over 15 min was used, followed by 5 min of flushing with 100% B. MALDI-TOF-MS spectra 
were acquired with a high performance nitrogen laser (337 nm), using the positive and reflector mode 
with delayed extraction.  The matrix solution utilized was as follows: 4-5 mg α-cyano-4-
hydroxycinnamic acid in 500μL MeCN, 490μL mQ, 10μL 1M ammoniumcitrate, 1μL TFA. CD spectra 
were measured using an Aviv 410 CD spectrophotometer equipped with a Peltier temperature control 
unit 
 
III. Peptide Synthesis and HPLC/LC-MS/MALDI-TOF Data 
 
1.  Protocol for deprotection of peptides 
Protected peptide-resin is treated with TFA/TIS/mQ = 95:2.5:2.5 (4 mL/100 mg). After 4 hours, the 
liquid is filtered of and the resin is washed 2 times with neat TFA. The filtrate is evaporated followed 
by precipitation (twice) by centrifugation at 4000 rpm at 0°C in cold MTBE (-20°C).  The peptide was 
then redissolved in milliQ H2O for RP-HPLC, LC-MS analysis, RP-HPLC purification or lyophilized 
for the next step. 
 
2.  Syntheses of peptides 1-7 
 
Figure 1: Syntheses of peptides 1-7 
 
The resin is preswollen in NMP for 10 min and then filtered off. Peptide synthesis is performed on an 
automated peptide synthesizer using the following protocols for Fmoc deprotection and coupling: 
Fmoc deprotection: Fmoc deprotection is performed by adding a solution of 20% piperidine in NMP to 
the resin and shaking for 2 min, 5 min & 15 min durations.  After each addition and shaking cycle, the 
resin is filtered off and washed with NMP (6 x 45 s). 
Coupling: 10 equivalents of a 0.5 M solution of amino acid in NMP, 10 equivalents of a 0.5 M solution 
of HBTU in DMF and 10 equivalents of a 2.0 M solution of DIPEA in NMP are added to the resin. The 
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reaction mixture is shaken for 1 hour. The resin is filtered off and washed with NMP (9 x 2 min). The 
peptide is analyzed according to the above protocol for deprotection of peptides. 
Capping: ABA was used for capping and was coupled using the protocol in coupling above. 
Coupling of Fluorescein: 3 eq. of NHS-fluorescein predissolved in 0.5 mL DMF. 6 eq. of DIPEA and 
3 eq. of HOBt predissolved in 0.5 mL DMF and are added successively to the resin. After shaking for 
15 h, the reaction mixture was filtered off and the resin washed with 3x DMF, 3x MeOH, 3x DMF and 
3x Et2O. 
 
No. Sequence 
 
Chemical 
Formula 
Exact 
Mass 
Obsd. 
Mass 
1 ABA-DPAALKRARNTCAARRSRCRKLQ-
CONH2 
C115H201N47O31S2 2800.50 2801.88 
2 ABA-DPACLKRCRNTEAARRSRARKLQ-
CONH2 
C117H203N47O33S2 2858.51 2859.47 
3 ABA-DPAALKRCRNTCAARRSRARKLQ-
CONH2 
C115H201N47O31S2 2800.50 2801.60 
4 ABA-DPAALKRARNTEAARRSRARKLQ-
CONH2 
C117H203N47O33 2794.57 2795.28 
I Fluorescein-DPAALKRARNTCAARRSRCRKLQ-
CONH2 
C127H204N46O35S2 2997.50 2997.57 
II Fluorescein-DPACLKRCRNTEAARRSRARKLQ-
CONH2 
C129H206N46O37S2 3055.51 3056.61 
IV Fluorescein-DPAALKRARNTEAARRSRARKLQ-
CONH2 
C129H206N46O37 2991.57 2992.54 
 
Table 1: Calculated and observed masses of peptides 
 
 
Figure 2: RP-HPLC trace from LC-MS of peptide 1 (0-100% ACN in 6 min on Kinetex C18 100 Å, 
150 x 2.1 mm, 2.6 µm, at 35 °C) 
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Figure 3: ESI-MS from LC-MS at t = 3.191 min. E.M. Calcd. for C115H201N47O31S2 = 2800.50 and 
deconvoluted mass found 2801.85 
 
 
 
Figure 4: RP-HPLC trace from LC-MS of peptide 2 (0-100% ACN in 6 min on Kinetex C18 100 Å, 
150 x 2.1 mm, 2.6 µm, at 35 °C) 
 
 
 
Figure 5: ESI-MS from LC-MS at t = 3.175 min. E.M. Calcd. for C117H203N47O33S2 = 2858.51 and 
deconvoluted mass found 2859.47  
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Figure 6: RP-HPLC trace from LC-MS of peptide 3 (0-100% ACN in 6 min on Kinetex C18 100 Å, 
150 x 2.1 mm, 2.6 µm, at 35 °C) 
 
 
 
Figure 7: ESI-MS from LC-MS at t = 3.176 min. E.M. Calcd. for C115H201N47O31S2 = 2800.50 and 
deconvoluted mass found 2801.60 
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Figure 8: RP-HPLC trace of peptide 4 (0-100% ACN in 15 min on Luna C18(2) 100 Å, 250 x 2.1 mm, 
2.6 µm, at 35 °C) 
 
 
 
Figure 9: MALDI-MS spectrum of peak at tR= 9.681. E.M. Calcd. for C115H201N47O31S2 = 2794.57 and 
mass found M+H+= 2796.28 
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Figure 10: RP-HPLC trace from LC-MS of HPLC purified peptide 4 (0-100% ACN in 6 min on Kinetex 
C18 100 Å, 150 x 2.1 mm, 2.6 µm, at 35 °C) 
  
 
 
Figure 11: ESI-MS from LC-MS at t = 3.078 min. E.M. Calcd. for C115H201N47O31S2 = 2794.57 and 
deconvoluted mass found 2795.60 
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Figure 12: RP-HPLC trace from LC-MS of peptide I (0-100% ACN in 6 min on Kinetex C18 100 Å, 
150 x 2.1 mm, 2.6 µm, at 35 °C) 
 
 
Figure 13: ESI-MS from LC-MS at t = 3.367 min. E.M. Calcd. for C127H204N46O35S2 = 2997.50 and 
deconvoluted mass found 2997.57 
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Figure 14: RP-HPLC trace from LC-MS of peptide II (0-100% ACN in 6 min on Kinetex C18 100 Å, 
150 x 2.1 mm, 2.6 µm, at 35 °C) 
 
 
 
Figure 15: ESI-MS from LC-MS at t = 4.314 min. E.M. Calcd. for C129H206N46O37S2 = 3055.51 and 
deconvoluted mass found 3056.61 
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Figure 16: RP-HPLC trace of crude peptide IV (0-100% ACN in 6 min on Kinetex C18 100 Å, 150 x 
2.1 mm, 2.6 µm, at 35 °C) 
 
 
Figure 17: ESI-MS from LC-MS at t = 4.277 min for crude compound 7. E.M calcd. for 
C129H206N46O37 = 2991.57 and deconvoluted mass found 2992.54. 
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Figure 18: RP-HPLC trace of HPLC purified peptide IV (0-100% ACN in 6 min on Kinetex C18 100 
Å, 150 x 2.1 mm, 2.6 µm, at 35 °C) 
 
Figure 19: ESI-MS from LC-MS at t = 3.332 min. E.M calcd. for HPLC purified peptide 7 
C129H206N46O37 = 2991.57 and deconvoluted mass found 2992.80. 
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IV. Synthesis of N,N'-(1,4-phenylene)bis(2-bromoacetamide) 
 
 
 
To a solution of p-Phenylenediamine 5 (54 mg, 0.5 mmol) in CH2Cl2 (5 mL), dry pyridine (96 µL, 1.2 
mmol) and 4-(dimethylamino)pyridine (1.5 mg) was added bromoacetyl bromide (96 µL, 1.1 mmol) at 
0°C, and the mixture was stirred at 25°C for 3h.  The resulting precipitates were collected by filtration 
and washed with CH2Cl2 (3 x 5 mL) to give N,N'-(1,4-phenylene)bis(2-bromoacetamide) b (145 mg, 
0.41 mmol, 82%) as a white amorphous solid and therefore a melting point was not determined for the 
compound. 1H NMR (DMSO-d6, 300 MHz): δ 4.02 (s, 4H), δ 7.54 (s, 4H), δ 10.43 (s, 2H) ESI-MS: 
Calcd. for C10H10Br2N2O2: 350.01, obsd. M+H+= 350.8 
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 V. Synthesis of 5,5’-bis(bromomethyl)-2,2’-bipyridine 
 
 
5, 5’-dimethyl-2,2’ bipyridine 6 (2 mmol, 368 mg) was dissolved in 20 mL dry CCl4 together with NBS 
(10 mmol, 1.78 g) and AIBN (20 mg) was stirred under reflux for 4 hrs at 55°C.  The reaction mixture 
was then dried under vacuum and purified by silica gel column chromatography using EtOAc/Hexane 
(1:1) to obtain pure 5,5'-bis(bromomethyl)-2,2'-bipyridine c. 1H NMR (DMSO-d6, 300 MHz): δ 8.85 
(d, 2H), δ 8.43 (d, 2H), δ 8.10 (d, 2H), δ 4.88 (s, 4H), δ 2.63 (s, 1.5H) ESI-MS: Calcd. for C12H10Br2N2 
: 342.01, obsd. M+H+= 342.9 
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 VI. Stapled peptides 
The following stapled peptides were synthesized: 
No. 
 
Peptide 
 
Chemical 
Formula 
 
Exact 
Mass 
[M] 
 
 
Observed 
 
1a 
 
C129H211N47O31S2 2978.58 
M + H+ = 
2980.88 
Ia 
 
C141H214N46O35S2 3175.58 
M + H+ = 
3178.31 
1b 
 
C125H209N49O33S2 2988.56 
M + H+ = 
2991.49 
Ib 
 
C137H212N48O37S2 3185.56 3186.73 
1c 
 
C127H209N49O31S2 2980.57 2981.74 
Ic 
 
C139H212N48O35S2 3177.57 3178.83 
2d 
 
C125H209N47O33S2 2960.56 
M + H+ = 
2962.74 
IId 
 
C137H212N46O37S2 3157.56 
M + H+ = 
3161.14 
3d 
 
C123H207N47O31S2 2902.55 
M + H+ = 
2904.71 
Table 2: Calculated and observed masses of stapled peptides. 
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Figure 20: RP-HPLC trace of HPLC purified peptide 1a with tR= 10.526 min (0-100% ACN in 15 min 
on Luna C18(2) 100 Å, 250 x 2.1 mm, 2.6 µm, at 35 °C). 
 
 
Figure 21: MALDI-MS spectrum of RP-HPLC purified peptide 1a. E.M. Calcd. for C129H211N47O31S2 
= 2978.58 and mass found M+H+= 2980.88 
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Figure 22: RP-HPLC trace of HPLC purified peptide Ia with tR= 10.526 min (0-100% ACN in 15 min 
on Luna C18(2) 100 Å, 250 x 2.1 mm, 2.6 µm, at 35 °C) 
 
 
Figure 23: MALDI-MS spectrum of RP-HPLC purified peptide Ia. E.M. Calcd. for C141H214N46O35S2 
= 3175.58 and mass found M+H+= 3178.31 
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Figure 24: RP-HPLC trace of HPLC purified peptide 1b with tR= 10.155 min (0-100% ACN in 15 min 
on Luna C18(2) 100 Å, 250 x 2.1 mm, 2.6 µm, at 35 °C) 
 
 
 
 
Figure 25: MALDI-MS spectrum of RP-HPLC purified peptide 1b. E.M. Calcd. for C125H209N49O33S2 
= 2988.56 and mass found M+H+= 2991.49 
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Figure 26: RP-HPLC trace of HPLC purified peptide Ic (0-100% ACN in 6 min on Kinetex C18 100 
Å, 150 x 2.1 mm, 2.6 µm, at 35 °C) 
 
 
 
Figure 27: ESI-MS from LC-MS at t = 3.443 min. E.M calcd. for HPLC purified peptide Ic 
C137H212N48O37S2 = 3185.56 and deconvoluted mass found 3186.73. 
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Figure 28: RP-HPLC trace of HPLC purified peptide 1c (0-100% ACN in 6 min on Kinetex C18 100 
Å, 150 x 2.1 mm, 2.6 µm, at 35 °C) 
 
 
Figure 29: ESI-MS from LC-MS at t = 3.386 min. E.M calcd. for HPLC purified peptide 1c 
C127H209N49O31S2 = 2980.57 and deconvoluted mass found 2981.74. 
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Figure 30: RP-HPLC trace of HPLC purified peptide Ic (0-100% ACN in 6 min on Kinetex C18 100 
Å, 150 x 2.1 mm, 2.6 µm, at 35 °C) 
 
 
 
Figure 31: ESI-MS from LC-MS at t = 3.539 min. E.M calcd. for HPLC purified peptide Ic 
C139H212N48O35S2 = 3177.57 and deconvoluted mass found 3178.83. 
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Figure 32: RP-HPLC trace of HPLC purified peptide 2d with tR= 10.185 min (0-100% ACN in 15 min 
on Luna C18(2) 100 Å, 250 x 2.1 mm, 2.6 µm, at 35 °C) 
 
 
 
 
Figure 33: MALDI-MS spectrum of RP-HPLC purified peptide 2d. E.M. Calcd. for C125H209N47O33S2 
= 2960.56 and mass found M+H+= 2962.74 
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Figure 34: RP-HPLC trace of HPLC purified peptide IId with tR= 10.492 min (0-100% ACN in 15 min 
on Luna C18(2) 100 Å, 250 x 2.1 mm, 2.6 µm, at 35 °C) 
 
Figure 35: MALDI-MS spectrum of RP-HPLC purified peptide IId. E.M. Calcd. for C137H212N46O37S2 
= 3157.56 and mass found M+H+= 3161.14 
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Figure 36: RP-HPLC trace of HPLC purified peptide 3d with tR = 10.397 min (0-100% ACN in 15 min 
on Luna C18(2) 100 Å, 250 x 2.1 mm, 2.6 µm, at 35 °C) 
 
 
 
 
Figure 37: MALDI-MS spectrum of RP-HPLC purified peptide 3d. E.M. Calcd. for C123H207N47O31S2 
= 2902.55 and mass found M+H+= 2904.71 
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VII. Circular Dichroism studies 
All HPLC purified peptide solutions were prepared at 5 μM in 50 mM phosphate buffer (pH 7.0) without 
TFE. CD studies were conducted at 25 °C on an Aviv 410 CD spectrophotometer equipped with a 
Peltier temperature control unit.  Results (fig. 38) showed that the uncross-linked GCN4 sequence 4 
shows almost no helical character whereas cross-linking with Biphenyl as in the case of 1a shows most 
helical character. Surprisingly, cross-linking with Bipyridine does not improve the helicity significantly 
as can be seen from the curve of 1c.  Among the i, i+4 stapled peptides 2d is more helical than 3d which 
would explain its better DNA binding. In general the i, i+7 stapled peptides 1a & 1b show more helical 
character than the i, i+4 ones 2d & 3d which is expected given the two turn stabilization in case of the 
former. 
 
 
Figure 38: Plotted data obtained from Circular Dichroism studies showing Mean residue Ellipticity, 
θ, in deg.cm
2
 dm
-1 on the Y axis and Wavelength λ, in nm on the X axis for peptides 4, 1a, 1b, 1c and 
2d. 
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VIII. Electrophoretic Mobility Shift Assay (EMSA) 
The following stock solutions were prepared (fresh each time, except for DNA and peptide):  
DNA: 1.67 µM prepared from CRE (5’ – CGG ATG ACG TCA TTT TTT TTC – 3’) & CRE 
complement (5’ – GAA AAA AAA TGA CGT CAT CCG – 3’) and Random (5’ – GCG CGA GAA 
GGA AAG AAA GCC GG – 3’) & complement (5’ – CCG GCT TTC TTT CCT TCT CGC GC – 3’)  
DNA solutions (commercially purchased) by diluting with 20 µL 0.5 M Tris, pH = 8, 40 µL 2.5 M 
NaCl, 40 µL 0.025 M EDTA and then adding milliQ water such that the total volume is 1 mL.  The 
DNA was annealed by heating in a Thermomixer from room temperature to 95°C and maintaining the 
temperature at 95°C in total time of 24 min.  The machine was then turned off and the sample was 
allowed to cool down slowly.  
Loading buffer: 20 µL Tris 1 M, pH = 7.6, 20 µL KCl 0.2 M, 20 µL MgCl2 0.1 M, 40 µL EDTA 0.025 
M. 
Sucrose: 30% sucrose in mQ (300 mg/mL) 
Peptides: 10 µL stock solutions (10x) were prepared in MiliQ water (0, 1.67, 5.01, 6.68, 7.51, 8.35, 
10.02, 11.69, 13.36, 16.7 µM) 
Loading mixture:  The loading mixture comprised of: 10 µL mQ, 4 µL sucrose, 2 µL loading buffer, 2 
µL DNA, 2 µL peptide.  The loading mixture was prepared only 1-2 hr prior to running of gels and kept 
on ice as soon as ready. 
Preparation of Gels (for 2 Gels): In a clean falcon tube the following were added (in given order): 
15.595 mL mQ, 0.4 mL TBE, 4.005 mL of 40% acrylamide solution, 200 µL APS (10% w/w in mQ).  
The solution was mixed by sonication to remove any air bubbles and cooled to 0°C (1 h under ice).  20 
µL of TEMED was then added to the mixture and was again mixed properly before pouring it gently 
along parallel glass plates.  The glass plates were tapped gently to ensure removal of all air bubbles and 
the markers were squeezed between the plates to ensure uniform width of each well.  Sufficient time 
was given for polymerization (~1 h). 
Gel Electrophoresis:A pre-run of the gels was performed prior to loading them.  Care was taken to see 
that the gels were properly immersed in 0.2x TBE buffer (non-denaturing gel, without urea) and the 
loading wells were free from any air bubbles. Instrument settings: 150 V, 100 mA, 19 W for 30 mins at 
4°C. The wells were washed after the pre-run.  5 µL of the loading mixture was then loaded onto the 
wells.  Instrument settings: 150 V, 100 mA, 19 W for 45 mins at 4°C. 
Staining of gels: After the run, the gels were removed from the glass and were stained using 100 mL of 
0.2x TBE buffer + 10 µL Sybr Gold (commercially purchased stock solution 10,000X in DMSO).  The 
gels were then washed twice with mQ and gently placed under a UV lamp (dark room) to observe the 
gel pattern. 
Full gels and gels using random dsDNA are shown in figure 39-41. Figure 42 shows the gel of an 
additional gel to confirm that the black dot of peptide 3d at 2.5 µM (fig. 40, right) is an artifact. To 
investigate the double binding pattern of peptides 2d and 3d, additional tests with similar DNA 
containing only one binding site is shown in figure 43. Results show that scrambling the sequence is 
detrimental for the DNA binding capacity as binding is not observed with this mutated sequence 5’- 
CGG CGA TAG TCA TTT TTT TTC- 3’.  
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Figure 39: Full gels obtained from EMSA for peptides 1a, 1b and 1c (from left to right) respectively 
using CRE DNA. DNA concentration = 167 nM for all gels. Peptide concentrations in µM (from left to 
right) are indicated below each gel. 
 
 
Figure 40: Full gels obtained from EMSA for peptides 2d and 3d (from left to right) respectively using 
CRE DNA. DNA concentration = 167 nM for all gels. Peptide concentrations in µM (from left to right) 
are indicated below each gel.  
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Figure 41: Full gels obtained from EMSA for peptides 4 using CRE DNA (left) and 2d using random 
dsDNA (right). DNA concentration = 167 nM for both gels. Peptide concentrations in µM (from left to 
right) are indicated below each gel. 
 
 
Figure 42: Full gel obtained from EMSA for peptides 3d using CRE DNA (concentration = 167 nM). 
Peptide concentrations in µM (from left to right) are indicated below each gel. Gelred was used as 
staining agent instead of the previous used Sybr Gold. Therefore intensities are lower than in other gels. 
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Figure 43: Full gels obtained from EMSA for peptides 2d (left) and 3d (right) using scrambled CRE. 
DNA concentration = 167 nM for both gels. Peptide concentrations in µM (from left to right) are 
indicated below each gel. 
 
IX. DLS-measurement 
In order to investigate the aggregation of DNA and peptide, leading to precipitation and a subsequent 
decrease in intensity of the band, the dynamic light scattering (DLS) is measured of peptides 1a and 1c 
in the same mixture as the loading mixture in the gel electrophoresis. DLS measurement was performed 
in fivefold on a Zetasizer Nano series, Malvern in a 100 µL cuvette. The results are shown in figure 45. 
On the left, the volume distribution displays the aggregation of peptides 1a with DNA at higher 
concentration as a ‘particle’ with larger size is present. Also when looking to the count rate on the right 
of fig. 45, a higher amount of particles is present at high concentration which can be explained by 
aggregation. These results are conform the visual observation of the gels where peptide 1a shows a 
decreased intensity of the band at higher concentration. Also a decreased intensity of the band of 1a at 
higher concentration compared to peptide 1c at 2 µM is observed. 
 
Figure 44: DLS measurement of peptides 1a and 1c at a peptide concentration of 0.25 µM and 2 µM 
and a DNA concentration of 167nM. On the left, the volume distribution is shown in function of the 
size of the measured particles. On the right, the count rate of each samples in shown. 
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 X. Confocal Microscopy 
 
RAW264.7 cells cultivated in DMEM (105/well, 300 µL) were plated in a confocal plates and incubated 
overnight at 37 °C and 5 % CO2. Peptides were added in an overall concentration of 0.25 µM and 
incubated for 2 h at the same conditions or on ice. Cells were washed and fixated with 2 % of 
Paraformaldehyde for 30 min at 37°C. Cells were stained by 30 min incubation with a 0.2 % solution 
of CTB-AF647 and 0.2 % of Hoechst in PBS with 1 % BSA. This was done to visualize the cell nucleus 
(blue) and cell membrane (red) respectively. Cells were resuspended in PBS and measured with 
confocal microscope (Leica SP5 equiped with a 63x (1.4 NA) oil immersion objective) at 3 different 
wavelengths (405 nm, 488 nm and 643 nm). The peptides used were labeled with fluorescein which 
emits green light. To understand the uptake mechanism better, three samples are made in duplicates and 
incubated at 4 °C to inhibit active transport. Due to the difference in emission wavelength, the three 
dyes can be detected separately. Processing the data with Image J gave overlay images whereby the 
nucleus, cell membrane and fluorescein are shown in blue, red and green respectively. 
 
XI. Flow cytometry 
RAW264.7 cells cultivated in DMEM (105/well, 1 ml) were plated in a 24-well plates and incubated 
overnight at 37 °C and 5 % CO2. Peptides were added in an overall concentration of 0.25 µM and 1 µM 
and incubated for 2 h at the same conditions or on ice. Cells were washed with PBS and detached with 
Na4EDTA. Cells were re-suspended in PBS and added to the BD Accuri flow cytometer. Experiments 
were carried out in duplicate.  The amount of peptide associated to the cell was measured by flow 
cytometry. Blank cells were measured and the signal received corresponded to auto-fluorescence. A 
threshold was chosen to separate cells emitting light due to auto-fluorescence from cells containing 
fluorescently labeled peptides. The area under the histograms beyond this threshold correspond to the 
number of cells which actually emit sufficient intensity of fluorescence to make sure fluorescently 
labeled peptides are present. This number is further referred to as the percent of peptide positive cells 
(fig. 45, right). The percent of peptide positive cells for two peptides may be 100 % yet one may better 
due to its higher mean fluorescence value. If a peptide is not taken up by all cells, the percentage of 
peptide positive cells is lower than 100 % proportional to the colored area under the curve. It is therefore 
important to both compare the mean fluorescence and the amount of peptide positive cells. The raw 
data, represented as histograms, can be found in fig. 46-50. 
 
Figure 45: Mean fluorescence of fluorescently labelled peptides Ia, Ib, Ic, IId and IV (left) and peptide 
positive cells (right) using the following concentrations and incubation conditions: 0.25 µM at 4°C, 1 
µM at 4°C, 0.25 µM at 37°C and 1 µM at 37°C. 
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Figure 46: Histograms responding to the uptake of peptide Ia under different conditions and compared 
with the blank measurement. ‘Count’ represents the cell count during each measurement. FL1-A+ 
represents the peptide positive cells. 
 
Figure 47: Histograms responding to the uptake of peptide Ib under different conditions and compared 
with the blank measurement. ‘Count’ represents the cell count during each measurement. FL1-A+ 
represents the peptide positive cells. 
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Figure 48: Histograms responding to the uptake of peptide Ic under different conditions and compared 
with the blank measurement. ‘Count’ represents the cell count during each measurement. FL1-A+ 
represents the peptide positive cells. 
 
Figure 49: Histograms responding to the uptake of peptide IId under different conditions and compared 
with the blank measurement. ‘Count’ represents the cell count during each measurement. FL1-A+ 
represents the peptide positive cells. 
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Figure 50: Histograms responding to the uptake of peptide Ia under different conditions and compared 
with the blank measurement. ‘Count’ represents the cell count during each measurement. FL1-A+ 
represents the peptide positive cells. 
 
 XII. MTT Assay 
 
RAW264.7 cells cultivated in DMEM (104/well, 200 µL) were plated in a 96-well plates and incubated 
overnight at 37 °C and 5 % CO2. The peptides and control compounds were added in an overall 
concentration of 0.25 µM and 1 µM and incubated for 24h under the same conditions. The MTT solution 
was then added to the aspirated wells and incubated for 3 h. After removal of the cell medium, purple 
formazan crystals were dissolved in DMSO. Then, UV-measurement at 570 nm was performed with a 
plate reader to check cell viability quantitatively. An observation with the naked eye already gave a 
good idea about the toxicity of the compounds due to the disappearance of color in the well. Comparison 
of the absorbance of the formazan solution of the sample to the absorbance of a positive (incubation 
with ultrapure water) and a negative control (incubation with DMSO) gave quantitative results of cell 
viability as in the equation: 
 
𝐶𝑒𝑙𝑙 𝑣𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 (%) =  
𝐴 − 𝐴𝑝𝑜𝑠
𝐴𝑛𝑒𝑔 − 𝐴𝑝𝑜𝑠
∗ 100 
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XIII. Peptide stability 
Peptides dissolved in a 50 mM NH4HCO3 buffer at a concentration of 0.5 mg/mL are incubated at 37°C 
with a trypsin solution (trypsin/ peptide: 1/1000 wt%) in AcOH 50 mM buffer. The pH was optimized 
to 7-9. Samples were taken after 0 min, 30 min, 1h, 2 h and 24 h and injected on RP-HPLC (Jupiter C4 
300A, 0-100% CH3CN in 15 min). Peaks were collected and analysed using MALDI-TOF. Peaks were 
integrated. The peak area at 0 min was used as control. The degradation in function of time shows that 
the stapled peptides are more stable than the control peptide IV (fig. 51). Figures 52-55 displays the 
degradation of the peptide in function of time. 
 
Figure 51: Chromatograms of RP-HPLC of samples of peptide IV taken after 0 min (blue), 30 min 
(red), 1 h (green), 2 h (pink),  
 
 
 
Figure 52: Chromatograms of RP-HPLC of samples of peptide IV taken after 0 min (blue), 30 min 
(red), 1 h (green), 2 h (pink). 
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Figure 53: Chromatograms of RP-HPLC of samples of peptide Ib taken after 0 min (blue), 30 min 
(red), 1 h (green), 2 h (pink).  
Figure 54: Chromatograms of RP-HPLC of samples of peptide Ic taken after 0 min (blue), 30 min 
(red), 1 h (green), 2 h (pink). 
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Figure 55: Chromatograms of RP-HPLC of samples of peptide IId taken after 0 min (blue), 30 min 
(red), 1 h (green), 2 h (pink). 
  
  
 
Experimental Section for Chapter 6 
169 
EXPERIMENTAL SECTION FOR CHAPTER 6 
 
I. Materials 
Amino acids and oxyma were purchased from Merck Millipore. Diisoproplycarbodiimide, 
Triisopropylsilane, Heptafluorobutyric acid and Trifluoroacetic acid (TFA) were purchased from 
Fluorochem, UK. L-amino acids were used throughout the syntheses.  The protecting groups for the 
amino acids are tBu for Glu, Boc for Pro, Tyr, Lys, Pbf for Arg and Trt for Gln. Diisopropylethylamine, 
supplied as extra dry, redistilled, 99.5 % pure, piperidine, NH4HCO3 and fully deprotected amino acids 
Lys and Arg were purchased from Sigma Aldrich. Dimmethylformamide (DMF) peptide synthesis 
grade was purchased from Rathburn chemicals.  Diethyl ether, i-PrOH, MeOH (HPLC grade), 35% 
(S.G. 0.88) NH4OH solution and Acetonitrile (HPLC grade) were purchased from Fisher Scientific. 
Water with the Milli-Q grade standard was obtained in-house from an ELGA Purelab Flex system. 
Rink-Amide ChemMatrix resin (100-200 μm, manufacturer’s loading: 0.49 mmol/g) was obtained from 
Biotage. All chemicals were used without further purification. 
 
II. Isolation of Moenomycin A from Flavomycin 
Moenomycin was isolated according to the procedure described in literatureI. 
III. General Procedure for peptide syntheses: 
Peptide syntheses was performed using standard Fmoc Solid Phase Peptide Synthesis (SPPS) protocols 
on Rink Amide Chemmatrix Resin, loading = 0.49 mmol/g on a 0.1 mmol scale using a Biotage Initiator 
+ Alstra fully automated microwave peptide synthesizer. All amino acid couplings were performed 
using 5 eq. Amino Acid with 5 eq. DIC/Oxyma in DMF as a coupling cocktail by irradiating at 70°C 
for 5 min. Fmoc deprotection was performed using 20% piperidine in DMF by irradiating at 70°C for 
3 min, followed by shaking at r.t. for 10 min. 4 x 45s washes were performed after each coupling cycle 
and 3 x 30s washes were performed after each deprotection cycle. 
Peptide cleavage was performed using TFA/TIS/H2O = 95:2.5:2.5 (3 mL/100 mg resin). For sequences 
containing 1 or 2 Arg groups, the cleavage time was 2 h. For 3 or higher Arg containing peptides, 
cleavage time was 5h. Peptides were precipitated using cold Et2O (-20°C) by adding approximately 5x 
volume of the TFA used for cleavage and centrifuging at 7000 rpm at 0°C. 
IV. Analysis and Purification of peptides: 
All peptides were analysed on a Thermo Scientific Dionex Ultimate 3000 RP-HPLC equipped with a 
Phenomenex Gemini NX C18 110 Å (150 x 4.6 mm) column using the following buffer systems: A: 1 
mM Heptafluorobutyric acid in milliQ water. B: ACN using a flow rate of 1 ml/min unless specified 
otherwise. The column was flushed with 100% A for 5 min prior to an injection and was flushed for 5 
min with 95% B and 5% A after the run was finished. All samples except 7 were dissolved in buffer A 
at a concentration of 1 mg/mL. Peptide 7 was dissolved in 0.1% HCOOH in mQ water. 
Peptides were analysed using the following gradient: 100% A for 3 min. 0-95% B in 15 min. 95% 
B for 5 min. 100% A for 4 min. A: 1 mM Heptafluorobutyric acid in milliQ water. B: ACN 
                                                          
I Adachi, M.; Zhang, Y.; Leimkuhler, C.; Sun, B.; LaTour, J. V.; Kahne, D. E. J. Am. Chem. Soc. 2006, 128, 
14012. 
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Peptides were purified using the same gradient and buffer system as mentioned above, on a Thermo 
Scientific Dionex Ultimate 3000 RP-HPLC with a flow rate of 4 mL/min using a Phenomenex Gemini 
NX C18 110 Å (150 x 10 mm) semi-prep column. 
LC-MS/ESI-MS data were collected on an Agilent 1100 Series instrument with a Phenomenex Kinetex 
C18 100Å column (150 x 4.6 mm, 5 μm at 35 °C) connected to an ESMSD type VL mass detector with 
a flow rate of 1.5 ml/min was used with the following solvent systems: (A): 0.1% HCOOH in H2O and 
(B) MeCN. The column was flushed with 100% A for 2 min, then a gradient from 0 to 100% B over 6 
min was used, followed by 2 min of flushing with 100% B. 
V. HPLC/LC-MS/ESI-MS Data 
 
 
 
Fig. 1: HPLC trace of purified Moenomycin A using the following buffer system: A: 5 mM NH4OAc, 
B: ACN. Gradient: 0-100% in 6 min (tR = 4.779 min) 
 
Fig. 2: ESI-MS spectra in negative mode of Moenomycin A with deconvolution. Exact Mass calcd. for 
C69H108N5O34P = 1581.66, deconvoluted mass found 1581.73. 
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Sr. 
No. 
Peptide Chemical 
Formula 
Exact 
Mass 
Mass found 
1 H2N-RRRRRRRRR-CONH2 C54H111N37O9 1421.94 1422.59 
2 H2N-KRRKRRKRR-CONH2 C54H111N31O9 1337.92 1338.56 
3 H2N-KKKKKKKKK-CONH2 C54H111N19O9 1169.88 1170.31 
4 H2N-RRRRRRRR-CONH2 C48H99N33O8 1265.84 1266.44 
5 H2N-RKKRRQRRR-CONH2 C53H107N31O10 1337.88 1338.56 
6 H2N-KKKKKKKK-CONH2 C48H99N17O8 1041.79 1041.99 
7 H2N-RRWWRRWRR-CONH2 C69H105N31O9 1511.87 1512.44 
8 H2N-KKKKKR-CONH2 C36H75N15O6 813.60 813.88 
9 H2N-RRRRR-CONH2 C30H63N21O5 797.53 798.5 [M+H+] 
10 H2N-KKKKK-CONH2 C30H63N11O5 657.50 658.5 [M+H+]  
11 H2N-RRRR-CONH2 C24H51N17O4 641.43 642.4 [M+H+] 
12 H2N-KKKK-CONH2 C24H51N9O4 529.41 530.4 [M+H+] 
13 H2N-RRR-CONH2 C18H39N13O3 485.33 486.3 [M+H+] 
14 H2N-KKK-CONH2 C18H39N7O3 401.31 402.3 [M+H+] 
15 H2N-RR-CONH2 C12H27N9O2 329.23 330.2 [M+H+] 
16 H2N-KK-CONH2 C12H27N5O2 273.22 274.3 [M+H+] 
17 H2N-R-COOH C6H14N4O2 174.11 - 
18 H2N-K-COOH C6H14N2O2 146.11 - 
 
Table 1: Complete list of peptides synthesized along with their respective chemical formula, exact 
mass and obtained deconvoluted mass. 
Note: With the exception of peptide 7, all the peptides elute in the first minute itself in case of standard 
HCOOH and TFA buffers. Therefore, we use a 1mM Heptafluorobutyric acid buffer to analyze these 
peptides. The broad peak in each spectrum at t ~ 7.8 min is a result of the Heptafluorobutyric acid 
buffer. The peak just after 25 min is a result of the re-equilibration of the column after the analysis is 
complete. 
 
 
 
Fig. 3: RP-HPLC trace of mQ water using the gradient described in IV. 
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Fig. 4: RP-HPLC trace of HPLC purified peptide 1 showing product peak at r.t = 9.660 min using the 
gradient described in IV. 
 
 
Fig. 5: ESI-MS spectra of RP-HPLC purified peptide 1 with deconvolution. 
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Fig. 6: RP-HPLC trace of HPLC purified peptide 2 showing product peak at r.t = 9.320 min using the 
gradient described in IV. 
 
 
Fig. 7: ESI-MS spectra of RP-HPLC purified peptide 2 with deconvolution. 
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Fig. 8: RP-HPLC trace of HPLC purified peptide 3 showing product peak at r.t = 9.307 min using the 
gradient described in IV. 
 
 
Fig. 9: ESI-MS spectra of RP-HPLC purified peptide 3 with deconvolution. 
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Fig. 10: RP-HPLC trace of HPLC purified peptide 4 showing product peak at r.t = 9.487 min using the 
gradient described in IV. 
 
 
 
Fig. 11: ESI-MS spectra of RP-HPLC purified peptide 4 with deconvolution. 
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Fig. 12: RP-HPLC trace of HPLC purified peptide 5 showing product peak at r.t = 9.257 min using the 
gradient described in IV. 
 
 
Fig. 13: ESI-MS spectra of RP-HPLC purified peptide 5 with deconvolution. 
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Fig. 14: RP-HPLC trace of HPLC purified peptide 6 showing product peak at r.t = 9.270 min using the 
gradient described in IV. 
 
 
Fig. 15: ESI-MS spectra of RP-HPLC purified peptide 6 with deconvolution. 
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Fig. 16: HPLC trace of HPLC purified peptide 7 using the following gradient: 100% A for 2 min, then 
a gradient from 0 to 100% B over 6 min, followed by 2 min of flushing with 100% B. A: 0.1% HCOOH 
in mQ water. B: ACN 
 
 
Fig. 17: ESI-MS spectra from LC-MS of RP-HPLC purified peptide 7 with deconvolution. 
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Fig. 18: RP-HPLC trace of HPLC purified peptide 8 showing product peak at r.t = 9.380 min using the 
gradient described in IV. 
 
 
 
Fig. 19: ESI-MS spectra of RP-HPLC purified peptide 8 with deconvolution. 
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Fig. 20: RP-HPLC trace of HPLC purified peptide 9 showing product peak at r.t = 9.373 min using the 
gradient described in IV. 
 
 
 
Fig. 21: ESI-MS spectra of RP-HPLC purified peptide 9. 
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Fig. 22: RP-HPLC trace of HPLC purified peptide 10 showing product peak at r.t = 9.277 min using 
the gradient described in IV. 
 
 
 
Fig. 23: ESI-MS spectra of RP-HPLC purified peptide 10 
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Fig. 24: RP-HPLC trace of HPLC purified peptide 11 showing product peak at r.t = 9.363 min using 
the gradient described in IV. 
 
 
 
Fig. 25: ESI-MS spectra of RP-HPLC purified peptide 11. 
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Fig. 26: RP-HPLC trace of HPLC purified peptide 12 showing product peak at r.t = 9.063 min using 
the gradient described in IV. 
 
 
 
Fig. 27: ESI-MS spectra of RP-HPLC purified peptide 12. 
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Fig. 28: RP-HPLC trace of HPLC purified peptide 13 showing product peak at r.t = 9.030 min using 
the gradient described in IV. 
 
 
 
Fig. 29: ESI-MS spectra of RP-HPLC purified peptide 13. 
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Fig. 30: RP-HPLC trace of HPLC purified peptide 14 showing product peak at r.t = 8.780 min using 
the gradient described in IV. 
 
 
 
Fig. 31: ESI-MS spectra of RP-HPLC purified peptide 14. 
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Fig. 32: RP-HPLC trace of HPLC purified peptide 15 showing product peak at r.t = 8.650 min using 
the gradient described in IV. 
 
 
 
Fig. 33: ESI-MS spectra of RP-HPLC purified peptide 12. 
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Fig. 34: RP-HPLC trace of HPLC purified peptide 16 showing product peak at r.t = 8.230 min using 
the gradient described in IV. 
 
 
 
Fig. 35: ESI-MS spectra of RP-HPLC purified peptide 16. 
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VI. MIC protocols 
 
For MIC testing all peptides were dissolved in pure mQ water. Bacteria were grown on Mueller Hinton 
broth (oxoid) with no additional supplements unless otherwise stated. All incubations were at 37°C 
unless otherwise stated. When MoeA was tested in conjunction with the peptides, they were incubated 
together for 1 hour in a 1:1 ratio (in terms of mM, MoeA to peptide), before being used in the testing. 
All dilutions of MoeA and peptides were carried out using Mueller Hinton broth unless otherwise stated. 
100 µl of autoclaved Mueller Hinton broth was added to wells 2-12 on a 96-well plate. 200 µl of the 
inhibitor was added to well one at a concentration of 512 µg/ml. 100µl of MoeA in well one was taken 
up and pipetted into well two. The mixture was the pipetted up and down three times before 100µl was 
taken up and pipetted into well three. This process was repeated up to well 11. Once MoeA has been 
added to well 11 100 µl was taken up and then discarded ensuring the well 12 had no inhibitor present. 
Each well was then inoculated with 100µl of bacteria that had been diluted to an OD600nm of 0.1. This 
was repeated three times. The 96-well plates were then incubated for 24 hours. The results were 
measured using a plate reader (spectra max plus plate reader) where possible. The MIC was determined 
to be the lowest concentration at which there was no growth visible. 
 
VII. Cytotoxicity assay by Formazan bioreduction 
HeLa cells were seeded in a 96-well plate at 104 cells/cm2 density in Dulbecco’s Modified Eagles 
Medium (DMEM) supplemented with 10% serum. The cells were repeatedly rinsed with Hank’s 
Balanced Salt Solution (HBSS) prior to be exposed to different peptide – MoeA complex or MoeA 
concentrations in the range of 0.5 – 100 µM in HBSS 24 hrs post-seeding. Following 6 hrs of exposure 
to the complex or MoeA, CellTiter 96 AQueous Nonradioactive Cell Proliferation Assay (Promega) 
was used according to the manufacturer’s instructionsII. Not ingested complex or MoeA was removed 
by repeated washings with fresh medium. 20 μL of the combined MTS/PMS solution was added to 
100 μL fresh medium in each well and plates were incubated for 3 hrs at 37°C. Absorbance was 
measured at 490 nm on Tecan Infinite M200 PRO plate reader with i-control 1.10 software (Molecular 
Devices). 
 
VIII. NMR Data 
 
All NMR was performed on a Bruker Ascend 500 MHz equipped with a broadband probe. 600 µL 1mM 
solutions of MoeA and peptide 7 were made in 5 mM Ammonium acetate + 20 µL 0.1% acetic acid 
with 10% D2O. 1H-1H TOCSY and 1H-1H NOESY were recorded on each sample at 4°C and 27°C with 
2048 and 256 complex points in the direct and indirect dimensions, respectively. NOESY spectra were 
acquired with 200ms mixing time. MoeA was then titrated into the peptide at molar equivalents 0.1, 
0.2, 04, 0.6, 0.8 and 1.0, with 1H spectra recorded at each step. At a molar equivalence of 1:1 the NOESY 
and TOCSY experiments were repeated. Spectra were processed using Bruker TopSpin and analysed 
using CCPN AnalysisIII. The NOESY spectrum obtained from the complex was assigned iteratively, 
                                                          
II Cory, A. H.; et al. Cancer communications 1991, 3, 207 
III Vranken WF, Boucher W, Stevens TJ, Fogh RH, Pajon A, Llinas M, Ulrich EL, Markley JL, Ionides J, Laue ED 
(2005). The CCPN data model for NMR spectroscopy: development of  a software pipeline. Proteins 59:687-96 
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with structural calculations being performed using ARIA 2.3IV. The topology and parameters of MoeA 
were generated using PRODRGV. Distance restraints were calculated using NOE volume, and 
calibrated by optimising the NOE between anomeric sugar protons and other well-resolved sugar 
protons from the same sugar moiety of known distances. Rings B and F had suitable protons for NOE 
calibration. Calculated distances had an upper error bound of 20% applied. A lower bound of 1.72Å 
was used. Iterative NOE assignment was continued until all significant restraint violations had been 
eliminated. The generated ensemble was then subjected to a final round of refinement in explicit solvent 
and was visualised and analysed using PyMOLVI. Restraints have been deposited with the BMRB 
(accession no. xxxxx). Co-ordinates of the ensemble are available upon request. 
                                                          
IV Rieping W, Habeck M, Bardiaux B, Bernard A, Malliavin TE, Nilges M (2007) ARIA2: automated NOE 
assignment and data integration in NMR structure calculation. Bioinformatics 23:381-382 
V Schüttelkopf AW, van Aalten DMF (2004). PRODRG: a tool for high-throughput crystallography of protein-
ligand complexes. Acta Crystallogr D 60:1355–1363 
VI The PyMOL Molecular Graphics System, Version 1.8 Schrödinger, LLC 
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Figure 36: Interaction between peptide 7 and MoeA revealed by NMR.  
A. 1H-1H NOESY of amide and aromatic region of 1mM peptide (red contours), 1mM MoeA (blue 
contours) and 1:1 complex (green contours) recorded at 27°C, showing noticeable dispersion and clear 
evidence of intermolecular NOEs between 4Trp and the acyl chain of MoeA. Resolvable 4Trp protons 
and interacting MoeA protons are indicated by dashed grey lines. 600 µL 1mM solutions of MoeA and 
peptide 7 were made in 5 mM Ammonium acetate + 20 µL 0.1% acetic acid with 10% D2O.  
B. 1H-1H NOESY (MoeA and complex) and 1H-1H TOCSY (peptide) recorded at 4°C. Sample and 
spectrum descriptions as before. Significantly more NOEs were visible at this temperature, allowing for 
a full structural characterisation of the complex. Black arrow indicates an example of the chemical shift 
perturbation experienced by the peptide upon interaction with MoeA. 
 
Residue Atom 
Peptide Moenomycin Complex 
4°C 37°C 4°C 37°C 4°C 37°C 
1Arg H 
 
     
1Arg Hα 3.657 3.887 
  
3.659 3.910 
1Arg Hβ 1.098 1.710 
  
1.072 1.292 
1Arg Hγ 1.487 1.346 
  
1.458 
1.733 
1.728 
1Arg Hδ 2.642 2.889 
  
2.641 2.885 
1Arg Hε 6.605 6.821 
  
6.625 6.698 
1Arg Hη1*  
   
6.139 6.487 
1Arg Hη2*  
   
6.519 6.696 
2Arg H 8.522 
   
8.523 
 
2Arg Hα 4.003 4.226 
  
3.952 
 
2Arg Hβ 
1.137 
1.294 
1.515 
  
1.137 
1.238 
 
2Arg Hγ 
1.092 
1.085 
1.352 
  
1.077 
 
2Arg Hδ 2.705 2.945 
  
2.677 
 
2Arg Hε 6.712 6.908 
  
6.745 
 
2Arg Hη1*  
   
6.127 
 
2Arg Hη2*  
     
3Trp H 8.234 8.272 
  
8.206 
 
3Trp Hα 4.324 4.573 
  
4.295 4.541 
3Trp Hβ 2.887 3.098 
  
2.859 3.095 
3Trp Hδ1 6.911 7.121 
  
6.891 7.130 
3Trp Hε1 9.867 10.012 
  
9.858 10.031 
3Trp Hε3 7.239 7.474 
  
7.218 7.457 
3Trp Hη2 6.892 7.018 
  
6.854 7.103 
3Trp Hζ2  7.361 
  
7.109 7.353 
3Trp Hζ3 6.820 7.107 
  
6.769 
 
4Trp H 7.700 7.872 
  
7.666 7.942 
4Trp Hα 4.204 4.475 
  
4.180 4.453 
4Trp Hβ 2.785 
3.017 
3.036 
  
2.841 
2.762 
2.956 
4Trp Hδ1 6.794 7.021 
  
6.766 6.999 
4Trp Hε1 9.846 9.992 
  
9.858 10.023 
4Trp Hε3 7.131 7.516 
  
7.107 7.346 
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4Trp Hη2 6.877 7.019 
  
6.858 7.064 
4Trp Hζ2 7.132 7.516 
  
7.107 7.345 
4Trp Hζ3  7.019 
  
6.756 6.996 
5Arg H 7.757 7.874 
  
7.736 7.947 
5Arg Hα 3.683 3.943 
  
3.669 3.911 
5Arg Hβ 
1.269 
1.177 
1.401 
1.488 
  
1.245 
1.142 
 
5Arg Hγ 0.977 1.224 
  
0.954 1.162 
5Arg Hδ 2.678 2.907 
  
2.664 2.910 
5Arg Hε 6.783 6.928 
  
6.766 7.008 
5Arg Hη1* 6.143 
   
6.136 
 
5Arg Hη2* 6.384 
     
6Arg H 7.948 8.020 
  
7.934 8.067 
6Arg Hα 3.822 4.071 
  
3.802 4.060 
6Arg Hβ 
1.321 
1.121 
1.563 
  
1.326 
1.085 
1.339 
6Arg Hγ 1.321 1.354 
  
1.332 
 
6Arg Hδ 2.732 2.954 
  
2.698 2.954 
6Arg Hε 6.872 6.974 
  
6.835 7.087 
6Arg Hη1* 6.145 
   
6.113 
 
6Arg Hη2* 6.550 
   
6.514 
 
7Trp H 8.002 8.090 
  
7.960 
 
7Trp Hα 4.265 4.531 
  
4.244 4.455 
7Trp Hβ 2.895 3.105 
  
2.871 3.098 
7Trp Hδ1 6.905 7.125 
  
6.890 7.127 
7Trp Hε1 9.867 10.013 
  
9.858 10.029 
7Trp Hε3 7.228 7.387 
  
7.209 7.454 
7Trp Hη2 6.882 7.005 
  
6.872 7.102 
7Trp Hζ2  7.359 
  
7.109 7.353 
7Trp Hζ3 6.783 7.106 
  
6.758 7.009 
8Arg H 7.768 7.937 
  
7.739 8.071 
8Arg Hα 3.826 4.092 
  
3.805 4.084 
8Arg Hβ 
1.267 
1.361 
1.503 
1.615 
  
1.244 
1.339 
1.581 
1.622 
8Arg Hγ 1.091 1.344 
  
1.079 
1.072 
1.339 
1.304 
8Arg Hδ 2.721 2.980 
  
2.704 2.973 
8Arg Hε 6.862 6.998 
  
6.859 7.102 
8Arg Hη1* 6.145 
   
6.130 
 
8Arg Hη2* 6.575 
     
9Arg H 7.963 8.065 
  
7.950 8.073 
9Arg Hα 3.699 3.992 
  
3.673 3.990 
9Arg Hβ 1.276 1.666 
  
1.250 
1.100 
1.502 
1.295 
9Arg Hγ 
1.367 
1.435 
1.527 
1.553 
  
1.354 
1.403 
1.623 
9Arg Hδ 2.848 3.077 
  
2.848 3.076 
9Arg Hε 6.928 7.082 
  
6.898 7.134 
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9Arg Hη1* 6.162 
   
6.133 
 
9Arg Hη2* 6.615 
   
6.148 
 
10Nh2 Hn1 6.896 
   
6.886 7.192 
10Nh2 Hn2 7.431 
   
7.403 7.541 
11M0e Hdg  
 
3.785 
 
3.681 
 
11M0e Hdk  
 
4.254 4.502 3.800 
 
11M0e Hax  
 
5.431 5.677 5.434 5.755 
11M0e Haq  
 
4.096 4.340 3.679 
 
11M0e Hau 
 
 
7.001 
7.387 
7.121 
7.527 
6.888 
7.404 
7.009 
7.523 
11M0e Has*  
 
0.881 1.140 0.858 1.170 
11M0e Hap  
   
4.702 
 
11M0e Hat 
 
 
6.024 
6.407 
 
6.063 6.239 
11M0e Har  
 
3.514 3.755 3.524 3.760 
11M0e H1  
 
4.239 4.501 4.438 4.447 
11M0e H2  
 
3.359 3.629 3.236 
 
11M0e H3  
 
3.265 3.550 
  
11M0e Hn2  
 
7.844 7.891 7.878 7.959 
11M0e Hah*  
 
1.699 1.951 1.708 1.946 
11M0e H5  
 
3.270 
 
3.371 3.644 
11M0e H6  
 
3.786 4.036 3.796 4.029 
11M0e Hbj  
 
4.166 4.420 4.174 
 
11M0e Hbn  
 
3.146 3.379 3.279 3.375 
11M0e Hbo 
 
 
3.596 
3.605 
3.839 
3.848 
3.749 
 
11M0e Hbm  
 
3.057 3.318 3.205 
 
11M0e Hbl  
 
3.199 3.458 3.220 
 
11M0e Hbk 
  
2.964 3.220 
  
11M0e H4 
    
3.225 
 
11M0e Hbu 
  
4.248 4.505 4.302 
 
11M0e Hbv 
  
3.418 3.666 3.578 3.650 
11M0e Hbw 
  
3.315 3.573 3.461 3.520 
11M0e Hncc 
  
8.268 8.322 8.205 8.262 
11M0e Hcb* 
  
1.732 1.992 1.723 1.946 
11M0e Hby 
  
3.304 
   
11M0e Hbz* 
  
1.056 1.312 1.071 1.289 
11M0e Hbx 
  
3.226 3.472 3.225 3.422 
11M0e Hch 
  
4.293 4.536 4.257 4.440 
11M0e Hci 
  
3.256 
 
3.461 3.512 
11M0e Hcj 
  
3.421 3.658 3.379 3.655 
11M0e Hck 
  
3.976 
 
3.410 
 
11M0e Hcl 
  
3.974 4.222 3.928 4.197 
11M0e Hncs 
  
7.795 
 
7.740 7.950 
11M0e Hcw 
  
2.072 
 
2.250 2.304 
11M0e Hcx 
  
2.072 
 
2.250 2.304 
11M0e H31 
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11M0e H32 
  
5.074 5.313 5.212 5.167 
11M0e H34* 
  
1.417 1.651 1.408 1.643 
11M0e H35 
  
1.838 2.083 1.959 
 
11M0e H36 
  
1.803 2.039 1.950 
 
11M0e H7 
  
4.981 5.216 5.103 
 
11M0e H8 
  
5.085 5.304 5.005 
 
11M0e H10* 
  
0.616 0.844 0.421 0.647 
11M0e H11* 
  
0.616 0.844 0.486 0.647 
11M0e H12 
  
1.172 1.447 1.057 1.385 
11M0e H13 
  
1.288 1.528 1.534 1.574 
11M0e H15 
  
4.430 4.643 4.568 
 
11M0e H16 
  
2.422 2.512 
1.917 
2.040 
2.374 
11M0e H17 
  
4.874 5.168 4.861 4.991 
11M0e H19* 
  
1.594 1.737 1.324 1.752 
11M0e H20 
  
1.739 1.960 1.723 
 
11M0e H21 
  
1.806 
 
1.725 
 
11M0e H22 
  
5.079 
   
11M0e H24* 
  
1.051 1.236 1.236 1.296 
11M0e H25* 
  
1.590 1.723 1.255 1.746 
 
Table 3. Observed chemical shifts of peptide/MoeA complex constituents at 4°C and 37°C. 
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VII Core atoms are well ordered moieties. These are: the heavy atoms of the peptide; and sugars C, D, E and F 
and the lipid tail of MoeA. Sugars A and B were found to be disordered. 
VIII Laskowski RA, Rullmannn JA, MacArthur MW, Kaptein R, Thornton JM (1996). AQUA and PROCHECK-
NMR: programs for checking the quality of protein structures solved by NMR. J Biomol NMR 8:477-486 
Sr. 
No. 
Particulars Value 
1. Pairwise RMSD of complex components  
   Peptide  
     Heavy atom (Å) 0.91 ± 0.26 
     All Atoms (Å) 1.18 ± 0.32 
   Moenomycin A  
     Core atomsVII (Å) 1.48 ± 0.23 
     Heavy atom (Å) 1.81 ± 0.43 
     All atoms (Å) 2.04 ± 0.39 
2. Experimental restraints  
   Numbers of experimental restraints  
     Peptide  
       Intraresidue 212 
       Sequential 82 
       Total 397 
   Moenomycin A  
     Total 112 
   Complex  
     Intermolecular 98 
     Total 607 
   Restraint violations  
     NOE violations > 0.5 Å 2 
     NOE violations > 0.3 Å 1 
     NOE violations > 0.1 Å 3 
3. RMSD from idealized covalent geometry  
   Bond lengths (Å) 0.01 ± 0.00 
   Bond angles (°) 1.41 ± 0.05 
   Ramachandran analysis (determined by PROCHECKVIII)  
     Residues in allowed regions (%) 93.9 
     Residues in generously allowed regions (%) 6.1 
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Table 4: Structural Statistics of peptide/MoeA complex ensemble
 
                                                          
IX Wiederstein M, Sippl MJ (2007). ProSA-web: interactive web service for the recognition of errors in three-
dimensional structures of proteins. Nucl Acids Res 35:W407-W410 
X Chen VB, Arendall WB, Headd JJ, Keedy DA, Immormino RM, Kapral GJ, Murray LW, Richardson JS, 
Richardson DC (2010). MolProbity: all-atom structure validation for macromolecular crystallography. Acta 
Cryst D 66:12-21 
Sr. 
No. 
Particulars Value 
4. Statistics of overall structural quality  
   PROCHECK G-factors  
     Dihedrals -0.71 ± 0.06 
     Covalent 0.35 ± 0.04 
     Overall -0.33 ± 0.05 
   ProSAIX Z-score 0.81 ± 0.08 
   MolProbityX clash score 4.82 ± 0.09 
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EXPERIMENTAL SECTION FOR CHAPTER 7 
 
I. Materials 
All amino acids, Fmoc-Ɛ-Ahx-OH and oxyma pure were purchased from Merck Millipore. Fmoc-PEG3-
OH (16 atoms) was purchased from Novabiochem. Succinic anhydride was purchased from Alfa Aesar. 
5-Amino-2-Nitrobenzoic acid, Diisoproplycarbodiimide, Trifluoroacetic acid (TFA) and 
Triisopropylsilane were purchased from Fluorochem, UK. L-amino acids were used throughout the 
syntheses.  The protecting groups for the amino acids are tBu for Glu, Boc for Pro, Tyr, Lys, Trp, Pbf 
for Arg and Trt for Gln. 2,2’-(Ethylenedioxy)bis(ethylamine), Diisopropylethylamine, supplied as extra 
dry, redistilled, 99.5 % pure, piperidine and NH4HCO3 were purchased from Sigma Aldrich. 
Dimmethylformamide (DMF) peptide synthesis grade was purchased from Rathburn chemicals.  
Diethyl ether, i-PrOH, MeOH (HPLC grade), Dichloromethane (Analytical grade), 35% (S.G. 0.88) 
NH4OH solution and Acetonitrile (HPLC grade) were purchased from Fisher Scientific. Water with the 
Milli-Q grade standard was obtained in-house from an ELGA Purelab Flex system. Rink-Amide 
ChemMatrix resin (100-200 μm, manufacturer’s loading: 0.49 mmol/g) was obtained from Biotage. All 
chemicals were used without further purification.  Flavomycin, containing 12% by weight of 
Moenomycin A was purchased from Biovet J.S. Co, Sofia, Bulgaria. 
 
II. Isolation of Moenomycin A: 
Moenomycin A was isolated using the procedure described in literatureI. 
 
III. General procedure for peptide syntheses: 
Peptide syntheses was performed using standard Fmoc Solid Phase Peptide Synthesis (SPPS) protocols 
on Rink Amide Chemmatrix Resin, loading = 0.49 mmol/g on a 0.1 mmol scale using a Biotage Initiator 
+ Alstra fully automated microwave peptide synthesizer. All amino acid couplings were performed 
using 5 eq. Amino Acid with 5 eq. DIC/Oxyma in DMF as a coupling cocktail by irradiating at 70°C 
for 5 min. Fmoc deprotection was performed using 20% piperidine in DMF by irradiating at 70°C for 
3 min, followed by shaking at r.t. for 10 min. 4 x 45s washes were performed after each coupling cycle 
and 3 x 30s washes were performed after each deprotection cycle. 
 
Fmoc-Ɛ-Ahx-OH, Fmoc-PEG3-OH linker used in the peptides were coupled using 3 eq. of linker, 2.9 
eq. of HATU and 6 eq. of DIPEA. 5-Amino-2-Nitrobenzoic acid was coupled using 2 x 1h couplings 
using 3 eq. of linker, 2.9 eq. of HATU, 3 eq. of DMAP and 6 eq. of DIPEA. 
 
Peptide cleavage was performed using TFA/TIS/H2O = 95:2.5:2.5 (3 mL/100 mg resin). For sequences 
containing 1 or 2 Arg groups, the cleavage time was 2 h. For 3 or higher Arg containing peptides, 
cleavage time was 5h. Peptides were precipitated using cold Et2O (-20°C) by adding approximately 5x 
volume of the TFA used for cleavage and centrifuging at 7000 rpm at 0°C.  
IV. General procedure for syntheses of peptide-MoeA covalent conjugates 
IVa. For completely water soluble peptides (15 mg scale): 
                                                          
I Adachi, M.; Zhang, Y.; Leimkuhler, C.; Sun, B.; LaTour, J. V.; Kahne, D. E. J. Am. Chem. Soc. 2006, 128, 
14012. 
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15 mg Moenomycin A together with 135 mg of NaOAc was weighed out in a clean 25 mL round bottom 
flask. 7 mL of milliQ water was added and the mixture was cooled down to 0°C. In an eppendorf tube 
2 eq. of peptide was weighed out and dissolved in 800 µL 9% HCl and was cooled down to 0°C. 3 mg 
of NaNO2 was dissolved in 300 µL milliQ water another Eppendorf and cooled to 0°C. The NaNO2 was 
then added dropwise to the peptide whilst gently shaking the eppendorf. At this point, the yellow color 
of the peptide fades/disappears. The mixture was left standing for 5 min at 0°C and then added slowly 
to the 25 mL flask containing the Moenomycin. The yellow color of the peptide should now reappear. 
The reaction mixture was stirred for 4h and analyzed by RP-HPLC. If Moenomycin A was not 
completely consumed then the reaction mixture was left overnight. 
IVb. For partially water soluble peptides to Moenomycin A (15 mg scale): 
15 mg Moenomycin A together with 135 mg of NaOAc was weighed out in a clean 25 mL round bottom 
flask. 7 mL of milliQ water was added and the mixture was cooled down to 0°C. In a 10 mL falcon tube 
2 eq. of peptide was weighed out and dissolved in 750 µL 9% HCl + 750 µL ACN and was cooled down 
to 0°C. 3 mg of NaNO2 was dissolved in 300 µL milliQ water another Eppendorf and cooled to 0°C. 
The NaNO2 was then added dropwise to the peptide whilst gently shaking the falcon tube. At this point, 
the yellow color of the peptide fades/disappears. The mixture was left standing for 5 min at 0°C and 
then added slowly to the 25 mL flask containing the Moenomycin. The yellow color of the peptide 
should now reappear. If the reaction mixture is cloudy add acetonitrile dropwise till the solution clears 
up. The reaction mixture was stirred for 4h and analysed by RP-HPLC. If Moenomycin A was not 
completely consumed then the reaction mixture was left overnight. 
V. Analysis and purification of peptides/conjugates: 
All peptides/conjugates were analysed on a Thermo Scientific Dionex Ultimate 3000 RP-HPLC 
equipped with a Phenomenex Gemini NX C18 110 Å (150 x 4.6 mm) column using the following buffer 
systems:  
For peptides: Analysis of peptides was done using the conditions in chapter 6 using 1 mM 
Heptafluorobutyric acid buffer unless otherwise mentioned. 
For conjugates: A: 0.1% HCOOH in milliQ water. B: ACN using a flow rate of 1 ml/min. The column 
was flushed with 100% A for 5 min prior to an injection and was flushed for 5 min with 95% B and 5% 
A after the run was finished. The following gradient was used: 100% A for 2 min. 0-95% B in 15 min. 
95% B for 5 min. 100% A for 4 min. 
Conjugates were purified using the same gradient as the analyses, on a Thermo Scientific Dionex 
Ultimate 3000 RP-HPLC with a flow rate of 5 mL/min using a Phenomenex Gemini NX C18 110 Å 
(150 x 10 mm) semi-prep column. 
LC-MS data were collected on an Agilent 1100 Series instrument with a Phenomenex Kinetex C18 
100Å column (150 x 4.6 mm, 5 μm at 35 °C) connected to an ESMSD type VL mass detector with a 
flow rate of 1.5 ml/min was used with the following solvent systems: (A): 0.1% HCOOH in H2O and 
(B) MeCN. The column was flushed with 100% A for 2 min, then a gradient from 0 to 100% B over 6 
min was used, followed by 2 min of flushing with 100% B. 
VI. Synthesis of a PEG2 linker 
 
To a cooled (0 °C) stirred solution of 2,2'-(ethane-1,2-diylbis(oxy))diethanamine (2.94 mL; 20.1 mmol) 
in DCM (200 mL) was added a solution of Fmoc-ONSu (1.35 g; 4 mmol) in DCM (2 mL) and the 
mixture stirred at 0 °C for 2 hours. The mixture was analysed by TLC using: pure DCM (to verify that 
all the Fmoc-ONSu was consumed) and 20% MeOH in DCM + 2% Et3N (for identifying the product). 
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TLC was stained using ninhydrin. After reaction completion, the reaction mixture was washed 
successively with water (3 x 75 mL) before drying over Na2SO4. Removal of the solvent under vacuum 
afforded a brown oil A. Since the compound was found to be not stable under column chromatography 
conditions, no subsequent purification steps were performed. 
 
To a stirred solution of crude (9H-fluoren-9-yl)methyl (2-(2-(2-aminoethoxy)ethoxy)ethyl)carbamate 
(A, 1.25 g; 3.36 mmol) in DCM (10 mL) was added succinic anhydride (0.772 g; 7.72 mmol). The 
reaction was stirred at room temperature for 3 hours. The mixture was analysed by TLC using: 20% 
MeOH in DCM + 0.5% AcOH. TLC was stained using PMA. Removal of the solvent under vacuum 
yielded a brown solid. The brown solid was purified using silica gel column chromatography using 10% 
MeOH in DCM + 0.5% AcOH to obtain the pure product B as colourless oil (881 mg; 44% overall yield 
from 2 steps). 
1H NMR (CDCl3, 500MHz): δ = 7.73 (d, J = 7.3 Hz, 2 H), 7.59 (d, J = 7.3 Hz, 2 H), 7.36 (t, J = 7.5 Hz, 
2 H), 7.23 - 7.32 (m, 2 H), 4.37 (d, J = 7.0 Hz, 2 H), 4.19 (br. s., 1 H), 3.44 - 3.60 (8 H), 3.21 - 3.44 (4 
H), 2.54 - 2.64 (3 H), 2.42 - 2.52 ppm (2 H) (Figure 1) 
13C NMR (CDCl3, 125 MHz) δ = 29.62, 31.77, 39.20, 40.81, 45.11, 47.18, 51.59, 66.54, 69.69, 70.08, 
70.16, 119.93, 125.10, 127.05, 127.67, 141.21, 143.94, 156.69, 173.04, 173.50 (Figure 2) 
Exact mass calcd. for C25H30N2O7 = 470.21, found M + H+ = 471.1 (Figure 3) 
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Figure 1: 1H NMR spectra of B. 
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Figure 2: 13C NMR spectra of B. 
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Figure 3: ESI-MS of compound B. Exact mass calcd. for C25H30N2O7 = 470.21, found M + H+ = 471.1 
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VII. Complete list of peptides/conjugates synthesized 
Complete list of peptides conjugated to Moenomycin A: 
Sr. 
No. 
Code Peptide sequence Chemical 
Formula 
Exact 
Mass 
Mass 
found 
1. 1 X-Ahx-RRRR-CONH2 C37H66N20O8 918.54 919.54 
2. 2 X-RRRRRRRR-CONH2 C55H103N35O11 1429.86 1430.47 
3. 3 X-Ahx-RRRRRRRR-CONH2 C61H114N36O12 1542.94 1543.53 
4. 4 X-(Ahx)2-RRRRRRRR-CONH2 C67H125N37O13 1656.03 1656.38 
5. 5 X-(Ahx)-RRRRRRRRR-CONH2 C67H126N40O13 1699.04 1699.43 
6. 6 X-(Ahx)-RRRRRRRRRR-CONH2 C73H138N44O14 1855.14 1855.61 
7. 7 X-Ahx-KKRRRRRRRR-CONH2 C73H138N40O14 1799.13 1799.52 
8. 8 X-KRRKRRKRR-CONH2 C61H115N33O12 1501.94 1502.51 
9. 9 X-Ahx-KRRKRRKRR-CONH2 C67H126N34O13 1615.02 1615.40 
10. 10 X-(Ahx)2-KRRKRRKRR-CONH2 C73H137N35O14 1728.11 1728.76 
11. 11 X-KKKKKR-CONH2 C43H79N17O9 977.62 978.50 
[M+H+] 
12. 12 X-Ahx-KKKKKR-CONH2 C49H90N18O10 1090.71 1090.6 
13. 13 X-(Ahx)2-KKKKKR-CONH2 C55H101N19O11 1203.79 1204.00 
14. 14. X-Ahx-RRWWRRWRR-CONH2 C82H120N34O13 1788.98 1789.47 
15. 15 X-R-CONH2 C13H19N7O4 337.15 338.1 
[M+ H+] 
16. 16 X-(PEG)3-KKKKKR-CONH2 C54H100N18O14 1224.77 1226.5 
[M+ H+] 
17. 17 X-(PEG)2-KKKKKR-CONH2 C53H97N19O13 1207.75 1208.08  
18. 18 X-(PEG)3-RRRRRRRR-CONH2 C66H124N36O16 1677.00 1677.50 
19. 19 X-(PEG)2-RRRRRRRR-CONH2 C65H121N37O15 1659.98 1660.43 
20. 20 X-(PEG)3-RRRR-CONH2 C42H76N20O12 1052.59  
21. 21 X-(PEG)3-RRRRR-CONH2 C48H88N24O13 1208.70 1209.10 
22. 22 X-(PEG)2-RRRR-CONH2 C41H73N21O11 1035.58 1035.89 
 
Table 1: Complete list of peptides synthesized 
 
Figure 4: Structure of 5-amino-2-nitrobenzoic acid, PEG2 linker, PEG3 linker and 6-Aminohexanoic 
acid linker (Ahx). 
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Sr. 
No. 
Code Conjugate description Chemical 
Formula 
Exact 
Mass 
Mass 
found 
1. 23 Conjugate with peptide 1 C106H171N26O42P 2511.18 2512.2 
2. 24 Conjugate with peptide 2 C124H208N41O45P 3022.50 3023.35 
3. 25 Conjugate with peptide 3 C130H219N42O46P 3135.58 3137.1 
4. 26 Conjugate with peptide 4 C136H230N43O47P 3248.67 3249.46 
5. 27 Conjugate with peptide 5 C136H231N46O47P 3291.68 3292.46 
6. 28 Conjugate with peptide 6 C142H243N50O48P 3447.78 3448.61 
7. 29 Conjugate with peptide 7 C136H231N40O47P 3207.67 3208.34 
8. 30 Conjugate with peptide 8 C130H220N39O46P 3094.58 3095.52 
9. 31 Conjugate with peptide 9 C142H243N46O48P 3391.77 3392.52 
10. 32 Conjugate with peptide 10 C142H242N41O48P 3320.75 3321.82 
11. 33 Conjugate with peptide 11 C112H184N23O43P 2570.27 2571.00 
12. 34 Conjugate with peptide 12 C118H195N24O44P 2683.35 2683.99 
13. 35 Conjugate with peptide 13 C124H206N25O45P 2796.43 2797.00 
14. 36 Conjugate with peptide 14 C151H225N40O47P 3381.62 3383.55 
15. 37 Conjugate with peptide 15 C82H124N13O38P 1929.79 1930.65 
16. 38 Conjugate with peptide 16 C123H205N24O48P 2817.41 2818.11 
17. 39 Conjugate with peptide 17 C122H202N25O47P 2800.39 2801.07 
18. 40 Conjugate with peptide 18 C135H229N42O50P 3269.64 3270.46 
19. 41 Conjugate with peptide 19 C134H226N43O49P 3252.63 3253.47 
20. 42 Conjugate with peptide 20 C117H193N30O47P 2801.34 2801.99 
21. 43 Conjugate with peptide 21 C111H181N26O46P 2645.24 2645.85 
22. 44 Conjugate with peptide 22 C110H178N27O45P 2628.22 2628.86 
Table 2: Complete list of conjugates synthesized 
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VIII. HPLC/LC-MS/ESI-MS Data 
 
 
Figure 5: Structure of peptide 1 
 
Figure 6: HPLC trace of crude peptide 1, showing product peak at r.t. = 8.187 min. Gradient 0-95% 
ACN in 15 min. 
 
Figure 7: ESI-MS of peptide 1. Exact mass calcd. for C37H66N20O8 = 918.54, found M + H+ = 919.54. 
  
Experimental Section for Chapter 7 
206 
 
 
Figure 8: Structure of peptide 2 
 
Figure 9: HPLC trace of crude peptide 2, showing product peak at r.t. = 9.427 min. Gradient 0-95% 
ACN in 15 min. 
 
Figure 10: ESI-MS with deconvolution of peptide 2. Exact mass calcd. for C55H103N35O11 = 1429.86, 
deconvoluted mass found = 1430.47. 
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Figure 11: Structure of peptide 3 
 
Figure 12: HPLC trace of crude peptide 3, showing product peak at r.t. = 9.447 min. Gradient 0-95% 
ACN in 15 min. 
 
Figure 13: ESI-MS from LC-MS with deconvolution of peptide 3. Exact mass calcd. for C61H114N36O12 
= 1542.94, deconvoluted mass found = 1543.53. 
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Figure 14: Structure of peptide 4 
 
Figure 15: HPLC trace of crude peptide 4, showing product peak at r.t. = 2.682 min. Gradient 0-100% 
ACN in 6 min using 0.1% HCOOH buffer. 
 
Figure 16: ESI-MS from LC-MS with deconvolution of peptide 4. Exact mass calcd. for C67H125N37O13 
= 1656.03, deconvoluted mass found = 1656.38.  
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Figure 17: Structure of peptide 5 
 
Figure 18: HPLC trace of crude peptide 5, showing product peak at r.t. = 2.665 min. Gradient 0-100% 
ACN in 6 min using 0.1% HCOOH buffer. 
 
Figure 19: ESI-MS from LC-MS with deconvolution of peptide 5. Exact mass calcd. for C67H126N40O13 
= 1699.04, deconvoluted mass found = 1699.43.  
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Figure 20: Structure of peptide 6 
 
Figure 21: HPLC trace of crude peptide 6, showing product peak at r.t. = 2.657 min. Gradient 0-100% 
ACN in 6 min using 0.1% HCOOH buffer. 
 
Figure 22: ESI-MS from LC-MS with deconvolution of peptide 6. Exact mass calcd. for C73H138N44O14 
= 1855.14, deconvoluted mass found = 1855.61.  
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Figure 23: Structure of peptide 7 
 
Figure 24: HPLC trace of crude peptide 7, showing product peak at r.t. = 9.473 min. Gradient 0-95% 
ACN in 15 min. 
 
Figure 25: ESI-MS from LC-MS with deconvolution of peptide 7. Exact mass calcd. for C73H138N40O14 
= 1799.13, deconvoluted mass found = 1799.52.  
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Figure 26: Structure of peptide 8 
 
Figure 27: HPLC trace of crude peptide 8, showing product peak at r.t. = 9.483 min. Gradient 0-95% 
ACN in 15 min. 
 
Figure 28: ESI-MS from LC-MS with deconvolution of peptide 8. Exact mass calcd. for C61H115N33O12 
= 1501.94, deconvoluted mass found = 1502.51.  
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Figure 29: Structure of peptide 9 
 
Figure 30: HPLC trace of crude peptide 9, showing product peak at r.t. = 9.417 min. Gradient 0-95% 
ACN in 15 min. 
 
Figure 31: ESI-MS from LC-MS with deconvolution of peptide 9. Exact mass calcd. for C67H126N34O13 
= 1615.02, deconvoluted mass found = 1615.40.  
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Figure 32: Structure of peptide 10 
 
Figure 33: HPLC trace of crude peptide 10, showing product peak at r.t. = 2.728 min. Gradient 0-100% 
ACN in 6 min using 0.1% HCOOH buffer. 
 
Figure 34: ESI-MS from LC-MS with deconvolution of peptide 10. Exact mass calcd. for C73H137N35O14 
= 1728.11, deconvoluted mass found = 1728.76.  
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Figure 35: Structure of peptide 11 
 
Figure 36: HPLC trace of crude peptide 11, showing product peak at r.t. = 9.133 min. Gradient 0-95% 
ACN in 15 min. 
 
Figure 37: ESI-MS from LC-MS with deconvolution of peptide 11. Exact mass calcd. for C43H79N17O9 
= 977.62, deconvoluted mass found = 978.10.  
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Figure 38: Structure of peptide 12 
 
Figure 39: HPLC trace of crude peptide 12, showing product peak at r.t. = 9.160 min. Gradient 0-100% 
ACN in 15 min. 
 
Figure 40: ESI-MS from LC-MS with deconvolution of peptide 12. Exact mass calcd. for C49H90N18O10 
= 1090.71, deconvoluted mass found = 1091.38.  
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Figure 41: Structure of peptide 13 
 
Figure 42: HPLC trace of crude peptide 13, showing product peak at r.t. = 2.674 min. Gradient 0-100% 
ACN in 6 min using 0.1% HCOOH buffer. 
 
Figure 43: ESI-MS from LC-MS with deconvolution of peptide 13. Exact mass calcd. for C55H101N19O11 
= 1203.79, deconvoluted mass found = 1204.00.  
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Figure 44: Structure of peptide 14 
 
Figure 45: HPLC trace of crude peptide 14, showing product peak at r.t. = 3.365 min. Gradient 0-100% 
ACN in 6 min using 0.1% HCOOH buffer. 
 
Figure 46: ESI-MS from LC-MS with deconvolution of peptide 14. Exact mass calcd. for C82H120N34O13 
= 1788.98, deconvoluted mass found = 1789.47.  
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Figure 47: Structure of compound 15 
 
Figure 48: HPLC trace of crude compound 15, showing product peak at r.t. = 2.918 min. Gradient 0-
100% ACN in 6 min using 0.1% HCOOH buffer. 
 
Figure 49: ESI-MS from LC-MS of compound 15. Exact mass calcd. for C13H19N7O4 = 337.15, mass 
found M + H+ = 338.10.  
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Figure 50: Structure of peptide 16 
 
Figure 51: HPLC trace of crude peptide 16, showing product peak at r.t. = 2.729 min. Gradient 0-100% 
ACN in 6 min using 0.1% HCOOH buffer. 
 
Figure 52: ESI-MS from LC-MS of peptide 16. Exact mass calcd. for C54H100N18O14 = 1224.77, mass 
found M + H+ = 1226.5, M/2 + H+ = 613.3, M/3 + H+ = 409.4, M/4 + H+ = 307.4.  
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Figure 53: Structure of peptide 17 
 
Figure 54: HPLC trace of crude peptide 17, showing product peak at r.t. = 9.283 min. Gradient 0-95% 
ACN in 15 min. 
 
Figure 55: ESI-MS from LC-MS with deconvolution of peptide 17. Exact mass calcd. for C53H97N19O13 
= 1207.75, deconvoluted mass found = 1208.08.  
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Figure 56: Structure of peptide 18 
 
Figure 57: HPLC trace of crude peptide 18, showing product peak at r.t. = 9.590 min. Gradient 0-95% 
ACN in 15 min. 
 
Figure 58: ESI-MS from LC-MS with deconvolution of peptide 18. Exact mass calcd. for C66H124N36O16 
= 1677.00, deconvoluted mass found = 1677.50.  
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Figure 59: Structure of peptide 19 
 
Figure 60: HPLC trace of crude peptide 19, showing product peak at r.t. = 2.748 min. Gradient 0-100% 
ACN in 6 min using 0.1% HCOOH buffer. 
 
Figure 61: ESI-MS from LC-MS with deconvolution of peptide 19. Exact mass calcd. for C65H121N37O15 
= 1659.98, deconvoluted mass found = 1660.43.  
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Figure 62: Structure of peptide 20 
 
Figure 63: HPLC trace of crude peptide 20, showing product peak at r.t. = 2.899 min. Gradient 0-100% 
ACN in 6 min. (Low crude purity due to an error in the peptide synthesizer – contains a mixture of 
peptide 20 & 21) 
 
Figure 64: ESI-MS from LC-MS with deconvolution of peptide 20. Exact mass calcd. for C42H76N20O12 
= 1052.59, deconvoluted mass found = 1052.84. 
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Figure 65: Structure of peptide 21 
 
Figure 66: HPLC trace of crude peptide 21, showing product peak at r.t. = 2.823 min. Gradient 0-100% 
ACN in 6 min. (Low crude purity due to an error in the peptide synthesizer – contains a mixture of 
peptides 20 & 21) 
 
Figure 67: ESI-MS from LC-MS with deconvolution of peptide 21. Exact mass calcd. for C48H88N24O13 
= 1208.70, deconvoluted mass found = 1209.10.  
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Figure 68: Structure of peptide 22 
 
Figure 69: HPLC trace of crude peptide 22, showing product peak at r.t. = 2.804 min. Gradient 0-100% 
ACN in 6 min. (Low crude purity due to an error in the peptide synthesizer) 
 
Figure 70: ESI-MS from LC-MS with deconvolution of peptide 22. Exact mass calcd. for C41H73N21O11 
= 1035.58, deconvoluted mass found = 1035.89.  
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Figure 71: Structure of compound 23 
 
Figure 72: HPLC trace of RP-HPLC purified compound 23, showing product peak at r.t = 10.793 min. 
Gradient 0-95% ACN in 15 min.  
 
Figure 73: ESI-MS of RP-HPLC purified compound 23. Exact mass calcd. for C106H171N26O42P = 
2511.18, mass found = M/2 + H+ = 1257.1378, M/3 + H+ = 838.4029. 
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Figure 74: Structure of compound 24 
 
Figure 75: HPLC trace of RP-HPLC purified compound 24, showing product peak at r.t. = 9.153 min. 
Gradient 0-95% ACN in 15 min.  
 
Figure 76: ESI-MS from LC-MS with deconvolution of compound 24. Exact mass calcd. for 
C124H208N41O45P = 3022.50, deconvoluted mass found = 3023.35.  
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Figure 77: Structure of compound 25 
 
Figure 78: HPLC trace of RP-HPLC purified compound 25, showing product peak at r.t. = 4.263 min. 
Gradient 0-100% ACN in 6 min. 
 
Figure 79: ESI-MS from LC-MS with deconvolution of compound 25. Exact mass calcd. for 
C130H219N42O46P = 3135.58, deconvoluted mass found = 3136.59.  
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Figure 80: Structure of compound 26 
 
Figure 81: HPLC trace of RP-HPLC purified compound 26, showing product peak at r.t. = 9.060 min. 
Gradient 0-95% ACN in 15 min. 
 
Figure 82: ESI-MS from LC-MS with deconvolution of compound 26. Exact mass calcd. for 
C136H230N43O47P = 3248.67, deconvoluted mass found = 3249.46.  
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Figure 83: Structure of compound 27 
 
Figure 84: HPLC trace of RP-HPLC purified compound 27, showing product peak at r.t. = 8.807 min. 
Gradient 0-95% ACN in 15 min. 
 
Figure 85: ESI-MS from LC-MS with deconvolution of compound 27. Exact mass calcd. for 
C136H231N46O47P = 3291.68, deconvoluted mass found = 3292.46.  
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Figure 86: Structure of compound 28 
 
Figure 87: HPLC trace of RP-HPLC purified compound 28, showing product peak at r.t. = 8.497 min. 
Gradient 0-95% ACN in 15 min. 
 
Figure 88: ESI-MS from LC-MS with deconvolution of compound 28. Exact mass calcd. for 
C142H243N50O48P = 3447.78, deconvoluted mass found = 3448.61.  
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Figure 89: Structure of compound 29 
 
Figure 90: HPLC trace of RP-HPLC purified compound 29, showing product peak at r.t. = 8.907 min. 
Gradient 0-95% ACN in 6 min. 
 
Figure 91: ESI-MS from LC-MS with deconvolution of compound 29. Exact mass calcd. for 
C136H231N40O47P = 3207.67, deconvoluted mass found = 3208.34.  
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Figure 92: Structure of compound 30 
 
Figure 93: HPLC trace of RP-HPLC purified compound 30, showing product peak at r.t. = 8.903 min. 
Gradient 0-95% ACN in 15 min. 
 
Figure 94: ESI-MS from LC-MS with deconvolution of compound 30, AI83-2. Exact mass calcd. for 
C130H220N39O46P = 3094.58, deconvoluted mass found = 3095.52.  
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Figure 95: Structure of compound 31 
  
Figure 96: HPLC trace of RP-HPLC purified compound 31, showing product peak at r.t. = 8.473 min. 
Gradient 0-95% ACN in 15 min. 
 
Figure 97: ESI-MS from LC-MS with deconvolution of compound 31. Exact mass calcd. for 
C142H243N46O48P = 3391.77, deconvoluted mass found = 3392.52.  
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Figure 98: Structure of compound 32 
 
Figure 99: HPLC trace of RP-HPLC purified compound 32, showing product peak at r.t. = 9.657 min. 
Gradient 0-95% ACN in 15 min. 
 
Figure 100: ESI-MS from LC-MS with deconvolution of compound 32. Exact mass calcd. for 
C142H242N41O48P = 3320.75, deconvoluted mass found = 3321.82.  
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Figure 101: Structure of compound 33 
  
Figure 102: HPLC trace of RP-HPLC purified compound 33, showing product peak at r.t. = 9.670 min. 
Gradient 0-95% ACN in 15 min. 
 
Figure 103: ESI-MS from LC-MS with deconvolution of compound 32. Exact mass calcd. for 
C112H184N23O43P = 2570.27, deconvoluted mass found = 2571.00.  
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Figure 104: Structure of compound 34 
 
Figure 105: HPLC trace of RP-HPLC purified compound 34, showing product peak at r.t. = 9.670 min. 
Gradient 0-95% ACN in 15 min. 
 
Figure 106: ESI-MS from LC-MS with deconvolution of compound 34. Exact mass calcd. for 
C118H195N24O44P = 2683.35, deconvoluted mass found = 2683.99.  
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Figure 107: Structure of compound 35 
 
Figure 108: HPLC trace of RP-HPLC purified compound 35, showing product peak at r.t. = 9.560 min. 
Gradient 0-95% ACN in 15 min. 
 
Figure 109: ESI-MS from LC-MS with deconvolution of compound 35. Exact mass calcd. for 
C124H206N25O45P = 2796.43, deconvoluted mass found = 2797.30.  
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Figure 110: Structure of compound 36 
  
Figure 111: HPLC trace of RP-HPLC purified compound 36, showing product peak at r.t. = 10.133 
min. Gradient 0-95% ACN in 6 min. 
 
Figure 112: ESI-MS from LC-MS with deconvolution of compound 36, AI117-3. Exact mass calcd. 
for C151H225N40O47P = 3381.62, deconvoluted mass found = 3383.55.  
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Figure 113: Structure of compound 37 
 
Figure 114: HPLC trace of RP-HPLC purified compound 37, showing product peak at r.t. = 15.043 
min. Gradient 0-95% ACN in 15 min 
Figure 115: ESI-MS from LC-MS with deconvolution of compound 37. Exact mass calcd. for 
C82H124N13O38P = 1929.79, deconvoluted mass found = M + NH4+ = 1948.85  
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Figure 116: Structure of compound 38 
 
Figure 117: HPLC trace of RP-HPLC purified compound 38, showing product peak at r.t. = 9.590. 
Gradient 0-95% ACN in 6 min. 
 
Figure 118: ESI-MS from LC-MS with deconvolution of compound 38, AI118-1. Exact mass calcd. 
for C123H205N24O48P = 2817.41, deconvoluted mass found = 2818.11.  
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Figure 119: Structure of compound 39 
 
Figure 120: HPLC trace of RP-HPLC purified compound 39, showing product peak at r.t. = 9.717 min. 
Gradient 0-95% ACN in 6 min. 
 
Figure 121: ESI-MS from LC-MS with deconvolution of compound 39. Exact mass calcd. for 
C122H202N25O47P = 2800.39, deconvoluted mass found = 2801.07.  
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Figure 122: Structure of compound 40 
 
Figure 123: HPLC trace of RP-HPLC purified compound 40, showing product peak at r.t. = 8.987 min. 
Gradient 0-95% ACN in 15 min. 
 
Figure 124: ESI-MS from LC-MS with deconvolution of compound 40. Exact mass calcd. for 
C135H229N42O50P = 3269.64, deconvoluted mass found = 3270.46.  
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Figure 125: Structure of compound 41 
 
Figure 126: HPLC trace of RP-HPLC purified compound 41, showing product peak at r.t. = 8.933 min. 
Gradient 0-95% ACN in 15 min. 
 
Figure 127: ESI-MS from LC-MS with deconvolution of compound 41. Exact mass calcd. for 
C134H226N43O49P = 3252.63, deconvoluted mass found = 3253.47.  
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Figure 128: Structure of compound 42 
  
Figure 129: HPLC trace of RP-HPLC purified compound 42, showing product peak at r.t. = 10.130 
min. Gradient 0-95% ACN in 15 min. 
 
Figure 130: ESI-MS from LC-MS with deconvolution of compound 42. Exact mass calcd. for 
C117H193N30O47P = 2801.34, deconvoluted mass found = 2801.99.  
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Figure 131: Structure of compound 43 
 
Figure 132: HPLC trace of RP-HPLC purified compound 43, showing product peak at r.t. = 10.623 
min. Gradient 0-95% ACN in 15 min. 
 
Figure 133: ESI-MS from LC-MS with deconvolution of compound 43. Exact mass calcd. for 
C111H181N26O46P = 2645.24, deconvoluted mass found = 2645.85.  
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Figure 134: Structure of compound 44 
 
Figure 135: HPLC trace of RP-HPLC purified compound 44, showing product peak at r.t. = 10.683 
min. Gradient 0-95% ACN in 15 min. 
 
Figure 136: ESI-MS from LC-MS with deconvolution of compound 44. Exact mass calcd. for 
C110H178N27O45P = 2628.22, deconvoluted mass found = 2628.86.  
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IX. Synthesis of a polymyxin analogue & its conjugation to MoeA 
 
 
Figure 137: Scheme for the synthesis of polymyxin analogue 44. 
 
The resin used for the synthesis of 44 is 2-chlorotritylchloride resin, manufacturer’s loading = 1.2 
mmol/g, 100 mg scale. Steps/reagents are as follows: (a) 4 eq. Fmoc-Thr(tBu)-OH, 8 eq. DIPEA were 
dissolved in in 2 mL DCM and the mixture was added to the resin and shaken for 3 h. The resin was 
then washed 6 times using DCM. Unreacted resin was capped with MeOH/DIPEA/DCM = 1:1:3, 2 mL 
by shaking for 30 min. Loading was calculated as = 0.68 mmol/g (b) Couplings were performed using 
4 eq. Amino acid, 4 eq. DIC/Oxyma in DMF using microwave assisted SPPS. (c) Fmoc deprotection 
was performed using 20% piperidine in DMF by shaking for 3 min using a µwave, followed by 10 min 
at r.t. (d) Alloc removal was performed using 0.2 eq. Pd(PPh3)4 and 24 eq. PhSiH3 in DCM (2 x 1h). (e) 
Partial cleavage was performed using 2% TFA/5% TIS in DCM, 2h. (f) Cyclization was performed 
using 1 eq. HATU/10 eq. DIPEA in DMF (peptide concentration: 15 mg/mL). (g) Full cleave was 
performed using 95% TFA/ 2.5% TIS/2.5% H2O, 2h. The filtrate was precipitated by adding cold 
diethyl ether (-20°C) and centrifuging twice with Et2O at 7000 rpm at 0°C to obtain a yellow solid. 
 
Crude 44 was conjugated to MoeA and the conjugate was purified using the protocols described in 
section IVa to obtain a polymyxin-MoeA conjugate 45. 
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Figure 138: Structure of compound 44 
 
Figure 139: HPLC trace of RP-HPLC purified compound 44, showing product peak at r.t. = 3.141 min. 
Gradient 0-100% ACN in 6 min. 
 
 
 
 
 
 
 
 
 
 
Figure 140: ESI-MS from LC-MS with deconvolution of compound 44. Exact mass calcd. for 
C60H97N19O16 = 1339.74, deconvoluted mass found = 1340.27.  
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Figure 138: Structure of compound 45 
 
Figure 139: HPLC trace of RP-HPLC purified compound 45, showing product peak at r.t. = 4.960 min. 
Gradient 0-100% ACN in 6 min. 
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Figure 140: ESI-MS from LC-MS with deconvolution of compound 45. Exact mass calcd. for 
C60H97N19O16 = 2933.27, deconvoluted mass found = 2933.27. 
 
X. MIC protocols: 
The protocol for the MICs are identical to those described in the experimental section of chapter 6. 
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Eﬃcient total syntheses and biological activities
of two teixobactin analogues†
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The discovery of the new antibiotic teixobactin has been timely in
the race for unearthing novel antibiotics wherein the emergence of
drug resistant bacteria poses a serious threat worldwide. Herein, we
present the total syntheses and biological activities of two teixobactin
analogues. This approach is simple, eﬃcient and has several
advantages: it uses commercially available building blocks (except
AllocHN-D-Thr-OH), has a single purification step and a good
recovery (22%). By using this approach we have synthesised two
teixobactin analogues and established that the D-amino acids are critical
for the antimicrobial activity of these analogues. With continuing
high expectations from teixobactin, this work can be regarded as
a stepping stone towards an in depth study of teixobactin, its
analogues and the quest for synthesising similar molecules.
The decreased potency of drugs such as penicillin,1 vancomycin2
and oxacillin3 due to their excessive use is a consequence of
the emergence of drug resistant bacteria. It has been predicted
that antimicrobial resistance (AMR) will have disastrous conse-
quences and it is estimated that by 2050 an additional 10 million
people yearly could succumb to drug resistant infections.4 The
recently published article in Nature5 describing the discovery
of teixobactin has provided a much needed breakthrough in the
challenging field of antibiotic peptides. The bacteria against
which it is eﬀective have, thus far, not shown any detectable
resistance to teixobactin. Moreover, given themultiplemechanisms
of attack by teixobactin described by Su¨ssmuth6 resistance is
unlikely in the near future. Unfortunately, although teixobactin
provides somemuch needed answers, the problem is far from over.
Organic chemists have worked round the clock to synthesise
novel antibiotics and although progress has been steady,
bacteria have time and again confounded even the best in this
field.7 This is where the multichannel device, iChip,8 has made
a considerable contribution enabling the identification of
molecules like teixobactin, some of which could be active
against drug resistant bacteria. However, the iChip device has
its limitations. The probability of finding an antibiotic is
extremely low (107 percent) and even with high-throughput
screening, which takes considerable time and resources, there
is no guarantee when will be the discovery of the next drug like
teixobactin. Undeniably, breakthroughs via organic synthesis
have to be made to keep the drug resistance problem under
check. The time for this is indeed now and teixobactin is a good
starting point. This study is aimed at doing so and provides a
general approach through which, not only teixobactin, but also
other analogues can be synthesised. The total synthesis of
teixobactin will give access to analogues which nature cannot
provide us with and therefore an organic synthesis approach
to the bigger problem at hand should not be prematurely
discarded. It is to be noted that during the preparation of
this manuscript a report from the Albericio group appeared
describing the synthesis of teixobactin analogue 1 obtained in a
6% yield. Moreover, the role of the D-amino acids have not been
proven.9 Our work presents an eﬃcient syntheses of both the D
and L versions of the analogues of teixobactin (22% yield for 1)
and their role in antimicrobial activity.
Since teixobactin has been fully characterised by NMR and
LC-MS, the structural complexity of teixobactin can be described
as moderate to diﬃcult. It has also been described as an unusual
depsipeptide due to the presence of the non-natural amino acids
L-allo-enduracididine and N-methylphenylalanine along with
four D-amino acids (Fig. 1). Despite not possessing a lipid tail,
the commercial unavailability of the enduracididine amino acid
makes the total synthesis of the molecule more time consuming
than expected.10 The commercially available natural amino acid
arginine (a linear guanidine) is the closest structural match suitable
for the replacement of the L-allo-enduracididine (a cyclic guanidine)
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as can be seen in Fig. 1 (green). In this work, arginine was
selected as a replacement of enduracididine for synthesis of
teixobactin analogue 1. A first approach towards tackling this
molecule was to synthesise the complete peptide on solid phase
and cyclise post-cleavage from the resin via an ester bond (ESI,†
Fig. S1). This route has been used with success for the synthesis
of the analogues of callipeltin B.11
Following this strategy, a fully protected linear peptide was
synthesised and cleaved from the resin without cleaving
the protecting groups. However, the synthesis failed at the
esterification step. Several conditions have been tested for the
esterification as described in Table S1 (ESI†). Unfortunately,
none of them yielded the esterified product. This could be due
to the steric bulk of protecting groups on the amino acids. This
led to the conclusion that a direct and linear route is not
the way to cyclisation. Therefore a new second synthetic route
had been devised which involves cyclisation via amide bond
formation (Fig. 1b). For the total synthesis of analogue 1, an
optimised pathway for the synthesis of the core ring structure
(2) of teixobactin was required. Therefore, the initial eﬀorts
were focussed on obtaining this key fragment (Fig. 2).
For optimisation of the synthesis, we chose Wang resin. Fmoc-
Ala-OH was loaded onto this resin via ester bond formation.
The unreacted resin was capped using 10% acetic anhydride/
diisopropylethylamine (Ac2O/DIPEA) followed by (a) the attach-
ment of Fmoc-D-Thr(Trt)-OH via amide bond formation and
subsequent (b) Fmoc removal. The orthogonal Alloc protecting
group was installed on the amine (c) followed by (d) trityl group
removal by 1 : 5 : 96 TFA : TIS : DCM and proceeded with (e) the
challenging esterification reaction between Ile and Thr. It is to
be noted that excess Ile and base were required to drive the
reaction to completion.12 This was succeeded by (f) amide bond
formation using Arg and subsequent (g) cleavage from the resin
using 95 : 2.5 : 2.5 TFA : TIS :H2O. The final step was (h) the
amide bond formation between Arg and Ala which proceeds
smoothly yielding the desired cyclised fragment. This approach
was then slightly modified and used for the total synthesis of
the teixobactin analogue 1 as described in Fig. 3.
The approach used in this work involves synthesising the
peptide completely on solid phase and only a single purification
was required after the final cleavage. The synthesis of building
block AllocHN-D-Thr-OH (modified from ref. 13) was also reported
for first time and which can be directly coupled to the resin without
protecting the amino acid side chain. 2-Chlorotritylchloride resin
was chosen instead of Wang resin as the peptide could be cleaved
oﬀ from the resin without removing the side chain protecting
groups of the attached amino acids.14
(a) The first amino acid loaded on the resin in this case is
Fmoc-Ala-OH followed by (b) an amide bond coupling with
Alloc-D-Thr-OH. (c) Fmoc-Ile-OH is then coupled at this stage via an
ester bond to the free –OH side chain of threonine. Next, (d)
arginine was coupled via an amide bond, the Fmoc protecting
group is removed and (e) the N-terminus is protected via a trityl
protecting group15 (combining cleavage and deprotection in a
single step) to facilitate the cleavage and cyclisation as described
in reactions (h and i). (f) The Alloc group protecting the N-terminus
of the threonine is then removed16 and (g) the peptide chain is built
via standard solid phase peptide synthesis (SPPS). Partial cleavage
was performed using 2 :5 :93 TFA :TIS :DCM followed by cyclisation
using 1-[bis(dimethylamino) methylene]-1H-1,2,3-triazolo[4,5-b]-
pyridinium 3-oxid hexafluorophosphate (HATU) as a coupling
reagent and DIPEA as a base in DMF for 1 h. The protecting
groups are then cleaved off using 95 : 2.5 : 2.5 TFA : TIS :H2O
yielding the desired peptide (22% recovery, refer ESI,† S10). After
successful synthesis of analogue 1, the general applicability of
Fig. 1 (a) (left) Structure of teixobactin. (b) (right) Structure of the teixobactin analogue 1 showing the bonds to be cleaved for the synthesis routes A (in
blue) and B (in red) and the structural diﬀerences (in green).
Fig. 2 Synthesis scheme for the core teixobactin fragment 2 starting from
Wang resin: (a) 10 eq. Fmoc-Ala-OH, 10 eq. DIC, 1 eq. DMAP, 10% Ac2O/
DIPEA in DMF followed by 20% piperidine in DMF. (b) 2.5 eq. Fmoc-D-Thr(Trt)-
OH, 2.5 HATU/5 eq. DIPEA, 3 h DMF followed by 20% piperidine in DMF.
(c) 4 eq. allyl chloroformate/8 eq. DIPEA in DCM, 1 h. (d) 1 : 5 :96 TFA :TIS :
DCM. 3 15min. (e) 10 eq. Fmoc-Ile-OH, 10 eq. DIC, 10mol% DMAP in DCM,
2 h followed by 10% Ac2O/DIPEA in DMF, followed by 20% piperidine in DMF.
(f) 4 eq. Fmoc-Arg(Pbf)-OH, 4 eq. HATU/8 eq. DIPEA in DMF, 1 h followed by
20% piperidine in DMF. (g) TFA :TIS :H2O = 95 :2.5 : 2.5, 1 h. (h) 1 eq. HATU/
10 eq. DIPEA in DMF, 1 h, monitored on HPLC.
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this approach was tested for the synthesis of analogue 3 (Fig. 4). In
analogue 3, the three D-amino acids residues (Phe, Gln and Ile)
were replaced by L-amino acid residues. The synthesis of analogue
3 also worked efficiently (17% recovery, refer ESI,† S10).
The detailed characterisation of 1 and 3 were performed using
LC-MS and NMR. The NMR spectra of product 1 (refer ESI,† page
S15) was shown to be identical as reported previously.5,9 The NOEs
of 1 were characteristic of a random coil, however, the NOEs of 3
suggested a considerable degree of structure.
The analogues 1 and 3 were evaluated for their antibacterial
activity. MIC results showed a trend similar to teixobactin
for analogue 1 against both Gram-positive and Gram-negative
bacteria. Analogue 3 was not active against Gram-negative
bacteria. Moreover, analogue 1 was 64 times more eﬀective
than analogue 3 (Table 1) against Gram-positive bacteria.
This diﬀerence in antibacterial activity has established that
the three D-amino acids residues of 1 are critical for the
antibacterial activity.
Fig. 3 Total synthesis of analogue 1 starting from 2-chlorotritylchloride resin: (a) 4 eq. Fmoc-Ala-OH/8 eq. DIPEA in DCM, 3 h. (b) 20% piperidine in DMF
followed by 3 eq. AllocHN-D-Thr-OH, 3 eq. HATU/6 eq. DIPEA. (c) 10 eq. Fmoc-Ile-OH, 10 eq. DIC, 5 mol% DMAP in DCM, 2 h followed by capping with
Ac2O/DIPEA 10% in DMF, 20% piperidine in DMF (d) 4 eq. Fmoc-Arg(Pbf)-OH, 4 eq. HATU/8 eq. DIPEA in DMF, 1 h followed by 20% piperidine in DMF
(e) 10 eq. Trt-Cl, 15% Et3N in DCM, 1 h. (f) 0.2 eq. Pd(PPh3)4/24 eq. PhSiH3 in DCM, 2  1 h. (g) Fmoc/Boc-AA(PG)-OH (AA = amino acid, PG = protecting
group), HATU/DIPEA followed by 20% piperidine in DMF. (h) TFA : TIS : DCM = 2 : 5 : 93, 2 h. (i) 1 eq. HATU/10 eq. DIPEA in DMF, 1 h, monitored on HPLC.
(j) TFA : TIS : H2O = 95 : 2.5 : 2.5, 1 h.
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In conclusion, this work reports eﬃcient total syntheses of two
teixobactin analogues (22% yield of teixobactin analogue 1). Analo-
gue 1 is identical to teixobactin in all aspects with the exception of
the L-allo-enduracididine amino acid. The methodology described
here is not specific to only one molecule, but it can also be used as
a general strategy for synthesis of other analogues of teixobactin.
The role of three D-amino acids has also been established. The
three D-amino acids present in the teixobactin analogue 1 but
absent in analogue 3 are critical for antibacterial activity. This work
also reports the synthesis of new AllocHN-D-Thr-OH building block
and has incorporated it as such in the syntheses of teixobactin
analogues. We believe that this work to be pivotal for the synthesis
of teixobactin and its analogues and therefore will be helpful to
address the current challenges of antimicrobial resistance.
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Table 1 MIC (mg ml1) for 1 and 3 and Teixobactin
Entry Organism 1 3 Teixobactin
1 S. aureus ATCC 25 923 2 128 0.25a
2 E. coli ATCC 25 922 64 GAWb 25
a MIC from ref. 5 was from a diﬀerent strain of S. aureus. b Growth in
all wells.
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Sequence-selective DNA recognition and
enhanced cellular up-take by peptide–steroid
conjugates†
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Several GCN4 bZIP TF models have previously been designed and
synthesized. However, the synthetic routes towards these constructs
are typically tedious and diﬃcult. We here describe the substitution
of the Leucine zipper domain of the protein by a deoxycholic acid
derivative appending the two GCN4 binding region peptides through
an optimized double azide–alkyne cycloaddition click reaction. In
addition to achieving sequence specific dsDNA binding, we have
investigated the potential of these compounds to enter cells. Confocal
microscopy and flow cytometry show the beneficial influence of the
steroid on cell uptake. This unique synthetic model of the bZIP TF thus
combines sequence specific dsDNA binding properties with enhanced
cell-uptake. Given the unique properties of deoxycholic acid and the
convergent nature of the synthesis, we believe this work represents a
key achievement in the field of TF mimicry.
Gene expression at the transcriptional level is mainly regulated
by proteins that bind DNA in a sequence-specific manner. These
proteins, known as transcription factors (TFs), are responsible
for controlling the transfer of genetic information from DNA to
mRNA. More specifically, many oncoproteins are transcription
factors responsible for cell-growth proliferation and tumor
formation.1 As a consequence of the specificity of these onco-
proteins in the DNA sequence recognition during transcription,
several approaches have been explored to develop inhibitors or
modifiers of gene expression that can prevent specific genes
from being transcribed.2
In addition, the lack of a general recognition code for the
interaction between amino acid sequences within a protein and
its specific DNA-binding site has promoted the study of the
structure of TFs and their interaction with the DNA.3 We here
present our eﬀorts towards mimicking the GCN4 bZIP TF
(General Control Protein Leucine Zipper Transcription Factor)
by a simplified synthetic construct and towards understanding
how these protein mimics behave in a cellular context.4 The
GCN4 bZIP TF, which controls the activation of several genes in
response to amino acid starvation in yeast, has been chosen as
model system in order to allow comparison with previously
published TF miniaturisation attempts. Many eukaryotic
transcription factors feature homologous protein sequences
forming a family generally referred to as the basic-region-leucine-
zipper or bZIP motif of which the mammalian ATF/CREB family of
transcription factors represent a large group. Our target has
been to develop a new type of site-specific DNA binders which
can recognize dsDNA by specific binding in the major groove
and additionally show enhanced cellular uptake by exploiting
the unique properties of the steroid moiety. We have been
inspired by the bZIP (leucine zipper) and the b-HLH-ZIP
(helix–loop–helix leucine zipper) motifs, in which the basic
DNA recognition region binds to the major groove as a dimer,
inserting two a-helices held in the correct position by a dimerization
domain.5 The main residues of the protein involved in the DNA
recognition comprise the amino acids 226–248 of the basic
region of the GCN4 protein. Previously,models of such transcription
factors have been synthesized by different research groups
employing a series of different dimerization domain substitutes.
Pioneering work was carried out by the group of Kim,6 developing
an analogue in which the complete dimerization domain was
substituted by a simple disulfide bond. Building on this successful
idea of miniaturisation, Morii, Schepartz, Mascaren˜as and our
group have enforced the proof-of-concept by using a variety of
small dimerizing moieties.7–12 Subsequently, we have shown
that the attachment of the basic region peptides to a rigid
scaffold, a derivative of deoxycholic acid in this case, also allows
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selective recognition of DNA. Indeed, our previous work on
cMyc-Max b-HLH-ZIP and GCN4-bZIP proteins showed that this
type of steroid-based constructs show potential for binding
DNA.10,13 The specific choice of the steroid scaffold was inspired
by the fact that it is inexpensive, commercially available, versatile and
easy tomodify synthetically. In addition, its known ability to enhance
proteolytic stability of attached peptides,14–16 amphiphilicity,17
the conformational properties ensuring correct positioning of
the two appended chains18 and the potential to increase cellular
uptake and bioavailability19 render it an excellent candidate for
the attachment of the two DNA recognizing arms of the zipper
motif of GCN4. The incorporation of a spacer between the
peptides and the steroid scaffold was shown important in order
to provide the final conjugate with enough flexibility to adopt an
optimal conformation for specific interaction with the major
groove of the target DNA sequence.13 However, the concomitant
further lengthening of the 23-mer peptide chains caused increased
tendency of peptide aggregation necessitating the use of micro-
wave assistance for successful synthesis.13 In order to synthesize
these peptidosteroids in a more effective and convenient way,
we here explored a convergent approach involving the CuAAC
reaction (copper-catalyzed alkyne–azide cycloaddition) to conjugate
the recognition domains to a functionalized steroid scaffold. The
geometric, steric and electronic properties of the 1,2,3-triazole
resemble a trans-amide bond, while also affording resistance
to enzymatic degradation,20–23 hydrolysis and oxidation. In
addition, successful replacement of two amino acids in a-helical
peptides by a triazole unit has been shown to not significantly
influence the secondary peptide structure.20 To date the triazole
linkage has scarcely been used for peptide–steroid conjugation
and only to assemble short apolar tripeptides onto bile acid
scaffolds,24 despite the increasing interest of these type of
conjugates in diverse applications such as HIV inhibitors25,26
and immunogens for vaccine development.27
In the current work we have designed and synthesized four
diﬀerent scaﬀolds for peptide dimerization of the GCN4 basic
region, which was made possible by optimizing conditions for
the CuAAC mediated conjugation of the long, unprotected and
functionalized zipper peptides (Fig. 1). A small series of deoxy-
cholic acid derivatives was conceived, diﬀering with respect to
spacers between the peptide and the steroid skeleton, which
have diﬀerent lengths, rigidities and functionalities (Fig. 2).
Hereto, commercially available deoxycholic acid was modified
at the alcohol positions by attachment of diﬀerent linkers. The
linkers chosen for the study encompass pentynoic acid, azido
glycine, 4-azidomethyl-benzoic acid and (N-propynoylamino)-
p-toluic acid (PATA). The PATA linker has been specifically
developed for bioconjugation purposes as an active alkyne for
preparation of peptide–oligonucleotide conjugates via CuAAC.28
Functionalization of the steroid nucleus was performed by
Steglich esterification, affording final scaffolds (1–3). In case
of PATA as linker (4), the diamino derivative of deoxycholic acid
proved necessary for the coupling of the linker, as esterification
gave rise to byproducts due to the high reactivity of the alkyne.
The GCN4 basic DNA binding region consists of 23 amino
acids that specifically recognize the ATF/CREB binding site
(50-ATGA C/G TCAT-30), which is the functional target of GCN4
in vivo and involved in inducing amino acid biosynthesis in yeast.29
In order to append the peptides to the bile acid scaﬀolds,
peptides were modified at the C-terminus with unnatural
amino acids bearing an alkyne or an azide. Peptides 5 and 6
were synthesized in an automated fashion using Fmoc/tBu
based solid phase peptide synthesis (SPPS). The alkyne and
azide functionalized GCN4 basic region peptides, 5 and 6 were
then attached to the central steroid core, aﬀording four diﬀerent
transcription factor models. With this hydrophilic deprotected
peptide and the hydrophobic scaﬀold, the DMSO/H2O combinationFig. 1 Artificial DNA binder design.
Fig. 2 Deoxycholic acid derivatives for the substitution of the dimerization
domain with the corresponding peptides.
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was found to be optimal for the CuAAC reaction. As a catalyst,
Cu(CH3CN)4PF6 gave the best results. A high excess of catalyst
was needed possibly due to complexation of copper with the
nitrogen containing side chains of the peptide. However, reaction
proceeds well with excess of copper ion complex and the copper
ions can be readily removed after reaction by use of EDTA.28 An
excess of scaﬀold was also required for complete reaction of the
peptide, the dipodal construct being favoured over the monopodal
one under these conditions. The reaction was complete after
3 hours at room temperature and compatible with the presence
of all unprotected amino acids in the sequence. Purification of
final constructs after completion of the reaction was possible via
RP-HPLC, aﬀording compounds 7–10 in high purity for DNA
binding studies. DNA binding affinity of mimics 7–10 was
evaluated using an Electrophoretic Mobility Shift Assay (EMSA).
The study was based on titration of a duplex DNA sequence
containing the ATF/CREB recognition site with increasing
concentrations of compounds 7–10 (Fig. 3).
No clear specific binding to DNA could be observed for
mimics 8 and 10 (gel not shown). On the other hand, EMSA
for compounds 7 and 9 in the absence of any competitor DNA
shows that both compounds have a high aﬃnity for the CRE
DNA sequence (Fig. 3A). A closer visual inspection of the gels
reveals that 7 has slightly higher DNA binding aﬃnity as
compared to 9. Due to the more or less complete up-shifting
of bands even at the lowest concentration, accurate determination
of the dissociation constant (KD) was not possible under these
conditions. However, by a simple visual inspection we can
conclude that almost all the DNA is completely bound at
50 nM in case of compound 7 and at 62.5 nM in case of 9.
Decreasing the peptide concentration to a valueo50 nM results
in large standard deviations in KD calculations. Also, decreasing
the ratio of DNA : peptide further without lowering the DNA
concentration is not feasible due to problems in detection of
the isotope. Therefore we conducted a second series of EMSA
studies which involved a competitor DNA which allows for both
checking of nonspecific interactions and calculation of the KD.
EMSA for compounds 7 and 9 in the presence of 500 nM
competitor DNA reveal that nonspecific interactions do exist,
however the specificity of the compounds towards the CRE
sequence is still present to a large extent. This can be seen
from the gradual gel shift in contrast to the previous gel
(Fig. 3B). In support of this is that KD calculations from
competition experiments with 0.5–2 mM competitor DNA give
values of 4–8  10 nm for 7 and 1–3  102 nm for 9 (see ESI†).
We can also state here more conclusively that 7 is clearly not
only the better DNA binding construct but also shows greater
specificity as compared to 9.
A series of experiments were set up to investigate the cell
up-take capacity of the various synthetic constructs. For this
purpose the best DNA binding cholic acid based mimic 7 of the
GCN4 protein was resynthesized incorporating a fluorescein tag
to give 14. The properties of this construct were compared to
the labelled but otherwise unmodified GCN4 peptide dimer 12
and monomer 11 as well as the monomeric steroid conjugate
13. The toxicity (MTT assay), quantification of uptake (flow
cytometry) and intracellular localization of these constructs
were studied on RAW264.7 mouse macrophages, which have
been already used for cell penetration studies with a similar
GCN4 peptide.30 Compounds 12 and 14 showed a cell viability
at 0,25 mM of 88% and 86% respectively (ESI†) and both are
taken up at 37 1C but to a diﬀerent degree. There is clearly an
enhanced uptake when deoxycholic acid is used as a scaﬀold, as
seen from the mean fluorescence values obtained by flow
cytometry analysis, as they are more than four times higher
for 14 than for 12 (Fig. 4II). The monopodal cholic acid
derivative 13, although non-DNA binding and more hydrophobic,
also exhibits enhanced uptake. However, a decreased uptake is
seen when the concentration is increased to 1 mM (ESI†). This
could be attributed to the denaturant like properties of the cholic
acid. Themost interesting results were obtained when comparing
the localisation of the DNA binding cholic acid dimer 14 at 4 1C
and 37 1C (Fig. 4IA and B). At 4 1C, where endocytosis is blocked,
only binding to the cell membrane was observed. This resulted in
a high percentage of peptide positive cells (Fig. 4II left and
middle). However, at 37 1C, whereby both passive and active
uptake is possible, the uptake is considerably higher as evidenced
by the higher mean cell fluorescence. This indicates that the
deoxycholic acid coupled peptides are mainly internalized via
active transport at 37 1C. The most likely ex-planation is that the
peptides follow an endocytotic pathway.
In conclusion, we here have illustrated a strategy to conjugate
relatively long, unprotected peptides to bile acid scaﬀolds in a
convergent manner. From the four models of the GCN4 bZIP
transcription factor presented, the one with the most flexible
linker (7) proved to be the best synthetic DNA binder. This can be
attributed to the fact that the linker allows the construct to grip
the major groove of the DNA like a pair of tweezers which is less
optimal in the case of the other linkers, whichmay be too long, too
short, or too inflexible. The binding aﬃnity of 7 is comparable
with that of earlier described models of GCN4 TFs with KDs
in the nM range, while the synthetic route is considerably less
Fig. 3 (A) EMSA titration of the dipodal peptidosteroid conjugates 7 and 9 to
the 50-labeled 32P-CRE sequence (50-CGG ATG ACG TCA TTT TTT TTC-30)
and its complementary strand (50-GAA AAA AAA TGA CGT CAT CCG-30) at
5 nM: first lane in all the gels: pyrimidine strand (50-labeled 32P-CRE sequence).
Lanes 2–9 contain peptide concentrations of 0, 0.05, 0.0625, 0.075, 0.0875,
0.1, 0.1125 and 0.125 mM for 7 and 9. (B) EMSA titration of the dipodal
peptidosteroid conjugates 7 and 9 to the 50-labeled 32P-CRE sequence
(5-CGG ATG ACG TCA TTT TTT TTC-30) at 5 nM in the presence of
competitor DNA sequence (50-AGCAGAGGGCGTGGGGGAAAAGAAAAAAG
ATCCACCGGTCGCCAC-30) at 500 nM: first lane in all the gels: pyrimidine
strand. Lanes 2 and 20 to 5 and 50 contain peptide concentrations of 0, 0.05,
0.125 and 0.312 mM for 7 and 9 respectively.
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complicated. In addition, compound 7 is more readily taken up
by cells than non-steroid constructs as evidenced by the uptake
in RAW264.7 mouse macrophages. This illustrates the particular
properties of the peptide combined with the steroid nucleus,
which allows uptake at low concentrations. Using four models of
the GCN4 bZIP TF we were able to identify some of the parameters
that aﬀect dsDNA recognition in synthetic constructs. Additionally
we also for the first time discuss and reveal the interesting cell-
uptake properties of this type of peptidosteroid based TF mimics.
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Fig. 4 (I) Confocal microscopy of RAW264.7 cells incubated with (A) 14 at
4 1C, (B) 14 at 37 1C, (C) 12 at 4 1C, and (D) 12 at 37 1C at 0.25 mM (green
fluorescence signal). Cell nuclei were labeled with Hoechst (blue) and cell
membranes with AlexaFluor647 conjugated cholera toxin subunit B
(red). The lower panels only show the green fluorescence channel. (Scale
bar = 20 mm). (II) Flow cytometry analysis of mean cell fluorescence (left)
and peptide positive cells (middle) of the synthesized compounds 12 and
14 incubated with RAW264.7 cells at 4 1C and 37 1C at 0.25 mM. Mean
fluorescence of compounds 12 and 14 at 0.25 mM and 1 mM.
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Cyclodextrin–peptide conjugates for sequence
speciﬁc DNA binding†
Yara Ruiz García,a Jan Zelenka,b Y. Vladimir Pabon,c Abhishek Iyer,a
Miloš Buděšínský,b Tomáš Kraus,b C. I. Edvard Smithc and Annemieke Madder*a
Synthetic models of bZIP transcription factors have been developed with the capability of speciﬁc DNA
recognition. Our design is based on the CuAAC mediated conjugation of basic region Leucine Zipper
peptides to diﬀerent derivatives of α, β and γ-cyclodextrins equipped with azide functionalities. Thorough
optimization of reaction conditions allowed convergent and simultaneous conjugation of two long
unprotected cationic peptides to cyclodextrin-bis azide derivatives. The resulting constructs were shown
to speciﬁcally recognize their cognate DNA sequence with nM aﬃnities. In comparison with previously
developed TF models, the derivatives described here combine the enhanced DNA binding capabilities
with an easy and convergent synthetic route.
Introduction
The study of gene expression regulation is currently of particu-
lar interest due to the upcoming development of gene therapy
strategies. Indeed, altered expression of particular genes can
cause interferences with biological processes in the cell. There-
fore, selective up- or down-regulation of specific gene tran-
scription could ultimately result in a therapeutic platform with
biomedical applications. In the last decade, biologists and
medicinal chemists have been working together in order to
target specific genes for this purpose.1–3
In this context, Transcription Factors (TFs) have been
studied in great detail for the modification of gene expression
and the study of DNA binding aﬃnity in the cellular
environment.4–7 In particular, bZIP proteins have gained atten-
tion due to the simple arrangement of the protein structure
consisting of a well-defined dimerization domain and a basic
binding region.8 These proteins are able to interact with DNA
in a sequence-specific manner by means of inserting their rec-
ognition domains, consisting of defined sequences of amino
acids, in the DNA major groove. Simplification of such pro-
teins could ultimately result in peptide-based drugs for
alternative disease treatment. Moreover, due to the improve-
ments in peptide manufacturing, peptide drugs can now be
produced in a straightforward way through synthetic methods
and many techniques have been developed for improved
peptide stability.
Therefore, the idea of transferring the protein properties to
smaller systems whilst conserving the DNA recognition ability
has received considerable attention. The bZIP leucine zipper
TF binds double-stranded DNA as a dimer, presented as un-
interrupted α-helices that grip the major groove and interact
with the DNA through basic residues. The main residues
involved in DNA recognition are the amino acids 226–248,
located in the N-terminal basic region of the GCN4 protein.8
The optimal position and spatial arrangement of the dimeric
peptides are ensured by the leucine zipper domain. Simplified
models of these proteins have been designed based on the
substitution of the dimerization domain by a scaﬀold for the
appendage of the basic region peptides in a correct geometry.9
The first proof of this concept was delivered by Kim et al.10
using a disulfide bond as a connector between the extended
basic region of the peptides. Since then, several models have
been developed trying to improve upon the pioneered one.11–15
Herein we report on cyclodextrin based TF models where
the dimerization domain of the GCN4 protein is substituted by
a scaﬀold which allows accurate regulation of the geometry
and the mutual distance between the two peptide strands.
This has been achieved by the use of α, β and γ-cyclodextrin
derivatives in order to scan and evaluate the importance of the
distance between the two anchoring points for the dimerizing
peptides (Fig. 1). Due to the rigid structure of the cyclo-
†Electronic supplementary information (ESI) available: Reaction conditions,
RP-HPLC traces, ESI-MS, NMR spectra and EMSA studies. See DOI: 10.1039/
c5ob00609k
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dextrins, attachment of the basic region peptide of the GCN4
protein onto the opposite positions of the primary rim of the
cyclodextrins indeed allows control of the dimerization dis-
tance. Based on the diameters of the primary rim of α, β and
γ-cyclodextrins, which are 5.7, 7.8 and 9.5 Å respectively,16
three diﬀerent peptide–cyclodextrin conjugates have been syn-
thesized, keeping in mind that the width of the major groove
is 11.2 Å. For this purpose, we have synthesized 6I,6IV-diazido-
α-cyclodextrin, 6I,6IV-diazido-β-cyclodextrin and 6I,6V-diazido-
γ-cyclodextrin (Fig. 2), in order to conjugate peptides which
are functionalized with an alkyne at the C-terminus via
CuAAC.
The CuAAC is a broadly developed strategy for the bioconju-
gation of peptides to diﬀerent building blocks due to its mild-
ness, compatibility with a large variety of functional groups
and the possibility of performing the reaction in a wide range
of solvents and buﬀers. In view of the specific geometry, steric
and electronic properties, a 1,2,3-triazole can be regarded as a
trans-amide bond mimic.17 Moreover, this linkage is stable
under physiological conditions, thus representing a perfect
heterocyclic moiety to replace unstable linkers.18–20 In
addition, successful replacement of dipeptide sequences
in α-helical peptides by triazole units has been shown to only
insignificantly influence the secondary peptide structure.17
Peptide–cyclodextrin conjugates have been previously devel-
oped for a broad range of applications, such as drug release
systems,21,22 enantioselective ester hydrolysis catalysis,23 and
for the creation of new types of chemosensors,24 enzyme
mimics25 and self-assembling materials.26,27 Although CD con-
jugation to peptides has been intensively studied, we here for
the first time used the cyclodextrin moiety as an artificial
dimerizing unit for mimicking protein–DNA interactions.
Results and discussion
The required diazido cyclodextrin derivatives 4–6 were pre-
pared in one step (Fig. 3) by reaction of the known 6I,6IV-
dibromo-α-cyclodextrin28a, 6I,6IV-dibromo-β-cyclodextrin28b
and 6I,6V-dibromo-γ-cyclodextrin29 with three-fold excess of
sodium azide in DMF at 50 °C. Pure compounds 4–6 were
isolated from the reaction mixtures by reversed-phase column
chromatography with yields of 90%, 87% and 77% for the α, β
and γ-cyclodextrin derivatives, respectively.
As we have previously illustrated, peptides attached directly
to a dimerization unit are unable to adopt an adequate posi-
tion for major groove binding.30 Thus, a spacer is needed
between the dimerization scaﬀold and the basic region GCN4
peptide to aﬀord some flexibility required for binding. In
addition to that, a C-terminal propargylglycine residue was
introduced for conjugation of the deprotected peptide to the
azide containing cyclodextrin scaﬀolds. The GCN4 basic
region consists of the following 23 amino acids: DPAALK-
RARNTEAARRSRARKLQ which specifically recognize the ATF/
CREB-binding site (5′-ATGA C/G TCAT-3′). The monomeric
GCN4 sequence was synthesized using standard Fmoc SPPS on
a Rink-amide ChemMatrix resin. After cleavage and deprotec-
Fig. 1 Design of cyclodextrin based DNA binders.
Fig. 2 Molecular visualization of the cyclodextrin derivatives syn-
thesized as dimerization domains. From left to right: 6I,6IV-diazido-
α-cyclodextrin 4, 6I,6IV-diazido-β-cyclodextrin 5 and 6I,6V-diazido-
γ-cyclodextrin 6. Exact structures are described in the ESI.†
Fig. 3 Synthesis scheme for the conjugation of the diﬀerent cyclodex-
trins 4, 5 and 6 and peptide 7 to obtain the ﬁnal compounds 8, 9 and 10.
Residues that can chelate copper are marked in red.
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tion, the peptide could be used for the next steps without
intermediate purification.
The basic region GCN4 peptide functionalized with an
alkyne at the C-terminus was then anchored to the opposite
positions at the primary rim of α, β and γ-cyclodextrin deriva-
tives (Fig. 3). In order to prevent aggregation of the peptide
during the reaction, high polarity media were needed. In
addition, polar solvents prevent copper species from aggrega-
tion. Therefore, we chose DMSO–H2O as a solvent mixture. It
is known that sodium ascorbate can cause covalent modifi-
cations of lysines and arginines, and can form reactive oxygen
species.31,32 Therefore, Cu(CH3CN)4PF6 was chosen as the cata-
lyst after carefully studying diﬀerent reaction conditions. It is
to be noted that a high excess of catalyst is needed which can
probably be ascribed to the chelation of copper by the nitrogen
containing amino acid side chains, which are intensely rep-
resented within this particular DNA binding peptide sequence.
The reaction was stopped after 3 hours at room temperature
under argon. The final purification of the reaction mixture was
achieved via RP-HPLC and all conjugates were obtained in
high purity (Fig. 4).
After successful synthesis of the constructs, the DNA
binding capabilities of the systems were investigated. Quanti-
tative binding analysis was performed by the Electrophoretic
Mobility Shift Assay (EMSA) using double stranded 32P-labeled
CRE DNA (CRE: 5′-ATGACGTCAT-3′), which is the natural palin-
dromic binding site of the GCN4 protein. This technique
allows the sensitive determination of the dissociation constant
(Kd) (Fig. 5).
The results show all conjugates to bind to the target DNA
sequence as evident from the appearance of an up-shifted
band. In contrast, no binding was observed when incubating
the conjugates with random DNA sequences (see ESI†). Pre-
vious models developed by Morii and Mascareñas possess the
same length of the basic region peptides (D226-Q248) and are
therefore comparable to our systems. The group of Morii devel-
oped a system in which the dimerization unit consisted of a
complex of cyclodextrin and adamantane. Both counterparts
were anchored to a GCN4 basic region peptide and bind only
when dimerized. EMSA studies were performed with <1 nM
radiolabelled CRE, obtaining a Kd < 150 nM.
11 More recent
models designed by the group of Mascareñas employed a di-
azobenzene moiety for dimerization, with a Kd < 5 nM using
<1 nM radiolabelled CRE. They also reported the aﬃnity of a
disulfide-bridged GCN4 basic region, with a Kd of <150 nM
approximately for a DNA concentration of 50 nM.33 The latest
model represents a dual mimic in which the dimerization
arrangement and DNA selectivity are controlled by adjusting
selected external parameters.34 The basic region peptides were
functionalized with a cysteine and a terpyridine moiety
attached to the residues at the N- and C-termini of the peptide
chain to achieve selective dimerization at both sites. Depend-
ing on the conditions, the disulfide-based or the metal–terpyri-
dine complex-based dimers were preferred, and diﬀerent DNA
sequences could be targeted. By dimerizing the peptide in the
presence of Ni2+, the constructs were bound to the CRE
sequence with a Kd of 299 ± 26 nM, using a DNA concentration
of 100 nM, ∼100 pM labeled with 32P. For these last 3 models,
it should be noted that the nonionic detergent (NP-40) and
BSA were used during EMSA, known to decrease aggregation of
peptides and proteins and therefore favor the interaction with
DNA.35,36 In our case, the obtained Kd values at 4 °C for com-
pounds 8, 9 and 10 were 50 ± 20, 30 ± 20 and 100 ± 60 nM
respectively. A rough comparison thus indicates that our new
constructs, apart from being synthesized in a straightforward
and convergent manner, display comparable binding pro-
Fig. 4 Structure of the ﬁnal compounds 8 (α), 9 (β) and 10 (γ) and
RP-HPLC chromatograms of puriﬁed compounds (0–100% ACN for
15 min on C4, 300 Å).
Fig. 5 EMSA titration at 4 °C of the dipodal peptidocyclodextrin conju-
gates to the 5’-labeled 32P-CRE sequence (CRE: 5’-
CGGATGACGTCATTTTTTTTC-3’ underlined portion indicates the
binding region): concentrations: 5 nM dsDNA; ﬁrst lane in all the gels:
pyrimidine strand. Concentration of peptides in the lanes 2–9 for gel
1 and 2 (8 and 9): 0, 0.05, 0.0625, 0.075, 0.0875, 0.1, 0.1125 and
0.125 µM. Concentration of peptides in the lanes 2–8 for gel 3 (10): 0,
0.06, 0.125, 0.25, 0.5, 1, 2 µM. A Fuji FLA3000 phosphorimager was used
for gel analysis and Multi Gauge V 3.0 software (Fujiﬁlm) was used for
quantiﬁcation of the electrophoretic band intensities.
Organic & Biomolecular Chemistry Paper
This journal is © The Royal Society of Chemistry 2015 Org. Biomol. Chem., 2015, 13, 5273–5278 | 5275
Pu
bl
ish
ed
 o
n 
01
 A
pr
il 
20
15
. D
ow
nl
oa
de
d 
by
 U
N
IV
ER
SI
TY
 O
F 
LI
N
CO
LN
 o
n 
23
/0
6/
20
15
 1
0:
17
:4
2.
 
View Article Online
perties to those described in the literature. The obtained
values are further within the same order of magnitude as
those calculated for the binding of bacterially expressed GCN4
and synthetic versions thereof. For instance, a dimer compris-
ing of a 56mer GCN4 basic region (residues 226–281) also
binds CRE in the nanomolar range (Kd ∼ 12 nM).37–39 No data
for the dissociation constant of the natural protein have been
reported so far.
In order to better explain the results obtained from the
binding pattern on the gels and the determination of the Kd
values, we performed molecular visualization of the dimeriza-
tion interface of the bZIP GCN4 TF obtained by discarding the
leucine zipper domain from the crystal structure of the natural
protein (Fig. 6D). The distance between the C-termini of the
basic regions is shown in Fig. 6 at diﬀerent perspectives of the
protein–DNA interface, and is found to be 15.052 Å. The Kd
values showed that derivative 9 was the one with the best
binding capability to the CRE sequence. Therefore, we con-
sider that beta CD is the dimerizer which allows optimal
anchoring of the peptides on the major groove of DNA. In the
protein, the C-termini are placed at a distance of approxi-
mately 15 Å. In the case of our constructs, although the dia-
meter of the primary rim of the cyclodextrins is known (Fig. 6,
left), due to the flexibility of the linker, the exact distance
between the C-termini of the peptides on 8, 9 and 10 cannot
be predicted accurately. However, we observed that increasing
or decreasing the distance between the attachment points of
the peptides by the use of diﬀerent CD scaﬀolds results in a
deviation of the optimum geometry of the system. This is
reflected in terms of decreased binding aﬃnity and lower Kds.
It should also be noted that these results are specific for the
basic region GCN4 peptide sequence and the given spacers.
Conclusions
In conclusion, three peptide–cyclodextrin conjugates for
sequence-selective DNA recognition were obtained. This was
achieved by the use of α, β and γ-cyclodextrin diazido deriva-
tives as scaﬀolds for the appendage of the peptides by CuAAC.
We have successfully synthesized and fully characterized 6I,6IV-
diazido-α-cyclodextrin (4), 6I,6IV-diazido-β-cyclodextrin (5)
and 6I,6V-diazido-γ-cyclodextrin (6). Though examples exist of
CuAAC reactions with CD derivatives,26,40 to the best of our
knowledge long, deprotected peptides of this size have so far
not been conjugated to cyclodextrins via CuAAC. We here pres-
ented the optimized conditions for the anchoring of such long
peptides to cyclodextrin units via click chemistry.
Our results indicate the usefulness of an optimized dimeri-
zation configuration between both peptides in artificial TF
models. Indeed, it was shown that the distance between the
anchoring points has a notable influence on DNA binding.
Successful models can be obtained by trying to approach the
exact features of the protein at the interface between the
dimerization and the basic region domains of the bZIP TF to
achieve DNA binding comparable to that of the natural TF.
Experimental
Materials
All organic solvents were purchased from commercial suppli-
ers and used without further purification or drying. DMF extra
dry (with molecular sieves, water < 50 ppm) was acquired from
ACROS Organics. DMF and NMP (peptide synthesis grade)
were purchased from Biosolve. Ethyl acetate, acetonitrile,
methanol, diethyl ether, DIPEA, supplied as extra dry, redis-
tilled, 99.5% pure and triisopropylsilane were purchased from
Sigma Aldrich. Water with the Milli-Q grade standard was
obtained in-house from either a Millipore ROs 5 purification
system or a Sartorius Arium 611 DI. Rink-Amide ChemMatrix
(100–200 μm, manufacturer’s loading: 0.52–0.54 mmol g−1)
from Biotage. All reagents were acquired from commercial
sources and used without prior purification. Fmoc-Propargyl-
glycine-OH (Fmoc-Pra-OH), tris-borate-EDTA buﬀer 10× pH 8.3
(TBE buﬀer), ammonium persulfate (APS), tetramethyl-
ethylenediamine (TEMED), PyBOP and HBTU coupling
reagents were obtained from either Merck Novabiochem or
IRIS Biotech GmbH, while HATU (purum ≥98.0%) was
acquired from Fluka. TFA was obtained from IRIS Biotech
GmbH. The Nα-Fmoc protected amino acids were purchased at
Merck Novabiochem, IRIS Biotech GmbH and Fluka, or sup-
plied by MultiSynTech GmbH. All chiral α-amino acids pos-
sessed the l configuration. Throughout this work, residues
with standard acid-sensitive side-chain PGs were used: Asp-
(OtBu) [D], Cys(Trt) [C], Glu(OtBu) [E], His(Trt) [H], Lys(Boc)
[K], Asn(Trt) [N], Gln(Trt) [Q], Arg(Pbf) [R], Ser(tBu) [S], Thr-
(tBu) [T]. All oligonucleotides used were commercially pur-
chased from Eurogentec (HPLC purified using RP-cartridge-
Gold, 200 nm scale) and were used as such.
Peptide syntheses
All automated peptide syntheses were synthesized on Rink
Amide Chemmatrix resin with a loading of 0.54 mmol g−1
Fig. 6 3D structure of α, β and γ-cyclodextrins and the primary rim dia-
meter distance (A, B and C respectively) and crystal structure of the
GCN4 basic region peptides appended to the major groove of the DNA
from diﬀerent perspectives. The distance between C-termini is indicated
in angstroms (PDB: 1YSA) (D).
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using 10 eq. of amino acid, 10 eq. HBTU and 20 eq. DIPEA
using Fmoc/tBu SPPS. The coupling time was 1 h. Attachment
of the first two residues glycine and GABA was performed
manually. This was done to increase the space between the
scaﬀold and the peptide. Residues D226-Q248 were then
coupled via automated peptide synthesis. 20% piperidine/
NMP was used for Fmoc deprotection. As the last residue and
to increase UV-absorption and facilitate HPLC analysis, 4-acet-
amidobenzoic acid was coupled to the N-terminus. Cleavage
and deprotection of the peptide was performed with a cocktail
mixture containing TFA–TIS–H2O (95/2.5/2.5) for 4 hours at
room temperature. The peptide was obtained by precipitation
with cold ether and lyophilization. No further purification was
performed at this stage.
Peptide–CD conjugation via CuAAC
The selected deriviatized cyclodextrin scaﬀold 4, 5 or 6 (4 eq.)
was dissolved in dry DMSO in a round bottom flask. Peptide 7
(1 eq.) was dissolved in MilliQ water and added it to the
reactor. Cu(CH3CN)4PF6 (10 eq.) was dissolved in dry DMSO
and added to the reaction mixture. The reaction was stirred for
3 h at room temperature under argon. The reaction was moni-
tored by RP-HPLC and purified by fraction collection in
RP-HPLC to obtain compound 8. Fractions were lyophilized
and analyzed by RP-HPLC and MALDI-TOF.
Electrophoretic mobility shift assay (EMSA) for quantification
of the dissociation constant
Preparation of 32P-labeled double-stranded DNA target. Oligo-
nucleotide CRE (5′-CGG ATG ACG TCA TTT TTT TTC-3′) was
5′-labeled using [γ-32P] ATP and T4 polynucleotide kinase
(Fermentas) according to the manufacturer’s protocol and
then purified using a QIAquick Nucleotide Removal Kit
(Qiagen). The 5′-end labeled pyrimidine oligonucleotide was
annealed with the unlabeled complementary strand. An
amount of 5 nM dsDNA was prepared by diluting 20 µL of
0.5 M Tris, pH = 8, 40 µL of 2.5 M NaCl, 40 µL of 0.025 M
EDTA and then adding MilliQ water such that the total volume
is 1 mL. The DNA was annealed in a heat block by heating
from 95 °C for 5 minutes and then slowly cooling to room
temperature. Loading buﬀer: 20 µL Tris 1 M, pH = 7.6, 20 µL
KCl 0.2 M, 20 µL MgCl2 0.1 M, 40 µL EDTA 0.025 M. Sucrose:
30% sucrose in mQ (300 mg mL−1). Peptides: 10 µL stock solu-
tions (10×) were prepared in MilliQ water. The first set of experi-
ments were performed with 10× solutions of 8, 9 and 10 at
concentrations of 0, 0.6, 1.25, 2.5, 5, 10 and 20 µM. Loading
mixture: The loading mixture was comprised of 10 µL mQ,
4 µL sucrose, 2 µL loading buﬀer, 2 µL DNA and 2 µL peptide.
The loading mixture was prepared only 1 hour prior to
running of gels and kept on ice as soon as it was ready.
Preparation of gels (for 1 gel). In a clean glass beaker the
following were added (in the given order): 21.57 mL mQ,
0.6 mL 10× TBE, 7.5 mL of 40% acrylamide solution (29 : 1),
and 0.3 mL APS (10% w/w in mQ), and 30 µL of TEMED was
then added to the mixture and mixed properly before pouring
it gently along parallel glass plates. The glass plates were
tapped gently to ensure the removal of all air bubbles and the
markers were squeezed between the plates to ensure uniform
width of each well. Suﬃcient time was given for polymeri-
zation (40 minutes).
Electrophoresis. A pre-run of the gels was performed prior
to loading them. Care was taken to see that the gels were prop-
erly immersed in 0.2× TBE buﬀer (non-denaturing gel, without
urea) and the loading wells were free from any air bubbles.
The wells were washed after the pre-run. Instrument settings:
150 V, 100 mA, 19 W for 30 minutes with a circulation water-
cooling system. 5 µL of the loading mixture was then loaded
onto the wells. Instrument settings: 150 V, 100 mA, 19 W for
45 minutes with a circulation water-cooling system.
Analysis of gels. The gels were frozen and analyzed by phos-
phor imaging using a Molecular Imager FX and the data were
processed using Quantity One software (BioRad).
Acknowledgements
Tim Courtin is acknowledged for the determination of the con-
centration of the final compounds by ERECTIC-NMR. Jan
Goeman is acknowledged for the LC-MS analysis. Yara Ruiz
García and Abhishek Iyer are indebted to the Marie Curie Early
Stage Research Training Fellowship of the European Commu-
nity’s Seventh Framework Programme under contract number
PITN-GA-2010-238679. Support from the Ministry of Education,
Youth and Sport of the Czech Republic to T. Kraus (LD12019)
is greatly appreciated. Y. Vladimir Pabon is indebted to the
Departamento Admistrativo de Ciencia, Tecnología e Innova-
ción COLCIENCIAS, grant 02007/24122010. Ellen Gyssels and
Nathalie de Laet are acknowledged for the determination of
the DNA concentration using the Trinean Dropsense multi-
channel spectrophotometer.
Notes and references
1 S. Goverdhana, M. Puntel, W. Xiong, J. M. Zirger, C. Barcia,
J. F. Curtin, E. B. Soﬀer, S. Mondkar, G. D. King, J. Hu,
S. A. Sciascia, M. Candolfi, D. S. Greengold,
P. R. Lowenstein and M. G. Castro, Mol. Ther., 2005, 12,
189–211.
2 A. Klug, Annu. Rev. Biochem., 2010, 79, 213–231.
3 X. Li, S. Chen, T. Sun, Y. Xu, Y. Chen, Y. Liu, R. Xiang and
N. Li, Clin. Lab., 2014, 60, 909–918.
4 P. C. Ma, M. A. Rould, H. Weintraub and C. O. Pabo, Cell,
1994, 77, 451–459.
5 J. N. Glover and S. C. Harrison, Nature, 1995, 373, 257–261.
6 T. Shimizu, A. Toumoto, K. Ihara, M. Shimizu, Y. Kyogoku,
N. Ogawa, Y. Oshima and T. Hakoshima, EMBO J., 1997, 16,
4689–4697.
7 J. E. Darnell Jr., Nat. Rev. Cancer, 2002, 2, 740–749.
8 T. E. Ellenberger, C. J. Brandl, K. Struhl and S. C. Harrison,
Cell, 1992, 71, 1223–1237.
Organic & Biomolecular Chemistry Paper
This journal is © The Royal Society of Chemistry 2015 Org. Biomol. Chem., 2015, 13, 5273–5278 | 5277
Pu
bl
ish
ed
 o
n 
01
 A
pr
il 
20
15
. D
ow
nl
oa
de
d 
by
 U
N
IV
ER
SI
TY
 O
F 
LI
N
CO
LN
 o
n 
23
/0
6/
20
15
 1
0:
17
:4
2.
 
View Article Online
9 E. Pazos, J. Mosquera, M. E. Vázquez and J. L. Mascareñas,
ChemBioChem, 2011, 12, 1958–1973.
10 R. V. Talanian, C. J. McKnight and P. S. Kim, Science, 1990,
249, 769–771.
11 M. Ueno, A. Murakami, K. Makino and T. Morii, J. Am.
Chem. Soc., 1993, 115, 12575–12576.
12 B. Cuenoud and A. Schepartz, Science, 1993, 259, 510–513.
13 A. M. Caamano, M. E. Vazquez, J. Martinez-Costas,
L. Castedo and J. L. Mascarenas, Angew. Chem., Int. Ed.,
2000, 39, 3104–3107.
14 L. L. G. Carrette, T. Morii and A. Madder, Eur. J. Org.
Chem., 2014, 2883–2891.
15 E. Oheix and A. F. a. Peacock, Chem. – Eur. J., 2014, 20,
2829–2839.
16 M. E. Brewster and T. Loftsson, Adv. Drug Delivery Rev.,
2007, 59, 645–666.
17 W. S. Horne, M. K. Yadav, C. D. Stout and M. R. Ghadiri,
J. Am. Chem. Soc., 2004, 126, 15366–15367.
18 H. C. Kolb and K. B. Sharpless, Drug Discovery Today, 2003,
8, 1128–1137.
19 C. W. Tornoe, C. Christensen and M. Meldal, J. Org. Chem.,
2002, 67, 3057–3064.
20 I. E. Valverde, A. Bauman, C. A. Kluba, S. Vomstein,
M. A. Walter and T. L. Mindt, Angew. Chem., Int. Ed., 2013,
52, 8957–8960.
21 N. Schaschke, I. Assfalg-Machleidt, W. Machleidt,
T. Laßleben, C. P. Sommerhoﬀ and L. Moroder, Bioorg.
Med. Chem. Lett., 2000, 10, 677–680.
22 C. Decroocq, A. Joosten, R. Sergent, T. Mena Barragán,
C. Ortiz Mellet and P. Compain, ChemBioChem, 2013, 14,
2038–2049.
23 H. Tsutsumi, H. Ikeda, H. Mihara and A. Ueno, Bioorg.
Med. Chem. Lett., 2004, 14, 723–726.
24 M. A. Hossain, K. Hamasaki, K. Takahashi, H. Mihara and
A. Ueno, J. Am. Chem. Soc., 2001, 123, 7435–7436.
25 H. Tsutsumi, K. Hamasaki, H. Mihara and A. Ueno,
J. Chem. Soc., Perkin Trans. 2, 2000, 1813–1818.
26 Y.-C. Lin, P.-I. Wang and S.-W. Kuo, Soft Matter, 2012, 8,
9676.
27 J. N. Beck, A. Singh, A. R. Rothenberg, J. H. Elisseeﬀ and
A. J. Ewald, Biomaterials, 2013, 34, 9486–9495.
28 (a) L. Kumprecht, M. Budesínský, J. Vondrásek, J. Vymetal,
J. Cerný, I. Císarová, J. Brynda, V. Herzig, P. Koutník,
J. Závada and T. J. Kraus, Org. Chem., 2009, 74, 1082;
(b) A. Grishina, S. Stanchev, L. Kumprecht, M. Buděšínský,
M. Pojarová, M. Dušek, M. Rumlová, I. Křížová,
L. Rulíšek and T. Kraus, Chem. – Eur. J., 2012, 18,
12292–12304.
29 S. Volkov, L. Kumprecht, M. Buděšínský, M. Dušek and
T. Kraus, Org. Biomol. Chem., 2015, 13, 2980–2985.
30 D. Verzele and A. Madder, Eur. J. Org. Chem., 2013, 673–
687.
31 V. Hong, S. I. Presolski, C. Ma and M. G. Finn, Angew.
Chem., Int. Ed. Engl., 2009, 48(52), 9879–9883.
32 V. Hong, N. F. Steinmetz, M. Manchester and M. G. Finn,
Bioconjugate Chem., 2010, 21, 1912–1916.
33 A. Jiménez-Balsa, E. Pazos, B. Martínez-Albardonedo,
J. L. Mascareñas and M. E. Vázquez, Angew. Chem., Int. Ed.,
2012, 51, 8825–8829.
34 J. Mosquera, A. Jiménez-Balsa, V. Dodero, M. E. Vázquez
and J. L. Mascareñas, Nat. Commun., 2013, 4, 1874–1878.
35 L. M. Hellman and M. G. Fried, Nat. Protoc., 2007, 2, 1849–
1861.
36 P. L. Molloy, Cell Biology (Page 330), Elsevier, Oxford (UK),
3rd edn, Vol. 4, 2006.
37 J. J. Hollenbeck and M. G. Oakley, Biochemistry, 2000, 39,
6380–6389.
38 G. H. Bird, A. R. Lajmi and J. A. Shin, Biopolymers, 2002,
65, 10–20.
39 I.-S. Chan, A. V. Fedorova and J. a. Shin, Biochemistry, 2007,
46, 1663–1671.
40 P.-A. Faugeras, B. Boëns, P.-H. Elchinger, F. Brouillette,
D. Montplaisir, R. Zerrouki and R. Lucas, Eur. J. Org.
Chem., 2012, 4087–4105.
Paper Organic & Biomolecular Chemistry
5278 | Org. Biomol. Chem., 2015, 13, 5273–5278 This journal is © The Royal Society of Chemistry 2015
Pu
bl
ish
ed
 o
n 
01
 A
pr
il 
20
15
. D
ow
nl
oa
de
d 
by
 U
N
IV
ER
SI
TY
 O
F 
LI
N
CO
LN
 o
n 
23
/0
6/
20
15
 1
0:
17
:4
2.
 
View Article Online
This article was downloaded by: [University of Gent]
On: 19 September 2014, At: 05:38
Publisher: Taylor & Francis
Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House,
37-41 Mortimer Street, London W1T 3JH, UK
Food Additives & Contaminants: Part A
Publication details, including instructions for authors and subscription information:
http://www.tandfonline.com/loi/tfac20
An immunogen synthesis strategy for the development
of specific anti-deoxynivalenol monoclonal antibodies
Melanie Sandersa, Yirong Guoab, Abhishek Iyerc, Yara Ruiz Garcíac, Anastasia Galvitaa, Arne
Heyerickd, Dieter Deforced, Martijn D.P. Risseeuwe, Serge Van Calenberghe, Marc Brackef,
Sergei Ereming, Annemieke Madderc & Sarah De Saegera
a Laboratory of Food Analysis, Ghent University, Ghent, Belgium
b Institute of Pesticide and Environmental Toxicology, Zhejiang University, Hangzhou, China
c Organic and Biomimetic Chemistry Research Group, Ghent University, Ghent, Belgium
d Laboratory of Pharmaceutical Biotechnology, Ghent University, Ghent, Belgium
e Laboratory for Medicinal Chemistry, Ghent University, Ghent, Belgium
f Laboratory of Experimental Cancer Research, Ghent University, Ghent, Belgium
g Department of Chemical Enzymology, Moscow State University, Moscow, Russia
Published online: 18 Sep 2014.
To cite this article: Melanie Sanders, Yirong Guo, Abhishek Iyer, Yara Ruiz García, Anastasia Galvita, Arne Heyerick, Dieter
Deforce, Martijn D.P. Risseeuw, Serge Van Calenbergh, Marc Bracke, Sergei Eremin, Annemieke Madder & Sarah De Saeger
(2014): An immunogen synthesis strategy for the development of specific anti-deoxynivalenol monoclonal antibodies, Food
Additives & Contaminants: Part A, DOI: 10.1080/19440049.2014.955887
To link to this article:  http://dx.doi.org/10.1080/19440049.2014.955887
PLEASE SCROLL DOWN FOR ARTICLE
Taylor & Francis makes every effort to ensure the accuracy of all the information (the “Content”) contained
in the publications on our platform. However, Taylor & Francis, our agents, and our licensors make no
representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the
Content. Any opinions and views expressed in this publication are the opinions and views of the authors, and
are not the views of or endorsed by Taylor & Francis. The accuracy of the Content should not be relied upon and
should be independently verified with primary sources of information. Taylor and Francis shall not be liable for
any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever
or howsoever caused arising directly or indirectly in connection with, in relation to or arising out of the use of
the Content.
This article may be used for research, teaching, and private study purposes. Any substantial or systematic
reproduction, redistribution, reselling, loan, sub-licensing, systematic supply, or distribution in any
form to anyone is expressly forbidden. Terms & Conditions of access and use can be found at http://
www.tandfonline.com/page/terms-and-conditions
An immunogen synthesis strategy for the development of speciﬁc anti-deoxynivalenol
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(Received 5 June 2014; accepted 13 August 2014)
An immunogen synthesis strategy was designed to develop anti-deoxynivalenol (DON) monoclonal antibodies with low
cross-reactivity against structurally similar trichothecenes. A total of eight different DON immunogens were synthesised,
differing in the type and position of the linker on the DON molecule. After immunisation, antisera from mice immunised
with different DON immunogens were checked for the presence of relevant antibodies. Then, both homologous and
heterologous enzyme-linked immunosorbent assays (ELISAs) were performed for hybridoma screening. Finally, three
monoclonal antibodies against DON and its analogues were generated. In addition, monoclonal antibody 13H1 could
recognise DON and its analogues in the order of HT-2 toxin > 15-acetyldeoxynivalenol (15-ADON) > DON, with IC50
ranging from 1.14 to 2.13 µg ml–1. Another monoclonal antibody 10H10 manifested relatively close sensitivities to DON,
3-acetyldeoxynivalenol (3-ADON) and 15-ADON, with IC50 values of 22, 15 and 34 ng ml
–1, respectively. Using an
indirect ELISA format decreases the 10H10 sensitivity to 15-ADON with 92%. A third monoclonal antibody 2A9 showed
to be very speciﬁc and sensitive to 3-ADON, with IC50 of 0.38 ng ml
–1. Using both 2A9 and 10H10 monoclonal antibodies
allows determining sole DON contamination.
Keywords: deoxynivalenol; monoclonal antibodies; immunogens; ELISA; cross-reactivity
Introduction
Trichothecene mycotoxins are a group of naturally
occurring secondary metabolites produced by Fusarium
species, in particular F. graminearum and F. culmorum.
Among the 150 related trichothecenes, deoxynivalenol
(DON) (Figure 1) is of special importance as it is
formed in the ﬁeld prior to harvest and because its
occurrence cannot be completely avoided by plant pro-
duction-minimising strategies due to the high impact of
weather conditions. Especially wheat, triticale and maize
are vulnerable for Fusarium infection and subsequent
DON production (Maragos et al. 2006; Döll & Dänicke
2011).
DON can cause disease in several animal species,
especially in swine, and causes symptoms including
reduced feed consumption, abdominal distress, increased
salivation, malaise, diarrhoea, anorexia, leucopenia, hae-
morrhage, shock and death in extremely high DON
doses (Maragos & McCormick 2000; Pestka 2007).
Besides these effects, DON is also generally considered
to be a potent inhibitor of protein and DNA synthesis
and is known to be immunosuppressive (Krska et al.
2001; Danicke et al. 2006). Highly dividing cells, such
as intestinal epithelial cells known to ensure a proper
barrier function, are especially sensitive to trichothe-
cenes. Exposure to DON can lead to a decrease in
absorption of nutrients and a decrease in cell prolifera-
tion and consequently cell differentiation (Pinton et al.
2012).
Next to DON two acetylated derivatives are known to
be coproduced, namely 3-acetyldeoxynivalenol (3-
ADON) and 15-acetyldeoxynivalenol (15-ADON).
JECFA stated that the acetylated DON levels were less
than 10% of the total DON found in cereal grains, whereas
De Boevre et al. (2012) found higher 3-ADON and 15-
ADON co-contamination for several food and feed sam-
ples. In 2010 JECFA considered the toxicity of the acety-
lated derivatives equal to DON, but a recent study
suggested that higher toxicity of 15-ADON should be
taken into account. Another DON masked form detected
in cereals and beers, namely DON-3-glucoside (DON-3-
G), also shows a non-negligible contribution to the overall
DON contamination (Berthiller et al. 2009; JECFA 2011;
De Boevre et al. 2012; Pinton et al. 2012).
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Because of the economic importance of this toxin and
from a food safety perspective, a variety of analytical
techniques have been developed for the detection of
DON and related trichothecene mycotoxins in food and
feed. Most commonly used techniques include TLC, GC,
HPLC and immunological approaches such as radioimmu-
noassay and ELISA. Recently, ELISA and ELISA-based
procedures have gained acceptance as they offer the
advantage of speciﬁcity, sensitivity, simplicity and rapid-
ity, which are of importance for routine testing of myco-
toxins (Maragos & McCormick 2000; Maragos et al.
2006, 2012). The speciﬁcity and sensitivity are dependent
on the antibody used in the ELISA assay. Several anti-
bodies for DON have been reported and all show high
cross-reactivity against the acetylated derivatives 3-
ADON and 15-ADON, which reduces their speciﬁc char-
acter. Sensitivity values of antibodies, measured by the
IC50 value, range from approximately 20 to 3 ng ml
–1
(Casale et al. 1988; Mills et al. 1990; Usleber et al.
1991; Sinha et al. 1995; Maragos & McCormick 2000).
The objective of this study is to improve the speci-
ﬁcity of the ELISA assay by developing highly speciﬁc
monoclonal anti-DON antibodies. The high afﬁnity of
the monoclonal antibody to 3-ADON or 15-ADON
likely derives from the chemistry used to prepare the
immunogen. The ester linkage of 3-ADON or 15-ADON
may resemble the linkage of the DON-carrier protein
immunogen. Therefore, it was decided to use different
procedures to make linkers with varying length and
chemical structure between DON and the carrier protein
(Figure 2).
Materials and methods
Reagents
DON, 3-ADON and 15-ADON standards were obtained
from Fermentek (Jerusalem, Israel). HT-2 toxin was pur-
chased from Sigma-Aldrich (Bornem, Belgium).
Colorburst™ blue 3,3´,5,5´-tetramethylbenzidine
(TMB) substrate solution containing hydrogen peroxide
was supplied by Alerchek (Springvale, ME, USA).
Rabbit anti-mouse immunoglobulins (anti-mouse IgG sec-
ondary antibody; protein concentration of 2.5 g l–1) were
purchased from DakoCytomation (Glostrup, Denmark). N,
N´-carbonyldiimidazole, cyanuric chloride (CC), N,N´-dii-
sopropylethylamine, glutaric anhydride, 1-ethyl-3-[3-
dimethylaminopropyl] carbodiimide hydrochloride
(EDC), 1-butane boronic acid, sodium tetraborate, carbox-
ymethoxylamine hemihydrochloride (CMO), γ-aminobu-
tyric acid, sulfo-N-hydroxysuccinimide (NHS),
tetrahydrofuran (THF), acetic acid, potassium carbonate,
copper (II) sulfate, sodium ascorbate, 4,7-diphenyl-1,10-
bathophenanthroline disulfonic acid disodium salt, argi-
nine, glycine, aspartic acid, D-phenylalanine, lysine, tri-
ﬂuoroacetic acid (TFA), triisopropylsilane (TIS), methyl
tertiary butyl ether (MTBE), polyethylene glycol (bovine
serum albumin (BSA), ovalbumin (OVA), horseradish
peroxidase (HRP), rabbit anti-mouse IgG secondary anti-
body labelled with horseradish peroxidase (Sec Ab-HRP),
PBS (0.01 M, pH 7.4) tablet, carbonate-buffered saline
(CBS, 0.05 M, pH 9.6) capsule, complete and incomplete
Freund’s adjuvants, Tween 20 and skim milk powder were
obtained from Sigma-Aldrich (Bornem, Belgium). O-pro-
pargyl-hydroxylamine hydrochloride was purchased from
Focus Synthesis (San Diego, CA, USA). Imidazole-1-sul-
fonylazide hydrochloride was kindly provided by the
Laboratory of Medicinal Chemistry (Ghent, Belgium).
The Oasis HLB cartridges were obtained from Waters
(Zellik, Belgium). Chlorotrityl chloride resin was pur-
chased from Merck (Darmstadt, Germany). Deionised
water was puriﬁed by a Millipore Milli-Q system
(Brussels, Belgium). Other chemicals and solvents were
of analytical grade.
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Figure 1. Chemical structure of deoxynivalenol.
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Nunc-Immuno™ F96-well microplates and Nunclon™
cell culture plates were from Nalge Nunc International
(Roskilde, Denmark). Protein concentrators (9K MWCO,
20 ml) were purchased from Thermo Scientiﬁc
(Rockford, USA).
Preparation of DON immunogens
DON is a hapten due to its small size and therefore cannot
elicit an immune response. Consequently, for the synthesis
of immunogens, DON was coupled to a protein via a
linker to increase the molecular weight. In search for
speciﬁc anti-DON antibodies, different synthetic strategies
were followed. Firstly, DON was coupled to a carrier
protein via the C3 and/or C15 position using a linker
with a carboxyl function (Series I, Figure 2). To minimise
the chance of cross-reacting monoclonal antibodies, a
second DON series of immunogens was generated by
coupling the carrier protein via a linker on C3 and/or
C15 without a carboxyl function (Series II, Figure 2). To
reduce even further the possibility of cross-reacting mono-
clonal antibodies the linkage to the carrier protein was
introduced through reaction with the C8 carbonyl function
of DON, delivering a last series of immunogens (Series
III, Figure 2). The used carrier proteins were bovine serum
albumin (BSA) for the immunogen and ovalbumin (OVA)
or horseradish peroxidase (HRP) for the coating/competi-
tive antigen in indirect or direct enzyme-linked immuno-
sorbent assay (ELISA), respectively. The synthetic
pathways underneath are described for BSA. The basic
chemical structure of the three different series of immuno-
gens is illustrated in Figure 2.
The ﬁrst immunogen of the series I is DON-3,15-
hemiglutaryl (HG)-BSA (Figure 3A) and was formed by
the reaction of DON with glutaric anhydride in dry pyr-
idine. Concisely, to a solution of 5 mg of DON in 500 µl
of dry pyridine, 100 mg of glutaric anhydride was added
and the solution was heated at 100°C for 8 h. After
evaporation, the residue was dissolved in 7.5 ml of chloro-
form and washed three times with 5 ml of 0.1 M HCl. A
puriﬁcation step was performed using Oasis HLB® car-
tridges by a method derived from De Smet et al. (2010).
Brieﬂy, 5 µg of the crude DON-HG conjugate was dis-
solved in 1 ml of methanol–water (10:90, v/v) pH 2.3 and
loaded onto a preconditioned column. After loading, the
sorbent was dried for 15 s by applying vacuum. DON-HG
was eluted by washing the column with 1 ml of methanol–
water (55:45, v/v) followed by 1 ml of methanol. The
sorbent was dried for 15 s by applying a vacuum. After
purity determination by time-of-ﬂight (TOF) MS, an ali-
quot of 1 mg of the synthesised DON-HG (1.92 µmol)
was dissolved in 0.5 ml PBS using ultrasonication and
transferred to 30 mg BSA (0.45 µmol) in 1 ml of PBS.
Then 20 mg of EDC (0.10 µmol) was added to the above
mixture and incubated for 5 h at RT with stirring (Mills
et al. 1990; Usleber et al. 1991; Kohno et al. 2003; De
Smet et al. 2010).
To obtain DON with one HG linker, namely DON-3-
HG-BSA (Figure 3B), prior protection of the 7-OH and
15-OH groups as a cyclic boronate ester allowed one to
use similar reaction conditions as for DON-3,15-HG-BSA
(Casale et al. 1988). Additionally in the ﬁrst series of
immunogens, a common DON-BSA carbamate conjugate
(Figure 3C and 3D) was synthesised by the N,N´-carbo-
nyldiimidazole (CDI) coupling reaction, adopted from the
published literature (Xiao et al. 1995; Maragos &
McCormick 2000).
Within-series II, DON-CC-BSA (Figure 3E and 3F)
was synthesised by ﬁrst dissolving 1 mg of DON
(3.374 × 10−3 mmol) in 480 µl of cold acetonitrile. A
solution of 620 µg of cyanuric chloride (3.362 × 10−3 mmol)
in 1.24 ml of acetonitrile was prepared and cooled until –
20°C. The DON solution was added over 1 h to the vigor-
ously stirred solution of cyanuric chloride. A solution of
870 µg N,N´-diisopropylethylamine in 260 µl of cold acet-
one was added to the solution of DON and cyanuric chlor-
ide and mixed for 5 h at 55–60°C followed by mixing for
16 h at RT. For coupling to BSA, a solution of 1830 µg of
BSA (0.0270 µmol) in 1090 µl of 0.1 M sodium tetraborate
(pH 9.2) was prepared. The solution was cooled to 4°C and
3.5 mg of DON, a 10-fold molar excess with respect to the
available amino groups was added and the resulting mixture
was stirred for 1 h at 4°C (Abuchowski et al. 1977;
Abuknesha & Grifﬁth 2005).
In an effort to reduce the cross-reactivity against
3-ADON and 15-ADON, we decided to use the C8
carbonyl function of DON to attach an appropriate lin-
ker via an oxime moiety (Series III). Hereto a carbox-
ymethyloxime (CMO) strategy was applied (Figure 3G)
(Burkin et al. 2000). To investigate the effect of the
length of the linker between DON and the protein and
with the aim of lowering the immune response against
the linker itself, we also introduced a carboxypropyl
imine (CPI) linker at the C8 position of DON (Figure
3H). For this purpose, 0.5 mg of DON (1.7 µmol) was
reacted with 750 µg of CMO (7 µmol) in 500 µl of dry
pyridine for the DON-CMO synthesis and with 1.6 mg
of γ-aminobutyric acid (15.5 µmol) in 1 ml dimethyl-
formamide (DMF) for the DON-CPI synthesis. After
overnight reaction at RT, the reaction mixture was con-
centrated and the residue redissolved in 200 µl of water/
DMSO (1:1.5, v/v). Next, 2 mg of sulfo-NHS and 4 mg
of EDC were added together with 1.775 mg of BSA and
the volume was adjusted to 1 ml by further dilution with
water. The reactions were performed for 2 h at RT
followed by washing and puriﬁcation as described for
previous immunogen synthesis.
Finally, click chemistry was adopted for linking C8 of
DON without a carboxyl function. Following a modiﬁed
procedure of Ikuina et al. (2003), DON was condensed to
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O-propargy-hydroxylamine hydrochloride (Figure 3I).
Brieﬂy, 2 mg of DON (6.76 µmol) was reacted with
1.81 mg of O-propargyl-hydroxylamine hydrochloride
(25.52 µmol) in the presence of THF/acetic acid (1:1, v/
v) at 40°C. After 2 h, an additional 170 µg of O-propar-
gyl-hydroxylamine hydrochloride was added and the mix-
ture was stirred for another 4.5 h to obtain DON-oxime.
For the synthesis of azido-BSA, 10.686 mg of BSA
(0.16 µmol) was dissolved in water together with 4 mg
of potassium carbonate and 0.5 mg of copper (II) sulfate.
Then, 1 mg of imidazole-1-sulfonylazide hydrochloride
(4.79 µmol) was added and the reaction was agitated
overnight. For the click reaction, 0.5 mg of DON-oxime
(1.43 µmol) was transferred to an aqueous solution of
azido-BSA (1.42 mg) containing 25 µg copper (II) sulfate
(10 mM), 20 µg sodium ascorbate (10 mM) and 54 µg
4,7-diphenyl-1,10-bathophenanthroline disulfonic acid
disodium salt (10 mM). The reaction went on for 14 h at
RT (Figure 3J) (Ikuina et al. 2003; Van Dongen et al.
2009; Horak et al. 2010).
The click chemistry immunogen product was further
expanded by the introduction of a N-azido cyclic peptide
(630.3 g mol–1) (Figure 3K). The cyclic peptide increases
the distance between DON and BSA and renders the DON
molecule more available for the immune system. Through
solid-phase peptide synthesis using 2-chlorotrityl chloride
resin and a Fmoc/tBu protection scheme, the amino acids
glycine, aspartic acid, D-phenylalanine, lysine and argi-
nine were successively coupled to each other. After mild
acid cleavage of the peptide from the resin, cyclisation of
the peptide was performed followed by treatment with
TFA–TIS–H2O (95:2.5:2.5, v/v/v) to remove the protect-
ing groups in solution. The peptide was then precipitated
in MTBE–hexane (1:1, v/v) and redissolved in methanol
for a diazo transfer. For the click chemistry, 1 mg of DON-
oxime (2.84 µmol) was reacted with 1.78 mg of cyclic
peptide (2.84 µmol) under the previously mentioned con-
ditions. Under CDI reaction conditions, the obtained
DON-cyclic peptide (2.84 µmol) was coupled to 3.9 mg
of BSA in water–DMSO (1/5, v/v) for 3 h at RT (Dai et al.
2000; Dijkgraaf et al. 2007).
All DON immunogens were dialysed against 4 L PBS
to remove low molecular weight substances and concen-
trated using Pierce Concentrator columns 20 ml/9K
MWCO.
Characterisation of immunogens
The successful synthesis of the DON-3,15-HG-linker was
conﬁrmed by mass spectrometry LCT Premier XETM TOF
(Waters, Milford, MA, USA) equipped with a standard elec-
trospray ionisation and modular LockSpray TM interface in
the positive and negative electrospray ionisation (ESI+/–)
mode. The puriﬁed DON-3,15-HG mixture was infused in
acetonitrile–water (1:1, v/v) at 10 µl min–1. The purity of the
ﬁnal product was assessed by HPLC and photo diode array
(PDA) detection (190–400 nm) using a Phenomenex Luna
2.5 mm C18 (2)-HST column. A mobile phase consisting of
eluents A (water, 0.1% formic acid) and B (acetonitrile, 0.1%
formic acid) was used at a ﬂow rate of 0.4 ml min–1. A linear
gradient of 10–100% solvent B was applied over 9 min.
Other mass measurements of DON-linker syntheses were
performed by direct injection of the reaction product into
the Quattro Premier XE mass spectrometer (Waters, Milford,
MA, USA) using the ESI+/–mode.Masslynx version 4.1 was
used for data acquisition.
After coupling to the protein, the immunogen concen-
tration was determined based on the amount of protein
coupled by the use of the NanoDrop 2000c (Thermo
Scientiﬁc, Rockford, USA) and the immunogen was char-
acterised by the use of indirect competitive ELISA. All
incubations except for the ﬁrst coating step were carried
out at 37°C. After each incubation, the plates were washed
three times (300 µl/well) with PBST (PBS containing
0.05% Tween 20). High-binding Nunc-ImmunoTM F96-
well microplates were coated with 10 µg ml–1 of the
synthesised conjugate in CBS (100 µl/well). After incuba-
tion at 4°C overnight, the plates were blocked with 2%
skimmed milk in PBS (300 μl/well) for 30 min. Standard
solutions of DON and PBS control were added (50 μl/
well), followed by adding 50 μl/well of diluted DON
monoclonal antibodies (clone 4 or 22) in PBS kindly
provided by C. Maragos (USDA). After shaking and incu-
bation for 1 h, 100 μl/well of Sec Ab-HRP was added and
incubated for another 1 h. Then, 100 μl/well of TMB
substrate solution was added. The reaction was stopped
after 15 min with 2 M sulphuric acid (50 μl/well), and the
absorbance at 450 nm was measured by a Bio-Rad 550
microplate reader (Richmond, CA, USA).
Immunisations
To obtain antibody-producing B-lymphocytes against
DON, 6–8-week-old Balb/C female mice (ethical approval
according to ethical commission for animals (ECD) 10/08)
were subjected to an injection with the different DON
immunogens emulsiﬁed with complete or incomplete
Freund’s adjuvant. For each group of mice, 100 µg of
the DON immunogen was administered. Once the mice
had reached a sufﬁcient titre, cell fusion of mouse spleen
cells and myeloma cells (NSO cells) was performed.
Polyethylene glycol (PEG) 1500 was added as fusing
reagent and hypoxanthine, aminopterine and thymidine
(HAT) for the selection of the fused cells. The cells were
distributed into 96-well culture plates and cultured in a
humidiﬁed, 37°C, 5% CO2 incubator. Culture supernatant
was screened by indirect ELISA to determine the positive
hybridomas producing antibody against DON. These
hybridomas were further screened for the production of
the target antibody and subcloned by limiting dilution.
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Characterisation of monoclonal antibodies
Checkerboard assays, in which antibodies were titrated
against various amounts of coating antigens, were con-
ducted to select appropriate working concentrations for
evaluation of assay sensitivities to DON. Standard compe-
titive curves were obtained by plotting relative absorbance
(ratio of absorbance measured at the standard concentra-
tion and zero concentration: B/B0 × 100%) against the
logarithm of analyte concentration. IC50 values (i.e., ana-
lyte concentrations at which the maximum absorbances
were inhibited by 50%) were determined to assess the
assay sensitivity. To evaluate the speciﬁcity or assay selec-
tivity of the antibody, a set of DON analogues were
utilised to perform cross-reactivity studies. The IC50 of
each tested compound was based on its corresponding
competitive curve. Cross-reactivity (CR) values were cal-
culated according to the following equation: CR
(%) = [IC50 (DON)/IC50 (analogue)] × 100%, where CR
values were calculated using IC50 values with units of
µg ml–1.
Results and discussion
Characterisation of immunogens
When the desired synthesis products were obtained based
on the exact mass measurements performed by direct
injection into the Quattro Premier XE mass spectrometer
or the LCT Premier XETM TOF mass spectrometer,
further coupling to BSA and OVA or HRP was performed.
The synthesised immunogens were characterised by com-
petitive ELISA using reference DON monoclonal antibo-
dies (clone 4 or 22, USDA). If the B0 value was equal to
or higher than 1 and decreasing B values were obtained
when using increasing standard DON concentrations, the
testing conjugates were conﬁrmed and used for immunisa-
tion or further ELISA experiments.
Determination of antisera titres by using indirect ELISA
Antisera titres were determined by an indirect homologous
ELISA using the immunising haptens coupled to OVA
instead of BSA as coating antigen (Guo et al. 2014). By
using the same format, the cross-reactivity against OVA
was determined as well. The best antisera titres were
obtained for the mice injected with DON-BSA and
DON-CC-BSA. For DON-3,15-HG-BSA, high antisera
titres were found, but the cross-reactivity against OVA
was high. It was concluded that antibodies were probably
formed against the protein instead of the target DON. This
could be explained by the presence of two linkers on the
DON molecule, which makes it less free for activation of
the immune system of the mouse. For DON-CMO-BSA,
DON-CPI-BSA, DON-azido-BSA and DON-cyclic pep-
tide-BSA, a relatively lower titre, but no cross-reactivity
against OVA was determined. When the ELISA response
reached a plateau phase using a high serum dilution, the
mice were sacriﬁced by cervical dislocation.
Hybridoma selection and subcloning
By screening and subcloning of the hybridomas, ﬁnally, a
total of three different anti-DON monoclonal antibodies
were obtained. Corresponding to the derived antisera
titres, one DON-CC-BSA mouse produced the 13H1
monoclonal antibody, while the 10H10 and 2A9 mono-
clonal antibodies were produced by two different DON-
BSA mice. Previous statement about the immunogenic
importance of the C8 carbonyl function in the DON mole-
cule was conﬁrmed as no anti-DON monoclonal antibo-
dies were derived using immunogens with a linker
coupled to the C8 carbonyl function (Usleber et al. 1991).
Characterisation of monoclonal antibodies
The characterisation of monoclonal antibodies 13H1 and
10H10 by direct ELISA is described in detail by Guo et al.
(2014). The 13H1 and 10H10 monoclonal antibody showed
sensitivity values of 2.13 and 0.022 µgml–1, respectively. For
the 13H1 monoclonal antibody the highest cross-reactivity
was observed for 15-ADON (CR = 131%) and HT-2 toxin
(CR = 187%). Monoclonal antibody 10H10 showed the
highest cross-reactivity for 3-ADON (CR = 147%) and 15-
ADON (CR = 65%). Characterisation of 10H10 was also
repeated by indirect competitive ELISA using DON-OVA
(4 µg ml–1) and DON-CC-OVA (4 µg ml–1) coating and
DON, 3-ADON and 15-ADON for competition. This com-
parison between direct and indirect ELISA is illustrated in
Table 1. The sensitivity of the antibody towards DON and 3-
ADON measured by indirect ELISA is approximately half
(DON-OVA coating) and 1/5 (DON-CC-OVA coating) of the
value measured by direct ELISA. For 15-ADON, the sensi-
tivity decreased at least ten times when using indirect ELISA.
When looking to the CRmolar values for direct ELISA and
indirect ELISA with DON-OVA coating, the same cross-
reactivity is seen for 3-ADON, but the cross-reactivity
towards 15-ADON lowered 6.7 times when using indirect
ELISA. It can even be concluded that the 10H10 antibody
shows only cross-reactivity to 3-ADON when using indirect
ELISA with DON-OVA coating. When using an indirect
ELISA format with DON-CC-OVA coating, the cross-reac-
tivity against 3-ADON increased three times and the cross-
reactivity against 15-ADON decreased four times compared
to the direct ELISA format. So, the characterisation of the
monoclonal antibody depends on the type of ELISA and the
coating antigen used.
Characterisation of monoclonal antibody 2A9 was
performed using direct ELISA and the standard curve
using 3-ADON standard for competition is shown in
Figure 4. The curve represents the relative absorbance
6 M. Sanders et al.
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values (B/B0) of the ELISA experiment performed on 3
consecutive days. A very sensitive anti-3-ADON antibody
was developed with an IC50 value of 0.38 ng ml
–1. Setting
the monoclonal antibody activity for 3-ADON as 100%,
the cross-reactivity values for DON, 15-ADON and DON-
3-G (Table 2) were determined as 0.188%, 0.088% and
1.498% and can be considered as negligible. In compar-
ison with other previously reported monoclonal antibodies
for 3-ADON, the newly developed clone 2A9 is likely the
most sensitive and speciﬁc antibody to 3-ADON (Casale
et al. 1988; Maragos & McCormick 2000; Maragos et al.
2006; Baumgartner et al. 2010).
Conclusions
By using a three-series synthesis strategy for the develop-
ment of speciﬁc monoclonal antibodies against DON,
previous statements were conﬁrmed and new conclusions
could be made. The place of the linker on the DON
molecule is of importance for the immunogenic response.
When a linker is positioned on the C3 or C15 of DON for
the synthesis of an immunogen, the produced antibody
shows higher cross-reactivity against 3-ADON or 15-
ADON, respectively. When coupling a linker to the car-
bonyl C8 of DON, no high anti-DON immune response
was observed. This emphasises the immunogenic impor-
tance of the C8 carbonyl function. The size of the linker
does not seem to inﬂuence the immunogenicity of the
injected conjugate. The kind of linker has an inﬂuence
on the electronic conﬁguration of the DON molecule and
therefore on the antigenic determinant of DON which is
available for the immune system of the mouse.
Three different monoclonal antibodies were devel-
oped. One of them (2A9) can be called an anti-3-ADON
monoclonal antibody, because of its very sensitive and
speciﬁc characteristics towards 3-ADON. The second
10H10 monoclonal antibody is a broad speciﬁc antibody
against DON and its acetylated derivatives 3-ADON and
Table 1. Comparison between direct and indirect ELISA for 10H10 antibody characterisation.
IC50 (µg ml
–1) CR (%) IC50 molar (nmol ml
–1) CR molar (%)
Direct ELISA DON 0.022 100 0.074 100
3-ADON 0.015 147 0.044 167
15-ADON 0.034 65 0.101 74
Indirect ELISA DON-OVA DON 0.040 100 0.135 100
3-ADON 0.028 142 0.083 162
15-ADON 0.421 9 1.250 11
DON-CC-OVA DON 0.113 100 0.383 100
3-ADON 0.024 480 0.070 547
15-ADON 0.637 18 1.885 20
0
10
20
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40
50
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80
90
100
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B/
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3-ADON concentration (ng/mL)
Figure 4. Standard curve of clone 2A9 for 3-ADON by direct
competitive ELISA (n = 3).
Table 2. Comparison of cross-reactivity results between clone 2A9 and other DON-MAbs.a
Clone 2A9 direct ELISA Mab 1–6.2.6 (1) indirect ELISA
USDA Clone 22 (4)
direct ELISA
Compound IC50 (ng ml
–1) CR (%) IC50 (ng ml
–1) CR (%) IC50 (ng ml
–1) CR (%)
3-ADON 0.38 100 1.70 100 2.88 100
DON 202.14 0.188 15.80 10.7 18.20 15.8
15-ADON 431.79 0.088 68.90 2.4 558.00 0.52
DON-3-G 25.36 1.498 n.a. − n.a. −
Notes: aHerein, CR (%) = [IC50 (3-ADON)/IC50 (analogue)] × 100%.
For comparison, the results from reference (4) by Maragos & McCormick (2000) were competitive direct ELISA for clone 22; the results from reference
(1) by Maragos et al. (2006) were competitive indirect ELISA for Mab 1–6.2.6.
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15-ADON when using it in a direct ELISA format. By
using an indirect ELISA format with DON-OVA or DON-
CC-OVA coating, the selectivity of this antibody changes
resulting in only cross-reactivity against 3-ADON. When
combining the 2A9 and 10H10 antibodies in an indirect
ELISA format, it is possible to measure the sole DON
contamination.
Therefore, we conclude that it is possible to produce
speciﬁc antibodies against trichothecene mycotoxins such
as 3-ADON by synthesising the proper immunogen with
the suitable linker and screening the hybridomas carefully.
By changing the ELISA format and/or coating antigen, it
is possible to inﬂuence the selectivity and cross-reactivity
of the monoclonal antibody.
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The cyclic peptide was synthesized using manual Fmoc solid phase peptide synthesis (SPPS) 
according to the following procedure: 
 
Coupling of first Amino acid:  
Chlorotrityl chloride resin (100 mg, 0.16 mmol, loading = 1.6 mmol/g) was swollen in 
dichloromethane (dry, 10 mL/g) prior to the loading of the first amino acid. Fmoc-Gly-OH (0.190 g, 
0.64 mmol) was dissolved in dry DCM with N,N’-diisopropylethylamine (DIPEA) (0.22 mL, 1.28 
mmol) and the reaction was shaken for 3 h.  The resin was then washed with 3 x DCM, 3 x DMF, 3 x 
DCM and was dried under vacuum for 2 h. The loading was determined via Fmoc determination and 
was calculated to be 0.9 mmol/g (82% yield).  The resin was then capped with 
methanol/DIPEA/DCM = 2:1:17 by shaking for 2 h. 
 
Fmoc deprotection for the first amino acid: 
The resin was swollen in DMF prior to Fmoc deprotection. A solution of 20% piperidine in DMF was 
added to the resin and the mixture was shaken for 30 min. The solution was then washed with 3 x 
DMF, 3 x methanol, 3 x DMF.  This protocol was repeated to ensure complete Fmoc removal. 
 
Coupling for the remaining amino acids: 
Fmoc protected glycine (38.9 mg, 0.131 mmol) along with benzotriazol-1-yl 
oxytripyrrolidinophosphonium hexafluorophosphate (PyBOP) (273.2 mg, 0.525 mmol) were 
dissolved in dry DMF.  DIPEA (0.183 mL, 1.048 mmol) was added to it and the mixture was shaken 
for 30 s. The mixture was then added to resin pre-swollen in DMF (dry, 10 mL/g) and the reactor was 
shaken for 3 h. The solution was filtered followed by washing with 3 x DMF, 3 x methanol, 3 x DMF.  
Using this protocol, Fmoc-L-Arg(Pbf)-OH, Fmoc-L-Lys(Boc)-OH, Fmoc-D-Phe-OH and Fmoc-L-
Asp-OH were coupled consecutively. 
 
Fmoc deprotection for the remaining amino acids: 
The resin was swollen in DMF prior to Fmoc deprotection.  A solution of 20% piperidine in DMF was 
added to the resin and the mixture was shaken for 2 min, 5 min and 15 min.  The solution was washed 
with 3 x DMF, 3 x methanol, 3 x DMF after each deprotection step. 
 
Mild acid resin cleavage: 
After assembly of the linear peptide, the resin pre-swollen in DCM (dry, 10 mL/g) was treated with 
trifluoroethanol (TFE)/acetic acid (AcOH)/DCM (1/1/3, v/v/v) for 2 h to ensure complete cleavage of 
the protected peptide from the resin. The solvents were evaporated under vacuum and the residual 
material was analysed using reversed phase (RP)-HPLC/MS (Phenomenex Luna C18 column (250 x 
4.6 mm, 5 μm at 35 °C) connected to an ESI mass spectrometer. A mobile phase consisting of 5 mM 
ammonium acetate (A) and acetonitrile (B) was used at a flow rate of 1 mL/min. The gradient elution 
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programme started with 100% mobile phase A for 2 min with a linear decrease to 0% mobile phase A 
in 15 min. An isocratic gradient of 100% mobile phase B was continued for 5 min.  
 
 
 
HPLC trace of the protected linear peptide (C49H75N9O13S): eluting at 15.68 min with calculated m/z: 
1029.52 and observed m/z (ESI+): 1030.4 
 
Peptide Cyclisation: 
The crude linear peptide (77.5 mg, 0.077 mmol) was dissolved in 5 mL dry DCM, followed by the 
addition of 1-hydroxybenzotriazole (HOBt) (10.4 mg, 0.077 mmol), PyBOP (40.1 mg, 0.077 mmol) 
and DIPEA (30.5 mL, 0.175 mmol).  The mixture was stirred for 24 h at room temperature. Only the 
cyclic peptide was observed as the main peptide product on HPLC/MS (HPLC/MS conditions same as 
above). 
 
 
HPLC trace of the protected cyclic peptide (C49H73N9O12S): eluting at 17.66 min with calculated m/z: 
1011.53 and observed m/z (ESI+): 1012.4 
 
Removal of protecting groups: 
The reaction mixture was dissolved in 5 mL TFA/TIS/H2O (95/2.5/2.5, v/v/v) to remove the 
protecting groups in solution.  The peptide was then precipitated in MTBE/Hexane (1/1, v/v) and the 
reaction mixture was analysed using RP-HPLC/MS (Phenomenex Kinetex C18 100Å column (150 x 
4.6 mm, 5 μm at 35 °C) connected to an ESI mass spectrometer. A mobile phase consisting of 5 mM 
ammonium acetate (A) and acetonitrile (B) was used at a flow rate of 1 mL/min. The gradient elution 
programme started with 100% mobile phase A for 1.5 min with a linear decrease to 0% mobile phase 
A in 6 min. An isocratic gradient of 100% mobile phase B was continued for 2.5 min.  
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HPLC trace of the deprotected cyclic peptide (C27H41N9O7) ): eluting at 3.10 min with calculated m/z: 
603.31 and observed m/z (ESI+): 604.2 
 
Diazo transfer: 
A diazo transfer was performed on 50.5 mg of the deprotected cyclic peptide using the imidazole-1-
sulfonylazide hydrochloride reagent as described by Goddard-Borger and Stick (2007). The 
conversion was complete and no starting material was observed when analysed with HPLC/MS. The 
reaction mixture was redissolved in methanol and purified using RP-HPLC. 
 
HPLC trace of the deprotected crude cyclic peptide after diazo transfer (C27H39N11O7): eluting at 4.10 
min with calculated m/z: 629.30 and observed m/z (ESI+): 630.2 
 
HPLC purification of crude peptide: 
The crude peptide was purified using RP-HPLC on an Agilent 1100 Series using a Phenomenex 
semiprep Luna C18 (250 x 10 mm) column. A mobile phase consisting of 0.1% TFA in H2O (A) and 
acetonitrile (B) was used at a flow rate of 4.5 mL/min at 35°C. The gradient elution programme 
started with 100% mobile phase A for 2 min with a linear decrease to 0% mobile phase A in 15 min. 
An isocratic gradient of 100% mobile phase B was continued for 5 min.  
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HPLC trace of the final cyclic peptide after HPLC purification eluting at a retention time of 10.95 min.  
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